List of Headings: Add Heading
| S.no | Heading Name | Date | Edit | Delete |
|---|---|---|---|---|
| 1 | Consent for Publish | 2025-12-09 | ||
| 2 | Consent for Participate | 2025-12-09 | ||
| 3 | Authorship Conformation/ Contribution Statement | 2025-11-17 | ||
| 4 | Ethics Statement (Animals) | 2025-11-15 | ||
| 5 | Implications and Further Research Directions | 2025-11-01 | ||
| 6 | Ethical Approval and Consent Form | 2025-11-01 | ||
| 7 | Strength and Limitations of Study | 2025-11-01 | ||
| 8 | Supplementary Data and Availability | 2025-11-01 | ||
| 9 | Consent Statements | 2025-10-16 | ||
| 10 | Patients, Method and Material | 2025-09-29 | ||
| 11 | Challenges and Future Directions in Immunotherapy: Unlocking New Horizons in Cancer Immunotherapy | 2025-09-22 | ||
| 12 | Untangling the Sweet Mechanics of Liquid Tumors | 2025-09-22 | ||
| 13 | Conclusion | 2025-09-16 | ||
| 14 | Hodgkin Lymphoma and Non-Hodgkin Lymphoma | 2025-09-12 | ||
| 15 | Ethical Consent to Participate | 2025-09-09 | ||
| 16 | Description of a Rare Case of a Gestational Trophoblastic Tumor of the Choriocarcinoma Type Metastatic to the Brain, Lung and Kidney | 2025-09-08 | ||
| 17 | Significant Statement | 2025-09-06 | ||
| 18 | Declaration of Generative AI and AI-Assisted Technologies in the Writing Process | 2025-08-22 | ||
| 19 | Strength of This Narrative | 2025-08-12 | ||
| 20 | Suggested Area of Research | 2025-08-12 | ||
| 21 | Recommendations or Suggestions for The Future | 2025-08-08 | ||
| 22 | Disclosures Section | 2025-08-07 | ||
| 23 | Role of the Financial Funder | 2025-08-07 | ||
| 24 | Source of Financial Support | 2025-08-07 | ||
| 25 | Case Studies in The Use of Tiltrotor Uavs for Cargo Transportation | 2025-08-06 | ||
| 26 | Combined Review On Autonomous Vehicle | 2025-08-06 | ||
| 27 | Animal Care | 2025-08-04 | ||
| 28 | Acknowledgment Statement | 2025-08-04 | ||
| 29 | Funding/Support and Role of the Sponsor | 2025-08-04 | ||
| 30 | Clinical Implications and Future Scope | 2025-08-01 | ||
| 31 | Funding Clearance | 2025-07-31 | ||
| 32 | Minocycline as an Adjunct Therapy | 2025-07-29 | ||
| 33 | Ofloxacin’s Contribution to Leprosy Treatment | 2025-07-29 | ||
| 34 | The Role of Rifampicin in Leprosy Management | 2025-07-29 | ||
| 35 | Ethical and Legal Aspect of Study | 2025-07-25 | ||
| 36 | Policy Issues | 2025-07-21 | ||
| 37 | Disclosure Summary | 2025-07-16 | ||
| 38 | CS Statement | 2025-07-16 | ||
| 39 | Consent to Data Processing and Publication of Images | 2025-07-16 | ||
| 40 | Recruitment and Procedure | 2025-07-15 | ||
| 41 | A Historical Overview | 2025-07-07 | ||
| 42 | Data Avaliability | 2025-06-05 | ||
| 43 | Flow Diagram | 2025-06-05 | ||
| 44 | Research Registration | 2025-06-05 | ||
| 45 | Author’s Contributions and Approval of Manuscript | 2025-06-02 | ||
| 46 | VDA-1275 Effects on Immune System | 2025-06-02 | ||
| 47 | Declaration of Anonymity | 2025-05-22 | ||
| 48 | Patient Selection and Methodology | 2025-05-16 | ||
| 49 | Aims of the Study | 2025-05-14 | ||
| 50 | Future Study | 2025-05-14 | ||
| 51 | LDH assessment | 2025-05-14 | ||
| 52 | Ethics Approval and Informed Consent to Participate | 2025-05-14 | ||
| 53 | IEIs Associated with Chromosomal Abnormalities and Chromosomal Remodeling | 2025-05-06 | ||
| 54 | Conclusions | 2025-04-25 | ||
| 55 | RCTS Endpoints | 2025-04-11 | ||
| 56 | RCTS Workflow | 2025-04-11 | ||
| 57 | Key Findings | 2025-04-08 | ||
| 58 | ACKNOWLWDGEMENT | 2025-04-08 | ||
| 59 | Introduction | 2025-03-28 | ||
| 60 | AVAILABILITY OF DATA AND MATERIAL | 2025-03-28 | ||
| 61 | Clinical Case Report | 2025-02-26 | ||
| 62 | The Role of Artificial Intelligence in Cybersecurity | 2025-01-09 | ||
| 63 | Cybersecurity Risk Management Frameworks | 2025-01-09 | ||
| 64 | The Importance of Cybersecurity in Oil and Gas Pipelines | 2025-01-09 | ||
| 65 | Overall Assessment | 2025-01-08 | ||
| 66 | ID Strength Assessment System Design | 2025-01-08 | ||
| 67 | Relevance for Clinical Practice | 2025-01-03 | ||
| 68 | Mechanisms of Treatment Resistance | 2025-01-02 | ||
| 69 | The Main Causes of Cancer | 2024-12-30 | ||
| 70 | Intellectual Property | 2024-12-30 | ||
| 71 | Research Ethics Approval, Protocol Amendments and Consent | 2024-12-13 | ||
| 72 | Limitations and Strenghts | 2024-12-13 | ||
| 73 | Patient Consent Statement | 2024-12-10 | ||
| 74 | Appendix/supplemental material | 2024-12-06 | ||
| 75 | Experiments | 2024-12-05 | ||
| 76 | Applications of Bionanomaterials in Cardiac Regeneration | 2024-12-03 | ||
| 77 | Nanoscale Drug Delivery Systems | 2024-12-03 | ||
| 78 | Nanocomposites and Nanogels | 2024-12-03 | ||
| 79 | Nanofibers | 2024-12-03 | ||
| 80 | Nanoparticles | 2024-12-03 | ||
| 81 | Therapeutic Delivery and Precision Medicine | 2024-12-03 | ||
| 82 | Future of Shrimp Farming | 2024-11-30 | ||
| 83 | Treatment of Osteopetrosis Depends on The Form of The Disease | 2024-11-29 | ||
| 84 | Osteopetrosis Manifests as More than Just a Bone Disease | 2024-11-29 | ||
| 85 | Diagnosis Depends on Clinical Presentation and Radiographic Findings | 2024-11-29 | ||
| 86 | Osteopetrosis is a Genitic Disease of Osteoclast Dysfunction | 2024-11-29 | ||
| 87 | Challenges and Future Directions for Using Bionanomaterials in Cardiac Regeneration | 2024-11-29 | ||
| 88 | Bionanomaterials in Tissue Engineering | 2024-11-29 | ||
| 89 | Bionanomaterials in Regenerative Medicine: Pioneering the Future of Healing | 2024-11-29 | ||
| 90 | The Emergence of Tissue Engineering and Bionanomaterials | 2024-11-29 | ||
| 91 | The Rise of Stem Cell Therapies | 2024-11-29 | ||
| 92 | Cardiac Regeneration: A Quest for Healing the Ailing Heart | 2024-11-29 | ||
| 93 | Gut Microbiota Associated with NMOSD | 2024-11-29 | ||
| 94 | Brief Comments and Concluding Remarks | 2024-11-29 | ||
| 95 | Results Analysis | 2024-11-29 | ||
| 96 | Challenges and Future Directions | 2024-11-29 | ||
| 97 | Quantum Algorithms | 2024-11-28 | ||
| 98 | Representation and its Relations | 2024-11-26 | ||
| 99 | Change of Prime Numbers in Progression | 2024-11-26 | ||
| 100 | The Real World Violation | 2024-11-26 | ||
| 101 | General Examples of Progressive Set Theory | 2024-11-26 | ||
| 102 | Specific Examples of Progression Set Theory | 2024-11-26 | ||
| 103 | Examples of Major and Minor Numerical Progressions | 2024-11-26 | ||
| 104 | Representations of Simple and Varied Numbers | 2024-11-26 | ||
| 105 | Progression Depends on Physical Space | 2024-11-26 | ||
| 106 | Relationship of Space with Numbers | 2024-11-26 | ||
| 107 | The Various Physical Spaces | 2024-11-25 | ||
| 108 | The Use of Mathematics in Everything | 2024-11-25 | ||
| 109 | Detailed Examples of the Use of Mathematics | 2024-11-25 | ||
| 110 | Math Sense | 2024-11-25 | ||
| 111 | Experiments and Results | 2024-11-25 | ||
| 112 | Future Directions and Challenges | 2024-11-20 | ||
| 113 | Analysis of Questionaire by Doctors | 2024-11-19 | ||
| 114 | Anti-trust Law Issues and Pharmaceuticals sector | 2024-11-19 | ||
| 115 | Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) | 2024-11-19 | ||
| 116 | Drugs and Cosmetics Rules, 1945 | 2024-11-19 | ||
| 117 | Author’s Contributory Statement | 2024-11-19 | ||
| 118 | Authorâ??s Contributory Statement | 2024-11-19 | ||
| 119 | Extension of K-Dependence Coefficient | 2024-11-19 | ||
| 120 | K-Dependence is a Measure with Additive Structure | 2024-11-19 | ||
| 121 | Understanding K-Dependence Coefficient | 2024-11-19 | ||
| 122 | Challenges and Considerations | 2024-11-16 | ||
| 123 | PATHOLOGICAL FINDINGS | 2024-11-15 | ||
| 124 | Details of Ethics Approval | 2024-11-13 | ||
| 125 | Contribution to Authorship | 2024-11-13 | ||
| 126 | Future Research and Consideratons | 2024-11-12 | ||
| 127 | The Genotypic Frequencies of APO E | 2024-11-12 | ||
| 128 | Genetic Study of APOE | 2024-11-12 | ||
| 129 | Materials and Methods | 2024-11-11 | ||
| 130 | Data Avalibility | 2024-11-07 | ||
| 131 | Notes on Contributor | 2024-11-06 | ||
| 132 | Informed Consent Statement | 2024-11-05 | ||
| 133 | Recommendation for Future Research | 2024-11-05 | ||
| 134 | Study Recommendation | 2024-11-01 | ||
| 135 | History and Clinical Assessment | 2024-10-29 | ||
| 136 | Excessive Fibrosis after Strabismus Surgery | 2024-10-29 | ||
| 137 | Wound Healing | 2024-10-29 | ||
| 138 | Ethical Committee Consent | 2024-10-29 | ||
| 139 | Alternative Control Measures | 2024-10-23 | ||
| 140 | Efficiency Of Antimicrobial Agents | 2024-10-23 | ||
| 141 | Pathogenecity and Virulence | 2024-10-23 | ||
| 142 | Importance In The Food Industry | 2024-10-23 | ||
| 143 | Symptoms Of Cronobacter Spp. Infection | 2024-10-23 | ||
| 144 | Characterization Of The Microorganism | 2024-10-23 | ||
| 145 | Cronobacter Spp | 2024-10-23 | ||
| 146 | CRONOBACTER SPP | 2024-10-23 | ||
| 147 | Future Research Directions | 2024-10-14 | ||
| 148 | Case Studies and Statistics | 2024-10-14 | ||
| 149 | Regulatory Framework and Guidelines | 2024-10-14 | ||
| 150 | Preventive Measures and Control Strategies | 2024-10-14 | ||
| 151 | Psychosocial Risk Factors | 2024-10-14 | ||
| 152 | Physical Risk Factors | 2024-10-14 | ||
| 153 | Chemical Risk Factors | 2024-10-14 | ||
| 154 | Biological Risk Factors | 2024-10-14 | ||
| 155 | Types of Occupational Risks | 2024-10-14 | ||
| 156 | Overview of Medical Laboratory Personnel | 2024-10-14 | ||
| 157 | Challenges and Future Directions | 2024-10-04 | ||
| 158 | To the Editor | 2024-10-03 | ||
| 159 | Result Analysis | 2024-10-03 | ||
| 160 | Challenges and Ethical Considerations | 2024-09-23 | ||
| 161 | AI in Cancer Treatment | 2024-09-23 | ||
| 162 | AI in Cancer Diagnosis | 2024-09-23 | ||
| 163 | Precision Medicine in Cancer Treatment | 2024-09-23 | ||
| 164 | Framework for Requirements Management | 2024-09-19 | ||
| 165 | Safety Management System (SMS) | 2024-09-19 | ||
| 166 | Development of MASS Management and Operation | 2024-09-19 | ||
| 167 | Regulatory Framework for MASS | 2024-09-19 | ||
| 168 | Dataset | 2024-09-19 | ||
| 169 | Outcome and Follow-up | 2024-09-16 | ||
| 170 | Ethic Statement | 2024-09-12 | ||
| 171 | Materials and Methodologies | 2024-09-11 | ||
| 172 | The Origin and Development of Intelligence | 2024-09-10 | ||
| 173 | The Representation of Object Shape | 2024-09-10 | ||
| 174 | The Radial Basis Function and the Representations of Color and Sound Attributes in NeuralSystem | 2024-09-10 | ||
| 175 | The Characteristics of Neuron | 2024-09-10 | ||
| 176 | Prediction of Consumed Energy and Its Use | 2024-09-10 | ||
| 177 | Benefits of Measuring | 2024-09-10 | ||
| 178 | Home Energy Management System (HEMS) | 2024-09-10 | ||
| 179 | Amputation Often Leads to Psychopathology, Including Depression, Anxiety and Loss of Self-Esteem | 2024-09-10 | ||
| 180 | Amputation Alters Body Mechanics, Increasing Risk for Injury and Degeneration | 2024-09-10 | ||
| 181 | The Vast Majority of People Who Undergo Amputation Experience Difficult-To-Treat Pain | 2024-09-10 | ||
| 182 | The Importance of Data Security | 2024-09-02 | ||
| 183 | Discursive Analysis | 2024-09-02 | ||
| 184 | Scalable Digital Health Ecosystems | 2024-08-29 | ||
| 185 | Mathematical Reformulation of Cost/Benefit Analysis | 2024-08-29 | ||
| 186 | Cost/Benefit Analysis | 2024-08-29 | ||
| 187 | Mathematical Formulation of Multilayer Networks in the Context of Digital Health | 2024-08-29 | ||
| 188 | Multilayer Networks and Public Driven Digital Health | 2024-08-29 | ||
| 189 | Multilayer Networks | 2024-08-29 | ||
| 190 | Digital Health and Public Healthcare | 2024-08-29 | ||
| 191 | The Following is a Presentation of the Designs I have Designed and Implemented | 2024-08-28 | ||
| 192 | Terminology | 2024-08-28 | ||
| 193 | Case Presentation | 2024-08-27 | ||
| 194 | Visual Memory and Spatial Navigation as Longitudinal Pre-clinial Indicators of Alzheimer’s Disease | 2024-08-27 | ||
| 195 | Episodic Memory Trajectories as Preclinical Indicators of Alzheimer’s Disease and Spatial Navigation Deficits | 2024-08-27 | ||
| 196 | Longitudinal Screening for Preclinical Alzheimer’s Disease and Safety Risks: A Feasibility Study | 2024-08-27 | ||
| 197 | Exploratory Data Analysis (EDA) Visualizations | 2024-08-27 | ||
| 198 | Model Descriptions | 2024-08-27 | ||
| 199 | Longitudinal Screening for Preclinical Alzheimerâ??s Disease and Safety Risks: A Feasibility Study | 2024-08-27 | ||
| 200 | Audible Sound Holograms Applications for Neurologic and Physiologic Rehabilitation | 2024-08-26 | ||
| 201 | Case Studies and Applications | 2024-08-26 | ||
| 202 | Importance of Continuous Tracking and Evaluation | 2024-08-26 | ||
| 203 | Metrics in Practical Applications | 2024-08-26 | ||
| 204 | User Satisfaction Metrics | 2024-08-26 | ||
| 205 | Performance Metrics | 2024-08-26 | ||
| 206 | The Sensomotor System is a Feedback Loop in Dynamic Systems | 2024-08-23 | ||
| 207 | State Differences in CNA Functions may Dictate the Level of Care Required | 2024-08-23 | ||
| 208 | CNAS can Provide Basic Care Under the Supervision of Higher-Level Nursing Staff | 2024-08-23 | ||
| 209 | CNAS can Provide Basic Care Under the Supervision of Higher-Level Nursing Staff | 2024-08-23 | ||
| 210 | LPNS can Range of Nursing Care Services | 2024-08-23 | ||
| 211 | RNS are more Highly Educated and Medically Trained than LPNS and CNAS | 2024-08-23 | ||
| 212 | Available Data and Materials | 2024-08-13 | ||
| 213 | Declaration and Ethical Consent | 2024-08-13 | ||
| 214 | Strategies for Managing Food-Drug Interactions | 2024-08-07 | ||
| 215 | Common Food-Drug Interactions | 2024-08-07 | ||
| 216 | Directions for Future Research | 2024-08-06 | ||
| 217 | Content Analysis | 2024-08-06 | ||
| 218 | Understanding | 2024-08-06 | ||
| 219 | Ethical Issue | 2024-07-30 | ||
| 220 | Challenges of Pharmaceutical Reviews | 2024-07-29 | ||
| 221 | Case study 3 | 2024-07-29 | ||
| 222 | Case study 2 | 2024-07-29 | ||
| 223 | Case study 1 | 2024-07-29 | ||
| 224 | Empiricals Findings | 2024-07-19 | ||
| 225 | Off-Line Programming | 2024-07-17 | ||
| 226 | Descriptions of the Measurements | 2024-07-17 | ||
| 227 | Design Methodology | 2024-07-17 | ||
| 228 | Conclusion | 2024-07-16 | ||
| 229 | Networks Construction | 2024-07-16 | ||
| 230 | Data Preparation | 2024-07-16 | ||
| 231 | Ethics Approval Statement | 2024-07-16 | ||
| 232 | Demand-Supply Management | 2024-07-16 | ||
| 233 | Fraud Detection | 2024-07-16 | ||
| 234 | Personalization | 2024-07-16 | ||
| 235 | AI and Platform Economics | 2024-07-16 | ||
| 236 | Coi Statement | 2024-07-10 | ||
| 237 | Drug Repurposing for Drug Discovery | 2024-07-10 | ||
| 238 | Target Identification for Drug Discovery | 2024-07-10 | ||
| 239 | Molecular Modeling for De Novo Drug Design | 2024-07-10 | ||
| 240 | Virtual Screening for Drug Discovery | 2024-07-10 | ||
| 241 | Artificial Intelligence Fundamentals | 2024-07-10 | ||
| 242 | Heparin | 2024-07-08 | ||
| 243 | Inflammation and Coagulation Players | 2024-07-08 | ||
| 244 | Literature Paper | 2024-07-05 | ||
| 245 | Future Studies | 2024-07-04 | ||
| 246 | Study Tools and Procedures | 2024-06-25 | ||
| 247 | Ethical Endorsement | 2024-06-25 | ||
| 248 | Proposals | 2024-06-25 | ||
| 249 | Physiatrists are ideally Positioned to help interested Third parties understand a Patient’s future medical costs | 2024-06-18 | ||
| 250 | Physiatrists are ideally Positioned to help interested Third parties understand a Patientâ??s future medical costs | 2024-06-18 | ||
| 251 | Physiatrists are ideally Positioned to help interested Third parties understand a Patientâ??s future medical costs | 2024-06-18 | ||
| 252 | The court system serves as a Gateway for many americans to Access medical care | 2024-06-18 | ||
| 253 | Americans are forced to Choose between obtaining Vital care and avoiding medical Debt | 2024-06-18 | ||
| 254 | U.S. Healthcare spending exceeds those of other highincome nations with worse outcomes | 2024-06-18 | ||
| 255 | Disclosures and Conflict of Interest | 2024-05-09 | ||
| 256 | Statement of Consent to Participate | 2024-05-02 | ||
| 257 | Acknowledgement/Funding | 2024-05-02 | ||
| 258 | Declarations Ethics | 2024-05-02 | ||
| 259 | Funding Disclosures | 2024-05-01 | ||
| 260 | Preface of the Book | 2024-04-25 | ||
| 261 | Data Available Statement | 2024-04-19 | ||
| 262 | Paraplegia Often Results from Traumatic Accidents | 2024-04-11 | ||
| 263 | Acute Boutonniere Deformity | 2024-04-10 | ||
| 264 | The Right Level and Amount of Care is Critical for the Well-Being of Paraplegics | 2024-04-08 | ||
| 265 | Paraplegics Face Significant Social and Economic Costs | 2024-04-08 | ||
| 266 | Paraplegics Experience Bodily Changes that Increase Risk for Complications | 2024-04-08 | ||
| 267 | Paraplegics Tend to be at Highest Risk for Traumatic Accidents | 2024-04-08 | ||
| 268 | Null Hypothesis | 2024-04-08 | ||
| 269 | Ethics Approval and Consent to Publish | 2024-03-28 | ||
| 270 | Abbrivations | 2024-03-26 | ||
| 271 | Limitation and Suggestion | 2024-03-26 | ||
| 272 | Simulation result and discussion | 2024-03-26 | ||
| 273 | Review Of Literature,Rol | 2024-03-26 | ||
| 274 | Design and Methodology | 2024-03-25 | ||
| 275 | Ethical Committee | 2024-03-20 | ||
| 276 | Data Access Statement | 2024-03-20 | ||
| 277 | Ethical Statements | 2024-03-19 | ||
| 278 | Recent Findings | 2024-03-19 | ||
| 279 | PTW UNIDOS® E-electrometer | 2024-03-18 | ||
| 280 | Main Report | 2024-03-18 | ||
| 281 | Study Limitations and Future Directions | 2024-03-12 | ||
| 282 | Soft Tissue Fillers | 2024-03-05 | ||
| 283 | Research Registration Unique Identifying Number (Uin) | 2024-03-01 | ||
| 284 | Androgen (Receptor) and Prostate Zones | 2024-02-26 | ||
| 285 | Embryonic Origins of the Different Zones of the Prostate | 2024-02-26 | ||
| 286 | Significant Variability Between Prostate Zones | 2024-02-26 | ||
| 287 | Evolution of the Prostate Zones | 2024-02-26 | ||
| 288 | Limitations and future applications | 2024-02-22 | ||
| 289 | testt | 2024-02-19 | ||
| 290 | Author Disclosure | 2024-02-17 | ||
| 291 | Author Confirmation | 2024-02-17 | ||
| 292 | Conflicts of Interest/Competing Interest | 2024-02-16 | ||
| 293 | The Evolving Landscape of Stroke Rehabilitation: Unraveling Global Trends and Innovations | 2024-02-16 | ||
| 294 | Evolution of Stroke Rehabilitation on A Global Scale: A Historical Journey | 2024-02-16 | ||
| 295 | Cytological Description | 2024-02-15 | ||
| 296 | Treatment Objectives | 2024-02-13 | ||
| 297 | Ethical Approval and Consent to Participate | 2024-02-12 | ||
| 298 | Authorship Contributor Statement | 2024-02-07 | ||
| 299 | Registration of research studies | 2024-02-02 | ||
| 300 | Review Results | 2024-02-01 | ||
| 301 | Patients and Study Methods | 2024-01-26 | ||
| 302 | Study Framework | 2024-01-26 | ||
| 303 | Strengths and Limitations of Our Study | 2024-01-25 | ||
| 304 | Future Scope of Study | 2024-01-25 | ||
| 305 | Ethical Adherence | 2024-01-23 | ||
| 306 | Declaration of conflicting of interest | 2024-01-23 | ||
| 307 | Statement on informed consent | 2024-01-23 | ||
| 308 | Outcomes can be Optimized by Ensuring Proper Type and Level of Care | 2024-01-19 | ||
| 309 | Quadriplegia is Associated with Poor Outcomes | 2024-01-19 | ||
| 310 | Quadriplegia Is Associated With Poor Outcomes | 2024-01-19 | ||
| 311 | Quadriplegia Patients Suffer Significant Complicatins | 2024-01-19 | ||
| 312 | Quadriplegia Often Occurs Due to Preventable Causes and Risk Depends on Race, Sex and Age | 2024-01-19 | ||
| 313 | Patient and Public Involvement | 2024-01-09 | ||
| 314 | test12 | 2024-01-02 | ||
| 315 | System For Reporting Mes | 2024-01-02 | ||
| 316 | Pharmacovigilance Database and System In Italian | 2024-01-02 | ||
| 317 | Contrasts Between United States, Europe And Indian Pv | 2024-01-02 | ||
| 318 | Pv In Europe, Usa, India | 2024-01-02 | ||
| 319 | Pharmacovigilance In Practice | 2024-01-02 | ||
| 320 | Need For Pharmacovigilance | 2024-01-02 | ||
| 321 | Pv History | 2024-01-02 | ||
| 322 | Ethical Declaration | 2024-01-02 | ||
| 323 | Treatment Objective | 2023-12-29 | ||
| 324 | Treatment Results | 2023-12-29 | ||
| 325 | Ethical approval statement or statement of informed consent for case studies | 2023-12-22 | ||
| 326 | Competing Interest Declaration | 2023-12-22 | ||
| 327 | Method of Research | 2023-12-22 | ||
| 328 | Ethics Approval and Cosent to Participate | 2023-12-19 | ||
| 329 | Future directions and implications | 2023-12-14 | ||
| 330 | Conclusion and Further Advances | 2023-12-13 | ||
| 331 | Atm Signaling Contributes to Apoptosis and other Negative Factors in Leukemia Cells | 2023-12-13 | ||
| 332 | Chemotherapy | 2023-12-13 | ||
| 333 | Mitochondria's Contribution to Ros Production Aids in Leukemia Cell Resistance | 2023-12-13 | ||
| 334 | Leukemia Adaptive Mechanisms with Glycolysis | 2023-12-13 | ||
| 335 | PPP Pathway Importance to Leukemia Cells | 2023-12-13 | ||
| 336 | Glycolysis in Regards to Leukemia Cell’s Protection Against Oxidative Stress | 2023-12-13 | ||
| 337 | Oxidative Stress and Its Inducer | 2023-12-13 | ||
| 338 | Prognostic role of pd/pd-l1 | 2023-12-13 | ||
| 339 | Correlation between pd-l1 expression and clinicopathological factors of serous ovarian carcinoma | 2023-12-13 | ||
| 340 | Statement of Funding Sources, if any, and Acknowledgments for Grants and Technical Support | 2023-12-08 | ||
| 341 | Exploration of cell morphology | 2023-12-05 | ||
| 342 | Study of cell morphology | 2023-12-05 | ||
| 343 | Materials and techniques | 2023-12-05 | ||
| 344 | Methodology and Materials | 2023-11-21 | ||
| 345 | Statement | 2023-11-20 | ||
| 346 | Limitations and Further Research | 2023-11-17 | ||
| 347 | Description | 2023-11-14 | ||
| 348 | Outcome Measurements | 2023-11-09 | ||
| 349 | Patient and Public Involvement (PPI) | 2023-11-09 | ||
| 350 | Withdrawal or Discontinuation of the Participants | 2023-11-09 | ||
| 351 | Delivery of Intervention | 2023-11-09 | ||
| 352 | Baseline and Follow-Ups | 2023-11-09 | ||
| 353 | Screening Procedures | 2023-11-09 | ||
| 354 | Participant Timeline | 2023-11-09 | ||
| 355 | Participants, Interventions, and Outcomes | 2023-11-09 | ||
| 356 | Costly and Unpleasant Complications Accumulate without Proper Care | 2023-11-08 | ||
| 357 | There are a Few Established Predictors of Survival and Long-term Outcomes | 2023-11-08 | ||
| 358 | A Lack of Clear Guidance Complicates Severe TBI Treatment | 2023-11-08 | ||
| 359 | Severe TBI is Associated with Long-Lasting Effects Across Several Domains of Life | 2023-11-08 | ||
| 360 | Author Contributions Statement | 2023-11-07 | ||
| 361 | Author Contributions Statements | 2023-11-07 | ||
| 362 | Limitation of This Study | 2023-11-06 | ||
| 363 | Conclusion and Prospective | 2023-11-04 | ||
| 364 | Application Drug Development | 2023-11-04 | ||
| 365 | Experience Development | 2023-11-04 | ||
| 366 | Methods Development | 2023-11-04 | ||
| 367 | Basic Methods | 2023-11-04 | ||
| 368 | Proposed method | 2023-11-02 | ||
| 369 | Funding Agency | 2023-11-01 | ||
| 370 | Ethical Consent | 2023-11-01 | ||
| 371 | Skills and Qualities of a Data Analyst | 2023-10-28 | ||
| 372 | The Importance of Data Analysts | 2023-10-28 | ||
| 373 | . | 2023-10-28 | ||
| 374 | Data-driven Recommendations | 2023-10-28 | ||
| 375 | Predictive Modeling | 2023-10-28 | ||
| 376 | Hypothesis Testing | 2023-10-28 | ||
| 377 | Reporting and Visualization | 2023-10-28 | ||
| 378 | Data Cleaning and Preprocessing | 2023-10-28 | ||
| 379 | The Role of a Data Analyst | 2023-10-28 | ||
| 380 | The Importance of Cybersecurity | 2023-10-27 | ||
| 381 | Motivations behind Cyber Attacks | 2023-10-27 | ||
| 382 | Types of Cyber Attacks | 2023-10-25 | ||
| 383 | Conclusion and Implication | 2023-10-20 | ||
| 384 | 3. Results and Discussion | 2023-10-19 | ||
| 385 | 2. Materials and Methods | 2023-10-19 | ||
| 386 | Dedication | 2023-10-17 | ||
| 387 | Author Contributory Statement | 2023-10-17 | ||
| 388 | Optimization | 2023-10-17 | ||
| 389 | Benefits of herbal mouthwash | 2023-10-13 | ||
| 390 | 1. Description | 2023-10-11 | ||
| 391 | Arrive Guidelines | 2023-10-09 | ||
| 392 | The Global Burden of Cervical Cancer | 2023-10-05 | ||
| 393 | Public Interest Statement | 2023-10-04 | ||
| 394 | Funding Institution | 2023-10-04 | ||
| 395 | Nikbut | 2023-09-29 | ||
| 396 | Supporting information available | 2023-09-28 | ||
| 397 | Global Developments and Future Perspectives | 2023-09-27 | ||
| 398 | Presentations | 2023-09-27 | ||
| 399 | Final Support and Sponsorship | 2023-09-27 | ||
| 400 | Assistance for the Study | 2023-09-27 | ||
| 401 | Right to Privacy and Informed Consent | 2023-09-27 | ||
| 402 | Confidentiality of Data | 2023-09-27 | ||
| 403 | Protection of Human and Animal Subjects | 2023-09-27 | ||
| 404 | Research and Methods | 2023-09-27 | ||
| 405 | Research and Method | 2023-09-27 | ||
| 406 | Clinical Trial Registration Number | 2023-09-25 | ||
| 407 | Ethical Compliance | 2023-09-20 | ||
| 408 | Techniques and research methods | 2023-09-13 | ||
| 409 | Treatment Options For Hie Are Limited | 2023-09-08 | ||
| 410 | The Developing Brain Responds to Insults Differently Than The Adult Brain, Making Childern Vulnerable | 2023-09-08 | ||
| 411 | Clinical Implication of the Present Study | 2023-09-08 | ||
| 412 | Strengths and Weakness of the Study | 2023-09-08 | ||
| 413 | Strength and Limitations of Current Study | 2023-09-07 | ||
| 414 | Clinical Implications for Further Studies | 2023-09-07 | ||
| 415 | Coronary Complications | 2023-09-02 | ||
| 416 | Risk Stratification and Risk Scores | 2023-09-02 | ||
| 417 | Data and Materials Avialability | 2023-09-02 | ||
| 418 | Contribution List | 2023-09-01 | ||
| 419 | Igrt | 2023-09-01 | ||
| 420 | Conclusions & Recommendations | 2023-08-26 | ||
| 421 | STATEMENT OF ANIMAL RIGHTS | 2023-08-24 | ||
| 422 | Implications for Practice and Future Directions | 2023-08-24 | ||
| 423 | Ethic Statements | 2023-08-18 | ||
| 424 | Disclaimer/Publisher’s Note | 2023-08-16 | ||
| 425 | Publisher’s Note | 2023-08-14 | ||
| 426 | Human Research Statement | 2023-08-10 | ||
| 427 | BIBLIYOGRAFYA | 2023-08-09 | ||
| 428 | Metabolic Homeostacis and Adipokines | 2023-08-03 | ||
| 429 | Method of Data Analysis | 2023-08-03 | ||
| 430 | Taxonomic treatment | 2023-08-01 | ||
| 431 | Declaration Section | 2023-07-31 | ||
| 432 | Source Of Fund | 2023-07-29 | ||
| 433 | Supplementary Note | 2023-07-25 | ||
| 434 | Concerns and Challenges | 2023-07-25 | ||
| 435 | Research Objective | 2023-07-25 | ||
| 436 | Future of Brain Implants | 2023-07-19 | ||
| 437 | AUTHOR'S CONTRIBUTION | 2023-07-17 | ||
| 438 | Interpretation of Tsh Levels | 2023-07-12 | ||
| 439 | Final conclusion | 2023-07-12 | ||
| 440 | Comparing results of implementations | 2023-07-12 | ||
| 441 | Results of research | 2023-07-12 | ||
| 442 | Concluded results | 2023-07-12 | ||
| 443 | Implementation plan | 2023-07-12 | ||
| 444 | Limitations and Future Reasearch | 2023-07-06 | ||
| 445 | Implications and Next Steps | 2023-07-06 | ||
| 446 | Policy Consideration and Recommendations | 2023-07-06 | ||
| 447 | Stakeholders and Their Perspectives | 2023-07-06 | ||
| 448 | Ownership of AI-Generated Images in India | 2023-07-06 | ||
| 449 | Legal Framework in India | 2023-07-06 | ||
| 450 | Analysis of the System | 2023-07-05 | ||
| 451 | IMUS Transport Plaza Terminal | 2023-07-05 | ||
| 452 | Scope of the Project | 2023-07-04 | ||
| 453 | Project Development | 2023-07-04 | ||
| 454 | Context Free Language | 2023-07-04 | ||
| 455 | Finite State Machine | 2023-07-04 | ||
| 456 | Recognition | 2023-07-03 | ||
| 457 | Face Detection using Cascade Classifiers in Open CV | 2023-07-03 | ||
| 458 | Image Capture | 2023-07-03 | ||
| 459 | Types of Aquaculture | 2023-06-30 | ||
| 460 | Research Highlights | 2023-06-29 | ||
| 461 | Simulation and Sensor Design Using Two Waveguides and Three Cavities | 2023-06-28 | ||
| 462 | Simulation and Design of a Sensor Using Two Waveguides and Five Cavities | 2023-06-28 | ||
| 463 | Simulation and Design of a Sensor Using Two Waveguides and a Cavity | 2023-06-28 | ||
| 464 | Sensor Simulation and Design Methods Using Refractive Index Measurement | 2023-06-28 | ||
| 465 | Structural Model and Theory Analysis | 2023-06-28 | ||
| 466 | Author Biographies | 2023-06-26 | ||
| 467 | Scope of Further Research | 2023-06-26 | ||
| 468 | Authors Statement | 2023-06-23 | ||
| 469 | Declarations of Interests | 2023-06-23 | ||
| 470 | Limits of the Study | 2023-06-22 | ||
| 471 | Informed Consent and Data Availability Statement | 2023-06-21 | ||
| 472 | Instrument | 2023-06-20 | ||
| 473 | Fisher’s experimentation | 2023-06-16 | ||
| 474 | Fisherâ??s experimentation | 2023-06-16 | ||
| 475 | Fisherâ??s experimentation | 2023-06-16 | ||
| 476 | Fisherâ??s experimentation | 2023-06-16 | ||
| 477 | Discrete fractal numbers | 2023-06-16 | ||
| 478 | Unified aco | 2023-06-16 | ||
| 479 | Negation domains | 2023-06-16 | ||
| 480 | A Review of Literature | 2023-06-15 | ||
| 481 | Disclosure of Ethical Statements | 2023-06-13 | ||
| 482 | Study Investigators | 2023-06-13 | ||
| 483 | Contribution | 2023-06-13 | ||
| 484 | Funding and Governance | 2023-06-13 | ||
| 485 | Material and Analysis | 2023-06-13 | ||
| 486 | Cirriculum System | 2023-06-13 | ||
| 487 | Evaluation of ESR1, EGFR2 and HUMAN VITAMIN D3 serum concentrations | 2023-06-12 | ||
| 488 | Discussion & Conclusion | 2023-06-09 | ||
| 489 | Estimated Results of QMLS and Comparison to Other Methods | 2023-06-09 | ||
| 490 | Quantum Based Simulation (CS) | 2023-06-09 | ||
| 491 | Machine Learning Molecule Generation (MLMG) & Machine Learning Molecule Variation (MLMV) | 2023-06-09 | ||
| 492 | Content | 2023-06-06 | ||
| 493 | Comparative Analysis: Adaptive vs. Traditional Feature Fusion Techniques | 2023-06-06 | ||
| 494 | Experimentation and Evaluation: Datasets and Performance Metrics | 2023-06-06 | ||
| 495 | Designing and Implementing Fusion Layers for Deep Learning Architectures | 2023-06-06 | ||
| 496 | The Adaptive Feature Fusion(AFF) Framework | 2023-06-06 | ||
| 497 | Results/ Findings of this Study | 2023-06-06 | ||
| 498 | Constructions and Sea Fill On Tyre Shoreline | 2023-06-06 | ||
| 499 | Sand Extraction | 2023-06-06 | ||
| 500 | Coastal Management | 2023-06-06 | ||
| 501 | Land Use and Land Cover (LULC) | 2023-06-06 | ||
| 502 | Recent Studies On Shoreline Analysis Change That Has Depended On DSAS | 2023-06-06 | ||
| 503 | Digital Shoreline Analysis System (Dsas) | 2023-06-06 | ||
| 504 | Data Avialability Statement | 2023-06-05 | ||
| 505 | Data Availaibility | 2023-06-05 | ||
| 506 | Avialability of Data and Materials | 2023-06-05 | ||
| 507 | Study Outcomes | 2023-06-05 | ||
| 508 | Effects On Work Andorganization | 2023-06-02 | ||
| 509 | 1. Editorial | 2023-06-02 | ||
| 510 | 2. Description | 2023-06-02 | ||
| 511 | Em-Wave Velocity Analysis and Moisture Map | 2023-06-01 | ||
| 512 | Recommendation And Further Research Directions | 2023-05-27 | ||
| 513 | The Result And Discussion | 2023-05-27 | ||
| 514 | Literature Analysis & Discussion | 2023-05-27 | ||
| 515 | Results of Analysis and Discussion | 2023-05-25 | ||
| 516 | Management of tomato leaf Miner | 2023-05-22 | ||
| 517 | Ethical and Consent to Participate | 2023-05-22 | ||
| 518 | Subject Confidentiality | 2023-05-20 | ||
| 519 | Patients & Method | 2023-05-20 | ||
| 520 | Conflicts of interest and others declarations | 2023-05-19 | ||
| 521 | Availability | 2023-05-18 | ||
| 522 | Availablility of data and materials | 2023-05-17 | ||
| 523 | Dietary energy and cerebrum disease | 2023-05-17 | ||
| 524 | Conflict of Interest Declaration | 2023-05-15 | ||
| 525 | Authors’ Information | 2023-05-10 | ||
| 526 | Conclusion and Prospections | 2023-05-10 | ||
| 527 | Finidings to Investigate | 2023-05-10 | ||
| 528 | Consent and Ethical Approval | 2023-05-04 | ||
| 529 | Supplementary Material File Captions | 2023-05-04 | ||
| 530 | Future Aspect | 2023-05-04 | ||
| 531 | Interventional Roles of Phytochemicals on Various Toxicity Outcomes | 2023-05-03 | ||
| 532 | Overview of Phytochemicals | 2023-05-03 | ||
| 533 | Toxicity of Some Selected Environmental Toxicants | 2023-05-03 | ||
| 534 | Drugs of Abuse | 2023-05-03 | ||
| 535 | Agricultural Chemicals (Pesticides) | 2023-05-03 | ||
| 536 | Classes of Toxicants | 2023-05-03 | ||
| 537 | Literature Review of Environmental Toxicants | 2023-05-03 | ||
| 538 | Research approval | 2023-05-02 | ||
| 539 | Etiology and Pathogenesis | 2023-04-27 | ||
| 540 | Potential Health Hazards | 2023-04-26 | ||
| 541 | Postoperative Analgesia Process | 2023-04-26 | ||
| 542 | Postoperative Multimodal Opioid-Sparing Analgesia | 2023-04-26 | ||
| 543 | Intraoperative Anesthesia Management | 2023-04-26 | ||
| 544 | Preoperative Sedation | 2023-04-26 | ||
| 545 | Participant Consent | 2023-04-24 | ||
| 546 | FUNDING/ACKNOWLEDGEMENTS | 2023-04-24 | ||
| 547 | Daignosis | 2023-04-19 | ||
| 548 | Multiplex Pcr Amplification | 2023-04-19 | ||
| 549 | Author Declarations | 2023-04-19 | ||
| 550 | Ethical Statement Approval and Consent to Participate | 2023-04-19 | ||
| 551 | Implications for Nursing Research | 2023-04-17 | ||
| 552 | Conclusion | 2023-04-14 | ||
| 553 | 6. Effect of Preemptive Polling Scheme | 2023-04-14 | ||
| 554 | 5. Implementation | 2023-04-14 | ||
| 555 | 4. Algorithm 1: Parallel Search with PPS | 2023-04-14 | ||
| 556 | 3. System Design | 2023-04-14 | ||
| 557 | Results and Finding | 2023-04-13 | ||
| 558 | Results and Funding | 2023-04-13 | ||
| 559 | Aims | 2023-04-13 | ||
| 560 | 7. Declaration of Conflicting Interests | 2023-04-13 | ||
| 561 | Conclusion | 2023-04-13 | ||
| 562 | 5. Uncertainty Estimation | 2023-04-13 | ||
| 563 | 4. Obtained Results | 2023-04-13 | ||
| 564 | 3.Input-Output Linearization | 2023-04-13 | ||
| 565 | 2. Methodology | 2023-04-13 | ||
| 566 | 7. Interpretation and Conclusions | 2023-04-12 | ||
| 567 | 6. Implementation | 2023-04-12 | ||
| 568 | 5. Data Collection and Pre-Processing | 2023-04-12 | ||
| 569 | 4. Machine Learning in Methodology | 2023-04-12 | ||
| 570 | 3. Main Flaws Found in Breathalyzers | 2023-04-12 | ||
| 571 | 2. Breathalyzers and Their Construction | 2023-04-12 | ||
| 572 | 6. Declarations | 2023-04-12 | ||
| 573 | 4. Results and Discussion | 2023-04-12 | ||
| 574 | 2. Literature Review | 2023-04-12 | ||
| 575 | Conclusion | 2023-04-12 | ||
| 576 | 7.Analysis | 2023-04-12 | ||
| 577 | 6. Conceptual Model and Framework | 2023-04-12 | ||
| 578 | 5. Objectives | 2023-04-12 | ||
| 579 | 4. Research Methodology | 2023-04-12 | ||
| 580 | 3. Research Problem | 2023-04-12 | ||
| 581 | 2. Review of Literature | 2023-04-12 | ||
| 582 | 3. Summary and Conclusion | 2023-04-12 | ||
| 583 | 2. System design | 2023-04-12 | ||
| 584 | 5. Challenges of Block chain | 2023-04-11 | ||
| 585 | 4. Applications of Block Chain | 2023-04-11 | ||
| 586 | 3. Types of Block Chain Networks | 2023-04-11 | ||
| 587 | 2. How does block chain work? | 2023-04-11 | ||
| 588 | Conclusion | 2023-04-11 | ||
| 589 | 4. System Module and Setup | 2023-04-11 | ||
| 590 | 2. Related Work | 2023-04-11 | ||
| 591 | 7. Scope for future research | 2023-04-11 | ||
| 592 | 6. Limitations | 2023-04-11 | ||
| 593 | 5. Key recommendations | 2023-04-11 | ||
| 594 | Conclusion | 2023-04-11 | ||
| 595 | 3. Results | 2023-04-11 | ||
| 596 | 2. Parameters for visualization | 2023-04-11 | ||
| 597 | Associated Data Availability | 2023-04-07 | ||
| 598 | Regression Results | 2023-04-07 | ||
| 599 | Result Reading | 2023-04-03 | ||
| 600 | Human Ethics | 2023-04-03 | ||
| 601 | Code and Data Availability | 2023-04-01 | ||
| 602 | Table of Contents | 2023-03-30 | ||
| 603 | History of Diabetes Mellitus | 2023-03-24 | ||
| 604 | Primary Hormones | 2023-03-23 | ||
| 605 | Statement Of Conflict Of Interest | 2023-03-21 | ||
| 606 | Data Management and Analysis | 2023-03-21 | ||
| 607 | Ethical Conduct of Research | 2023-03-20 | ||
| 608 | Research Contributions | 2023-03-20 | ||
| 609 | Materials and Methods | 2023-03-17 | ||
| 610 | Author Contribution Statement | 2023-03-16 | ||
| 611 | Preliminary Analysis of the Potential Function of the Somatic Cells in Warm-Blooded Animals | 2023-03-15 | ||
| 612 | Preliminary Analysis of the Potential Function of a Single Cell in Warm-Blooded Animals | 2023-03-15 | ||
| 613 | Determination of Extractive Value | 2023-03-04 | ||
| 614 | Ethical Expertise | 2023-03-04 | ||
| 615 | Ethical Expertise | 2023-03-04 | ||
| 616 | Financing Source | 2023-03-04 | ||
| 617 | Ethical Approval and Cosent to Participate | 2023-03-02 | ||
| 618 | Comparisions | 2023-03-02 | ||
| 619 | Results Of SBP | 2023-02-28 | ||
| 620 | Results Of Dbp | 2023-02-28 | ||
| 621 | Results of pap | 2023-02-28 | ||
| 622 | Geochemical Studies Outcomes | 2023-02-27 | ||
| 623 | Geologic Setting of Region | 2023-02-27 | ||
| 624 | Mode of cancer | 2023-02-17 | ||
| 625 | Drug development conundrum | 2023-02-17 | ||
| 626 | Immune barriers to xeno-transplantation | 2023-02-16 | ||
| 627 | History and future of xenotransplantation | 2023-02-16 | ||
| 628 | CONCLUSION AND RECOMMENDATIONS | 2023-02-13 | ||
| 629 | CONCLUSION AND RECOMMENDATIONS | 2023-02-13 | ||
| 630 | Novel Drug Delivery System | 2023-02-09 | ||
| 631 | Declaration for Conflict of Interest | 2023-02-09 | ||
| 632 | Material-Method | 2023-02-08 | ||
| 633 | Expected Results | 2023-02-08 | ||
| 634 | Rationale | 2023-02-08 | ||
| 635 | Etiology and Pathophysiology | 2023-02-08 | ||
| 636 | Kaempferide | 2023-02-07 | ||
| 637 | Prognostic Factors | 2023-02-07 | ||
| 638 | Treatment Compliance | 2023-02-07 | ||
| 639 | Outcomes After Surgery | 2023-02-07 | ||
| 640 | Radiotherapy, Chemotherapy, And Toxicities | 2023-02-07 | ||
| 641 | Follow-up | 2023-02-07 | ||
| 642 | What This Study Adds | 2023-02-07 | ||
| 643 | What Is Already Known On This Topic | 2023-02-07 | ||
| 644 | Radiotherapy technique | 2023-02-07 | ||
| 645 | Trends | 2023-02-06 | ||
| 646 | The Process of Review | 2023-02-06 | ||
| 647 | Actions by MDA | 2023-02-06 | ||
| 648 | Problems with MDA | 2023-02-06 | ||
| 649 | MDA to support IT growth | 2023-02-06 | ||
| 650 | MDA for business process transformation | 2023-02-06 | ||
| 651 | MDA to facilitate process harmonization and IT implementation | 2023-02-06 | ||
| 652 | Model driven architecture | 2023-02-06 | ||
| 653 | Review of MDAs | 2023-02-06 | ||
| 654 | Consent and Ethics Approval | 2023-02-06 | ||
| 655 | IRB Information | 2023-02-03 | ||
| 656 | Kaynaklar | 2023-02-02 | ||
| 657 | Patient Perspective | 2023-02-02 | ||
| 658 | Recommendation For Further Research | 2023-02-02 | ||
| 659 | Clinical Implications of Study | 2023-02-02 | ||
| 660 | Strength and Weakness of Our Study | 2023-02-02 | ||
| 661 | Statement of Significance | 2023-02-02 | ||
| 662 | Availability and Data Material | 2023-02-01 | ||
| 663 | Recommendation For Future Studies | 2023-02-01 | ||
| 664 | Implication in Clinical Practice | 2023-02-01 | ||
| 665 | Strength and Limitation of Our Study | 2023-02-01 | ||
| 666 | Data Statement | 2023-02-01 | ||
| 667 | Conflicts of Interest and Source of Funding | 2023-01-30 | ||
| 668 | Assessment of Digital Literacy Skills of the POST Graduate Students of Bangalore North University, Kolar, Karnataka, India: A Study | 2023-01-28 | ||
| 669 | Flacc Pain Scale | 2023-01-27 | ||
| 670 | Cries pain scale | 2023-01-27 | ||
| 671 | Premature Infant Pain Profile (PIPP) | 2023-01-27 | ||
| 672 | Funding/Financial Support | 2023-01-25 | ||
| 673 | Compliance Dimension | 2023-01-23 | ||
| 674 | Future Considerations and Conclusion | 2023-01-23 | ||
| 675 | HER2-NEGATIVE TARGETED THERAPIES | 2023-01-20 | ||
| 676 | Pros and Cons of PDT | 2023-01-18 | ||
| 677 | Purpose/Objectives of study | 2023-01-17 | ||
| 678 | Transfer of Basant to Industry | 2023-01-13 | ||
| 679 | Elimination of Human Papilloma Virus (HPV) | 2023-01-13 | ||
| 680 | Efficacy Against Hiv | 2023-01-13 | ||
| 681 | Sexual Tract Infections | 2023-01-13 | ||
| 682 | Immunotherapy | 2023-01-10 | ||
| 683 | Her2-Positive Targeted Teraphies | 2023-01-10 | ||
| 684 | The Integration Of Nanotechnology In Breast Cancer Treatment | 2023-01-10 | ||
| 685 | Different Treatments For Breast Cancer | 2023-01-10 | ||
| 686 | Types of breast cancer | 2023-01-10 | ||
| 687 | Interpretation | 2023-01-10 | ||
| 688 | Disclaimers | 2023-01-10 | ||
| 689 | Funding Acquisition | 2023-01-09 | ||
| 690 | Ethics Commmittee Approval | 2023-01-09 | ||
| 691 | Ethical Disclosure | 2023-01-07 | ||
| 692 | Contribution to authors | 2023-01-02 | ||
| 693 | Supplementary Information | 2023-01-02 | ||
| 694 | Psycho-Social Support | 2022-12-30 | ||
| 695 | Summary Statement | 2022-12-28 | ||
| 696 | REFERENCES | 2022-12-27 | ||
| 697 | Foot Notes | 2022-12-27 | ||
| 698 | A Possible Mechanism for Viral Infection Mediated MS Development | 2022-12-26 | ||
| 699 | Encephalitis, Encephalopathy and Acute Disseminated Encephalomyelitis (ADEM) In SARSCov-2 Infection | 2022-12-26 | ||
| 700 | The Cellular Interplay in Multiple Sclerosis | 2022-12-26 | ||
| 701 | Multiple Sclerosis and Coronavirus Infection | 2022-12-26 | ||
| 702 | Glial cells in the CNS | 2022-12-26 | ||
| 703 | Materials and Methdos | 2022-12-23 | ||
| 704 | Misconceptions | 2022-12-23 | ||
| 705 | Further Study | 2022-12-22 | ||
| 706 | CONFLICT OF INTERESTING | 2022-12-22 | ||
| 707 | Pharmacokinetic benefits from solid drug nanoparticles | 2022-12-21 | ||
| 708 | Nanomaterial Applications in Medicine | 2022-12-21 | ||
| 709 | Mechanisms of Nanotechnology in Medicine | 2022-12-21 | ||
| 710 | Cyber Security Techniques | 2022-12-21 | ||
| 711 | Benefits of Allicin in Cardiovascular Diseases | 2022-12-21 | ||
| 712 | Health benefits of Allicin Anticancer | 2022-12-21 | ||
| 713 | Pharmacology of Allicin | 2022-12-21 | ||
| 714 | Synthesis of Allicin | 2022-12-21 | ||
| 715 | Biosynthesis of Allicin | 2022-12-21 | ||
| 716 | Ethics Statement And Conflict Of Interest Disclosures | 2022-12-21 | ||
| 717 | Consequence of Menstrual and Wdp | 2022-12-21 | ||
| 718 | Waste Disposal Process (WDP) | 2022-12-21 | ||
| 719 | Edible coating | 2022-12-21 | ||
| 720 | Competing of Interest | 2022-12-21 | ||
| 721 | Statement of Declaration | 2022-12-21 | ||
| 722 | Results of the Study of Biopsies | 2022-12-20 | ||
| 723 | Method and Patients | 2022-12-20 | ||
| 724 | Authorship Declaration | 2022-12-19 | ||
| 725 | Institutional Review | 2022-12-19 | ||
| 726 | Statistical Processing of Research Results | 2022-12-19 | ||
| 727 | Results and statistical analysis | 2022-12-15 | ||
| 728 | Data Avalability | 2022-12-15 | ||
| 729 | Conclusions of The Study | 2022-12-15 | ||
| 730 | Discussions and Limitations | 2022-12-15 | ||
| 731 | Main Expressions of Test Anxiety | 2022-12-14 | ||
| 732 | Statements and Declarations | 2022-12-14 | ||
| 733 | Factors | 2022-12-14 | ||
| 734 | Urodynamic function | 2022-12-13 | ||
| 735 | Mood symptoms | 2022-12-13 | ||
| 736 | Sexual dysfunction | 2022-12-13 | ||
| 737 | Measurements and Evaluations | 2022-12-12 | ||
| 738 | Conflict Of Interest | 2022-12-08 | ||
| 739 | FUNDING SUPPORTING | 2022-12-08 | ||
| 740 | Authorâ??s Contribution | 2022-12-07 | ||
| 741 | Authorâ??s Contribution | 2022-12-07 | ||
| 742 | Effects of bioactive compounds obtained from Turmeric on various types of Cancers: | 2022-12-07 | ||
| 743 | Spices | 2022-12-07 | ||
| 744 | Punica Granatum | 2022-12-07 | ||
| 745 | Biomechanical View | 2022-12-07 | ||
| 746 | Green Tea | 2022-12-07 | ||
| 747 | Ocimum Sanctum | 2022-12-07 | ||
| 748 | Solanum lycopersicum | 2022-12-07 | ||
| 749 | Emblica officinalis | 2022-12-07 | ||
| 750 | Momordica charantia | 2022-12-07 | ||
| 751 | Moringa Oleifera | 2022-12-07 | ||
| 752 | Allium Genus | 2022-12-07 | ||
| 753 | Cosent for Publication | 2022-12-06 | ||
| 754 | RÉSUMÉ | 2022-12-06 | ||
| 755 | Criticisms and Concerns | 2022-12-05 | ||
| 756 | Benefits of Corporate Social Responsibility | 2022-12-05 | ||
| 757 | Co-Ordination between Primary and Secondary Care | 2022-12-05 | ||
| 758 | Secondary Care | 2022-12-05 | ||
| 759 | Definition of Primary Health Care (PHC) | 2022-12-05 | ||
| 760 | Health and Medical Administration in Today’s World | 2022-12-05 | ||
| 761 | Tasks and Responsibilities | 2022-12-05 | ||
| 762 | Discription | 2022-12-05 | ||
| 763 | Patient & Methods | 2022-12-03 | ||
| 764 | Sponsor | 2022-12-02 | ||
| 765 | Reducing the negative effects of chemotherapy | 2022-11-30 | ||
| 766 | Current cancer therapies | 2022-11-30 | ||
| 767 | Types of cancer treatments | 2022-11-30 | ||
| 768 | Statement on Ethics Approval | 2022-11-30 | ||
| 769 | Sleep disorders: what are they? | 2022-11-28 | ||
| 770 | Indications for mammoplasty augmentation | 2022-11-26 | ||
| 771 | Collaboration with Faculty | 2022-11-26 | ||
| 772 | Characteristics of Adult Learners | 2022-11-26 | ||
| 773 | Author's Contrbutions | 2022-11-24 | ||
| 774 | Ethical Standards Compliance | 2022-11-22 | ||
| 775 | Toxicity Studies | 2022-11-18 | ||
| 776 | Estimation of Glutamate Content | 2022-11-18 | ||
| 777 | Estimation of Superoxide Dismutase | 2022-11-18 | ||
| 778 | Estimation of Reduced Glutathione | 2022-11-18 | ||
| 779 | Estimation of Brain GABA Level after MBEE Treatment | 2022-11-18 | ||
| 780 | Locomotor Activity and Motor Toxicity Test | 2022-11-18 | ||
| 781 | Estimation of Glutamate | 2022-11-18 | ||
| 782 | Superoxide Radical Scavenging Assay (SOD) | 2022-11-18 | ||
| 783 | Reduced Glutathione Estimation | 2022-11-18 | ||
| 784 | Estimation of Gaba Levels in RAT Brain after MBEE Treatment | 2022-11-18 | ||
| 785 | Evaluation of Anticonvulsant Activity of Muehlenbeckia Platyclada Extract (MBEE) | 2022-11-18 | ||
| 786 | Thyroidectomy | 2022-11-17 | ||
| 787 | Symptomatic Management and Anticoagulation | 2022-11-17 | ||
| 788 | Subclinical Graves' Disease | 2022-11-17 | ||
| 789 | Common side effects | 2022-11-15 | ||
| 790 | Magnetic Resonance Imaging (MRI) | 2022-11-15 | ||
| 791 | Positron Emission Tomography (PET) scanning | 2022-11-15 | ||
| 792 | Ultrasonography | 2022-11-15 | ||
| 793 | Invasive lobular carcinoma | 2022-11-15 | ||
| 794 | Invasive ductal carcinoma | 2022-11-15 | ||
| 795 | Kinds of Breast Cancer | 2022-11-15 | ||
| 796 | Statement of Contribution | 2022-11-15 | ||
| 797 | Fund | 2022-11-15 | ||
| 798 | Conclusion and Findings | 2022-11-14 | ||
| 799 | Authorâ??s Contributions | 2022-11-14 | ||
| 800 | What Is New | 2022-11-14 | ||
| 801 | What Is Known | 2022-11-14 | ||
| 802 | Function and dysfunction | 2022-11-11 | ||
| 803 | Mental health | 2022-11-11 | ||
| 804 | Anti-platelet activity | 2022-11-11 | ||
| 805 | Antidepressant activity | 2022-11-11 | ||
| 806 | Anticancer activity | 2022-11-11 | ||
| 807 | Antifungal activity | 2022-11-11 | ||
| 808 | Antimicrobial activity | 2022-11-11 | ||
| 809 | Anti-inflammatory and analgesic activity | 2022-11-11 | ||
| 810 | Limitations and Directions for Future Researchers | 2022-11-11 | ||
| 811 | Advantages and Disadvantages of a Thermal Power Plant | 2022-11-10 | ||
| 812 | Fundamental Concepts | 2022-11-10 | ||
| 813 | Future implications | 2022-11-09 | ||
| 814 | Harvest Maturity | 2022-11-09 | ||
| 815 | Physiology of Fruit Ripening | 2022-11-09 | ||
| 816 | Experimental Materials | 2022-11-08 | ||
| 817 | RISK FACTORS FOR EXTRAVASATION | 2022-11-04 | ||
| 818 | Recommendations for future study | 2022-11-03 | ||
| 819 | PERFORMANCE ANALYSIS | 2022-11-01 | ||
| 820 | AFM Results | 2022-11-01 | ||
| 821 | Data Availabilbity Statement | 2022-11-01 | ||
| 822 | Recommendations aand Limitations | 2022-11-01 | ||
| 823 | PROPOSED WORK | 2022-11-01 | ||
| 824 | Empirical Analysis and Results | 2022-10-27 | ||
| 825 | Data Collection and Descriptive Analysis | 2022-10-27 | ||
| 826 | Methodological Framework | 2022-10-27 | ||
| 827 | Informed Consents | 2022-10-21 | ||
| 828 | Outlook | 2022-10-21 | ||
| 829 | Computational Analysis | 2022-10-21 | ||
| 830 | Research results | 2022-10-20 | ||
| 831 | POTENTIAL RISKS OF BIOTECHNOLOGY | 2022-10-20 | ||
| 832 | TASTE ENHANCEMENT BY BIOLOGICAL TECHNIQUES | 2022-10-20 | ||
| 833 | FOOD BIOTECHNOLY IN NUTRITION ENHANCEMENT | 2022-10-20 | ||
| 834 | BIOTECHNOLOGY USES IN YIELD IMPROVEMENT | 2022-10-20 | ||
| 835 | FOOD BIOTECHNOLOGY ROLE IN PROCESSING OF FOODS | 2022-10-20 | ||
| 836 | Addendum | 2022-10-20 | ||
| 837 | Preface | 2022-10-20 | ||
| 838 | Sources of Financial Support | 2022-10-20 | ||
| 839 | Problematic | 2022-10-19 | ||
| 840 | Epidemiology of Covid-19 | 2022-10-19 | ||
| 841 | Expected Outcomes/Results | 2022-10-18 | ||
| 842 | Work Plan and Budget | 2022-10-18 | ||
| 843 | Suggested Future Research | 2022-10-18 | ||
| 844 | Educational Recommendations | 2022-10-18 | ||
| 845 | The Summary of the Results | 2022-10-18 | ||
| 846 | Research Results and Discussion | 2022-10-18 | ||
| 847 | Public Health Impacts | 2022-10-18 | ||
| 848 | Methods, Results and Discussion | 2022-10-18 | ||
| 849 | Historical Review | 2022-10-18 | ||
| 850 | Material and Subjects | 2022-10-18 | ||
| 851 | Conclusion and Discussion | 2022-10-17 | ||
| 852 | Data Reading | 2022-10-14 | ||
| 853 | Parameters affecting ADCP setup | 2022-10-14 | ||
| 854 | Administrative Design | 2022-10-14 | ||
| 855 | Patients and Procedures | 2022-10-14 | ||
| 856 | Consent to Particpate/Informed Cosent | 2022-10-12 | ||
| 857 | On the Definitions of Sport | 2022-10-10 | ||
| 858 | Western blot | 2022-10-10 | ||
| 859 | Body Measurements Using Anthropometry | 2022-10-10 | ||
| 860 | Orcid Id | 2022-10-07 | ||
| 861 | Application of Machine Learning in Preventing HSPN | 2022-10-07 | ||
| 862 | Management Recommendations | 2022-10-07 | ||
| 863 | Diagnosis and Treatment | 2022-10-07 | ||
| 864 | Epidemiology and Pathology | 2022-10-07 | ||
| 865 | Designed Nurses | 2022-10-04 | ||
| 866 | Specialist Density | 2022-10-04 | ||
| 867 | Trained Physicians | 2022-10-04 | ||
| 868 | Training of Child Neurologists | 2022-10-04 | ||
| 869 | Organization of Child Neurological Services | 2022-10-04 | ||
| 870 | Prognosis for Schizophrenics | 2022-10-04 | ||
| 871 | Functional Deficits and Behavioural Symptoms | 2022-10-04 | ||
| 872 | Data Sharing-Statement | 2022-10-01 | ||
| 873 | Patient Cosent | 2022-10-01 | ||
| 874 | The history of the lithium discovery | 2022-09-30 | ||
| 875 | Objective and tasks | 2022-09-30 | ||
| 876 | No Conflict declaration | 2022-09-29 | ||
| 877 | Microbial Analysis | 2022-09-22 | ||
| 878 | Relief Measures Undertaken 2005 Flash Flood in Himachal Pradesh | 2022-09-21 | ||
| 879 | Relief Measures Initiated by the State Government Year 2000 | 2022-09-21 | ||
| 880 | Main Mitigation Stratagies (Flood) | 2022-09-21 | ||
| 881 | Flash Flood in Satluj During Rainy Season of the Year 2005 | 2022-09-21 | ||
| 882 | Fear of Flash Flood in Himachal Pradesh 2004 | 2022-09-21 | ||
| 883 | Indicator of Direct Action of a Magnetic Storm on the Transmission System | 2022-09-21 | ||
| 884 | A New Way of Protecting Transformer Windings | 2022-09-21 | ||
| 885 | Effect of Magnetic Storm on Unprotected Transmission System | 2022-09-21 | ||
| 886 | Geomagnetically Induced Currents (GIC) | 2022-09-21 | ||
| 887 | External Geomagnetic Field | 2022-09-21 | ||
| 888 | Internal Geomagnetic Field | 2022-09-21 | ||
| 889 | Geomagnetism and Geomagnetic Storms | 2022-09-21 | ||
| 890 | Next Steps and a Conclusion | 2022-09-15 | ||
| 891 | Case 2: Background | 2022-09-14 | ||
| 892 | Case 1: Background | 2022-09-14 | ||
| 893 | CASE 1 Tracking response to treatment | 2022-09-13 | ||
| 894 | Author information | 2022-09-12 | ||
| 895 | Implications of all the Available Evidence | 2022-09-12 | ||
| 896 | Added Value of this Study | 2022-09-12 | ||
| 897 | Evidence Before this Study | 2022-09-12 | ||
| 898 | Research Hypothesis | 2022-09-08 | ||
| 899 | Community Involvement Statement Not Applicable | 2022-09-07 | ||
| 900 | Nuclear Reaction Model Codes for Theoretical Study | 2022-09-06 | ||
| 901 | Other Disclosure | 2022-09-06 | ||
| 902 | Implication | 2022-09-05 | ||
| 903 | Outcome Mesures | 2022-09-05 | ||
| 904 | Expected Result | 2022-09-05 | ||
| 905 | Future Works | 2022-09-01 | ||
| 906 | Memantine for Neurodegenerative Disorders Including AD | 2022-08-31 | ||
| 907 | Memantine: Anti-Inflammatory Effect Mediated by Attenuation of Microglial Activation | 2022-08-31 | ||
| 908 | Memantine: Non-competitive NMDA Receptor Antagonist | 2022-08-31 | ||
| 909 | Diagnoses and symptoms | 2022-08-26 | ||
| 910 | Organ failure pathophysiology | 2022-08-26 | ||
| 911 | Urosepsis epidemiology and causes | 2022-08-26 | ||
| 912 | Conclusions and Prospects of Further Research | 2022-08-26 | ||
| 913 | Literature data analysis and problem statement | 2022-08-26 | ||
| 914 | Funding and Acknowledgement | 2022-08-25 | ||
| 915 | Methods for Antibody Purification | 2022-08-23 | ||
| 916 | Ethics Committee and Consent to Participate | 2022-08-23 | ||
| 917 | Highlights of Article | 2022-08-23 | ||
| 918 | Additional Information | 2022-08-23 | ||
| 919 | Study area and data analysis | 2022-08-23 | ||
| 920 | Results of the research | 2022-08-22 | ||
| 921 | Objectives and Research Methods | 2022-08-22 | ||
| 922 | sPEP-Optimized Proteogenomics unmasks sPEPS in the human fungal Cryptococcus Neoformans | 2022-08-22 | ||
| 923 | Ribosome profiling reveals sPEPS during Schizosaccharomyces Pombe Meiosis | 2022-08-22 | ||
| 924 | High-Throughput CRISPR/CAS9 to characterize sPEPS in S. Cerevisiae | 2022-08-22 | ||
| 925 | High-Throughput CRISPR/CAS9 to characterize sPEPS in S. Cerevisiae | 2022-08-22 | ||
| 926 | High-Throughput CRISPR/CAS9 to characterize sPEPS in S. Cerevisiae | 2022-08-22 | ||
| 927 | Safety and Efficacy of Spinal Anesthesia | 2022-08-19 | ||
| 928 | Spinal Anesthesia in Lumbar Surge | 2022-08-19 | ||
| 929 | IRB Approval Status | 2022-08-17 | ||
| 930 | Serum Electrolytes are normal | 2022-08-17 | ||
| 931 | Pharmacokinetic Properties of Myricetin | 2022-08-17 | ||
| 932 | Practical Applications | 2022-08-17 | ||
| 933 | Genetic and Biochemical Analysis | 2022-08-17 | ||
| 934 | Clinical And Mental Tests | 2022-08-17 | ||
| 935 | HIV-associated neurocognitive impairment: clinical studies on the effect of drug abuse | 2022-08-17 | ||
| 936 | HIV infection and substance abuse | 2022-08-17 | ||
| 937 | HIV and heroin | 2022-08-17 | ||
| 938 | HIV and marijuana | 2022-08-17 | ||
| 939 | HIV and psychedelics | 2022-08-17 | ||
| 940 | HIV and nicotine | 2022-08-17 | ||
| 941 | The Model Applied To The Women Diabetic Patients | 2022-08-17 | ||
| 942 | Multifactorial Description of Data | 2022-08-17 | ||
| 943 | Abbreviation | 2022-08-10 | ||
| 944 | Corresponding Author | 2022-08-10 | ||
| 945 | Affiliations | 2022-08-10 | ||
| 946 | Author Notes | 2022-08-10 | ||
| 947 | The Abstractness of Chemical Thermodynamics | 2022-08-10 | ||
| 948 | Chemistry as a Difficult Subject | 2022-08-10 | ||
| 949 | Budget, Fund or Grant | 2022-08-09 | ||
| 950 | Implications for future research and direction | 2022-08-09 | ||
| 951 | Non-communicable diseases and implementation of telemedicine | 2022-08-09 | ||
| 952 | Execution of brain measures | 2022-08-06 | ||
| 953 | Directing ecological neuroscience | 2022-08-06 | ||
| 954 | Interoceptive precision | 2022-08-06 | ||
| 955 | Interoceptive self-report | 2022-08-06 | ||
| 956 | Interoceptive knowledge | 2022-08-06 | ||
| 957 | Interoceptive attribution | 2022-08-06 | ||
| 958 | Interoceptive consideration | 2022-08-06 | ||
| 959 | Interoceptive aspects as arbiters of profound experience | 2022-08-06 | ||
| 960 | How the body shapes feeling | 2022-08-06 | ||
| 961 | Pandemic stressors | 2022-08-06 | ||
| 962 | Clinical weaknesses | 2022-08-06 | ||
| 963 | Anticipation targets | 2022-08-06 | ||
| 964 | Anticipation for customized treatment | 2022-08-04 | ||
| 965 | Anticipation and early finding of MS | 2022-08-04 | ||
| 966 | Communicable diseases and implementation of telemedicine | 2022-08-01 | ||
| 967 | Model-II | 2022-08-01 | ||
| 968 | Stability Analysis | 2022-08-01 | ||
| 969 | Equilibrium Analysis | 2022-08-01 | ||
| 970 | Model-I | 2022-08-01 | ||
| 971 | Distribution method insights | 2022-07-29 | ||
| 972 | Intervention insights | 2022-07-29 | ||
| 973 | Complementary and alternative medicine market, by intervention, 2013-2025 (USD billion) | 2022-07-29 | ||
| 974 | Industry insights | 2022-07-29 | ||
| 975 | Importance of Public Health Dentistry | 2022-07-29 | ||
| 976 | Aim of dental health | 2022-07-29 | ||
| 977 | Study goals and objective | 2022-07-29 | ||
| 978 | Myopathy | 2022-07-29 | ||
| 979 | Facet arthropathy | 2022-07-29 | ||
| 980 | Declaration of Patients Consent | 2022-07-29 | ||
| 981 | Animal Welfare Statement | 2022-07-27 | ||
| 982 | Research in the Future | 2022-07-27 | ||
| 983 | Category Criteria | 2022-07-27 | ||
| 984 | Related literature | 2022-07-27 | ||
| 985 | Trail Status | 2022-07-27 | ||
| 986 | Full Protocol | 2022-07-27 | ||
| 987 | Author Collaboration | 2022-07-23 | ||
| 988 | About the License © | 2022-07-21 | ||
| 989 | About The License© | 2022-07-21 | ||
| 990 | Similarity Check | 2022-07-21 | ||
| 991 | Acknowledgment and Funding | 2022-07-21 | ||
| 992 | Patients | 2022-07-20 | ||
| 993 | The Implication For Future Re-Search | 2022-07-20 | ||
| 994 | The Implication for Practice | 2022-07-20 | ||
| 995 | Recommendations for Future Research | 2022-07-18 | ||
| 996 | Recommendations for Practice | 2022-07-18 | ||
| 997 | Ethics and Consent | 2022-07-13 | ||
| 998 | Authorship Contribution Statement | 2022-07-12 | ||
| 999 | Acknowledgement of Funding | 2022-07-08 | ||
| 1000 | Author Consent | 2022-07-07 | ||
| 1001 | Statistical Calculation | 2022-07-07 | ||
| 1002 | In Vitro Culture Studies | 2022-07-07 | ||
| 1003 | Docking | 2022-07-07 | ||
| 1004 | Methodology Proposed | 2022-07-05 | ||
| 1005 | Nomenclature | 2022-07-02 | ||
| 1006 | Materials and Methods | 2022-07-01 | ||
| 1007 | Perceptions of Financial Situation | 2022-07-01 | ||
| 1008 | Future Perspective of Vesicles in Malaria Vaccine Development | 2022-07-01 | ||
| 1009 | Vesicles from Plasmodium Infected Red Blood Cells in the Pathogenesis of Malaria | 2022-07-01 | ||
| 1010 | Vesicles from Plasmodium Infected Red Blood Cells in the Pathogenesis of Malaria | 2022-07-01 | ||
| 1011 | General Overview of Biogenesis and Function of Extracellular Vesicle | 2022-07-01 | ||
| 1012 | Clinical practice and health-related quality of life | 2022-06-29 | ||
| 1013 | Quality of life measures related to health | 2022-06-29 | ||
| 1014 | Suggested Framework | 2022-06-29 | ||
| 1015 | Previous Works | 2022-06-29 | ||
| 1016 | Future Scope of the Study | 2022-06-29 | ||
| 1017 | Ethical Standards and Patient’s Rights | 2022-06-27 | ||
| 1018 | Ethical Standards and Patientâ??s Rights | 2022-06-27 | ||
| 1019 | Lemborexant | 2022-06-27 | ||
| 1020 | Suvorexant | 2022-06-27 | ||
| 1021 | Orexin Receptor Antagonists | 2022-06-27 | ||
| 1022 | Pharmacological Treatment of Insomnia | 2022-06-27 | ||
| 1023 | Non-Pharmacological Treatment of Insomnia | 2022-06-27 | ||
| 1024 | Postponed arrangement of adequate care (Phase 3) | 2022-06-24 | ||
| 1025 | Postponed arrival in wellbeing office (Phase 2) | 2022-06-24 | ||
| 1026 | Deferred choice to look for care (Phase 1) | 2022-06-24 | ||
| 1027 | 3. YONTEM | 2022-06-22 | ||
| 1028 | 5. SONUC | 2022-06-22 | ||
| 1029 | 2. KULTUREM KAVRAMI VE ETIMOLOJISI | 2022-06-22 | ||
| 1030 | Conclusion | 2022-06-22 | ||
| 1031 | 2. LITERARY ANALYSIS | 2022-06-22 | ||
| 1032 | Different Types of Leukemia | 2022-06-21 | ||
| 1033 | How does Leukemia Develop? How does Leukemia affect the Body? | 2022-06-21 | ||
| 1034 | Health-Related Quality | 2022-06-20 | ||
| 1035 | The role of antioxidants in neurodegenerative diseases | 2022-06-20 | ||
| 1036 | Authors' Information (Optional) | 2022-06-20 | ||
| 1037 | MATERIAL AND INTERVENTIONS | 2022-06-20 | ||
| 1038 | GOAL OF THE STUDY | 2022-06-20 | ||
| 1039 | Biographies | 2022-06-20 | ||
| 1040 | Future Scopes | 2022-06-20 | ||
| 1041 | Finite element application | 2022-06-20 | ||
| 1042 | Applications of Centrifugation | 2022-06-20 | ||
| 1043 | Principle of Centrifugation | 2022-06-20 | ||
| 1044 | Models of Mass Analyzer | 2022-06-20 | ||
| 1045 | Oxidative Damage | 2022-06-15 | ||
| 1046 | Parkinson's Disease Addictive Syndromes | 2022-06-15 | ||
| 1047 | Parkinsonian Personality Before Parkinson's Disease | 2022-06-15 | ||
| 1048 | 5. SONUC VE ONERILER | 2022-06-13 | ||
| 1049 | 4. TARTISMA | 2022-06-13 | ||
| 1050 | 2. YONTEM | 2022-06-13 | ||
| 1051 | Need of Coating | 2022-06-13 | ||
| 1052 | 4. TARTISMA VE SONUC | 2022-06-10 | ||
| 1053 | 3. Bulgular | 2022-06-10 | ||
| 1054 | 2. Materyal ve Yontem | 2022-06-10 | ||
| 1055 | 2. Materyal ve Yöntem | 2022-06-10 | ||
| 1056 | Conclusion | 2022-06-10 | ||
| 1057 | 5. THE CHALLENGES OF PET PRACTICES: THE PRODUCTION OF RELIGIOUS SPACE | 2022-06-10 | ||
| 1058 | 4. DISCUSSIONS ON THE PLACE OF DOGS IN ISLAM | 2022-06-10 | ||
| 1059 | 3. METHODOLOGY | 2022-06-10 | ||
| 1060 | 2. THEORETICAL FRAMEWORK | 2022-06-10 | ||
| 1061 | Introduction | 2022-06-10 | ||
| 1062 | 4. SONUC VE ONERI | 2022-06-10 | ||
| 1063 | OZET | 2022-06-10 | ||
| 1064 | 2. FUTBOL, SOSYOLOJIK BIR YAKLASIM | 2022-06-10 | ||
| 1065 | 2. FUTBOL, SOSYOLOJIK BIR YAKLAÅ?IM | 2022-06-10 | ||
| 1066 | Oz | 2022-06-10 | ||
| 1067 | Ã?z | 2022-06-10 | ||
| 1068 | Interpretation and Conclusion | 2022-06-09 | ||
| 1069 | One of Limitation in this Study | 2022-06-07 | ||
| 1070 | Ethical Approval Statement | 2022-06-07 | ||
| 1071 | Conclusion and Future Perspective | 2022-06-07 | ||
| 1072 | Review of the Paper | 2022-06-07 | ||
| 1073 | Molecular Docking | 2022-06-07 | ||
| 1074 | Disclosure of Funding | 2022-06-06 | ||
| 1075 | Tree for Solving Global Problems | 2022-06-06 | ||
| 1076 | Author's Statement | 2022-06-03 | ||
| 1077 | Disclaimer and Disclosure | 2022-06-03 | ||
| 1078 | Methodologies | 2022-06-02 | ||
| 1079 | Available Softwares For Docking | 2022-06-02 | ||
| 1080 | Molecular docking approaches | 2022-06-02 | ||
| 1081 | Flexible Docking | 2022-06-02 | ||
| 1082 | Rigid Docking | 2022-06-02 | ||
| 1083 | Sources of Grant | 2022-05-31 | ||
| 1084 | Availability of Data and Material Statement | 2022-05-30 | ||
| 1085 | Secondary Headache | 2022-05-28 | ||
| 1086 | TTH | 2022-05-28 | ||
| 1087 | Migraine | 2022-05-28 | ||
| 1088 | Classification of Headache | 2022-05-28 | ||
| 1089 | Cardiovascular Manifestation | 2022-05-25 | ||
| 1090 | Reporting Checklist | 2022-05-25 | ||
| 1091 | Final Study Classification | 2022-05-25 | ||
| 1092 | Data Collection Procedures | 2022-05-25 | ||
| 1093 | Data Collection Procedures | 2022-05-25 | ||
| 1094 | Data Collection Procedures | 2022-05-25 | ||
| 1095 | Data Collection Procedures | 2022-05-25 | ||
| 1096 | Data Collection Procedures | 2022-05-25 | ||
| 1097 | Data Collection Procedures | 2022-05-25 | ||
| 1098 | UiPath | 2022-05-25 | ||
| 1099 | Best RPA implements list | 2022-05-25 | ||
| 1100 | Best RPA implements list: | 2022-05-25 | ||
| 1101 | Self-learning RPA solutions | 2022-05-25 | ||
| 1102 | Availabilty of Data and Materials | 2022-05-24 | ||
| 1103 | Definitions[8] | 2022-05-24 | ||
| 1104 | Definitions[8] | 2022-05-24 | ||
| 1105 | Annexure 1 | 2022-05-23 | ||
| 1106 | Appendix | 2022-05-21 | ||
| 1107 | Ethics Declaration | 2022-05-20 | ||
| 1108 | Cancer and Covid-19 | 2022-05-19 | ||
| 1109 | Cowpea | 2022-05-18 | ||
| 1110 | Peanut | 2022-05-18 | ||
| 1111 | Pigeon Pea | 2022-05-18 | ||
| 1112 | Teff | 2022-05-18 | ||
| 1113 | Finger Millet | 2022-05-18 | ||
| 1114 | Cassava | 2022-05-18 | ||
| 1115 | Major Orphan Crops | 2022-05-18 | ||
| 1116 | Advancement in Plant Breeding | 2022-05-18 | ||
| 1117 | Employment Generation | 2022-05-18 | ||
| 1118 | Impact of Natural Disasters | 2022-05-18 | ||
| 1119 | Poverty Line | 2022-05-18 | ||
| 1120 | Major Growing Crops | 2022-05-18 | ||
| 1121 | Overgrowing Population | 2022-05-18 | ||
| 1122 | Injection strategies | 2022-05-17 | ||
| 1123 | Patient's sickness experience | 2022-05-17 | ||
| 1124 | Policy and regulatory responses | 2022-05-17 | ||
| 1125 | Economic evaluation | 2022-05-17 | ||
| 1126 | Radiogenomic | 2022-05-17 | ||
| 1127 | Genomics | 2022-05-17 | ||
| 1128 | Radiomics | 2022-05-17 | ||
| 1129 | Metabolomic | 2022-05-17 | ||
| 1130 | Health Technology Assessment | 2022-05-17 | ||
| 1131 | Management of Medical Emergencies in Diabetics | 2022-05-17 | ||
| 1132 | Key Considerations Related to Dental Treatment of the Diabetic Patient Include | 2022-05-17 | ||
| 1133 | Periodontal Considerations | 2022-05-17 | ||
| 1134 | Periodontal Management of Patients with Diabetes | 2022-05-17 | ||
| 1135 | Dental Implant Considerations in the Diabetic Patients | 2022-05-17 | ||
| 1136 | The Rationale for Improved Glycemic Control after Periodontal Therapy | 2022-05-17 | ||
| 1137 | Two Way Inter-Relationship Between Diabetes Mellitus and Periodontal Disease | 2022-05-17 | ||
| 1138 | Infections in Patients with Diabetes | 2022-05-17 | ||
| 1139 | Influence of Diabetes on Oral Health | 2022-05-17 | ||
| 1140 | Morphology of RE | 2022-05-17 | ||
| 1141 | Prevalence of RE | 2022-05-17 | ||
| 1142 | Types and Pathogenicity of Psoriasis | 2022-05-13 | ||
| 1143 | Role of Natural Killer (NK) Cells in Psoriasis | 2022-05-13 | ||
| 1144 | Final Comments | 2022-05-13 | ||
| 1145 | Clinical Cases | 2022-05-12 | ||
| 1146 | Interactions of elements of integrated control measures | 2022-05-12 | ||
| 1147 | Reclamation | 2022-05-12 | ||
| 1148 | Phyto-Reclamation Measures Involving Hydraulic Devices | 2022-05-12 | ||
| 1149 | Organization of the Territory as an Important Part of Erosion Control | 2022-05-12 | ||
| 1150 | Integrated Erosion Control Measures on the Slopes | 2022-05-12 | ||
| 1151 | The Scientific Basis for the Protection of Soils from Water Erosion | 2022-05-11 | ||
| 1152 | Objects and Methods | 2022-05-10 | ||
| 1153 | YARARLANILAN KAYNAKLAR | 2022-05-10 | ||
| 1154 | Ethical Permissions | 2022-05-09 | ||
| 1155 | Methods and Measurement | 2022-05-09 | ||
| 1156 | Thermodynamics is Classified into Four Categories | 2022-05-07 | ||
| 1157 | Thermodynamic Anomalies of Liquid Water | 2022-05-07 | ||
| 1158 | Funding Support and Author Disclosures | 2022-05-07 | ||
| 1159 | Most Common Complications | 2022-05-07 | ||
| 1160 | Most Common Methods | 2022-05-07 | ||
| 1161 | Types of Mass Spectrometer | 2022-05-06 | ||
| 1162 | Principle of Mass Spectrometer | 2022-05-06 | ||
| 1163 | Components of Two-Component Phosphorelay System | 2022-05-06 | ||
| 1164 | Limitation of Our Study | 2022-05-04 | ||
| 1165 | Author Discloures | 2022-05-03 | ||
| 1166 | Study Subjects and Methods | 2022-05-03 | ||
| 1167 | Medicinal uses | 2022-05-03 | ||
| 1168 | Competiting Interests | 2022-05-03 | ||
| 1169 | Benefits of Honey Bee | 2022-05-02 | ||
| 1170 | Corrosion in Dental Implants | 2022-05-02 | ||
| 1171 | Dental and Orofacial Allergic Reactions | 2022-05-02 | ||
| 1172 | Liquid Chromatography-Tandem Mass Spectroscopy (LC-MS-MS) | 2022-05-02 | ||
| 1173 | Liquid Chromatography-Electron Spray Ionization-Mass Spectrometry (LC-ESI-MS) | 2022-05-02 | ||
| 1174 | Liquid Chromatography-Diode Array Detector (HPLC-DAD) | 2022-05-02 | ||
| 1175 | Liquid Chromatography-Nuclear Magnetic Resonance (LC-NMR) | 2022-05-02 | ||
| 1176 | Liquid Chromatography-Mass Spectroscopy (LC-MS) | 2022-05-02 | ||
| 1177 | Liquid Chromatography-Infrared Spectroscopy (LC-IR) | 2022-05-02 | ||
| 1178 | Consent to Participate and Publish | 2022-04-29 | ||
| 1179 | Advanced Techniques of Proteomics | 2022-04-29 | ||
| 1180 | Diagnosis of Neonatal Lupus | 2022-04-28 | ||
| 1181 | Symptoms of Neonatal Lupus | 2022-04-28 | ||
| 1182 | A Case Report | 2022-04-28 | ||
| 1183 | Background Study | 2022-04-27 | ||
| 1184 | Final Diagnosis | 2022-04-27 | ||
| 1185 | QUALITY OF LIFE ASSESSMENT | 2022-04-26 | ||
| 1186 | TOXICITIES AT 1 MONTH POST TREATMENT | 2022-04-26 | ||
| 1187 | Shift Work and Interventions | 2022-04-26 | ||
| 1188 | Shift Work and Performance | 2022-04-26 | ||
| 1189 | Shift Work and Injuries | 2022-04-26 | ||
| 1190 | Shift Work and Health | 2022-04-26 | ||
| 1191 | Neurobiological Aspects | 2022-04-26 | ||
| 1192 | ACUTE TOXICITY ASSESSMENT DURING TREATMENT | 2022-04-26 | ||
| 1193 | Time to surgery | 2022-04-26 | ||
| 1194 | TREATMENT DELAY | 2022-04-26 | ||
| 1195 | OVERALL DURATION OF NACT | 2022-04-26 | ||
| 1196 | RESPONSE ASSESSMENT | 2022-04-26 | ||
| 1197 | TUMOR CHARACTERISTICS | 2022-04-26 | ||
| 1198 | PATIENT CHARACTERISTICS | 2022-04-26 | ||
| 1199 | TREATMENT PROTOCOL | 2022-04-26 | ||
| 1200 | CO2 Levels in Cell Culture | 2022-04-26 | ||
| 1201 | Importance of CO2 in Cell Culture | 2022-04-26 | ||
| 1202 | The Eventual Fate of Perioperative Consideration | 2022-04-26 | ||
| 1203 | The Perioperative Consideration Approach | 2022-04-26 | ||
| 1204 | LF | 2022-04-26 | ||
| 1205 | AMF | 2022-04-26 | ||
| 1206 | Influence of Vermicompost on Insect Pests and Diseases | 2022-04-25 | ||
| 1207 | Influence of Vermicompost on Physiological Growth | 2022-04-25 | ||
| 1208 | Influence of Vermicompost on Plant Emergent | 2022-04-25 | ||
| 1209 | Vermicompost a Control for Invasive Plants | 2022-04-25 | ||
| 1210 | Influence of Vermicompost on the Mineral Constituent of the Soil | 2022-04-25 | ||
| 1211 | Influence of Vermicompost on Soil Properties | 2022-04-25 | ||
| 1212 | Significant of Earthworm in Mineralization of Waste | 2022-04-25 | ||
| 1213 | The Photon Decoupling Era Definition and Explanations | 2022-04-25 | ||
| 1214 | Factors That Determine Successful Production Of Vermicompost | 2022-04-25 | ||
| 1215 | Characteristics of Vermicompost as a Non-Volatile Gas | 2022-04-25 | ||
| 1216 | Earthworm Type and Characteristics | 2022-04-25 | ||
| 1217 | Vermicompost a Better Intervention for Conventional Farming | 2022-04-25 | ||
| 1218 | Earthworms and Vermicompost Development | 2022-04-25 | ||
| 1219 | Influence of Ecological Zoningon Agricultural Practice | 2022-04-25 | ||
| 1220 | Agricultural Productivity and Climatic Influence | 2022-04-25 | ||
| 1221 | Introduction and Problem Statement | 2022-04-25 | ||
| 1222 | Prevention and Treatment Prospects of Natural Phyto Bioactive Compounds | 2022-04-22 | ||
| 1223 | Prevention and Treatment Prospects of NatÂural Phyto Bioactive Compounds | 2022-04-22 | ||
| 1224 | Mechanisms of Mtx-Induced Hepatotoxicity | 2022-04-22 | ||
| 1225 | Consent to Publications | 2022-04-22 | ||
| 1226 | Protocol | 2022-04-22 | ||
| 1227 | In Sports | 2022-04-22 | ||
| 1228 | In Medicine | 2022-04-22 | ||
| 1229 | Normative Data | 2022-04-22 | ||
| 1230 | Types of Grip | 2022-04-22 | ||
| 1231 | Competing Interests Disclaimer | 2022-04-22 | ||
| 1232 | Permission | 2022-04-21 | ||
| 1233 | The following are the approved anti-SARS-CoV-2 mAb products, listed sequentially: | 2022-04-21 | ||
| 1234 | Molecular application and antibiotic resistance | 2022-04-21 | ||
| 1235 | Future Perspective on Clinical Application | 2022-04-21 | ||
| 1236 | Abbreviations/acronyms | 2022-04-20 | ||
| 1237 | PMDD DIAGNOSIS | 2022-04-20 | ||
| 1238 | CAUSES AND RISK FACTORS FOR PMDD | 2022-04-20 | ||
| 1239 | PMDD SYMPTOMS | 2022-04-20 | ||
| 1240 | WHAT IS PMDD AND HOW DOES IT AFFECT YOU? | 2022-04-20 | ||
| 1241 | Scientific Sessions | 2022-04-20 | ||
| 1242 | General Commentaries | 2022-04-20 | ||
| 1243 | Limitations and scope | 2022-04-19 | ||
| 1244 | Prospects | 2022-04-19 | ||
| 1245 | Other organo-halogenated micro-pollutants | 2022-04-19 | ||
| 1246 | Disinfection by-products | 2022-04-19 | ||
| 1247 | Pesticides | 2022-04-19 | ||
| 1248 | Pharmaceuticals | 2022-04-19 | ||
| 1249 | The Presence of Organo-halogenated Micro-pollutants in DWTPs | 2022-04-19 | ||
| 1250 | Microcentrifuges | 2022-04-19 | ||
| 1251 | Result and Discussions | 2022-04-19 | ||
| 1252 | Problem Formulation | 2022-04-19 | ||
| 1253 | Future Research Areas | 2022-04-19 | ||
| 1254 | Surgery and Radiation | 2022-04-19 | ||
| 1255 | Treatment and Medication | 2022-04-19 | ||
| 1256 | Diagnostic Studies | 2022-04-19 | ||
| 1257 | Genetic Engineering: Scopes and Limitations in Agriculture | 2022-04-19 | ||
| 1258 | Treatment of superficial vein thrombosis | 2022-04-19 | ||
| 1259 | Factors that increase the risk of a thromboembolic event | 2022-04-19 | ||
| 1260 | Venous thromboembolic recurrence | 2022-04-19 | ||
| 1261 | Superficial vein thrombosis of the lower limbs occurrence | 2022-04-19 | ||
| 1262 | Commentory | 2022-04-19 | ||
| 1263 | Overview of UCDs | 2022-04-19 | ||
| 1264 | Current Developments (New Culture Systems) | 2022-04-18 | ||
| 1265 | Factors Affecting in vitro Growth | 2022-04-18 | ||
| 1266 | Micropropagation | 2022-04-18 | ||
| 1267 | Effect of Processing on the Anti-Nutritional Content of Lupine | 2022-04-16 | ||
| 1268 | Anti-Nutritional Content of Bitter and Sweet Lupine | 2022-04-16 | ||
| 1269 | Nutritional Composition of Lupine and Common Usage of Lupine in Ethiopia | 2022-04-16 | ||
| 1270 | Production and Utilization of Lupine | 2022-04-16 | ||
| 1271 | Public Health and Food Security | 2022-04-16 | ||
| 1272 | Reccomendations | 2022-04-15 | ||
| 1273 | Types of Popular Mobile Operating System | 2022-04-15 | ||
| 1274 | OS's Functions | 2022-04-15 | ||
| 1275 | Geological Setting and Petrographic Analysis | 2022-04-14 | ||
| 1276 | Double Ballon Enteroscopy | 2022-04-14 | ||
| 1277 | Small Bowel Tumors Diagnosis | 2022-04-14 | ||
| 1278 | Space Time Distortion | 2022-04-14 | ||
| 1279 | Extraction method | 2022-04-13 | ||
| 1280 | The Link Between Nuclear Fusion and the Temperature of the Earth | 2022-04-13 | ||
| 1281 | The Relationship Between Nuclear Fusion and Plate Motion | 2022-04-13 | ||
| 1282 | Analyze Whether Nuclear Fusion Occurs in the Earth From the Perspective of Quantum Tunneling | 2022-04-13 | ||
| 1283 | Falsification of the Proposition of Three Sources of Geothermal Energy | 2022-04-13 | ||
| 1284 | Conflict-of-Interest Statement | 2022-04-13 | ||
| 1285 | Bibliography | 2022-04-12 | ||
| 1286 | Hypokalaemia | 2022-04-07 | ||
| 1287 | Hyperkalaemia | 2022-04-07 | ||
| 1288 | Potassium in Fish Physiology and its Homeostatis | 2022-04-07 | ||
| 1289 | Disclosure and Conflict of Interests Estatement | 2022-04-06 | ||
| 1290 | Chromatin Structures Beyond Tads and Chromatin Loops in CTCF and Cohesion Depleted Cells | 2022-04-06 | ||
| 1291 | Transcription Associated Fine-Scale Chromatin Structures | 2022-04-06 | ||
| 1292 | Conflict of Interest Statement | 2022-04-06 | ||
| 1293 | Equipment and Method | 2022-04-05 | ||
| 1294 | Characterization of Snedds | 2022-04-05 | ||
| 1295 | Categorization of Snedds | 2022-04-05 | ||
| 1296 | Techniques Used for Solidification of Snedds | 2022-04-05 | ||
| 1297 | Categorization of Sedds | 2022-04-05 | ||
| 1298 | Mechanism of Formation of Snedds | 2022-04-05 | ||
| 1299 | Composition of Snedds | 2022-04-05 | ||
| 1300 | Pharmacological and Medicinal Uses of Mistletoes | 2022-04-05 | ||
| 1301 | Constituents Found In Mistletoes | 2022-04-05 | ||
| 1302 | Biology | 2022-04-05 | ||
| 1303 | Introduction | 2022-04-04 | ||
| 1304 | Nonmotor Manifestations | 2022-04-01 | ||
| 1305 | Conclusion of Parkinson's Infection | 2022-04-01 | ||
| 1306 | Extrapyramidal Framework Brokenness | 2022-04-01 | ||
| 1307 | Recent Publications | 2022-04-01 | ||
| 1308 | Bile Acids in Hbv-Related Liver Disease | 2022-03-31 | ||
| 1309 | Bile Acids in Cholestatic Liver Disease | 2022-03-31 | ||
| 1310 | Bile Acids in Non-Alcoholic Fatty Liver Disease | 2022-03-31 | ||
| 1311 | Diagnosis of Subacute Cutaneous Lupus Erythematosus | 2022-03-30 | ||
| 1312 | Clinical Features of Subacute Cutaneous Lupus Erythematosus | 2022-03-30 | ||
| 1313 | Treatment for Lupus Anticoagulant | 2022-03-30 | ||
| 1314 | Testing for Lupus Anticoagulant | 2022-03-30 | ||
| 1315 | Symptoms of Lupus Snticoagulants | 2022-03-30 | ||
| 1316 | Ethics Statement | 2022-03-30 | ||
| 1317 | Ethics Statement | 2022-03-30 | ||
| 1318 | Ethics Statement | 2022-03-30 | ||
| 1319 | Consent to Publication Statement | 2022-03-30 | ||
| 1320 | Ethical Expertise | 2022-03-30 | ||
| 1321 | Therapeutic Application of Implantable Drug Delivery System | 2022-03-30 | ||
| 1322 | Magnetic Tweezers | 2022-03-29 | ||
| 1323 | Imaging Applications | 2022-03-29 | ||
| 1324 | Dsc | 2022-03-26 | ||
| 1325 | Xrd (2θ Values) | 2022-03-26 | ||
| 1326 | Abemaciclib (Bemaciclib, Ly2835219) | 2022-03-26 | ||
| 1327 | Ribociclib (Lee 011) | 2022-03-26 | ||
| 1328 | Palbociclib (Pd-0332991) | 2022-03-26 | ||
| 1329 | Modulation of the Gut Microbiome | 2022-03-25 | ||
| 1330 | The Aberrations of Microbiota and Dysbiosis | 2022-03-25 | ||
| 1331 | Altered Host-Microbiota Symbiotic Co-Existence | 2022-03-25 | ||
| 1332 | Gut Microbiota Modulation During Childhood | 2022-03-25 | ||
| 1333 | The Expansion of Gut Microbiome | 2022-03-25 | ||
| 1334 | Recommended Solution | 2022-03-25 | ||
| 1335 | Research Objectives | 2022-03-25 | ||
| 1336 | Infection-Associated Urticaria | 2022-03-25 | ||
| 1337 | Consent to participate and publication | 2022-03-25 | ||
| 1338 | Consent Form | 2022-03-25 | ||
| 1339 | Oils | 2022-03-25 | ||
| 1340 | Fats | 2022-03-25 | ||
| 1341 | Functional Properties | 2022-03-25 | ||
| 1342 | Author Statement | 2022-03-25 | ||
| 1343 | Sustainable Methods of Maternal Mortality Rate | 2022-03-25 | ||
| 1344 | Conclusion and Perspectives | 2022-03-25 | ||
| 1345 | PROPOSED THERAPIES FOR THE TREATMENT OF ALS | 2022-03-25 | ||
| 1346 | THE IMMUNE ACTIVATION SPREADS LIKE PRIONS THROUGHOUT ALL THE NEUROMOTOR SYSTEM | 2022-03-25 | ||
| 1347 | THE CHAPERONE SIGMA1R IS A KEY REGULATOR IN TDP43 PROTEINOPATHY | 2022-03-25 | ||
| 1348 | THE SUBCELLULAR COMMUNICATION BETWEEN ORGANELLES, ESPECIALLY MITOCHONDRIAL-ASSOCIATED-MEMBRANE (MAMS), MODULATES ION CURRENTS AND THRESHOLDS OF MOTONEURONAL ACTION POTENTIALS | 2022-03-25 | ||
| 1349 | THE SUBCELLULAR COMMUNICATION BETWEEN ORGANELLES, ESPECIALLY MITOCHONDRIAL-ASSOCIATED-MEMBRANE (MAMS), MODULATES ION CURRENTS AND THRESHOLDS OF MOTONEURONAL ACTION POTENTIALS | 2022-03-25 | ||
| 1350 | THERE ARE MANY CAUSES OF ENERGY FAILURE IN ALS | 2022-03-25 | ||
| 1351 | ALS IS AN IMMUNOMETABOLIC DISEASE THAT COMMENCES WITH P53-MODULATED SKELETAL MUSCLE ENERGY IMPAIRMENT | 2022-03-25 | ||
| 1352 | Advantages and Types of Exercises During Pregnancy | 2022-03-25 | ||
| 1353 | WHEN TO SEE A DOCTOR | 2022-03-25 | ||
| 1354 | What is already known about nutrition and surgery? | 2022-03-23 | ||
| 1355 | Contributorship Statement | 2022-03-23 | ||
| 1356 | Trial Registration | 2022-03-23 | ||
| 1357 | 1. Giris | 2022-03-22 | ||
| 1358 | Giris | 2022-03-22 | ||
| 1359 | Method and Methodology | 2022-03-22 | ||
| 1360 | RAAS Perturbations | 2022-03-18 | ||
| 1361 | Altered Myocardial Coagulation | 2022-03-18 | ||
| 1362 | A pro-inflammatory myocardial Background | 2022-03-18 | ||
| 1363 | KAYNAKÇA | 2022-03-16 | ||
| 1364 | Elisa | 2022-03-16 | ||
| 1365 | Radiological Examination | 2022-03-16 | ||
| 1366 | Resources | 2022-03-16 | ||
| 1367 | Infrastructure | 2022-03-16 | ||
| 1368 | Consent to Participate and Ethics Approval | 2022-03-15 | ||
| 1369 | Contributions of The Authors | 2022-03-15 | ||
| 1370 | Participant recruitment and participation | 2022-03-15 | ||
| 1371 | Clinical trial protocol | 2022-03-15 | ||
| 1372 | Clinical trials | 2022-03-15 | ||
| 1373 | Clinical research | 2022-03-15 | ||
| 1374 | Block-Chain and Its Features | 2022-03-15 | ||
| 1375 | JEL code | 2022-03-15 | ||
| 1376 | ACE Gene PCR Amplification | 2022-03-15 | ||
| 1377 | Understanding Molecular Mechanisms of HPV Carcinogenesis | 2022-03-15 | ||
| 1378 | Bradford Hill Criteria of Causation | 2022-03-15 | ||
| 1379 | Affirmation Confirming The Character of HPV | 2022-03-15 | ||
| 1380 | Detection Method | 2022-03-15 | ||
| 1381 | HPV Head and Neck Cancer (HPV-HNC)-A Different Entity | 2022-03-15 | ||
| 1382 | Consideration About Oral and Oropharyngeal Topography | 2022-03-15 | ||
| 1383 | HPV-Induced Carcinogenesis | 2022-03-15 | ||
| 1384 | Structure of HPV | 2022-03-15 | ||
| 1385 | Prevalence of HPV in OSCC | 2022-03-15 | ||
| 1386 | Medicinal Bee Venom | 2022-03-15 | ||
| 1387 | Apitherapy in Health Field | 2022-03-15 | ||
| 1388 | History of Bee Therapy | 2022-03-15 | ||
| 1389 | Bees | 2022-03-15 | ||
| 1390 | Informed Consent Statement | 2022-03-15 | ||
| 1391 | Young scientist benefits | 2022-03-10 | ||
| 1392 | Purpose and Objectives | 2022-03-09 | ||
| 1393 | Papermaking Wastewater Treatment Processes Using Dynamic Multiblock Partial Least Squares | 2022-03-09 | ||
| 1394 | Palm Fatty Acid Distillate Biodiesel through Vacuum Distillation | 2022-03-09 | ||
| 1395 | Bio-Based Materials for Food Bundling | 2022-03-09 | ||
| 1396 | Preparation of Platform Compounds from Lignocellulosic Biomass | 2022-03-09 | ||
| 1397 | Production of Chitosan from Fungal Mycelia: Fermentation, Extraction and Purification | 2022-03-09 | ||
| 1398 | Funding/Sponsorship | 2022-03-08 | ||
| 1399 | Observation/Results | 2022-03-08 | ||
| 1400 | Information Base | 2022-03-07 | ||
| 1401 | Patient, Materials and Methods | 2022-03-07 | ||
| 1402 | Sessions/Tracks | 2022-03-07 | ||
| 1403 | Deficiencies or Nonconformities of Audit | 2022-03-04 | ||
| 1404 | Pharmaceutical Audit Management Software Systems | 2022-03-04 | ||
| 1405 | Procedure of Audit | 2022-03-04 | ||
| 1406 | Types of Audit | 2022-03-04 | ||
| 1407 | Objectives of Audit | 2022-03-04 | ||
| 1408 | Implantable Drug Delivery Devices | 2022-03-04 | ||
| 1409 | Classification of Implantable Drug Delivery Systems | 2022-03-04 | ||
| 1410 | Results and Observations | 2022-03-04 | ||
| 1411 | Advantages of Implantable Drug Delivery System | 2022-03-04 | ||
| 1412 | Financial Disclosure or Funding | 2022-03-04 | ||
| 1413 | Effects of Acid Rain | 2022-03-03 | ||
| 1414 | History of Acid Rain | 2022-03-03 | ||
| 1415 | Control of Water Pollution | 2022-03-03 | ||
| 1416 | Effect of Water Pollution | 2022-03-03 | ||
| 1417 | Types of Angiogenesis | 2022-03-03 | ||
| 1418 | Other Gynecological Conditions | 2022-03-03 | ||
| 1419 | Impact of Deforestation on The Environment | 2022-03-02 | ||
| 1420 | Causes of Deforestation | 2022-03-02 | ||
| 1421 | Biology of Germ Cells and Viruses | 2022-03-02 | ||
| 1422 | Basic Information About SNP | 2022-03-02 | ||
| 1423 | Honey as A Multiple Facets of Atherosclerosis | 2022-03-02 | ||
| 1424 | Chemical Composition of Honey | 2022-03-02 | ||
| 1425 | Antifungal Activity of AgNPs | 2022-03-02 | ||
| 1426 | Measuring Adherence | 2022-03-02 | ||
| 1427 | When Adherence is Important? | 2022-03-02 | ||
| 1428 | Citation | 2022-03-02 | ||
| 1429 | Pathway to Safe and Successful Endodontics in Everyday Clinical Practice | 2022-02-28 | ||
| 1430 | Complete Mouth Reconstruction with Upper Fixed Dental Prostheses and Lower Complete Arch Implant-Supported Monolithic Zirconia Prostheses with Feldspathic Porcelain Veneering Lim | 2022-02-28 | ||
| 1431 | Kill the Drill! Minimally Invasive Pediatric Dentistry | 2022-02-28 | ||
| 1432 | Dental-Related Sicknesses are Largely Preventable | 2022-02-28 | ||
| 1433 | Preferred Dentists are Over the Counter Carriers of Dental Care to People of all Ages | 2022-02-28 | ||
| 1434 | Ethical Approval and Consent | 2022-02-27 | ||
| 1435 | Changing Paradigms in Maxillary Sinus Management and Alveolar Augmentation in Modern 3D Implant Dentistry | 2022-02-26 | ||
| 1436 | Functional Restructuring and Repositioning of Facial tissues. Complete Facial Technique With Different Associations | 2022-02-26 | ||
| 1437 | Clinical Tips for Durable Dentin Bonding | 2022-02-26 | ||
| 1438 | Activity of Zinc Oral Dispersible Tablet on Marjory Clinical Type of Recurrent Aphthous Stomatitis Ulceration, a Clinical Trial Human study. | 2022-02-26 | ||
| 1439 | Validation of a Low-Cost Portable Device for Three-Dimensional Facial Imaging | 2022-02-26 | ||
| 1440 | Operational Definition of Terms | 2022-02-25 | ||
| 1441 | Descriptive | 2022-02-25 | ||
| 1442 | Medication that falls under this Class Should be Stayed Away | 2022-02-24 | ||
| 1443 | Introduction to Micro organisms | 2022-02-24 | ||
| 1444 | Introduction To Industrial Microbiology | 2022-02-24 | ||
| 1445 | Invisalign Lowers The Chance of An Orthodontic Emergency | 2022-02-24 | ||
| 1446 | Invisalign Treatment Is Easy To Troubleshoot | 2022-02-24 | ||
| 1447 | Invisalign Is Convenient | 2022-02-24 | ||
| 1448 | Root Resorption and Clear Aligners | 2022-02-24 | ||
| 1449 | Post Orthodontic Treatment Stability of Clear Aligners | 2022-02-24 | ||
| 1450 | Effects of Clear Aligners on Periodontal Status and Oral Health | 2022-02-24 | ||
| 1451 | Time Efficiency of Clear Aligners | 2022-02-24 | ||
| 1452 | Clinical Effectiveness of Clear Aligners | 2022-02-24 | ||
| 1453 | Efficacy and Efficiency of Clear Aligners | 2022-02-24 | ||
| 1454 | Scope and Limitations of Treatment With Aligners | 2022-02-24 | ||
| 1455 | Aligner Treatment Biomechanics | 2022-02-24 | ||
| 1456 | CAD-CAM Technologies Produce Aligners | 2022-02-24 | ||
| 1457 | Manufactured Aligners Using Manual Setup | 2022-02-24 | ||
| 1458 | Consequences for Clinical and Research | 2022-02-24 | ||
| 1459 | Accidental Swallow | 2022-02-24 | ||
| 1460 | Extrapyramidal System Dysfunction | 2022-02-24 | ||
| 1461 | Role of Ultraviolet Radiation | 2022-02-24 | ||
| 1462 | Drug Discovery | 2022-02-24 | ||
| 1463 | Summary and Conclusions | 2022-02-24 | ||
| 1464 | Author’s Information | 2022-02-23 | ||
| 1465 | Authorâ??s Information | 2022-02-23 | ||
| 1466 | Authorâ??s Information | 2022-02-23 | ||
| 1467 | Authorâ??s Information | 2022-02-23 | ||
| 1468 | Final kinetic Enzyme Activity Assay | 2022-02-23 | ||
| 1469 | Optimized Buffer Conditions | 2022-02-23 | ||
| 1470 | Bicinchoninic Acid Assay | 2022-02-23 | ||
| 1471 | Recombinant Production of Prolyl Oligopeptidase | 2022-02-23 | ||
| 1472 | Its Benefits | 2022-02-23 | ||
| 1473 | Primary and Secondary Endpoints | 2022-02-22 | ||
| 1474 | Patient Assessment | 2022-02-22 | ||
| 1475 | Results and Methods | 2022-02-22 | ||
| 1476 | Editorial Note on etiological factor in multiple sclerosis caused by mercury | 2022-02-21 | ||
| 1477 | MMP Genes extracted of Tcell cell line by Oleuropein | 2022-02-21 | ||
| 1478 | Brain MRI in detection of Multiple Sclerosis | 2022-02-21 | ||
| 1479 | King Devick Test and MoCA can be used in Routine Clinical Visits to Help detect Cognitive Impairment in Multiple Sclerosis | 2022-02-21 | ||
| 1480 | The Clinical Outcomes of Familial Multiple Sclerosis Patients | 2022-02-21 | ||
| 1481 | Postpartum Support | 2022-02-19 | ||
| 1482 | Risks During Pregnancy | 2022-02-19 | ||
| 1483 | Funding and Sponsorship | 2022-02-18 | ||
| 1484 | Immune Response to Infections | 2022-02-18 | ||
| 1485 | Skin as Immune System | 2022-02-18 | ||
| 1486 | Learning Point | 2022-02-18 | ||
| 1487 | Obesity is a Crucial Risk Factor in the Development of Heart Failure | 2022-02-18 | ||
| 1488 | Good Practice in Traditional Chinese Medicine | 2022-02-18 | ||
| 1489 | Pharmacognosy Should Define its Position in Academic Research | 2022-02-18 | ||
| 1490 | Wearable Sensors | 2022-02-18 | ||
| 1491 | Organic Photochemistry | 2022-02-18 | ||
| 1492 | Photochemistry Principles | 2022-02-18 | ||
| 1493 | The Future of Medicine: Traditional Medicine | 2022-02-17 | ||
| 1494 | Focusing on the Negative Response to Glycyrrhizin Combination Therapy | 2022-02-17 | ||
| 1495 | Treatment for Fish-Handler's Disease | 2022-02-17 | ||
| 1496 | Symptoms and Signs of Fish-Handler's Disease | 2022-02-17 | ||
| 1497 | Causes of Fish-Handler's Disease | 2022-02-17 | ||
| 1498 | Prevention, Therapeutic and Future Aspects of Aquaculture | 2022-02-17 | ||
| 1499 | Diagnostic and Therapeutic Measures In Aquaculture | 2022-02-17 | ||
| 1500 | Construction of Ponds and Designs | 2022-02-17 | ||
| 1501 | Construction of Fish Ponds | 2022-02-17 | ||
| 1502 | Constraints and Suggestions | 2022-02-15 | ||
| 1503 | Limitations and Future Prospects | 2022-02-15 | ||
| 1504 | Supplementary Tables | 2022-02-15 | ||
| 1505 | Scientific Responsibilities Statements | 2022-02-15 | ||
| 1506 | Animal and Human Rights Statements | 2022-02-15 | ||
| 1507 | Culture and Analysis of Microbes | 2022-02-15 | ||
| 1508 | Preparation of Culture Media | 2022-02-15 | ||
| 1509 | Mechanical Tests Results | 2022-02-15 | ||
| 1510 | Food Allergies | 2022-02-14 | ||
| 1511 | Postpartum Complications | 2022-02-14 | ||
| 1512 | Child Development | 2022-02-14 | ||
| 1513 | Hard Forks | 2022-02-12 | ||
| 1514 | Block Time | 2022-02-12 | ||
| 1515 | Blocks | 2022-02-12 | ||
| 1516 | Application and Practices | 2022-02-12 | ||
| 1517 | IOT Applications | 2022-02-12 | ||
| 1518 | Diagnosis of Chilblain Lupus | 2022-02-10 | ||
| 1519 | Symptoms of Chilblain Lupus | 2022-02-10 | ||
| 1520 | Causes of Chilblain Lupus | 2022-02-10 | ||
| 1521 | Challenges of E-Learning | 2022-02-09 | ||
| 1522 | Benefits of E-Learning | 2022-02-09 | ||
| 1523 | Strategy Towards Digital Education | 2022-02-09 | ||
| 1524 | Health Effects Due to Exposure to Heavy Metals | 2022-02-09 | ||
| 1525 | A Primary Care Physician's Role in Your Health Care | 2022-02-07 | ||
| 1526 | Role of the Funding Source | 2022-02-07 | ||
| 1527 | Ethical Consideration and Accessibility | 2022-02-07 | ||
| 1528 | Patient Inform Consent | 2022-02-04 | ||
| 1529 | Diagnostic Assessment | 2022-02-04 | ||
| 1530 | Empirical Literature Review | 2022-02-04 | ||
| 1531 | Targeting Syn Pathology with Therapeutics | 2022-02-04 | ||
| 1532 | Gut-to-Brain Transmission and Prion-like Behavior | 2022-02-04 | ||
| 1533 | Treatment for Alzheimer's Disease | 2022-02-04 | ||
| 1534 | Alzheimer's Disease Symptoms and Causes | 2022-02-04 | ||
| 1535 | Primary Progressive Aphasia Logopenic Variant | 2022-02-04 | ||
| 1536 | Phenotypes of Variant EOAD | 2022-02-04 | ||
| 1537 | Inconsistent Previous Research | 2022-02-03 | ||
| 1538 | Consequences | 2022-02-03 | ||
| 1539 | Who Can Participate in Yoga? | 2022-02-03 | ||
| 1540 | What Is The Process? | 2022-02-03 | ||
| 1541 | Chronotype For The Evening | 2022-02-03 | ||
| 1542 | Disruption of The Body Clock | 2022-02-03 | ||
| 1543 | Reasons That Could Be Given | 2022-02-03 | ||
| 1544 | Symptoms of Sundown Syndrome | 2022-02-03 | ||
| 1545 | Characteristics of Fast Dissolving Delivery Systems | 2022-02-02 | ||
| 1546 | Lipid Metabolism As A Potential Biomarker For Disease Phenotype and Treatment Efficacy | 2022-02-02 | ||
| 1547 | The Role of Mycolic Acid For Mycobacteria | 2022-02-02 | ||
| 1548 | Essential Roles of Tag and Cholesterol in M. Leprae Infection | 2022-02-02 | ||
| 1549 | Peroxisome Proliferator-Activated Receptors Contribute to Lipid Droplet Formation in M.Leprae -Infected THP-1 Cells | 2022-02-02 | ||
| 1550 | M. Leprae Induces Lipid Accumulation in Host Cells | 2022-02-02 | ||
| 1551 | M. Leprae Cell-Wall Lipids | 2022-02-02 | ||
| 1552 | Peroxisome Proliferator-Activated Receptors Contribute to Lipid Droplet Formation in M. Leprae -Infected THP-1 Cells | 2022-02-02 | ||
| 1553 | Types of Polycythemia | 2022-02-01 | ||
| 1554 | Strengths and Limitations of the Analysis | 2022-02-01 | ||
| 1555 | Note on Incidence Estimates for Arbovirus Infections | 2022-02-01 | ||
| 1556 | Damage-Response Curves | 2022-02-01 | ||
| 1557 | Pathogenicity and Virulence Redefined | 2022-02-01 | ||
| 1558 | Microorganism-and Host-Centred Views | 2022-02-01 | ||
| 1559 | Causes and Risk Factors | 2022-02-01 | ||
| 1560 | Ocular Oncology | 2022-02-01 | ||
| 1561 | Blood Type in Pregnancy | 2022-02-01 | ||
| 1562 | Ethics and Dissemination | 2022-01-31 | ||
| 1563 | Results: Data Collection, Management, and Analysis | 2022-01-31 | ||
| 1564 | Methods: Participants, Interventions and Outcomes | 2022-01-31 | ||
| 1565 | Data Descriptions, Results and Interpretations | 2022-01-28 | ||
| 1566 | Metals in Food Chain | 2022-01-28 | ||
| 1567 | Role of Food for Health | 2022-01-28 | ||
| 1568 | Mechanism of Toxicity and Carcinogenicity | 2022-01-28 | ||
| 1569 | Potential for Human Exposure | 2022-01-28 | ||
| 1570 | Human Health Effects by Consumption of Lead Contaminated Food | 2022-01-28 | ||
| 1571 | Methods of Data Collection | 2022-01-28 | ||
| 1572 | Treatment Given | 2022-01-24 | ||
| 1573 | Requirement of Desalination Technology | 2022-01-22 | ||
| 1574 | Discussion and Conculsion | 2022-01-20 | ||
| 1575 | Other Antidotes | 2022-01-20 | ||
| 1576 | Sodium Bicarbonate | 2022-01-20 | ||
| 1577 | Renal Replacement Therapy | 2022-01-20 | ||
| 1578 | Specific Treatments | 2022-01-20 | ||
| 1579 | General Approach | 2022-01-20 | ||
| 1580 | Specific Investigations | 2022-01-20 | ||
| 1581 | Isopropanol | 2022-01-20 | ||
| 1582 | Diethylene Glycol | 2022-01-20 | ||
| 1583 | Ethylene Glycol | 2022-01-20 | ||
| 1584 | Methanol | 2022-01-20 | ||
| 1585 | Literature Analysis and Problem Statement | 2022-01-20 | ||
| 1586 | Recommendations for future research | 2022-01-20 | ||
| 1587 | Results of Systematic Review | 2022-01-19 | ||
| 1588 | Controversy over Intravenous Thrombolytic Therapy for Mild Stroke | 2022-01-19 | ||
| 1589 | Controversy over the Concept of Mild Stroke | 2022-01-19 | ||
| 1590 | Clinical Utility of Immature Reticulocyte Fraction (IRF) | 2022-01-18 | ||
| 1591 | Present Treatment Approaches | 2022-01-18 | ||
| 1592 | Diabetes Classification | 2022-01-18 | ||
| 1593 | Mode of Generation of βcells Failure, Insulin Resistance, Along With Type2 Diabetes | 2022-01-18 | ||
| 1594 | Etiopathogenesis of Diabetes Mellitus | 2022-01-18 | ||
| 1595 | Animal Toxins as a Source of Therapeutic Agents | 2022-01-17 | ||
| 1596 | Spider Venom Toxins | 2022-01-17 | ||
| 1597 | Scorpion Venom Toxins | 2022-01-17 | ||
| 1598 | Snake Venom Serine Proteinases | 2022-01-17 | ||
| 1599 | Snake Venom Metalloproteinases | 2022-01-17 | ||
| 1600 | Snake Venom Toxin Families | 2022-01-17 | ||
| 1601 | Secondary Breast Carcinoma Treatment | 2022-01-13 | ||
| 1602 | HR-Positive Breast Cancer | 2022-01-13 | ||
| 1603 | Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer | 2022-01-13 | ||
| 1604 | Invasive Breast Carcinoma (Stages I-III) | 2022-01-13 | ||
| 1605 | The Non-Invasive Carcinoma (DCIS) | 2022-01-13 | ||
| 1606 | Modern hazard | 2022-01-12 | ||
| 1607 | Traditional hazard | 2022-01-12 | ||
| 1608 | Availability of Data and Supplementary Materials | 2022-01-10 | ||
| 1609 | Probability Of Developing RA | 2022-01-10 | ||
| 1610 | Authors's Note | 2022-01-07 | ||
| 1611 | Conflicts /Competing Interests | 2022-01-06 | ||
| 1612 | Number Two Enemy: Transportation and Mobility | 2022-01-05 | ||
| 1613 | The Heritage of Roma Culture | 2022-01-05 | ||
| 1614 | Roma in Slovakia | 2022-01-05 | ||
| 1615 | Mutations in Genes Involved in Pigment Synthesis Pathways | 2022-01-05 | ||
| 1616 | Phenotype of Conidial Pigmentation in A. Luchuensis and Albino Strains | 2022-01-05 | ||
| 1617 | Pluralism in Educational Institutions of India | 2021-12-31 | ||
| 1618 | Pluralism in Education | 2021-12-31 | ||
| 1619 | Pluralism in Society | 2021-12-31 | ||
| 1620 | Factors which Helped in the Development of Pluralism | 2021-12-31 | ||
| 1621 | Theories, Main Features and Factors of Pluralism | 2021-12-31 | ||
| 1622 | Types of Pluralism | 2021-12-31 | ||
| 1623 | Biorefinery Approach for Commercial Level Production | 2021-12-31 | ||
| 1624 | Commercial Uses of Isolated Products | 2021-12-31 | ||
| 1625 | Bioprocesses for Effluent Treatment | 2021-12-31 | ||
| 1626 | Green Processes for Resource Recovery | 2021-12-31 | ||
| 1627 | Bioconversion Processes | 2021-12-31 | ||
| 1628 | Circadian effects and impact on warm-blooded and cold-blooded vertebrates | 2021-12-31 | ||
| 1629 | Cost "Rule of Thumb" | 2021-12-31 | ||
| 1630 | What Else is Important? | 2021-12-31 | ||
| 1631 | What are some of the Misconceptions of Fish Passage ? | 2021-12-31 | ||
| 1632 | Technical Fish way Overview | 2021-12-31 | ||
| 1633 | Technical Fish way Ovewview | 2021-12-31 | ||
| 1634 | Types of Robots | 2021-12-31 | ||
| 1635 | Smyptomatology and Proposed Classification | 2021-12-31 | ||
| 1636 | What is Thoracic Aortic Aneurysm, and itâ??s Symptoms & Treatment | 2021-12-30 | ||
| 1637 | What is Thoracic Aortic Aneurysm, and itâ??s Symptoms & Treatment | 2021-12-30 | ||
| 1638 | What is Thoracic Aortic Aneurysm, and itâ??s Symptoms & Treatment | 2021-12-30 | ||
| 1639 | What is Thoracic Aortic Aneurysm, and itâ??s Symptoms & Treatment | 2021-12-30 | ||
| 1640 | Application of Traditional Medicine To Prevent and Treat Covid-19 | 2021-12-30 | ||
| 1641 | Recent Prophylactics Development of Covid-19 | 2021-12-30 | ||
| 1642 | Conflicts of Interest and Funding | 2021-12-30 | ||
| 1643 | Characteristics | 2021-12-29 | ||
| 1644 | Factors Influencing Pelletization | 2021-12-29 | ||
| 1645 | Filling Techniques | 2021-12-29 | ||
| 1646 | Multi-Unit Pellet Technology | 2021-12-29 | ||
| 1647 | Study Weakness | 2021-12-29 | ||
| 1648 | Future Outlook (Compared With Mr-Linac) | 2021-12-29 | ||
| 1649 | Clinical Practice | 2021-12-29 | ||
| 1650 | Structure of Sperm Cell | 2021-12-29 | ||
| 1651 | What is Thoracic Aortic Aneurysm, and itâ??s Symptoms & Treatment | 2021-12-29 | ||
| 1652 | What is Thoracic Aortic Aneurysm, and itâ??s Symptoms & Treatment. | 2021-12-29 | ||
| 1653 | Case Details | 2021-12-28 | ||
| 1654 | Source of Interest | 2021-12-28 | ||
| 1655 | Well-Being at Work and Game Playing | 2021-12-28 | ||
| 1656 | Institutional Ethics Commitee Approval | 2021-12-28 | ||
| 1657 | Evaluation of Marginal Fit | 2021-12-28 | ||
| 1658 | Scanning of The Prepared Model | 2021-12-28 | ||
| 1659 | Sleep Hygiene is Really Important | 2021-12-28 | ||
| 1660 | What is Biphasic Sleep and How Does it Work? | 2021-12-28 | ||
| 1661 | Chronotypes and Their Variations | 2021-12-28 | ||
| 1662 | What is Thoracic Aortic Aneurysm, and itâ??s Symptoms & Treatment | 2021-12-28 | ||
| 1663 | Management challenges | 2021-12-27 | ||
| 1664 | What is Thoracic Aortic Aneurysm, and itâ??s Symptoms & Treatment | 2021-12-27 | ||
| 1665 | What is Thoracic Aortic Aneurysm, and itâ??s Symptoms & Treatment | 2021-12-27 | ||
| 1666 | What is Thoracic Aortic Aneurysm, and itâ??s Symptoms & Treatment | 2021-12-27 | ||
| 1667 | What is Thoracic Aortic Aneurysm, and itâ??s Symptoms & Treatment | 2021-12-27 | ||
| 1668 | A Brief Introduction of Endarterectomy | 2021-12-27 | ||
| 1669 | Effect of Angiogram and how does it Work | 2021-12-27 | ||
| 1670 | An Introduction and Causes, Symptoms of Hyperlipidaemia | 2021-12-27 | ||
| 1671 | What is Thoracic Aortic Aneurysm, and itâ??s Symptoms & Treatment | 2021-12-27 | ||
| 1672 | What is Thoracic Aortic Aneurysm, and itâ??s Symptoms & Treatment | 2021-12-27 | ||
| 1673 | What is Thoracic Aortic Aneurysm, and itâ??s Symptoms & Treatment | 2021-12-27 | ||
| 1674 | A Medical Definition and Overview of Vein | 2021-12-27 | ||
| 1675 | Method and Materials | 2021-12-27 | ||
| 1676 | Neuro-HIV Animal Models | 2021-12-27 | ||
| 1677 | The Impact of Addictive Drug on Neuro-impairment in HIV Disease | 2021-12-27 | ||
| 1678 | The Impact of Addictive Drug on Systemic Immunities in HIV Disease | 2021-12-27 | ||
| 1679 | The Impact of Addictive Drug on HIV Viral Replication | 2021-12-27 | ||
| 1680 | Criteria for Selection of Excipients for Lipid-Based Formulations | 2021-12-27 | ||
| 1681 | Types of Lipid-Based Drug Delivery Systems | 2021-12-27 | ||
| 1682 | Factors Affecting LBDDS | 2021-12-27 | ||
| 1683 | Advantages and Disadvantages | 2021-12-27 | ||
| 1684 | Lipid Based Formulations | 2021-12-27 | ||
| 1685 | The Influence of Flexibility on Turbulent Aerodynamic Forces | 2021-12-21 | ||
| 1686 | Hyperoil | 2021-12-21 | ||
| 1687 | Editorial Announcement: | 2021-12-20 | ||
| 1688 | Most Effective Combination of Nutraceuticals Among Multivitamins, Zinc, Polyphenols, Omega Fatty Acids, and Probiotics for Improved Memory and Cognitive Performance in Acheta Domes | 2021-12-20 | ||
| 1689 | Most Effective Combination of Nutraceuticals Among Multivitamins, Zinc, Polyphenols, Omega Fatty Acids, and Probiotics for Improved Memory and Cognitive Performance in Acheta Domes | 2021-12-20 | ||
| 1690 | Biochemical And Organoleptic Perspectives In Novel Product Development Using Cinnamon | 2021-12-20 | ||
| 1691 | Diet Mordification A Major Citeria To Healthy Living And Longevity; The Role Of Diet To Achieving Standard Healthcare Outcomes And Life Span Sustainability | 2021-12-20 | ||
| 1692 | Study on development nutritional quality evaluation, storage stability of weaning food prepared from multipurpose flour, papaya powder and milk powder | 2021-12-20 | ||
| 1693 | Declaration of Conflicting Interests | 2021-12-17 | ||
| 1694 | Current and Future Technologies to Help Map the Location and Connection of Proteins | 2021-12-16 | ||
| 1695 | Protein Complex and Protein-Protein Interactions (PPI) | 2021-12-16 | ||
| 1696 | Single-Cell Protmeomics | 2021-12-16 | ||
| 1697 | Spatial and Subcellular Proteomics | 2021-12-16 | ||
| 1698 | Composition of Artificial Blood | 2021-12-16 | ||
| 1699 | Cryptococcosis Status In Ethiopia | 2021-12-16 | ||
| 1700 | Role of International Organizations | 2021-12-16 | ||
| 1701 | Clinical Signs | 2021-12-16 | ||
| 1702 | History Of Cryptococcosis | 2021-12-16 | ||
| 1703 | Soil Moisture | 2021-12-16 | ||
| 1704 | Technologies | 2021-12-15 | ||
| 1705 | Advantages of IoT | 2021-12-15 | ||
| 1706 | Tourism Risk Perception of Local Communities | 2021-12-14 | ||
| 1707 | Teorethical Background | 2021-12-14 | ||
| 1708 | Overview of Knowledge and Palliative Care | 2021-12-14 | ||
| 1709 | Pain and Palliative Care Education in Mozambique | 2021-12-14 | ||
| 1710 | Reference | 2021-12-14 | ||
| 1711 | Importance of The Work | 2021-12-14 | ||
| 1712 | The Value Of Monitoring By Combination Of Qb And Pa | 2021-12-14 | ||
| 1713 | Limitations in Current Practise and Previous Research | 2021-12-14 | ||
| 1714 | The Life of a Sea Horse | 2021-12-14 | ||
| 1715 | Limitation of Flies Abundance | 2021-12-13 | ||
| 1716 | Options Include | 2021-12-13 | ||
| 1717 | Emotional Modifications May Also Include | 2021-12-13 | ||
| 1718 | Cognitive Modifications May Also Include | 2021-12-13 | ||
| 1719 | Physical Signs Include | 2021-12-13 | ||
| 1720 | Limitations and Recommendations | 2021-12-13 | ||
| 1721 | Research Includes | 2021-12-13 | ||
| 1722 | Alzheimer's Disease and Down Syndrome Research | 2021-12-13 | ||
| 1723 | Appreciation | 2021-12-13 | ||
| 1724 | The Link Between Bone and Cardiac Inflammation | 2021-12-10 | ||
| 1725 | Cardiovascular Involvement In Spondyloarthropathies | 2021-12-10 | ||
| 1726 | Rsi | 2021-12-10 | ||
| 1727 | Editorial on Acute Patient Care | 2021-12-10 | ||
| 1728 | Modern Methods of Preservation and Conservation of Mutilated Health Records | 2021-12-10 | ||
| 1729 | Diagnostic Approaches for Care of Severely Injured Patient | 2021-12-10 | ||
| 1730 | Funding Conclusion | 2021-12-10 | ||
| 1731 | Results and Dicsussion | 2021-12-08 | ||
| 1732 | Early childhood to adult | 2021-12-08 | ||
| 1733 | Infants | 2021-12-08 | ||
| 1734 | Epigenetics and Development | 2021-12-08 | ||
| 1735 | Non-coding RNA | 2021-12-08 | ||
| 1736 | Histone-modified | 2021-12-08 | ||
| 1737 | Histone-modifie | 2021-12-08 | ||
| 1738 | Mitochondrial inheritance | 2021-12-08 | ||
| 1739 | Stages | 2021-12-08 | ||
| 1740 | Company Support | 2021-12-08 | ||
| 1741 | Patient Conset | 2021-12-08 | ||
| 1742 | Is Sleep Paralysis a Sign of Something More Serious? | 2021-12-07 | ||
| 1743 | What is Chronotherapy and How Does it Work? Sleep Disorders and Depression: The Benefits of Chronotherapeutic Treatment | 2021-12-07 | ||
| 1744 | Cataplexy how it is Diagnosed and Treated | 2021-12-07 | ||
| 1745 | Editorâ??s Note on Different Types of Parasomnia | 2021-12-07 | ||
| 1746 | Editorâ??s Note on Different Types of Parasomnia | 2021-12-07 | ||
| 1747 | Editorâ??s Note on Different Types of Parasomnia | 2021-12-07 | ||
| 1748 | Parasomnia; How it is Diagnosed and Treated | 2021-12-07 | ||
| 1749 | Techniques by Chromatographic Bed Shape | 2021-12-07 | ||
| 1750 | Literature Review and Hypothesis | 2021-12-06 | ||
| 1751 | What is Drug Reactions and What its Side Effect | 2021-12-04 | ||
| 1752 | What is Epigenetics and What its Type | 2021-12-04 | ||
| 1753 | A Basic Overview of How Drugs Work | 2021-12-04 | ||
| 1754 | Interactions Between Different Drugs | 2021-12-04 | ||
| 1755 | An Overview of Pharmacology | 2021-12-04 | ||
| 1756 | An Overview of Bypass Surgery | 2021-12-04 | ||
| 1757 | A Briefly Introduction of Pulmonary Embolism. | 2021-12-04 | ||
| 1758 | A Briefly Introduction of Pulmonary Embolism | 2021-12-04 | ||
| 1759 | Symptoms and Causes of Carotid Artery Disease | 2021-12-04 | ||
| 1760 | Introduction and Presentation of Vascular Disease | 2021-12-04 | ||
| 1761 | An Overview and Symptoms of Aorta | 2021-12-04 | ||
| 1762 | Availability of Data and Information | 2021-12-03 | ||
| 1763 | Epidemiology of lymphobia disease | 2021-12-03 | ||
| 1764 | Therapies in alzheimer's disease | 2021-12-03 | ||
| 1765 | Management of amblyopia | 2021-12-03 | ||
| 1766 | Energy Balance and Conceptual Process Costs | 2021-12-02 | ||
| 1767 | Algae Feedstocks | 2021-12-02 | ||
| 1768 | Liquefaction Process Results | 2021-12-02 | ||
| 1769 | Wet Biomass Feedstocks-Properties and Preparation for Processing | 2021-12-02 | ||
| 1770 | Introduction on Hydrothermal Liquefaction | 2021-12-02 | ||
| 1771 | Evaluation Parameters | 2021-12-02 | ||
| 1772 | Formulations | 2021-12-02 | ||
| 1773 | Components of FFS | 2021-12-02 | ||
| 1774 | Properties of Film | 2021-12-02 | ||
| 1775 | Film Forming System | 2021-12-02 | ||
| 1776 | Skin | 2021-12-02 | ||
| 1777 | Drafting, Approval of the Submitted Manuscript | 2021-12-02 | ||
| 1778 | Interpretation of the Data | 2021-12-02 | ||
| 1779 | Conception and Design of Manuscript | 2021-12-02 | ||
| 1780 | Ethics Committee Record | 2021-12-01 | ||
| 1781 | Conflicts of Interest and Financial Support | 2021-12-01 | ||
| 1782 | End and Significance | 2021-12-01 | ||
| 1783 | Analysis of Images | 2021-12-01 | ||
| 1784 | Brain Connections | 2021-11-30 | ||
| 1785 | Review of Assessment of Msd | 2021-11-30 | ||
| 1786 | Bibliometric Analysis | 2021-11-30 | ||
| 1787 | Material | 2021-11-29 | ||
| 1788 | Results, Discussion and Achievements | 2021-11-29 | ||
| 1789 | Research Methodology and Materials | 2021-11-29 | ||
| 1790 | Using Clay Mineral as a Possible Seasonal Indicator for the Sunda Shelf | 2021-11-27 | ||
| 1791 | Composition of Clay Mineralogy | 2021-11-27 | ||
| 1792 | A Fusion of Mscs And The Crispr-Cas9 Technology in Bone Regeneration Therapy | 2021-11-27 | ||
| 1793 | Potential and Limitations of Mscs in Bone Regeneration Therapy | 2021-11-27 | ||
| 1794 | Hazard Factors | 2021-11-27 | ||
| 1795 | Conflicts of Interest and Source Funding | 2021-11-27 | ||
| 1796 | Structure Of Corona Virus | 2021-11-26 | ||
| 1797 | Black Fungus Infection (Mucormycosis) | 2021-11-26 | ||
| 1798 | Drugs Interaction | 2021-11-26 | ||
| 1799 | D-Dimer | 2021-11-26 | ||
| 1800 | Compliance and Severity of COVID-19 Associated ARDS | 2021-11-26 | ||
| 1801 | Research Funding | 2021-11-26 | ||
| 1802 | About the Story | 2021-11-26 | ||
| 1803 | Behaviour Changes | 2021-11-25 | ||
| 1804 | Analysis of Issue | 2021-11-24 | ||
| 1805 | Definition of Negligence | 2021-11-24 | ||
| 1806 | Vaccination Challengers | 2021-11-23 | ||
| 1807 | Discriminant Pcr Test | 2021-11-23 | ||
| 1808 | Results of Evaluation | 2021-11-23 | ||
| 1809 | Repurposing Accomplishments | 2021-11-23 | ||
| 1810 | Computer-Aided Drug Design | 2021-11-23 | ||
| 1811 | Rational Drug Discovery | 2021-11-23 | ||
| 1812 | Drug Targets | 2021-11-23 | ||
| 1813 | Pathophysiology of Fatigue in MS | 2021-11-22 | ||
| 1814 | All These Measures Yielded Negligible Improvements | 2021-11-22 | ||
| 1815 | Types of Thyroid Nodule | 2021-11-22 | ||
| 1816 | Advances in Adaptation to Biotic and Abiotic Stress | 2021-11-22 | ||
| 1817 | Tomato Production Output Index | 2021-11-22 | ||
| 1818 | PSYCHOLOGICAL ASPECTS OF CANNABIS | 2021-11-22 | ||
| 1819 | Covid-19 And Antimicrobial Resistance | 2021-11-22 | ||
| 1820 | Why antibiotics are used in a viral pandemic? | 2021-11-22 | ||
| 1821 | Use of Antibiotics During Covid-19 | 2021-11-22 | ||
| 1822 | Conceptual | 2021-11-22 | ||
| 1823 | Resilience-Building Management of The Gut Microbiota | 2021-11-20 | ||
| 1824 | Conclusion and Significance | 2021-11-20 | ||
| 1825 | Methodology and Theoretical Orientation | 2021-11-20 | ||
| 1826 | Potential implications for future antimicrobial drug discovery to treat Burkholderia -related diseases | 2021-11-19 | ||
| 1827 | Evaluation of Microspheres | 2021-11-19 | ||
| 1828 | Bacopa monniera | 2021-11-19 | ||
| 1829 | Ginko biloba | 2021-11-19 | ||
| 1830 | Ginko biloba | 2021-11-19 | ||
| 1831 | Need and Significance | 2021-11-19 | ||
| 1832 | Source funding | 2021-11-18 | ||
| 1833 | Ethical Analysis | 2021-11-17 | ||
| 1834 | Arguments of proponents and Critics | 2021-11-17 | ||
| 1835 | Advantages of TeleMedicine | 2021-11-17 | ||
| 1836 | TeleMedicine Vs TeleHealth | 2021-11-17 | ||
| 1837 | Addressing the Challenges | 2021-11-17 | ||
| 1838 | Ethical Questions | 2021-11-17 | ||
| 1839 | Challenges | 2021-11-17 | ||
| 1840 | Review Status | 2021-11-17 | ||
| 1841 | Dissemination | 2021-11-17 | ||
| 1842 | Meta Analytic Approach | 2021-11-17 | ||
| 1843 | Methods and Analysis | 2021-11-17 | ||
| 1844 | Fish in Paduan Dietetics in Relation to Other Diseases | 2021-11-15 | ||
| 1845 | Paduan Dietetics on Cancer and Fish | 2021-11-15 | ||
| 1846 | Promotion and Application of the Model | 2021-11-15 | ||
| 1847 | Model Evaluations | 2021-11-15 | ||
| 1848 | Conclusion Review | 2021-11-15 | ||
| 1849 | Treatment for Fibrosarcoma | 2021-11-12 | ||
| 1850 | Cause and Risk Factors | 2021-11-12 | ||
| 1851 | Symptons of Fibrosarcoma | 2021-11-12 | ||
| 1852 | Complications Associated With Bone Marrow Transplant | 2021-11-12 | ||
| 1853 | Different Types of Transplant | 2021-11-12 | ||
| 1854 | Aim of the Research | 2021-11-12 | ||
| 1855 | Establishment and Solution of The Model | 2021-11-12 | ||
| 1856 | Index Selection | 2021-11-12 | ||
| 1857 | Screening | 2021-11-11 | ||
| 1858 | Tests | 2021-11-11 | ||
| 1859 | Sperm Size | 2021-11-11 | ||
| 1860 | Sperm Quality | 2021-11-11 | ||
| 1861 | Signs and Symptoms of Sexually Transmitted Disease | 2021-11-11 | ||
| 1862 | Policy Recommendations | 2021-11-11 | ||
| 1863 | Therapeutic Modality | 2021-11-10 | ||
| 1864 | Chloroquine and Hydroxychloroquine | 2021-11-10 | ||
| 1865 | Natural Products | 2021-11-10 | ||
| 1866 | Protease Inhibitors | 2021-11-10 | ||
| 1867 | Interferons | 2021-11-10 | ||
| 1868 | Acknowledge | 2021-11-09 | ||
| 1869 | Severity of Symptomatic Infection | 2021-11-09 | ||
| 1870 | Research Review | 2021-11-09 | ||
| 1871 | Methodology and Results | 2021-11-08 | ||
| 1872 | Appendix I | 2021-11-08 | ||
| 1873 | Conclusion and Policy | 2021-11-08 | ||
| 1874 | Disclosure of Funding Support | 2021-11-05 | ||
| 1875 | Functions of Mitochondria | 2021-11-03 | ||
| 1876 | Functions of Mitochondria | 2021-11-03 | ||
| 1877 | Functions of Mitochondria | 2021-11-03 | ||
| 1878 | Functions of Mitochondria | 2021-11-03 | ||
| 1879 | Functions of Mitochondria | 2021-11-03 | ||
| 1880 | Structure of Mitochondria | 2021-11-03 | ||
| 1881 | Intoxication | 2021-11-03 | ||
| 1882 | Pharmacodynamics of Zopiclone | 2021-11-03 | ||
| 1883 | Zopiclone | 2021-11-03 | ||
| 1884 | Management and Insomnia | 2021-11-03 | ||
| 1885 | Historical Resources | 2021-11-03 | ||
| 1886 | Ecotourism Resources of The Area | 2021-11-03 | ||
| 1887 | Strengths of India Mice Brand | 2021-11-03 | ||
| 1888 | Acknowledgements and Funding | 2021-11-03 | ||
| 1889 | Safety Culture | 2021-11-03 | ||
| 1890 | Availability of Safety Data | 2021-11-03 | ||
| 1891 | Interoperability | 2021-11-03 | ||
| 1892 | Applying Human Factors Practices in Aviation to Healthcare | 2021-11-03 | ||
| 1893 | Medical and aviation error in the u.s. | 2021-11-03 | ||
| 1894 | Proceedings | 2021-11-03 | ||
| 1895 | Computer Software | 2021-11-02 | ||
| 1896 | Computer Hardware | 2021-11-02 | ||
| 1897 | Patients with an "impaired immune system" may nevertheless be able to benefit | 2021-11-02 | ||
| 1898 | Treatments with Monoclonal Antibodies | 2021-11-02 | ||
| 1899 | Antibodies are no longer useful | 2021-11-02 | ||
| 1900 | Serology | 2021-11-02 | ||
| 1901 | Virulence, Pathogenesis, and Clinical Presentation | 2021-11-02 | ||
| 1902 | Arthropod Vectors and Identification | 2021-11-02 | ||
| 1903 | Epidemiology and Transmission | 2021-11-02 | ||
| 1904 | Sneezing | 2021-11-02 | ||
| 1905 | Purification of Eosinophil MBP and CLC Proteins | 2021-11-02 | ||
| 1906 | Purification of Eosinophil Granules | 2021-11-02 | ||
| 1907 | Enterococcus | 2021-11-02 | ||
| 1908 | Escherichia coli | 2021-11-02 | ||
| 1909 | Staphylococcus Aureus | 2021-11-02 | ||
| 1910 | Campylobacter and Salmonella | 2021-11-02 | ||
| 1911 | Therapy in Children | 2021-11-02 | ||
| 1912 | Cost Effectiveness and Other Practical Aspects | 2021-11-02 | ||
| 1913 | Drug Interactions and Comorbidities | 2021-11-02 | ||
| 1914 | Titration | 2021-11-02 | ||
| 1915 | Dosage and Titration | 2021-11-02 | ||
| 1916 | Combination Therapy or Monotherapy | 2021-11-02 | ||
| 1917 | Initiation of Therapy | 2021-11-02 | ||
| 1918 | Mechanism of Action and Relevant Pharmacokinetics | 2021-11-02 | ||
| 1919 | Non-Obstructive Coronary Artery Disease Myocardial Infarction | 2021-11-02 | ||
| 1920 | Tissue Engineering Vascular Graft | 2021-11-01 | ||
| 1921 | Key Messages | 2021-11-01 | ||
| 1922 | Limitations for Further Studies | 2021-11-01 | ||
| 1923 | Invention | 2021-11-01 | ||
| 1924 | Recent Advances | 2021-11-01 | ||
| 1925 | Funding Declaration | 2021-11-01 | ||
| 1926 | Immunosuperssion | 2021-11-01 | ||
| 1927 | Antioxidation | 2021-11-01 | ||
| 1928 | Toxicokinetics | 2021-11-01 | ||
| 1929 | Mechanism of Toxicity | 2021-11-01 | ||
| 1930 | How did Life Begin? A Review of the Environmental and Biomolecular Hypotheses Surrounding Abiogenesis | 2021-11-01 | ||
| 1931 | Assessment of Cross-Reactivity (CR) | 2021-11-01 | ||
| 1932 | Diagnostic Approaches | 2021-11-01 | ||
| 1933 | Monitoring the Acute Response | 2021-11-01 | ||
| 1934 | Drug-Recognition and Immune Response | 2021-11-01 | ||
| 1935 | Other Drugs | 2021-11-01 | ||
| 1936 | Macrolids | 2021-11-01 | ||
| 1937 | Sulfonamides | 2021-11-01 | ||
| 1938 | Quinolones, Particularly Fluorquinolones (FQ) | 2021-11-01 | ||
| 1939 | Non-Steroidal Anti-Inflammatory Drugs | 2021-11-01 | ||
| 1940 | Betalactams | 2021-11-01 | ||
| 1941 | Iodinated Contrast Media | 2021-11-01 | ||
| 1942 | Anticonvulsants | 2021-11-01 | ||
| 1943 | Drugs Involved | 2021-11-01 | ||
| 1944 | Classification of T-Cell Drug Reactions | 2021-11-01 | ||
| 1945 | Conflicting Interest | 2021-11-01 | ||
| 1946 | What Are The Different Types of Sleep Disorders? | 2021-10-30 | ||
| 1947 | Sleeping Pills Its Usage And Their Side Effects | 2021-10-30 | ||
| 1948 | An Overview of Attention-deficit/Hyperactivity Disorder (ADHD) | 2021-10-30 | ||
| 1949 | Depression and its Side Effects | 2021-10-30 | ||
| 1950 | Alzheimer's Diseases: Symptoms and Signs | 2021-10-30 | ||
| 1951 | Treatment of Congenital Heart Disease | 2021-10-30 | ||
| 1952 | Pregnancy Considerations | 2021-10-30 | ||
| 1953 | Key Points in the Treatment of Gdm | 2021-10-30 | ||
| 1954 | Author's Contributions | 2021-10-30 | ||
| 1955 | Selected Heavy Metal Removals from Pharmaceutical Effluent | 2021-10-30 | ||
| 1956 | Methods of Treatments of Pharmaceutical Effluent | 2021-10-30 | ||
| 1957 | Pharmaceutical Effluent Impact | 2021-10-30 | ||
| 1958 | Concepts of Phytoremediation’s | 2021-10-30 | ||
| 1959 | Funding and Disclosure | 2021-10-29 | ||
| 1960 | Spread of Diseases | 2021-10-29 | ||
| 1961 | Different types of Microbes | 2021-10-29 | ||
| 1962 | Disclosure of Interests | 2021-10-29 | ||
| 1963 | Molecular Pathogenesis | 2021-10-28 | ||
| 1964 | Appendix a. Supplementary data | 2021-10-28 | ||
| 1965 | Various Measures For Analysis | 2021-10-28 | ||
| 1966 | Cell Passage | 2021-10-28 | ||
| 1967 | Extraction of Oleoropine | 2021-10-28 | ||
| 1968 | CONCLUSIONS AND IMPLICATIONS | 2021-10-28 | ||
| 1969 | Discussions of Findings | 2021-10-28 | ||
| 1970 | Disclosure of Conflicts of Interest | 2021-10-27 | ||
| 1971 | Authorship Contribution | 2021-10-27 | ||
| 1972 | Rapid Communication | 2021-10-27 | ||
| 1973 | Depression | 2021-10-27 | ||
| 1974 | Eating Disorders | 2021-10-27 | ||
| 1975 | Insomnia | 2021-10-27 | ||
| 1976 | Economic Analysis | 2021-10-27 | ||
| 1977 | Tau Hypothesis and AD | 2021-10-27 | ||
| 1978 | Tau Pathology | 2021-10-27 | ||
| 1979 | Amyloids and Alzheimer’s | 2021-10-27 | ||
| 1980 | Cost | 2021-10-27 | ||
| 1981 | What is Alzheimer ’s Disease? | 2021-10-27 | ||
| 1982 | Quality-of-Life | 2021-10-27 | ||
| 1983 | Induction of Platinum Resistance | 2021-10-27 | ||
| 1984 | Risk of Recurrence in Ovarian Cancer | 2021-10-27 | ||
| 1985 | The Data | 2021-10-27 | ||
| 1986 | Consent of Publication | 2021-10-27 | ||
| 1987 | Consent of Participate | 2021-10-27 | ||
| 1988 | Caprine Arthritis Encephalitis | 2021-10-27 | ||
| 1989 | Equine Infectious Anemia (Swamp Fever) | 2021-10-27 | ||
| 1990 | Animal Retrovirus Diseases | 2021-10-27 | ||
| 1991 | The HIV-1 | 2021-10-27 | ||
| 1992 | Human Immunodeficiency Viruses (HIV-1 and HIV-2) | 2021-10-27 | ||
| 1993 | Computer Code Availability | 2021-10-27 | ||
| 1994 | The Role of Terpene for Human | 2021-10-27 | ||
| 1995 | The Role of Terpene in Plants | 2021-10-27 | ||
| 1996 | Major Types of Terpene | 2021-10-27 | ||
| 1997 | Terpenoids Biosynthetic Pathways | 2021-10-27 | ||
| 1998 | Luminiferous Ether | 2021-10-27 | ||
| 1999 | Primary features of the IBM Module | 2021-10-26 | ||
| 2000 | Intelligence based Diabetes Management System(IBDM) | 2021-10-26 | ||
| 2001 | Liposuction Types | 2021-10-26 | ||
| 2002 | Functional Parameters | 2021-10-26 | ||
| 2003 | Drink | 2021-10-26 | ||
| 2004 | Eggs | 2021-10-26 | ||
| 2005 | Cheese | 2021-10-26 | ||
| 2006 | Vegetables | 2021-10-26 | ||
| 2007 | Birds | 2021-10-26 | ||
| 2008 | Goat, Hare, Deer, Venison | 2021-10-26 | ||
| 2009 | Beef, Pork, Lamb | 2021-10-26 | ||
| 2010 | Paduan Diets | 2021-10-26 | ||
| 2011 | Clinical Studies in Gynaecology | 2021-10-26 | ||
| 2012 | Clinical Studies in Obstetrics | 2021-10-26 | ||
| 2013 | Equipment Development | 2021-10-26 | ||
| 2014 | Qualities That Distinguish Fetal, Maternal, and Middle Sections of the Placenta | 2021-10-25 | ||
| 2015 | Quality Expression in Different Parts of Placenta | 2021-10-25 | ||
| 2016 | Gene Expression in Villus Parenchyma of Placenta Relative to Other Normal Human Tissues | 2021-10-25 | ||
| 2017 | Impacts | 2021-10-25 | ||
| 2018 | Hormonal Defects | 2021-10-25 | ||
| 2019 | Hereditary Factors | 2021-10-25 | ||
| 2020 | Climate and Lifestyle | 2021-10-25 | ||
| 2021 | Male Reproductive Organ | 2021-10-25 | ||
| 2022 | Takayasu's Arteritis and Kidney Association | 2021-10-25 | ||
| 2023 | Classification of 190 Countries | 2021-10-25 | ||
| 2024 | Infection Statuses of 190 Countries | 2021-10-25 | ||
| 2025 | Procedure for Fitting the Infection Curve | 2021-10-25 | ||
| 2026 | BARRIER-FREE' ENVIRONMENT AND INTERNAL CONTRASTS | 2021-10-25 | ||
| 2027 | HYPNOTIZED BY THE PAST | 2021-10-25 | ||
| 2028 | MORTALITY HOT SPOTS AND GLIMMERS OF HOPE | 2021-10-25 | ||
| 2029 | TRAGIC PRACTICES | 2021-10-25 | ||
| 2030 | Introduction and Etiology | 2021-10-25 | ||
| 2031 | Importance of Antibiotics on Human Health | 2021-10-25 | ||
| 2032 | Importanceâ??s of Antibiotics on Human Health | 2021-10-25 | ||
| 2033 | Importanceâ??s of Antibiotics on Human Health | 2021-10-25 | ||
| 2034 | Role of ketamine in emergency department | 2021-10-25 | ||
| 2035 | Challenges in trauma care | 2021-10-25 | ||
| 2036 | Overview of brain hematoma | 2021-10-25 | ||
| 2037 | Sepsis management in adults | 2021-10-25 | ||
| 2038 | A Report on various levels at trauma care | 2021-10-25 | ||
| 2039 | Biomarkers of Sickness Movement | 2021-10-23 | ||
| 2040 | Importance of B and T cells in the pathogenesis | 2021-10-23 | ||
| 2041 | ANCA and other antibodies | 2021-10-23 | ||
| 2042 | Terminology of vasculitides, AAV can be sorted into the accompanying kinds | 2021-10-23 | ||
| 2043 | Human immunodeficiency virus | 2021-10-23 | ||
| 2044 | Principle of Terahertz Sensing | 2021-10-23 | ||
| 2045 | Announcement: Call for Paper | 2021-10-22 | ||
| 2046 | For what reason do I need a prosthetic Ankle? | 2021-10-22 | ||
| 2047 | Ankle Replacement | 2021-10-22 | ||
| 2048 | Therapeutic Strategy for COVID-19 | 2021-10-21 | ||
| 2049 | Endothelial Biomarkers and Function Studies in COVID-19 | 2021-10-21 | ||
| 2050 | Clinical Manifestation of Endotheliitis in COVID-19 | 2021-10-21 | ||
| 2051 | Endothelial Damage and Immune Dysregulation in COVID-19 | 2021-10-21 | ||
| 2052 | Association between Endothelial Damage and Hypercoagulability in COVID-19 | 2021-10-21 | ||
| 2053 | Endothelial Dysfunction and Damage in COVID-19 | 2021-10-21 | ||
| 2054 | Characterization of Exosomes | 2021-10-21 | ||
| 2055 | Formation of Exosomes | 2021-10-21 | ||
| 2056 | Biogenesis of Exosomes | 2021-10-21 | ||
| 2057 | Life Cycle | 2021-10-21 | ||
| 2058 | Experimental Methods and Characterization | 2021-10-21 | ||
| 2059 | PER | 2021-10-20 | ||
| 2060 | Post-operative management and Assessment | 2021-10-20 | ||
| 2061 | Concluding Remark | 2021-10-20 | ||
| 2062 | Challenges in applications of intelligent Packaging systems | 2021-10-20 | ||
| 2063 | Sensors | 2021-10-20 | ||
| 2064 | Indicators | 2021-10-20 | ||
| 2065 | Stretching and Warming Up | 2021-10-20 | ||
| 2066 | Evidence against Pre-Workout Warmup | 2021-10-20 | ||
| 2067 | Warm-Up Evidence | 2021-10-20 | ||
| 2068 | Bone Adaptation to Exercise | 2021-10-20 | ||
| 2069 | Aging and Bone Loss | 2021-10-20 | ||
| 2070 | Home Remedies to Cure Knee Pain | 2021-10-20 | ||
| 2071 | Childhood Lupus | 2021-10-20 | ||
| 2072 | Drug-Induced Lupus Erythematosus | 2021-10-20 | ||
| 2073 | The effect of ALG on established immunity | 2021-10-19 | ||
| 2074 | Macrophage agglulinating activity of ALG | 2021-10-19 | ||
| 2075 | Equipment for Photocatalytic Air Treatment | 2021-10-19 | ||
| 2076 | Translation of DNA | 2021-10-19 | ||
| 2077 | Transcription of DNA | 2021-10-19 | ||
| 2078 | Replications of DNA | 2021-10-19 | ||
| 2079 | When does the â??Central Dogma' come into play? | 2021-10-19 | ||
| 2080 | When does the â??Central Dogma' come into play? | 2021-10-19 | ||
| 2081 | Importanceâ??s of Antibiotics on Human Health | 2021-10-19 | ||
| 2082 | Importanceâ??s of Antibiotics on Human Health | 2021-10-19 | ||
| 2083 | Importanceâ??s of Antibiotics on Human Health | 2021-10-19 | ||
| 2084 | High-performance liquid chromatography | 2021-10-19 | ||
| 2085 | Ultracentrifugation | 2021-10-19 | ||
| 2086 | Differential solubilisation and precipitation | 2021-10-19 | ||
| 2087 | Functions of Medication Errors | 2021-10-19 | ||
| 2088 | Antagonistic drug event | 2021-10-19 | ||
| 2089 | Medication Error | 2021-10-19 | ||
| 2090 | Materials required | 2021-10-19 | ||
| 2091 | How to use Phenol/Chloroform for DNA purification | 2021-10-19 | ||
| 2092 | Lab and Molecular Diagnosis | 2021-10-19 | ||
| 2093 | Clinical Manifestations | 2021-10-19 | ||
| 2094 | Liability Factors | 2021-10-19 | ||
| 2095 | Mucormycosis | 2021-10-19 | ||
| 2096 | Atherogenic Dyslipidemia in Diabetes (ADD) | 2021-10-19 | ||
| 2097 | Data Avaiability | 2021-10-19 | ||
| 2098 | Pediatrics | 2021-10-19 | ||
| 2099 | Pregnancy | 2021-10-19 | ||
| 2100 | Special Populations | 2021-10-19 | ||
| 2101 | Approach to treatment | 2021-10-19 | ||
| 2102 | General measures | 2021-10-19 | ||
| 2103 | Treatment of Supraventricular Tachycardia (SVT) | 2021-10-19 | ||
| 2104 | Temperature and time | 2021-10-19 | ||
| 2105 | Survey of clinical practice | 2021-10-19 | ||
| 2106 | Clinical uses of the PT/INR | 2021-10-19 | ||
| 2107 | Clinical uses of the Activated Partial Thromboplastin Time (APTT) | 2021-10-19 | ||
| 2108 | Laser photocoagulation | 2021-10-19 | ||
| 2109 | Symptoms and clinical signs | 2021-10-19 | ||
| 2110 | Hematological disorders | 2021-10-19 | ||
| 2111 | Degenerative changes of vessel wall | 2021-10-19 | ||
| 2112 | Systemic risk factors | 2021-10-19 | ||
| 2113 | Authors Contributions Statement | 2021-10-18 | ||
| 2114 | Retinal Vein Occlusion | 2021-10-18 | ||
| 2115 | Editorial Note on Photosynthetic Organisms in the Ocean | 2021-10-18 | ||
| 2116 | LHRH Agonist and Antagonist | 2021-10-18 | ||
| 2117 | Preparation | 2021-10-18 | ||
| 2118 | Harmone Medical Care may be Used | 2021-10-18 | ||
| 2119 | Why It's Done? | 2021-10-18 | ||
| 2120 | Narcolepsy and Cataplexy | 2021-10-18 | ||
| 2121 | Muscle disorders | 2021-10-18 | ||
| 2122 | Statistical Analyses | 2021-10-18 | ||
| 2123 | Information Collected on Physician Respondents | 2021-10-18 | ||
| 2124 | Phenotypic expression and 22q11.2DS | 2021-10-18 | ||
| 2125 | Survey Design and Measures | 2021-10-18 | ||
| 2126 | Genes on 22q11.2 that causes congenital disorders | 2021-10-18 | ||
| 2127 | Mechanism | 2021-10-18 | ||
| 2128 | Surgical treatment | 2021-10-18 | ||
| 2129 | Research Needs and Perspectives | 2021-10-18 | ||
| 2130 | Result and Interpretations | 2021-10-18 | ||
| 2131 | Management and Treatment | 2021-10-18 | ||
| 2132 | Strength and Limitations | 2021-10-18 | ||
| 2133 | Plan for Data Analysis | 2021-10-18 | ||
| 2134 | Covid-19 Epigenetics Market | 2021-10-18 | ||
| 2135 | Advantages of Participating at Webinar | 2021-10-18 | ||
| 2136 | Why to attend? | 2021-10-18 | ||
| 2137 | Glance at Global Genomics Market | 2021-10-18 | ||
| 2138 | Conference Highlights: | 2021-10-18 | ||
| 2139 | Market Analysis | 2021-10-18 | ||
| 2140 | Guest Editor Benefits | 2021-10-18 | ||
| 2141 | Roles and Responsibility | 2021-10-18 | ||
| 2142 | Announcement to Authors and Editors | 2021-10-18 | ||
| 2143 | Responsible Factors For Sperm DNA Fragmentation | 2021-10-16 | ||
| 2144 | Quantitative Statistical Methods to Understand AIDS Epidemic | 2021-10-16 | ||
| 2145 | Cardiac Risk Assessment among Patients with HIV Disease | 2021-10-16 | ||
| 2146 | Congenital Human Immunodeficiency Virus Risk during Pregnancy | 2021-10-16 | ||
| 2147 | HIV-Associated Dementia: A Neurocognitive Disorder | 2021-10-16 | ||
| 2148 | Molecular Diagnosis of HIV Wasting Syndrome | 2021-10-16 | ||
| 2149 | Study Limitation | 2021-10-14 | ||
| 2150 | Rare/Severe Side-Effects | 2021-10-14 | ||
| 2151 | COVID-19 Vaccine and Immunogenicity | 2021-10-14 | ||
| 2152 | Potential Link Between Symptoms of Covid-19 and Harmful Effects of Formaldehyde and Aniline | 2021-10-14 | ||
| 2153 | Fluorocarbons | 2021-10-14 | ||
| 2154 | Harmful Effects and Symptoms of Aniline | 2021-10-14 | ||
| 2155 | Aniline | 2021-10-14 | ||
| 2156 | Harmful Effects and Symptoms of Formaldehyde | 2021-10-14 | ||
| 2157 | Formaldehyde | 2021-10-14 | ||
| 2158 | Funding None | 2021-10-14 | ||
| 2159 | Contributon of Author | 2021-10-14 | ||
| 2160 | DNA Methylation and Mutation | 2021-10-14 | ||
| 2161 | Methylation and Carginogenesis | 2021-10-14 | ||
| 2162 | Unifying Themes in Carcinogenesis | 2021-10-14 | ||
| 2163 | Environmental Causes | 2021-10-14 | ||
| 2164 | Ethical review | 2021-10-14 | ||
| 2165 | DESIGN AND ANALYSIS | 2021-10-14 | ||
| 2166 | Leprosy Treatment | 2021-10-13 | ||
| 2167 | Key Facts | 2021-10-13 | ||
| 2168 | Applications of Alkanes | 2021-10-13 | ||
| 2169 | Structure and Bonding | 2021-10-13 | ||
| 2170 | Perspectives Towards Prevention and Control of Sth Infection In Bali | 2021-10-13 | ||
| 2171 | Hygiene and Sanitation and other Factors Associated with Sth Infection | 2021-10-13 | ||
| 2172 | Reinfection of Sth Infection Among Elementary School children | 2021-10-13 | ||
| 2173 | Anthelmintic Treatment Trial | 2021-10-13 | ||
| 2174 | Intensity of Infection | 2021-10-13 | ||
| 2175 | Single Species Infection vs Multiple Species Infection | 2021-10-13 | ||
| 2176 | Prevalence of Sth Infection among Elementary School children | 2021-10-13 | ||
| 2177 | Prevalence of Sth Infection in Different Groups of Population in Bali | 2021-10-13 | ||
| 2178 | Acknowledgements and Discloure of Funding | 2021-10-13 | ||
| 2179 | Drugs used for Treatment of Ischemic Heart Disease | 2021-10-13 | ||
| 2180 | Percutaneous Trans Luminal Coronary Angioplasty | 2021-10-13 | ||
| 2181 | Brief Note | 2021-10-13 | ||
| 2182 | Limitations and Challenges of Stem Cell Researc | 2021-10-13 | ||
| 2183 | Limitations and Challenges of Stem Cell Research | 2021-10-13 | ||
| 2184 | Application and Uses of Stem Cell Research | 2021-10-13 | ||
| 2185 | Properties of Stem Cells | 2021-10-13 | ||
| 2186 | Pulse Variability, Health and Well-Being | 2021-10-13 | ||
| 2187 | Hatchery Technology | 2021-10-13 | ||
| 2188 | Echinoculture | 2021-10-13 | ||
| 2189 | Nursing Care in Cancer Therapy | 2021-10-13 | ||
| 2190 | Editorial on Patient Safety | 2021-10-13 | ||
| 2191 | Long Term Care | 2021-10-13 | ||
| 2192 | Dissemination of Mangroves in Goa | 2021-10-13 | ||
| 2193 | The Board of Mangroves in India | 2021-10-13 | ||
| 2194 | Miscellaneous Uses | 2021-10-13 | ||
| 2195 | Significant Uses of Mangroves | 2021-10-13 | ||
| 2196 | Significance of Mangroves | 2021-10-13 | ||
| 2197 | Drug Resistances | 2021-10-13 | ||
| 2198 | Headache disorders | 2021-10-13 | ||
| 2199 | Dementia | 2021-10-13 | ||
| 2200 | Epilepsy | 2021-10-13 | ||
| 2201 | Editorial Note on Sources and Side Effects of Dioxins | 2021-10-13 | ||
| 2202 | Results the Future of Car T-Cell Therapy | 2021-10-13 | ||
| 2203 | BRIEF NOTE | 2021-10-13 | ||
| 2204 | Health Economics | 2021-10-12 | ||
| 2205 | Population Health | 2021-10-12 | ||
| 2206 | Diagnostic Evaluation | 2021-10-12 | ||
| 2207 | Types of Lung Cancer | 2021-10-12 | ||
| 2208 | Observation in Practice | 2021-10-12 | ||
| 2209 | Narcolepsy and Cataplexy | 2021-10-11 | ||
| 2210 | A Report on Ultra-Efficient 3D Printed Catalysts | 2021-10-11 | ||
| 2211 | Editorial Note on Introduction and Types of Proteomics | 2021-10-11 | ||
| 2212 | Introduction and Sources of Epigallocatechin-3-Gallate (EGCG) | 2021-10-11 | ||
| 2213 | Creation of Hydrogen Gas | 2021-10-11 | ||
| 2214 | Characteristics of Breast Cancer | 2021-10-11 | ||
| 2215 | Significance of COVID Vaccine | 2021-10-11 | ||
| 2216 | Risk Factors and Management Strategies | 2021-10-11 | ||
| 2217 | Presence of association | 2021-10-11 | ||
| 2218 | Letter from Editor | 2021-10-09 | ||
| 2219 | Basic Reproduction Number | 2021-10-08 | ||
| 2220 | Sidarthe Model Formulation | 2021-10-08 | ||
| 2221 | Pneumatic Systems for Aircraft | 2021-10-08 | ||
| 2222 | Computational Analysis and Study of Atmospheric Ice Accretion on Different NACA Profile Series | 2021-10-08 | ||
| 2223 | Review and Update | 2021-10-08 | ||
| 2224 | Pathophysiology of Hypertension in pregnancy | 2021-10-07 | ||
| 2225 | Complications of hypertensive Disorders of pregnancy | 2021-10-07 | ||
| 2226 | Risk Factors For Hypertension In Pregnancy | 2021-10-07 | ||
| 2227 | Diagnosis and Classification of Blood Pressure | 2021-10-07 | ||
| 2228 | Preventing Dengue Fever | 2021-10-07 | ||
| 2229 | Treatment for Dengue Fever | 2021-10-07 | ||
| 2230 | Diagnosing Dengue Fever | 2021-10-07 | ||
| 2231 | Warning Signs of Severe Dengue Fever | 2021-10-07 | ||
| 2232 | Warning Sings of Severe Dengue Fever | 2021-10-07 | ||
| 2233 | Symptoms of Dengue Fever | 2021-10-07 | ||
| 2234 | Types of Hypertension | 2021-10-07 | ||
| 2235 | Types of Congestive Heart Failure (CHF) | 2021-10-07 | ||
| 2236 | An Overview on Myocarditis | 2021-10-07 | ||
| 2237 | Models and Variables | 2021-10-07 | ||
| 2238 | Analytical Framework | 2021-10-07 | ||
| 2239 | Morphology | 2021-10-06 | ||
| 2240 | Causes and Prevention | 2021-10-06 | ||
| 2241 | Methods of Research | 2021-10-06 | ||
| 2242 | Supplementary Files | 2021-10-05 | ||
| 2243 | Availability of Data and Materials | 2021-10-05 | ||
| 2244 | Editorial-Announcement: | 2021-10-05 | ||
| 2245 | Plant growth promoting ability of halophilic Bacillus marisflavi K7SpZMAO002 isolated from coastal sand dune of Goa-India | 2021-10-05 | ||
| 2246 | Phenotypic and Genotypic Antibiotic Resistance Features of S. aureus isolated from Milk and Cheese | 2021-10-05 | ||
| 2247 | Potential application of selected phosphate solubilizing bacteria isolated from Chenopodium quinoa Willd rhizosphere in early plant growth promotion | 2021-10-05 | ||
| 2248 | Evaluation Of Antimicrobial Activity Of N-Hexane Extract Of Different Parts Of Pumpkin (Seed, Leaves And Pulp) | 2021-10-05 | ||
| 2249 | Pesticide residue Analysis in pea samples available in Hilly areas of Himachal Pradesh (Solan, India) (Conventionally and organically raised) by coupling QuEChERS technique with GC | 2021-10-05 | ||
| 2250 | Blood Test | 2021-10-05 | ||
| 2251 | Factors that Contribute to Colorectal Cancer | 2021-10-05 | ||
| 2252 | Risk of Colorectal Cancer | 2021-10-05 | ||
| 2253 | Darwin Process | 2021-10-05 | ||
| 2254 | Importance of Ethics | 2021-10-05 | ||
| 2255 | Ginseng | 2021-10-05 | ||
| 2256 | Ginkgo Biloba | 2021-10-05 | ||
| 2257 | Bacopa Monniera | 2021-10-05 | ||
| 2258 | Guarana | 2021-10-05 | ||
| 2259 | Yohimbine | 2021-10-05 | ||
| 2260 | Betel Nut | 2021-10-05 | ||
| 2261 | Herbal Cognitive Enhancers | 2021-10-05 | ||
| 2262 | CDP-Choline | 2021-10-05 | ||
| 2263 | Piracetam and Phenylpiracetam | 2021-10-05 | ||
| 2264 | Synthetic Cannabinoids | 2021-10-05 | ||
| 2265 | Flakka | 2021-10-05 | ||
| 2266 | Synthetic Cathinones | 2021-10-05 | ||
| 2267 | Designer Drugs | 2021-10-05 | ||
| 2268 | Marjuiana, Cannabis | 2021-10-05 | ||
| 2269 | Khat, Cathinone | 2021-10-05 | ||
| 2270 | Amphetamine | 2021-10-05 | ||
| 2271 | Nicotine | 2021-10-05 | ||
| 2272 | Caffeine | 2021-10-05 | ||
| 2273 | Further Use of Soda Ash and Lime Solutions from Caustic Plant | 2021-10-04 | ||
| 2274 | Bio-Fuels Production Versus Valorization of Biomass for Value added Product Manufacture | 2021-10-04 | ||
| 2275 | Possibility Envelope Mapping of Post Kraft Process Applications Progressive Sampling of Alternatives and Value-Added Derivatives | 2021-10-04 | ||
| 2276 | Life Cycle Stages of Microstructural Products and Processes | 2021-10-04 | ||
| 2277 | Utilization of Clozapine | 2021-10-04 | ||
| 2278 | High Energy Demand and Emissions and Waste Profile of Wood and Pulp Industries | 2021-10-04 | ||
| 2279 | Lists of Abbreviations | 2021-10-04 | ||
| 2280 | Open-Source Development & Distribution | 2021-10-04 | ||
| 2281 | Enzyme-Linked Immunosorbent Assay (ELISA) | 2021-10-01 | ||
| 2282 | Polymerase Chain Reaction (PCR) | 2021-10-01 | ||
| 2283 | Neural Engineering | 2021-10-01 | ||
| 2284 | Neuroscience | 2021-10-01 | ||
| 2285 | Dental Pulp Regeneration | 2021-10-01 | ||
| 2286 | Periodontal Regeneration | 2021-10-01 | ||
| 2287 | Clinical Trials Protocol Registration | 2021-10-01 | ||
| 2288 | Other Registrations | 2021-10-01 | ||
| 2289 | Key Activities | 2021-10-01 | ||
| 2290 | Conclusions and Perspectives | 2021-09-30 | ||
| 2291 | Results of Statistical Analysis | 2021-09-30 | ||
| 2292 | Microorganisms and Antimicrobial Textiles | 2021-09-30 | ||
| 2293 | Various Factors Affecting UV Protection on Textile Materials | 2021-09-30 | ||
| 2294 | UV Protective Textiles | 2021-09-30 | ||
| 2295 | Causes and Transmission Cycles | 2021-09-30 | ||
| 2296 | MALDI-TOF-MS | 2021-09-30 | ||
| 2297 | Forces of Nature | 2021-09-30 | ||
| 2298 | Types of Optical Fiber | 2021-09-30 | ||
| 2299 | Standard of Optical Fiber | 2021-09-30 | ||
| 2300 | Correspondence | 2021-09-30 | ||
| 2301 | Modern Nanotechnology | 2021-09-30 | ||
| 2302 | Refraction | 2021-09-30 | ||
| 2303 | ORCID ID | 2021-09-30 | ||
| 2304 | Consent for Publications | 2021-09-29 | ||
| 2305 | Hypoxia | 2021-09-29 | ||
| 2306 | Mortality and Its Risk Factors | 2021-09-29 | ||
| 2307 | Pathology | 2021-09-29 | ||
| 2308 | Pathogenesis and Clinical Features | 2021-09-29 | ||
| 2309 | Message for the General Community And Especially for People Who Have Comorbidity of Covid-19 | 2021-09-29 | ||
| 2310 | Consequences on Pregnant Mothers Who Have Comorbidity of Covid-19 | 2021-09-29 | ||
| 2311 | Comorbidity of Covid-19 on Pregnant Mothers | 2021-09-29 | ||
| 2312 | Latest Developments of Covid-19 Outbreak | 2021-09-29 | ||
| 2313 | Literature of Review | 2021-09-29 | ||
| 2314 | Overview of Endovascular Techniques for Foreign Body Removal | 2021-09-29 | ||
| 2315 | Venous Foreign Bodies | 2021-09-29 | ||
| 2316 | Plants as a Source of Antioxidants | 2021-09-29 | ||
| 2317 | Purification of the Bioactive Molecule | 2021-09-29 | ||
| 2318 | Ultrasonic-Assisted Extraction (UAE) | 2021-09-29 | ||
| 2319 | Microwave-Assisted Extraction (MAE) | 2021-09-29 | ||
| 2320 | Methods to Extract Bioactive Compounds from Plants | 2021-09-29 | ||
| 2321 | Disclosure Statements | 2021-09-29 | ||
| 2322 | Points to Remember | 2021-09-29 | ||
| 2323 | Patients, Materials and Methods | 2021-09-29 | ||
| 2324 | Conflicting Interests | 2021-09-29 | ||
| 2325 | Limitations Future Research | 2021-09-29 | ||
| 2326 | Cerebral Vessels in Aging Humans | 2021-09-29 | ||
| 2327 | Impact of Tattoos on the Disease Activity | 2021-09-28 | ||
| 2328 | Complications Related to Tattoos in SLE | 2021-09-28 | ||
| 2329 | Prevalance and Charateristics of Tattoos in SLE Patients | 2021-09-28 | ||
| 2330 | Motivations | 2021-09-28 | ||
| 2331 | Author's Information | 2021-09-28 | ||
| 2332 | Availability of Data and Material (Data Transparency) | 2021-09-28 | ||
| 2333 | Creatinine kinase-cardiac Muscle biomarker (CK-MB) | 2021-09-28 | ||
| 2334 | Contribution Details | 2021-09-27 | ||
| 2335 | Personal Data | 2021-09-27 | ||
| 2336 | Cancer | 2021-09-27 | ||
| 2337 | Industrial Multi Objective Optimization | 2021-09-27 | ||
| 2338 | Technical Report | 2021-09-25 | ||
| 2339 | Airships in the Arctic | 2021-09-25 | ||
| 2340 | Airships and Ecotourism | 2021-09-25 | ||
| 2341 | Challenges to Ecotourism in Canada | 2021-09-25 | ||
| 2342 | Vegan Consumption | 2021-09-25 | ||
| 2343 | Veganism | 2021-09-25 | ||
| 2344 | Discussion and Prospects | 2021-09-25 | ||
| 2345 | Analytical Discussion | 2021-09-25 | ||
| 2346 | Route of Transmission | 2021-09-25 | ||
| 2347 | Validation | 2021-09-24 | ||
| 2348 | Introduction to Chromatography | 2021-09-24 | ||
| 2349 | Introduction to Spectroscopy | 2021-09-24 | ||
| 2350 | Analytical Method | 2021-09-24 | ||
| 2351 | Transdermal Permeation: Factors Affecting It the Infiltrate Molecules' Physicochemical Properties | 2021-09-24 | ||
| 2352 | Essential Oils as Penetration Enhancers | 2021-09-24 | ||
| 2353 | Penetration-Enhancing Mechanism | 2021-09-24 | ||
| 2354 | Essential Oils and Their Compounds Can Penetrate the Skin | 2021-09-24 | ||
| 2355 | The Protein Transformation | 2021-09-24 | ||
| 2356 | Bacterial Culture | 2021-09-24 | ||
| 2357 | Analysis of the Study | 2021-09-23 | ||
| 2358 | Declaration of Competing Interest | 2021-09-23 | ||
| 2359 | Ethics Approval/Consent to Participate/Consent for Publication | 2021-09-23 | ||
| 2360 | Natural Rights | 2021-09-23 | ||
| 2361 | Factors of Consideration | 2021-09-23 | ||
| 2362 | Declaration For Conflict Of Interests | 2021-09-23 | ||
| 2363 | Brief Conceptualization of Cognitive Behavioral Therapy about Two Models | 2021-09-22 | ||
| 2364 | Rehm's Self-Control Theory | 2021-09-22 | ||
| 2365 | Lewinsohn's Behavioral Theory of Depression | 2021-09-22 | ||
| 2366 | Theory of Helplessness Learned from Seligman | 2021-09-22 | ||
| 2367 | Beck's Cognitive Model | 2021-09-22 | ||
| 2368 | Depression in DSM-IV; DSM-5 and ICD-10 | 2021-09-22 | ||
| 2369 | Depression in Statistics | 2021-09-22 | ||
| 2370 | Recommendations for Further Research | 2021-09-22 | ||
| 2371 | Stages in Diabetic Nephropathy | 2021-09-22 | ||
| 2372 | Suggestions and Restrictions | 2021-09-22 | ||
| 2373 | Antioxidant Study | 2021-09-22 | ||
| 2374 | Compound 2',4'-Dihydroxy-3',5'-Dimethyl-6'-Methoxychalcone | 2021-09-22 | ||
| 2375 | Bioassay Guided Fractionation & Isolation of the Constituent from Ethyl Acetate Extracts of the Leaves of Syzygium Balsame | 2021-09-22 | ||
| 2376 | Extraction of the Plant Material | 2021-09-22 | ||
| 2377 | How can we Maintain Environmental Sustainability? | 2021-09-21 | ||
| 2378 | Negative Natural Impacts of COVID-19 | 2021-09-21 | ||
| 2379 | Positive Natural Impacts of COVID-19 | 2021-09-21 | ||
| 2380 | Legacy of the Paralympic Games | 2021-09-21 | ||
| 2381 | Successful Treatment of Chronic Pain and Depression Likely Includes a Combination of Pharmacotherapy and Psychotherapy | 2021-09-21 | ||
| 2382 | Pain Patients Should be Assessed for Depression, and Depressed Patients Should be Assessed for Pain | 2021-09-21 | ||
| 2383 | There is a Vicious Cycle where Pain Begets Depression and Vice Versa | 2021-09-21 | ||
| 2384 | Molecular Patterns of Recognition | 2021-09-21 | ||
| 2385 | Immaturity of Dendritic Cells | 2021-09-21 | ||
| 2386 | Dimensionality | 2021-09-21 | ||
| 2387 | Confined Attribute Dysfunction | 2021-09-21 | ||
| 2388 | Distributional Biology | 2021-09-21 | ||
| 2389 | Funding Acknowledgements | 2021-09-20 | ||
| 2390 | Funding for the Study | 2021-09-18 | ||
| 2391 | Preoperative Assessment | 2021-09-18 | ||
| 2392 | Limitations of CBCT | 2021-09-17 | ||
| 2393 | Postoperative Assessment | 2021-09-17 | ||
| 2394 | Further recommendation | 2021-09-17 | ||
| 2395 | Funding Acknowledgement | 2021-09-16 | ||
| 2396 | Reproduction | 2021-09-15 | ||
| 2397 | Plant Production Platforms | 2021-09-14 | ||
| 2398 | Techniques Used for Measurements | 2021-09-14 | ||
| 2399 | Radon and Lung Cancer | 2021-09-14 | ||
| 2400 | Different Sources of Radon | 2021-09-14 | ||
| 2401 | Physical and Chemical Properties of Radon | 2021-09-14 | ||
| 2402 | Radon Decay | 2021-09-14 | ||
| 2403 | Bioethics Concerns | 2021-09-14 | ||
| 2404 | Review of Relevant Literature | 2021-09-14 | ||
| 2405 | TTP In Skin Diseases | 2021-09-14 | ||
| 2406 | Random Forest (RF) | 2021-09-14 | ||
| 2407 | Bootstrap Method | 2021-09-14 | ||
| 2408 | Stationary Wavelet Transforms | 2021-09-14 | ||
| 2409 | Adaptive Local Power-Law Transform (ALPLT) | 2021-09-14 | ||
| 2410 | Intelligent Feature Plaque Detection Model | 2021-09-14 | ||
| 2411 | Results of the Delphi Study | 2021-09-14 | ||
| 2412 | History of Centralized Sewage Treatment System | 2021-09-13 | ||
| 2413 | Design of Centralized Sewage Treatment System | 2021-09-13 | ||
| 2414 | Sewage Treatment Scenario in India | 2021-09-13 | ||
| 2415 | End-Matter | 2021-09-13 | ||
| 2416 | Aspects of Safety | 2021-09-13 | ||
| 2417 | Probiotics Commercially Available for Urogenital Tract | 2021-09-13 | ||
| 2418 | Relation between Probiotics and Fertility | 2021-09-13 | ||
| 2419 | Administration Vehicles | 2021-09-13 | ||
| 2420 | Drug Interactions | 2021-09-13 | ||
| 2421 | Exhaustively, the method of this strategy is partitioned into three stages: | 2021-09-13 | ||
| 2422 | Atom chromatography | 2021-09-13 | ||
| 2423 | Particle chromatograph | 2021-09-13 | ||
| 2424 | Paper chromatography | 2021-09-13 | ||
| 2425 | Elite fluid chromatography (HPLC) | 2021-09-13 | ||
| 2426 | Flimsy layer chromatography (TLC) | 2021-09-13 | ||
| 2427 | ELISA displays the accompanying benefits: | 2021-09-13 | ||
| 2428 | Naturally Fortified Fruits Salad | 2021-09-13 | ||
| 2429 | Remedial Egg Mix-Tip to Manage the Problem of Insomia | 2021-09-13 | ||
| 2430 | Standard | 2021-09-13 | ||
| 2431 | Tip to Enhance the Mouth Feel and to Beat the Hunger | 2021-09-13 | ||
| 2432 | Natural Cantaloupe, Honey Dew Melon, Musk Melon/Melon Juice | 2021-09-13 | ||
| 2433 | Natural Water Melon Fruity Juice | 2021-09-13 | ||
| 2434 | Naturally Fortified Grewia Fruity Juice | 2021-09-13 | ||
| 2435 | Naturally Fortified Mango Fruity Juice | 2021-09-13 | ||
| 2436 | Presentation | 2021-09-13 | ||
| 2437 | Opinion on Radioimmunoassay and its Important | 2021-09-13 | ||
| 2438 | Urbanism | 2021-09-09 | ||
| 2439 | Health | 2021-09-09 | ||
| 2440 | Economies | 2021-09-09 | ||
| 2441 | Cultural | 2021-09-09 | ||
| 2442 | FIELDS | 2021-09-09 | ||
| 2443 | INTERNATIONAL PERSPECTIVES | 2021-09-09 | ||
| 2444 | GENETIC REVOLUTION | 2021-09-09 | ||
| 2445 | HISTORICAL BACKGROUND | 2021-09-09 | ||
| 2446 | Neuroethnography | 2021-09-09 | ||
| 2447 | Neuroanthropology: A Humanistic Science | 2021-09-09 | ||
| 2448 | An Anthropological Definition of Culture | 2021-09-09 | ||
| 2449 | Result and Observation | 2021-09-08 | ||
| 2450 | Working Mechanism | 2021-09-08 | ||
| 2451 | Microfluid Crispr Chip Parts | 2021-09-08 | ||
| 2452 | Types of Wireless Sensor Networks | 2021-09-08 | ||
| 2453 | The Case | 2021-09-07 | ||
| 2454 | Diagnosis of Pre-Maglignant Lesions and Penile Cancer | 2021-09-07 | ||
| 2455 | Author's Contribution Statement | 2021-09-07 | ||
| 2456 | Mechanism of action of Cellulase | 2021-09-07 | ||
| 2457 | Improving Care | 2021-09-06 | ||
| 2458 | Cultural Responsivity | 2021-09-06 | ||
| 2459 | Key Highlights | 2021-09-06 | ||
| 2460 | Diet | 2021-09-04 | ||
| 2461 | A Typical Femur Fractures (AFF) | 2021-09-04 | ||
| 2462 | Strains | 2021-09-04 | ||
| 2463 | Neurologic Injury | 2021-09-04 | ||
| 2464 | Limit of Detection | 2021-09-04 | ||
| 2465 | Authors’ Contributions | 2021-09-04 | ||
| 2466 | Breif Report | 2021-09-04 | ||
| 2467 | Diet for a Healthy Heart | 2021-09-03 | ||
| 2468 | Abnormal Heart Rhythm Diseaseâ??Arrhythmia | 2021-09-03 | ||
| 2469 | Computer Tomography (CT) Coronary Angiogram | 2021-09-03 | ||
| 2470 | Heart Murmurs and its Causes | 2021-09-03 | ||
| 2471 | Mitral Valve Stenosis | 2021-09-03 | ||
| 2472 | Ceramic and Polymer Nanocomposites for Aerospace | 2021-09-02 | ||
| 2473 | Report of The Case | 2021-09-02 | ||
| 2474 | Paternal Testing | 2021-09-01 | ||
| 2475 | Monitoring Clinically Significant Antibodies | 2021-09-01 | ||
| 2476 | Science is Focused on Liver-Coordinated Quality Treatment for Cell Work | 2021-09-01 | ||
| 2477 | Genetic and Molecular Biological Approaches for Molecular Science | 2021-09-01 | ||
| 2478 | Ponderal Index of Real Body Mass Index and Basal Metabolic Rate | 2021-09-01 | ||
| 2479 | Tracing Physical Behavior in Virtual Reality in Social Psychology | 2021-09-01 | ||
| 2480 | Exploring the Brain and the Mind at the Edinburgh Functional Magnetic Resonance Imaging | 2021-09-01 | ||
| 2481 | Funding Acknowledgments | 2021-09-01 | ||
| 2482 | Tissue-Specific Transcriptome Sequencing Analysis Expands the Non-Human Primate Reference | 2021-09-01 | ||
| 2483 | Shotgun Sequencing in Human Genetics | 2021-09-01 | ||
| 2484 | Metagenomics can provide valuable insights into the functional | 2021-09-01 | ||
| 2485 | DNA Groupings of Numerous Creatures of Bacteriophage | 2021-09-01 | ||
| 2486 | DNA Sequencing Which is based on Nucleobase-Specific Partial Chemical Modification | 2021-09-01 | ||
| 2487 | Artificial Gene Synthesis Recombination Innovation in Engineered | 2021-09-01 | ||
| 2488 | Immune Properties of Stem Cells and Interactions with the Immune System | 2021-09-01 | ||
| 2489 | Resembling Embryonic Stem Cells are Immature Microorganisms | 2021-09-01 | ||
| 2490 | Monitoring of Diseases in Bio-Therapeutics | 2021-09-01 | ||
| 2491 | DNA is Isolated and Partially Digested with Restriction Enzymes | 2021-09-01 | ||
| 2492 | Hair Regeneration-Mesenchymal Stem Cell | 2021-09-01 | ||
| 2493 | Genome wide Association Study Medication and P4 Medication | 2021-09-01 | ||
| 2494 | Functional on Genomics, Proteomics, Metabolomics - Stem Cell | 2021-09-01 | ||
| 2495 | Chemical Synthesis of Proteins is a Valuable Tool in Chemical Biology | 2021-09-01 | ||
| 2496 | Can Stem Cells Beat COVID-19? | 2021-09-01 | ||
| 2497 | Diagnosis of Cracked Tooth Syndrome | 2021-09-01 | ||
| 2498 | How 5g Networks and Artificial Intelligence Can Help? | 2021-08-31 | ||
| 2499 | Combining 5g and Ai | 2021-08-31 | ||
| 2500 | Material and Research Methods | 2021-08-31 | ||
| 2501 | Healthcare | 2021-08-31 | ||
| 2502 | Key Parts of a Blockchain | 2021-08-31 | ||
| 2503 | Analyzing the Evolution of Aerospace Ecosystem Development | 2021-08-31 | ||
| 2504 | Designing a Low-Cost Space Simulator | 2021-08-31 | ||
| 2505 | Severity of allergic contact Dermatitis | 2021-08-31 | ||
| 2506 | Significance of allergic Contact dermatitis | 2021-08-31 | ||
| 2507 | ORCID | 2021-08-31 | ||
| 2508 | Skin Layers and NO Effects | 2021-08-31 | ||
| 2509 | Source of NO in the Skin | 2021-08-31 | ||
| 2510 | Soucre of NO in the Skin | 2021-08-31 | ||
| 2511 | Diabetes Insipidus | 2021-08-31 | ||
| 2512 | Hypophysitis | 2021-08-31 | ||
| 2513 | Thyroid Dysfunction | 2021-08-31 | ||
| 2514 | Extraction Procedures of Asiaticoside from Centella Asiatica | 2021-08-31 | ||
| 2515 | Neuroinfection & neuroimmunology | 2021-08-31 | ||
| 2516 | Executive function deficits in neurodevelopmental disorders | 2021-08-31 | ||
| 2517 | Enhancing The Process of Bone Augmentations in Craniofacial Region | 2021-08-31 | ||
| 2518 | Is peritoneal lavage with water the optimal washout as a preventative method for peritoneal disease following colorectal cancer resection? A systematic review | 2021-08-31 | ||
| 2519 | Retrosepective Study of Sagittal Split Ramus Osteotomy with Intraoral Vertical Ramus Osteotomy on Mandibular Prognathism Accompanied with Facial Asymmetry Patients | 2021-08-31 | ||
| 2520 | Socio-demographic characteristics, clinical profile and prevalence of existing mental illness among suicide attempters attending emergency services at two hospitals in Hawassa city | 2021-08-31 | ||
| 2521 | Body dysmorphic disorders enhanced by social media. What is our role as surgeons? | 2021-08-31 | ||
| 2522 | Socio-demographic characteristics, clinical profile and prevalence of existing mental illness among suicide attempters attending emergency services at two hospitals in Hawassa city | 2021-08-31 | ||
| 2523 | Socio-demographic characteristics, clinical profile and prevalence of existing mental illness among suicide attempters attending emergency services at two hospitals in Hawassa city | 2021-08-31 | ||
| 2524 | Socio-demographic characteristics, clinical profile and prevalence of existing mental illness among suicide attempters attending emergency services at two hospitals in Hawassa city | 2021-08-31 | ||
| 2525 | Socio-demographic characteristics, clinical profile and prevalence of existing mental illness among suicide attempters attending emergency services at two hospitals in Hawassa city | 2021-08-31 | ||
| 2526 | Socio-demographic characteristics, clinical profile and prevalence of existing mental illness among suicide attempters attending emergency services at two hospitals in Hawassa city | 2021-08-31 | ||
| 2527 | Designing a coordinate skin mapping system for skin cancer surgeries on the head for preventing wrong-site surgeries | 2021-08-31 | ||
| 2528 | Physical illness complicating the presentation of bipolar disorder in an elderly patient | 2021-08-31 | ||
| 2529 | Stem Cells (SC) therapy as an emerging therapy in neurology | 2021-08-31 | ||
| 2530 | What are the Early Indications of Type 2 Diabetes? | 2021-08-30 | ||
| 2531 | What are the Ideal Glucose Levels? | 2021-08-30 | ||
| 2532 | What occurs after you quit smoking? | 2021-08-30 | ||
| 2533 | Dental Fluorosis and its Diagnosis in Humans | 2021-08-30 | ||
| 2534 | What is Dyspnea? | 2021-08-30 | ||
| 2535 | Tooth Brightening for Delicate Teeth | 2021-08-30 | ||
| 2536 | Tooth Disintegration by Taking Acidic Food Varieties | 2021-08-30 | ||
| 2537 | Human Necessities Shortages Dental Cleanliness | 2021-08-30 | ||
| 2538 | Scientific Hypertension and High Blood Pressure | 2021-08-30 | ||
| 2539 | Microbial Biogeochemistry and Extreme Environments | 2021-08-30 | ||
| 2540 | Forensic Medication Uncovered Techniques | 2021-08-30 | ||
| 2541 | Epidemiological Research of Epilepsy | 2021-08-30 | ||
| 2542 | Applications of Extremophiles in Astrobiology | 2021-08-30 | ||
| 2543 | The Colon and Rectum Make up the Internal Organ | 2021-08-30 | ||
| 2544 | Cardiac Electrophysiology and Heart Rhythm in Human Body | 2021-08-30 | ||
| 2545 | Role of Allergy and Clinical Immunology in Medical Sciences | 2021-08-30 | ||
| 2546 | Diabetic Ketoacidosis: Evaluation and Treatment | 2021-08-30 | ||
| 2547 | Acetone Breathing Measurement for Diagnosis of Diabetic Ketoacidosis | 2021-08-30 | ||
| 2548 | Dissection of Human Body for Suicide Reason Identification | 2021-08-30 | ||
| 2549 | A Brief on Disorders which Leads to Death | 2021-08-30 | ||
| 2550 | Funding Acknowledgment | 2021-08-30 | ||
| 2551 | Radioactive Elements May Be Crucial To The Habitability of Rocky Planets | 2021-08-30 | ||
| 2552 | Applied Chemistry on Forensic Pathology Science | 2021-08-30 | ||
| 2553 | Nutritional Bioenergetics in Fish Relationship between Abstinence Metabolism | 2021-08-30 | ||
| 2554 | Endoscopic Ultrasound Utilizes Sound Waves | 2021-08-30 | ||
| 2555 | Choice Examination Utilizes an Assortment Of Instruments | 2021-08-30 | ||
| 2556 | Research Article | 2021-08-30 | ||
| 2557 | Interdisciplinary Consortium for Astrobiology Research | 2021-08-30 | ||
| 2558 | Mitochondrial Pathology of Genetics Mitochondrial Disease | 2021-08-30 | ||
| 2559 | Banquet Operations | 2021-08-30 | ||
| 2560 | Statistical Surveying and Market Research | 2021-08-30 | ||
| 2561 | To Get Familiar with Malignancy and How it Starts and Spreads | 2021-08-30 | ||
| 2562 | Disruptive Innovation in Dentistry | 2021-08-30 | ||
| 2563 | Mitochondrial Difficult Deficiency of Nuclear DNA in Chromosomes | 2021-08-30 | ||
| 2564 | Radioactive Elements May Make Planets Suitable or Hostile to Life | 2021-08-30 | ||
| 2565 | A Brief on Innovation towards Forensic Science | 2021-08-30 | ||
| 2566 | Leadership Management and Its Fundamentals | 2021-08-30 | ||
| 2567 | The Prostate Organ Begin to Outgrow Control | 2021-08-30 | ||
| 2568 | Cancer Cells And Oncogenes Driven Organic Chemistry | 2021-08-30 | ||
| 2569 | Clients' Assessment and Sentiments | 2021-08-30 | ||
| 2570 | A Mental or Behavioural Post Traumatic Disorder | 2021-08-30 | ||
| 2571 | Editorial Announcement | 2021-08-30 | ||
| 2572 | Acknowlegement | 2021-08-30 | ||
| 2573 | Types of Cell | 2021-08-30 | ||
| 2574 | Resistance | 2021-08-30 | ||
| 2575 | Mode of Action of Remdesivir | 2021-08-30 | ||
| 2576 | Remdesivir’s availability in India | 2021-08-30 | ||
| 2577 | Remdesivir Clinical Trials | 2021-08-30 | ||
| 2578 | Editorial Note on Magneto-plasma Dynamic Thruster | 2021-08-30 | ||
| 2579 | Potential Flow through a Cascade of Aerofoils | 2021-08-30 | ||
| 2580 | The Innovation of Laser Polishing | 2021-08-28 | ||
| 2581 | Regulation of Genetic Engineering Concerns Approaches Taken By Governments Assess | 2021-08-28 | ||
| 2582 | Professional Aspects of Engineering | 2021-08-28 | ||
| 2583 | Polymeric Nanoparticles: Production, Characterization | 2021-08-28 | ||
| 2584 | Biological Process of TCA Cycle in Synthesis Of DNA | 2021-08-28 | ||
| 2585 | The Stroma Contains Nonmalignant | 2021-08-28 | ||
| 2586 | Super Superior Fluid Chromatography | 2021-08-28 | ||
| 2587 | Ms Ionization Sources | 2021-08-28 | ||
| 2588 | Potential for novel treatment Approaches | 2021-08-28 | ||
| 2589 | A Mouse Model To Study Chronic Wound Development And Progression | 2021-08-28 | ||
| 2590 | New Regulatory Challenges for AI in the Healthcare System | 2021-08-28 | ||
| 2591 | Altai Gaps and Strengths | 2021-08-28 | ||
| 2592 | Building Up a Trustworthy AI-Based Tool for P5 Medicine | 2021-08-28 | ||
| 2593 | Preliminary Activities to Perform a Responsible Altai | 2021-08-28 | ||
| 2594 | Hegelian Applications | 2021-08-28 | ||
| 2595 | Kantian Implication for Children with ADHD | 2021-08-28 | ||
| 2596 | Immanuel Kant and the Paradoxes of Respecting (Moral) Rules | 2021-08-28 | ||
| 2597 | Sigmund Freud and the Psychoanalytic Tradition | 2021-08-28 | ||
| 2598 | In Search of Constructive Ideas | 2021-08-28 | ||
| 2599 | Review of Works | 2021-08-27 | ||
| 2600 | Molecular Mechanism Involved In Rhabdomyolysis | 2021-08-27 | ||
| 2601 | Study Selection | 2021-08-27 | ||
| 2602 | Source | 2021-08-27 | ||
| 2603 | Outcome | 2021-08-27 | ||
| 2604 | Conservative and Endodontic Therapy | 2021-08-27 | ||
| 2605 | Comparison | 2021-08-27 | ||
| 2606 | Intervention/Exposure | 2021-08-27 | ||
| 2607 | Population | 2021-08-27 | ||
| 2608 | Focused Question | 2021-08-27 | ||
| 2609 | Systematic Search Strategy | 2021-08-27 | ||
| 2610 | About to Study | 2021-08-27 | ||
| 2611 | Histone Code | 2021-08-27 | ||
| 2612 | Prognostic Diagnostic | 2021-08-27 | ||
| 2613 | Epigenetic Diagnostic | 2021-08-27 | ||
| 2614 | DNA Hypomethylation | 2021-08-27 | ||
| 2615 | Genome | 2021-08-27 | ||
| 2616 | Interventions | 2021-08-27 | ||
| 2617 | Recommendations for Screening and Assessment | 2021-08-27 | ||
| 2618 | How to Recognise Depression in Pregnancy? | 2021-08-27 | ||
| 2619 | Depression During Pregnancy | 2021-08-27 | ||
| 2620 | Stress During Pregnancy | 2021-08-27 | ||
| 2621 | Mental Health During Pregnancy | 2021-08-27 | ||
| 2622 | Effect of Vaccination | 2021-08-27 | ||
| 2623 | Confict of Interest | 2021-08-27 | ||
| 2624 | Future Trends | 2021-08-26 | ||
| 2625 | Various Agents Used As Local Drug Delivery | 2021-08-26 | ||
| 2626 | Devices used as Local Drug Delivery | 2021-08-26 | ||
| 2627 | Principle | 2021-08-26 | ||
| 2628 | Factors for the Emergence of Infectious Diseases | 2021-08-26 | ||
| 2629 | Emerging Zoonoses Burden in Ethiopia | 2021-08-26 | ||
| 2630 | Emerging Zoonoses Burden Globally | 2021-08-26 | ||
| 2631 | Funding and Conflict of Interest | 2021-08-26 | ||
| 2632 | Data Sharing | 2021-08-26 | ||
| 2633 | Why in UK and Europe | 2021-08-25 | ||
| 2634 | Breast Cancer Biology in USA and Canada | 2021-08-25 | ||
| 2635 | Breast Cancer in Middle East | 2021-08-25 | ||
| 2636 | Perioperative Phases | 2021-08-25 | ||
| 2637 | Multimodal Approach to Pain Management | 2021-08-25 | ||
| 2638 | Assessment of Opioid Risk | 2021-08-25 | ||
| 2639 | Opioid Prescription | 2021-08-25 | ||
| 2640 | Arthritic Knee and Hip Pain | 2021-08-25 | ||
| 2641 | Total Joint Arthroplasty and the Perioperative Pain Response | 2021-08-25 | ||
| 2642 | Refutation | 2021-08-25 | ||
| 2643 | Counterargument | 2021-08-25 | ||
| 2644 | Evidence | 2021-08-25 | ||
| 2645 | Argument | 2021-08-25 | ||
| 2646 | An Aid To Thought, Not a Substitute For It? | 2021-08-24 | ||
| 2647 | Beyond the Basics? | 2021-08-24 | ||
| 2648 | Only Efficiency? | 2021-08-24 | ||
| 2649 | What Does ‘Working Better’ Mean? | 2021-08-24 | ||
| 2650 | What Is ‘It’? | 2021-08-24 | ||
| 2651 | Prevention and Treatment | 2021-08-24 | ||
| 2652 | Chemistry and Treatment | 2021-08-24 | ||
| 2653 | Biology and Distribution | 2021-08-23 | ||
| 2654 | Data Analysis and Discussion | 2021-08-23 | ||
| 2655 | Conclusion and Policy Recommendations | 2021-08-21 | ||
| 2656 | Presentation and Discussion of Empirical Results | 2021-08-21 | ||
| 2657 | Description of the Study | 2021-08-21 | ||
| 2658 | Extraction | 2021-08-21 | ||
| 2659 | Review of Previous Studies | 2021-08-21 | ||
| 2660 | Plant Bio-Reactors | 2021-08-21 | ||
| 2661 | Plastids | 2021-08-21 | ||
| 2662 | Production in Transgenic Green Tissues | 2021-08-21 | ||
| 2663 | Seed Based Systems | 2021-08-21 | ||
| 2664 | Non-Surfactant Stabilizers | 2021-08-21 | ||
| 2665 | Surfactants | 2021-08-21 | ||
| 2666 | Initiators | 2021-08-21 | ||
| 2667 | Components | 2021-08-21 | ||
| 2668 | Free Radical Polymerization | 2021-08-21 | ||
| 2669 | Conclusions and Limitations | 2021-08-21 | ||
| 2670 | Cancelation | 2021-08-21 | ||
| 2671 | Results of SVAR | 2021-08-21 | ||
| 2672 | Cumulative Asymmetric Adjustments | 2021-08-21 | ||
| 2673 | Results of NARDL | 2021-08-21 | ||
| 2674 | Empirical Results and Discussion | 2021-08-21 | ||
| 2675 | Data, Model and Methods | 2021-08-21 | ||
| 2676 | Code Available | 2021-08-20 | ||
| 2677 | The Study Design | 2021-08-20 | ||
| 2678 | Type of Packing | 2021-08-20 | ||
| 2679 | Nano Materials | 2021-08-20 | ||
| 2680 | Role of Nanotechnology In Food Packaging | 2021-08-20 | ||
| 2681 | Test Procedure and Evaluation | 2021-08-20 | ||
| 2682 | Cause for Type 2 Diabetes | 2021-08-19 | ||
| 2683 | Cause for Type 1 Diabetes | 2021-08-19 | ||
| 2684 | Cause for Type 1 Diabetes | 2021-08-19 | ||
| 2685 | Types of Diabetes | 2021-08-19 | ||
| 2686 | Clinical Effects of Vitamin D | 2021-08-19 | ||
| 2687 | Vitamin D Deficiency | 2021-08-19 | ||
| 2688 | Recent Advancements in TUDSS | 2021-08-19 | ||
| 2689 | Physiology of Human Nail | 2021-08-19 | ||
| 2690 | Managing Research on Argotechnology | 2021-08-19 | ||
| 2691 | Transferring Agricultural Technology | 2021-08-19 | ||
| 2692 | Management of Pre-diabetes | 2021-08-19 | ||
| 2693 | Declaration of Conflict of Interests | 2021-08-19 | ||
| 2694 | Case Description and Method | 2021-08-19 | ||
| 2695 | Symptoms and Sign | 2021-08-18 | ||
| 2696 | Different kinds of Inserts | 2021-08-18 | ||
| 2697 | Working of Cochlear Insert | 2021-08-18 | ||
| 2698 | Success of Cochlear Inserts | 2021-08-18 | ||
| 2699 | Models of Political-Bureaucratic Relations | 2021-08-18 | ||
| 2700 | Conceptualisation of Successions Politics and Administration | 2021-08-18 | ||
| 2701 | Context and Historical Dimension of Succession Politics | 2021-08-18 | ||
| 2702 | Pharmacognostic Studies | 2021-08-18 | ||
| 2703 | Methodologys | 2021-08-18 | ||
| 2704 | Internal Iliac Artery Stenosis: Diagnosis and How To Manage It | 2021-08-18 | ||
| 2705 | Coronary Angioplasty and Stents Placement Surgery | 2021-08-18 | ||
| 2706 | Carotid Endarterectomy Surgery Recovery | 2021-08-18 | ||
| 2707 | An overview of Deep Vein Thrombosis | 2021-08-18 | ||
| 2708 | An Outlook: Carotid Artery Disease (CAD) | 2021-08-18 | ||
| 2709 | Review Analysis | 2021-08-17 | ||
| 2710 | Applications and Discussion | 2021-08-17 | ||
| 2711 | Methodology Adopted | 2021-08-17 | ||
| 2712 | Funding Support | 2021-08-17 | ||
| 2713 | Sources of Heavy Metals | 2021-08-17 | ||
| 2714 | The Bio-Materials Tests | 2021-08-17 | ||
| 2715 | Conclusions and Technologies | 2021-08-17 | ||
| 2716 | Need for New Initiative on Foliar | 2021-08-17 | ||
| 2717 | Structure-Based Drug Design | 2021-08-16 | ||
| 2718 | opinnion | 2021-08-16 | ||
| 2719 | Author's Funding | 2021-08-16 | ||
| 2720 | Management of the Safety Database | 2021-08-16 | ||
| 2721 | Contrast Between Us, Eu And Indian Pv | 2021-08-16 | ||
| 2722 | Pharmacovigilance System Workflow as per Indian Scenario | 2021-08-16 | ||
| 2723 | Legislation In India Pharmacovigilance | 2021-08-16 | ||
| 2724 | History of Pharmacovigilance in India | 2021-08-16 | ||
| 2725 | Particle Shape and Surface Area | 2021-08-16 | ||
| 2726 | Particle Size and Particle Size Distribution | 2021-08-16 | ||
| 2727 | Fabrication Protection and Cost Reduction | 2021-08-16 | ||
| 2728 | Application Areas and Limitations | 2021-08-16 | ||
| 2729 | Mutant Strains | 2021-08-13 | ||
| 2730 | Cross-Immunity | 2021-08-13 | ||
| 2731 | Age Variation | 2021-08-13 | ||
| 2732 | A Systematic Note of the Effects of WBV on Balance, Mobility, and Strength in Aging Adults | 2021-08-13 | ||
| 2733 | Antibacterial Properties of Rhazya stricta and Methicillin-Resistant Staphylococcus aureus | 2021-08-13 | ||
| 2734 | During Infection, S. scitamineum and U. esculenta have Confined Enzyme Activity at the Smut Gall | 2021-08-13 | ||
| 2735 | The Effect of Essential Oil from Guava (Psidium guajava) Leaves on Male Guinea Pig Reproductive Parameters (Cavia porcellus) | 2021-08-13 | ||
| 2736 | Curcumin Therapy's Efficacy in the Treatment of Inflammation and Cancer. | 2021-08-13 | ||
| 2737 | Roles and Responsibilities | 2021-08-13 | ||
| 2738 | New Member Added to the Editorial Board | 2021-08-13 | ||
| 2739 | Diagnosis and Management of Pneumonia | 2021-08-12 | ||
| 2740 | Treatment of Chronic Obstructive Pulmonary Ailment | 2021-08-12 | ||
| 2741 | Causes and Treatment | 2021-08-12 | ||
| 2742 | Sessions | 2021-08-12 | ||
| 2743 | Welcome Message | 2021-08-12 | ||
| 2744 | Mass Medication | 2021-08-12 | ||
| 2745 | Trail Registration | 2021-08-12 | ||
| 2746 | Proprietoship | 2021-08-12 | ||
| 2747 | Veins | 2021-08-12 | ||
| 2748 | Contribution of the Authors | 2021-08-11 | ||
| 2749 | Past Conference | 2021-08-11 | ||
| 2750 | Conflict of Interest | 2021-08-11 | ||
| 2751 | Conflict of Interest | 2021-08-11 | ||
| 2752 | Conflict of Interest | 2021-08-11 | ||
| 2753 | Roles and Responsibilites | 2021-08-11 | ||
| 2754 | Editorial Invitation | 2021-08-11 | ||
| 2755 | Areas for Further Study | 2021-08-10 | ||
| 2756 | Justice | 2021-08-10 | ||
| 2757 | Beneficence and Non-Maleficence | 2021-08-10 | ||
| 2758 | Respect for Autonomy | 2021-08-10 | ||
| 2759 | Medical Ethical Considerations | 2021-08-10 | ||
| 2760 | Children and COVID-19-Following the Science | 2021-08-10 | ||
| 2761 | Participants and Methods | 2021-08-10 | ||
| 2762 | Electrical Arrangement of the Heart | 2021-08-10 | ||
| 2763 | Normal Heartbeat | 2021-08-10 | ||
| 2764 | Treatment for Cardiovascular Disease | 2021-08-10 | ||
| 2765 | Prevention for Cardiovascular Disease | 2021-08-10 | ||
| 2766 | Symptoms of Cardiovascular Disease | 2021-08-10 | ||
| 2767 | Ageing and Covid-19 | 2021-08-10 | ||
| 2768 | Gratefulness | 2021-08-10 | ||
| 2769 | Research findings in Psychology which are quite surprising | 2021-08-09 | ||
| 2770 | Specializing | 2021-08-09 | ||
| 2771 | Scope of Practice | 2021-08-09 | ||
| 2772 | Educational Requirements for Counseling Psychologists | 2021-08-09 | ||
| 2773 | Educational Requirements for Counselors | 2021-08-09 | ||
| 2774 | Participants and Methodology | 2021-08-09 | ||
| 2775 | Decelerations | 2021-08-09 | ||
| 2776 | Drug Delivery System | 2021-08-09 | ||
| 2777 | Aspects of Development | 2021-08-09 | ||
| 2778 | Plain English Summary | 2021-08-09 | ||
| 2779 | Compliance with Ethical Requirement | 2021-08-09 | ||
| 2780 | Seminal Technical Approach CFDNAS from the Animal Model to Humans | 2021-08-09 | ||
| 2781 | Idiopathic Infertility and Other Functional Sperm Defects (DNA Fragmentation, ROS, Methylation, Proteomics, MI-RNA) | 2021-08-09 | ||
| 2782 | Circulating Nucleic Acids and Male Infertility | 2021-08-09 | ||
| 2783 | Circulating Nucleic Acids and Female Infertility | 2021-08-09 | ||
| 2784 | Free Nucleic Acids | 2021-08-09 | ||
| 2785 | Incidence and Frequency of Feeding Related Errors | 2021-08-07 | ||
| 2786 | Laboratory Tests | 2021-08-06 | ||
| 2787 | Conflict | 2021-08-06 | ||
| 2788 | About the Conference | 2021-08-06 | ||
| 2789 | Vulnerable | 2021-08-06 | ||
| 2790 | Providing Consultations | 2021-08-06 | ||
| 2791 | Discussion and Results | 2021-08-05 | ||
| 2792 | Types of Operations | 2021-08-05 | ||
| 2793 | Qualities of Good Litter Material | 2021-08-05 | ||
| 2794 | Recycling of Nutrients in Deep Litter System | 2021-08-05 | ||
| 2795 | Litter Management | 2021-08-05 | ||
| 2796 | Factors Effecting | 2021-08-05 | ||
| 2797 | Symptoms of A Brain Tumor | 2021-08-05 | ||
| 2798 | Types of Brain Tumors | 2021-08-05 | ||
| 2799 | Brain Tumor | 2021-08-05 | ||
| 2800 | Viewpoint | 2021-08-05 | ||
| 2801 | Types of Coma | 2021-08-05 | ||
| 2802 | Discussion and Recommendations | 2021-08-04 | ||
| 2803 | Finding and Discussion | 2021-08-04 | ||
| 2804 | Remarks | 2021-08-04 | ||
| 2805 | What I Saw in this Field? | 2021-08-04 | ||
| 2806 | Recommendation and Future Research | 2021-08-04 | ||
| 2807 | Discussion and Findings | 2021-08-04 | ||
| 2808 | Limitations of the Review | 2021-08-04 | ||
| 2809 | Strengths of the Review | 2021-08-04 | ||
| 2810 | Learning Objectives | 2021-08-04 | ||
| 2811 | Data Availability Statement | 2021-08-03 | ||
| 2812 | Informed Consent Statement | 2021-08-03 | ||
| 2813 | Institutional Review Board Statement | 2021-08-03 | ||
| 2814 | Image Article | 2021-08-02 | ||
| 2815 | Micronutrient Deficiency in Athletes and Inefficiency of Supplementation | 2021-08-02 | ||
| 2816 | Flexibility to Survive: the Potential Approaches for Disruption Management of the Food Truck Sector | 2021-08-02 | ||
| 2817 | The Covid-19 Disruption on the Food Truck Sector | 2021-08-02 | ||
| 2818 | Food Away from Home and Food Trucks | 2021-08-02 | ||
| 2819 | Mitochondrial Donation | 2021-08-02 | ||
| 2820 | Male Inheritance | 2021-08-02 | ||
| 2821 | Mitochondrial Bottleneck | 2021-08-02 | ||
| 2822 | Female Inheritance | 2021-08-02 | ||
| 2823 | Denaturation of Air | 2021-08-02 | ||
| 2824 | Synthetic Denaturation as another Option | 2021-08-02 | ||
| 2825 | Denaturation Because of Compound Specialists | 2021-08-02 | ||
| 2826 | Naturally Instigated Denaturation | 2021-08-02 | ||
| 2827 | Limitations and Suggestions for Further Research | 2021-08-02 | ||
| 2828 | Hormonal Deviations | 2021-08-02 | ||
| 2829 | An Epidemic Aspect | 2021-08-02 | ||
| 2830 | Clinical Investigations | 2021-08-02 | ||
| 2831 | Conclusion and Future Work | 2021-08-02 | ||
| 2832 | Integrative Approaches to Treating Chronic Pain: A Whole-Person Approach to Managing Symptoms | 2021-08-02 | ||
| 2833 | Integrative Approaches to Treating Chronic Pain: A Whole-Person Approach to Managing Symptoms | 2021-08-02 | ||
| 2834 | The Use and Efficacy of Invasive Procedures for Chronic Pain Conditions | 2021-08-02 | ||
| 2835 | Use of Glasses | 2021-08-02 | ||
| 2836 | Complexities from Eye Stress | 2021-08-02 | ||
| 2837 | Basic Reasons for Eye Strain | 2021-08-02 | ||
| 2838 | Additional Information and Declarations | 2021-08-02 | ||
| 2839 | Conclusion and The Way Forward | 2021-07-30 | ||
| 2840 | Overview of Minning Invetment in Ethiopia | 2021-07-30 | ||
| 2841 | Overview of Minning Investment in Ethiopia | 2021-07-30 | ||
| 2842 | Definitions of Research Variables | 2021-07-30 | ||
| 2843 | Urological Complications | 2021-07-30 | ||
| 2844 | Scope for Further Research | 2021-07-30 | ||
| 2845 | A New Device | 2021-07-29 | ||
| 2846 | Counter Measures | 2021-07-29 | ||
| 2847 | The “Baby Heart Syndrome” (BHS) Theory | 2021-07-29 | ||
| 2848 | Management of Potato Late Blight | 2021-07-29 | ||
| 2849 | Disease Cycle and Epidemiology | 2021-07-29 | ||
| 2850 | Institutional Review Board Statement | 2021-07-28 | ||
| 2851 | Treatment of Neurodegeneration | 2021-07-28 | ||
| 2852 | Neurodegeneration | 2021-07-28 | ||
| 2853 | Ailments | 2021-07-28 | ||
| 2854 | Medications | 2021-07-28 | ||
| 2855 | Causes of Psychosis | 2021-07-28 | ||
| 2856 | Sorts of Stroke | 2021-07-28 | ||
| 2857 | Stroke Manifestations | 2021-07-28 | ||
| 2858 | Factors Brain Tumor | 2021-07-28 | ||
| 2859 | Formulating an Institution-Specific Pathway | 2021-07-28 | ||
| 2860 | Testing for COVID Before Surgery | 2021-07-28 | ||
| 2861 | Method of Analysing Physicochemical Parameters | 2021-07-27 | ||
| 2862 | Determining the Depth of Deep Geological Repository | 2021-07-27 | ||
| 2863 | Setup of Deep Geological Repository | 2021-07-27 | ||
| 2864 | Developing Countries Affected By E Waste | 2021-07-27 | ||
| 2865 | Renal Artery | 2021-07-27 | ||
| 2866 | ANALYTICAL RELATIONS | 2021-07-27 | ||
| 2867 | Enabling People Proactively to Battle against COVID-19 | 2021-07-27 | ||
| 2868 | Mental Results of Pandemic in Different Nations | 2021-07-27 | ||
| 2869 | Government Responses to COVID-19 | 2021-07-27 | ||
| 2870 | COVID Aid, Relief and Economic Security Act, Department of Education | 2021-07-27 | ||
| 2871 | Conflict of Interest Self-Report | 2021-07-27 | ||
| 2872 | Threats and Decline | 2021-07-27 | ||
| 2873 | Reproduction of this Species | 2021-07-27 | ||
| 2874 | Habitat | 2021-07-27 | ||
| 2875 | Conservation | 2021-07-27 | ||
| 2876 | Habitat and Distribution | 2021-07-27 | ||
| 2877 | IMPORTANCE OF LANGUAGE EDUCATION | 2021-07-27 | ||
| 2878 | Diseases of Sponges | 2021-07-27 | ||
| 2879 | Evolution | 2021-07-27 | ||
| 2880 | Macrophage Therapy | 2021-07-26 | ||
| 2881 | DC Therapy | 2021-07-26 | ||
| 2882 | Stem Cell Therapy | 2021-07-26 | ||
| 2883 | Cytokine-Based Immunotherapy | 2021-07-26 | ||
| 2884 | Plasma Therapy | 2021-07-26 | ||
| 2885 | Ruxolitinib | 2021-07-26 | ||
| 2886 | Abidol-Umifenovir | 2021-07-26 | ||
| 2887 | Baricitinib | 2021-07-26 | ||
| 2888 | Tocilizumab | 2021-07-26 | ||
| 2889 | Vaccine Development Approach | 2021-07-26 | ||
| 2890 | Relationship to other Biological Sciences | 2021-07-26 | ||
| 2891 | Allele-Specific Oligonucleotide | 2021-07-26 | ||
| 2892 | Microarrays | 2021-07-26 | ||
| 2893 | Macromolecule Blotting and Probing | 2021-07-26 | ||
| 2894 | Polymerase Chain Reaction | 2021-07-26 | ||
| 2895 | Molecular Cloning | 2021-07-26 | ||
| 2896 | Oxysterols to the Rescue | 2021-07-26 | ||
| 2897 | Analytical Methods | 2021-07-24 | ||
| 2898 | Editor | 2021-07-24 | ||
| 2899 | Patient’s Consent | 2021-07-24 | ||
| 2900 | Methodos | 2021-07-23 | ||
| 2901 | Long-Term Effects on the Lungs | 2021-07-23 | ||
| 2902 | Branches of Aerodynamics | 2021-07-23 | ||
| 2903 | Aerodynamics | 2021-07-23 | ||
| 2904 | From the Lens of the Family | 2021-07-23 | ||
| 2905 | From the Lens of the Patient | 2021-07-23 | ||
| 2906 | From the Lens of Health Care Organization | 2021-07-23 | ||
| 2907 | Uses | 2021-07-23 | ||
| 2908 | Theories | 2021-07-23 | ||
| 2909 | Deep Learning Methods | 2021-07-23 | ||
| 2910 | About the Hepatitis B Virus | 2021-07-23 | ||
| 2911 | Artificial Intelligence-Brain Heuristic Comparison | 2021-07-23 | ||
| 2912 | Brain Disease and Mirror Neurons | 2021-07-23 | ||
| 2913 | Causes of Health Issues During Covid-19 | 2021-07-23 | ||
| 2914 | Medication | 2021-07-23 | ||
| 2915 | A Note on Angiography | 2021-07-22 | ||
| 2916 | In vivo Angiogenesis: Therapeutic potential and challenges | 2021-07-22 | ||
| 2917 | Techniques used to Diagnose Cardiovascular Diseases | 2021-07-22 | ||
| 2918 | Drugs to Treat Cardiovascular Diseases | 2021-07-22 | ||
| 2919 | Immunotheraphy | 2021-07-21 | ||
| 2920 | Ethical Standards Statement | 2021-07-21 | ||
| 2921 | Declaration of Interest Statement | 2021-07-21 | ||
| 2922 | Brief Report | 2021-07-21 | ||
| 2923 | Sequence Optimization and Oligo Design | 2021-07-20 | ||
| 2924 | Its Side Effects | 2021-07-20 | ||
| 2925 | Diet to be Taken | 2021-07-20 | ||
| 2926 | The four components of this model are: | 2021-07-20 | ||
| 2927 | Components of the Primary Respiratory Mechanism (PRM) | 2021-07-20 | ||
| 2928 | Current Concerns in Delaying the Second Jabs | 2021-07-19 | ||
| 2929 | Conceptual Acceptance of Single Jab Strategy | 2021-07-19 | ||
| 2930 | The Current Position of Vaccines Deployment in the UK | 2021-07-19 | ||
| 2931 | Study Section | 2021-07-19 | ||
| 2932 | Epidemology of Myopia | 2021-07-19 | ||
| 2933 | Essential Structure of Cell Membranes | 2021-07-17 | ||
| 2934 | Asymmetric Structure of the Membrane | 2021-07-17 | ||
| 2935 | Flavonoid Phloretin: Dermatological Applications | 2021-07-17 | ||
| 2936 | A New Target for Chemotherapy: The Footprint of Kynurenine Pathway in Every Cancer | 2021-07-17 | ||
| 2937 | Impact of Covid-19 | 2021-07-16 | ||
| 2938 | Reflection | 2021-07-16 | ||
| 2939 | The Study Output | 2021-07-16 | ||
| 2940 | Analysis and Findings | 2021-07-16 | ||
| 2941 | Situation Analysis | 2021-07-16 | ||
| 2942 | Fundamental Lupus versus LN | 2021-07-16 | ||
| 2943 | Limitation and Suggestions for Future Research | 2021-07-16 | ||
| 2944 | Alexithymia | 2021-07-16 | ||
| 2945 | The Concept of Disease as a Social Institution | 2021-07-16 | ||
| 2946 | Ideas and Beliefs of a Discourse | 2021-07-16 | ||
| 2947 | Definition and Types of Discourse | 2021-07-16 | ||
| 2948 | Review and Literature | 2021-07-15 | ||
| 2949 | Short Notes on Elimination Reactions | 2021-07-15 | ||
| 2950 | Editorial on Alkanes and Nomenclature | 2021-07-15 | ||
| 2951 | A Short Notes on Functional Groups | 2021-07-15 | ||
| 2952 | When Open Heart Surgery Needed? | 2021-07-15 | ||
| 2953 | How Does the New CoronaVirus Stoke Cardiac Damage? | 2021-07-15 | ||
| 2954 | Preliminaries of NN | 2021-07-15 | ||
| 2955 | Methodolgy | 2021-07-15 | ||
| 2956 | Editorial on Rearrangement Reactions | 2021-07-15 | ||
| 2957 | A Brief Note on Organometallics | 2021-07-15 | ||
| 2958 | Optimum Secure IOT Model | 2021-07-15 | ||
| 2959 | Credential Security | 2021-07-15 | ||
| 2960 | IOT and Block Chain: Security and Challenges | 2021-07-15 | ||
| 2961 | Simple Tips for Early Prevention of Pcos | 2021-07-15 | ||
| 2962 | Enantiomers: An Overview | 2021-07-15 | ||
| 2963 | Editorial on Carboxylic Acids and Derivatives | 2021-07-15 | ||
| 2964 | Editorial on Ring-Opening Reactions of Epoxides | 2021-07-15 | ||
| 2965 | Associated Maternal Risk Factors for Low Birth Weight Neonates | 2021-07-15 | ||
| 2966 | Treatment of Type B Aortic Dissection with TEVAR | 2021-07-15 | ||
| 2967 | Coronavirus, Influenza and COVID-19 Resisting | 2021-07-14 | ||
| 2968 | Immunity and Equilibrium Between Human and Microorganisms | 2021-07-14 | ||
| 2969 | SARS-COV-2 or COVID-19 | 2021-07-14 | ||
| 2970 | Chinese Medication | 2021-07-14 | ||
| 2971 | Breast Cancer | 2021-07-14 | ||
| 2972 | Illustration | 2021-07-14 | ||
| 2973 | Clinical Problem | 2021-07-14 | ||
| 2974 | Functions of Phytoconstituents in the Role of Wound Healing | 2021-07-14 | ||
| 2975 | Biology And Behaviour | 2021-07-14 | ||
| 2976 | Traditional Treatment of Wounds Improves with Medical Plants | 2021-07-14 | ||
| 2977 | Pest Control | 2021-07-14 | ||
| 2978 | Characteristics of a Good Herbal or Natural Agents in Wound Healing | 2021-07-14 | ||
| 2979 | Traditional Healthcare Practices using Herbal Medicines | 2021-07-14 | ||
| 2980 | Recent Advances in Agritourism | 2021-07-14 | ||
| 2981 | Recent Approaches in Sustainable Agriculture | 2021-07-14 | ||
| 2982 | Why We Should Ban All Toxic Agricultural Practices of Using NPK Fertilizers? | 2021-07-14 | ||
| 2983 | Models | 2021-07-14 | ||
| 2984 | Significance of Soil Fertility to Improve Crop Yield | 2021-07-14 | ||
| 2985 | Importance of Agrobiodiversity | 2021-07-14 | ||
| 2986 | Uses of Pesticides in Agriculture | 2021-07-14 | ||
| 2987 | Recent Systematic Study Outcomes in Agrotechnology | 2021-07-14 | ||
| 2988 | Importance and Advancement in Agriculture Technology | 2021-07-14 | ||
| 2989 | Importance of Crop Protection Management | 2021-07-14 | ||
| 2990 | Genetically Engineered Crops (Bacillus Thuringiensis Crops) | 2021-07-14 | ||
| 2991 | Upcoming Issue: Nutritional Status | 2021-07-14 | ||
| 2992 | About Conference | 2021-07-13 | ||
| 2993 | Gene Polymorphisms in Eating Disorders | 2021-07-13 | ||
| 2994 | The Development of a Survey Tool to Measuring Vaccine Hesitancy | 2021-07-13 | ||
| 2995 | Scientific Lessons to be shared for Public Health Actions | 2021-07-13 | ||
| 2996 | Epidemiology of the Infection | 2021-07-13 | ||
| 2997 | Search Method | 2021-07-13 | ||
| 2998 | Therapeutic Strategies | 2021-07-13 | ||
| 2999 | Clinical Lessons | 2021-07-13 | ||
| 3000 | Biologic Insights | 2021-07-13 | ||
| 3001 | Cell Therapy Strategies | 2021-07-13 | ||
| 3002 | Note | 2021-07-13 | ||
| 3003 | Conflicts of Interest and Acknowledgements | 2021-07-09 | ||
| 3004 | Distribution and Species Variation | 2021-07-09 | ||
| 3005 | Distribution and Species Variation< | 2021-07-09 | ||
| 3006 | Cold-Blooded Animals | 2021-07-09 | ||
| 3007 | Ionized Drugs | 2021-07-09 | ||
| 3008 | Ethics | 2021-07-08 | ||
| 3009 | Composition Of Green Tea | 2021-07-08 | ||
| 3010 | The Adverse Effect Of Green Tea Consumption | 2021-07-08 | ||
| 3011 | Health Benefits Of Consuming Green Tea | 2021-07-08 | ||
| 3012 | Molecular Mechanism of Posttranscriptional HIV Latency | 2021-07-08 | ||
| 3013 | HIV Latency | 2021-07-08 | ||
| 3014 | Maintaining Chlorophyll Content Predicts Drought Tolerance | 2021-07-08 | ||
| 3015 | Breeding For Drought Tolerance By Monitoring Chlorophyll Content | 2021-07-08 | ||
| 3016 | Methods to Quantify Chlorophylls | 2021-07-08 | ||
| 3017 | Chemical and Physical Properties of the Chlorophylls | 2021-07-08 | ||
| 3018 | Data and Materials | 2021-07-08 | ||
| 3019 | Purpose of the Work | 2021-07-08 | ||
| 3020 | Specific Sports Overview of the Problem | 2021-07-08 | ||
| 3021 | Development of Shear Wave Elastography | 2021-07-07 | ||
| 3022 | Editotrial Note | 2021-07-07 | ||
| 3023 | Perspectives | 2021-07-07 | ||
| 3024 | DC-OCs as Potent Players in the Context of Breast Tumor Bone Metastasis | 2021-07-07 | ||
| 3025 | Dendritic Cells Development into Osteoclasts Type Cells (DC-OCs) | 2021-07-07 | ||
| 3026 | T Cell-Dependent Formation of Breast Tumor Pre-Metastatic Bone Niche | 2021-07-07 | ||
| 3027 | A Propos a Man with Spectacles | 2021-07-07 | ||
| 3028 | Titanium in Spectacle Frames | 2021-07-07 | ||
| 3029 | Titanium and Autoimmune Reactions | 2021-07-07 | ||
| 3030 | Further Adverse Effects | 2021-07-07 | ||
| 3031 | The Yellow Nail Syndrome | 2021-07-07 | ||
| 3032 | Toxic and Allergic Consequences | 2021-07-07 | ||
| 3033 | Statements | 2021-07-07 | ||
| 3034 | Eventual Fate of Microbiology | 2021-07-07 | ||
| 3035 | Utilizations of Microbiology | 2021-07-07 | ||
| 3036 | Creation of Microbial Food Societies | 2021-07-07 | ||
| 3037 | Capacity of Microbial Food Societies in Food | 2021-07-07 | ||
| 3038 | Author Contributuion | 2021-07-07 | ||
| 3039 | Discussion and Recommendation | 2021-07-06 | ||
| 3040 | Comparison of Health Care System | 2021-07-06 | ||
| 3041 | Monitoring Framework WHO Six Building Blocks | 2021-07-06 | ||
| 3042 | Background and Demographic Profile of Iran and Nigeria | 2021-07-06 | ||
| 3043 | Restriction of Fundamental Human Rights during Times of National Emergency | 2021-07-06 | ||
| 3044 | Assessing the Bioethical Norms and International Human Rights Standards | 2021-07-06 | ||
| 3045 | Arguments for and Against COVID-19 Vaccination for School Children | 2021-07-06 | ||
| 3046 | Declaration of Conflict of Interest | 2021-07-06 | ||
| 3047 | Itinerary structure and port Organization | 2021-07-06 | ||
| 3048 | World Cruises | 2021-07-06 | ||
| 3049 | Questions to Further Research | 2021-07-06 | ||
| 3050 | Compare and Contrast Themes and Gaps in Literature | 2021-07-06 | ||
| 3051 | Psychosocial Support | 2021-07-06 | ||
| 3052 | Patient Education | 2021-07-06 | ||
| 3053 | Evidence-Based Prevention Methods for Phenylketonuria | 2021-07-06 | ||
| 3054 | Maintenance Therapy | 2021-07-05 | ||
| 3055 | Sequencing Therapy | 2021-07-05 | ||
| 3056 | Combination Therapy | 2021-07-05 | ||
| 3057 | Bimodal Effect of Vitamin A and Biphasic Immune Pathogenesis in COVID-19 | 2021-07-05 | ||
| 3058 | Pathogenesis of COVID-19, Viral Tropism and Retinoid Signaling Disorder | 2021-07-05 | ||
| 3059 | Retinol Depletion and Retinoid Signaling Mechanism in COVID-19 | 2021-07-05 | ||
| 3060 | PERMANENT BIRTH CONTROL METHODS | 2021-07-05 | ||
| 3061 | HORMONAL METHODS OF BIRTH CONTROL | 2021-07-05 | ||
| 3062 | BARRIER METHODS FOR BIRTH CONTROL | 2021-07-05 | ||
| 3063 | Researches about The Efficacy of Miswak | 2021-07-05 | ||
| 3064 | Chemical Constituents | 2021-07-05 | ||
| 3065 | Reasons behind Studying this Field | 2021-07-03 | ||
| 3066 | Work Environment | 2021-07-03 | ||
| 3067 | Specializations | 2021-07-03 | ||
| 3068 | What is Human Factors Psychology? | 2021-07-03 | ||
| 3069 | Perspectives on Educational Psychology from a Various Aspects | 2021-07-03 | ||
| 3070 | Diagnosis of Developmental Psychology | 2021-07-03 | ||
| 3071 | When to Consult a Developmental Psychologist? | 2021-07-03 | ||
| 3072 | Theories of Developmental Psychology | 2021-07-03 | ||
| 3073 | Questions About developmental Psychology | 2021-07-03 | ||
| 3074 | COQ10 AND HMG-COA Reductases | 2021-07-03 | ||
| 3075 | Cardiac Surgery | 2021-07-03 | ||
| 3076 | Arrhythmias | 2021-07-03 | ||
| 3077 | Cardiomyopathy | 2021-07-03 | ||
| 3078 | Congestive Heart Failure | 2021-07-03 | ||
| 3079 | Myocardial Infarction | 2021-07-03 | ||
| 3080 | Coronary Artery Disease | 2021-07-03 | ||
| 3081 | Hypertension | 2021-07-03 | ||
| 3082 | Atherosclerosis | 2021-07-03 | ||
| 3083 | Integrated Self-Driving Travel Scheme Planning | 2021-07-03 | ||
| 3084 | Dynamic Programming and Clustering-Based Heuristic Algorithm | 2021-07-03 | ||
| 3085 | Solution Methods | 2021-07-03 | ||
| 3086 | Hotel Selection in Travel Planning | 2021-07-03 | ||
| 3087 | Travel Routing Optimization | 2021-07-03 | ||
| 3088 | Orienteering Problem with Hotel Selection | 2021-07-03 | ||
| 3089 | Travel Salesman Problem with Hotel Selection | 2021-07-03 | ||
| 3090 | Opinion Note on Cystic Fibrosis | 2021-07-02 | ||
| 3091 | Opinion Note on Cystic Fibrosis | 2021-07-02 | ||
| 3092 | Opinion Note on Cystic Fibrosis | 2021-07-02 | ||
| 3093 | Opinion Note on Cystic Fibrosis | 2021-07-02 | ||
| 3094 | Review Article on Polymerase Response | 2021-07-02 | ||
| 3095 | Notes on Therapeutic Science | 2021-07-02 | ||
| 3096 | Notes on Genetically Modify Crops | 2021-07-02 | ||
| 3097 | Publications | 2021-07-02 | ||
| 3098 | Publication | 2021-07-02 | ||
| 3099 | Limitations and Future Research | 2021-07-02 | ||
| 3100 | UNESCO | 2021-07-02 | ||
| 3101 | Yoga Theraphy, Chronic low back pain (CLBP) | 2021-07-02 | ||
| 3102 | Environmental Health and Biodiversity | 2021-07-02 | ||
| 3103 | Environmental Health Perspectives | 2021-07-02 | ||
| 3104 | IMPACT | 2021-07-02 | ||
| 3105 | CAUSES OF IRRATIONAL PRESCRIBING OF DRUGS | 2021-07-02 | ||
| 3106 | MSC-Based Therapy | 2021-07-02 | ||
| 3107 | The Immunomodulatory Role of MSCS | 2021-07-02 | ||
| 3108 | Therapeutic Applications of MSC | 2021-07-02 | ||
| 3109 | Importance of Mesenchymal Stem Cell | 2021-07-02 | ||
| 3110 | Previous Publication | 2021-07-01 | ||
| 3111 | Future Of Social Media Research | 2021-06-28 | ||
| 3112 | Healthcare Providers On Social Media | 2021-06-28 | ||
| 3113 | Social Media Platforms Overtime | 2021-06-28 | ||
| 3114 | Chronic Conditions On Social Media | 2021-06-28 | ||
| 3115 | Case Discussion | 2021-06-25 | ||
| 3116 | Presentation of Case | 2021-06-25 | ||
| 3117 | Compliance with ethical statements | 2021-06-25 | ||
| 3118 | Simulated Clinical User Study Validation | 2021-06-24 | ||
| 3119 | Safety Pen Needle Description | 2021-06-24 | ||
| 3120 | When to Approach Doctors | 2021-06-24 | ||
| 3121 | List of Rare Skin Diseases | 2021-06-24 | ||
| 3122 | Statement of Authorship | 2021-06-23 | ||
| 3123 | Extreme Hyperglycemia in COVID-19 | 2021-06-18 | ||
| 3124 | Effect of Outpatient Glycemic Control on Severity of COVID-19 | 2021-06-18 | ||
| 3125 | Interrelationships Between Diabetes, Hyperglycemia and Severity of COVID-19 | 2021-06-18 | ||
| 3126 | Mortality | 2021-06-18 | ||
| 3127 | Incidence of Different Aetiology | 2021-06-18 | ||
| 3128 | Recent advance in direct ethanol fuel cell for sustainable energy produc- tion | 2021-06-18 | ||
| 3129 | Metal-organic framework membranes for CO2 capture, biofuel purifica- tion and water desalination: A computational perspective | 2021-06-18 | ||
| 3130 | Uses of Antipsychotic Drugs in the Treatment of Schizophrenia | 2021-06-18 | ||
| 3131 | Schizophrenia | 2021-06-18 | ||
| 3132 | Clinical Employments | 2021-06-18 | ||
| 3133 | Tumor in the Cerebellum | 2021-06-18 | ||
| 3134 | Division | 2021-06-18 | ||
| 3135 | Structure | 2021-06-18 | ||
| 3136 | Edotrial Note On Cerebellum | 2021-06-18 | ||
| 3137 | Employments | 2021-06-18 | ||
| 3138 | Metencephalon | 2021-06-18 | ||
| 3139 | Edotrial Note On Brain Stem | 2021-06-18 | ||
| 3140 | Relative Bioavailability and Bioequivalence | 2021-06-18 | ||
| 3141 | Outright Bioavailability | 2021-06-18 | ||
| 3142 | Bioavailability | 2021-06-18 | ||
| 3143 | Editorial Note on Anxiety Disorders | 2021-06-18 | ||
| 3144 | Obesrvations and Results | 2021-06-17 | ||
| 3145 | Contribution Author | 2021-06-16 | ||
| 3146 | Different Impact of Actin Isoforms on the Process of Cell Division | 2021-06-15 | ||
| 3147 | Cytoplasmic Actin Isoforms: Structures and Functions in the Interphase Non- Muscle Cells | 2021-06-15 | ||
| 3148 | Mechanism of Action of NCS 613 in Lupus Nephritis | 2021-06-15 | ||
| 3149 | PDE4 Inhibitors are Attracting Drugs for Chronic Inflammatory Diseases | 2021-06-15 | ||
| 3150 | Regulation of cAMP Signaling by PDE4 Isozymes in Immune Cells | 2021-06-15 | ||
| 3151 | Regulation of cAMP Signaling By PDE4 during Inflammation | 2021-06-15 | ||
| 3152 | Models of Health and Medicalization | 2021-06-14 | ||
| 3153 | Detection of Metals | 2021-06-14 | ||
| 3154 | Liquid Chromatography-Mass Spectrometry | 2021-06-14 | ||
| 3155 | Gas Chromatography-Mass Spectrometry | 2021-06-14 | ||
| 3156 | Detection and Classification | 2021-06-14 | ||
| 3157 | Reasons for sinus | 2021-06-14 | ||
| 3158 | Investigating | 2021-06-14 | ||
| 3159 | Radiological Analysis | 2021-06-14 | ||
| 3160 | Animals | 2021-06-14 | ||
| 3161 | Practical Application | 2021-06-14 | ||
| 3162 | Behaviour | 2021-06-14 | ||
| 3163 | Distribution And Habitat | 2021-06-14 | ||
| 3164 | Life Cycle | 2021-06-14 | ||
| 3165 | Trends Changing Cyber Security | 2021-06-11 | ||
| 3166 | Cyber Security | 2021-06-11 | ||
| 3167 | Cyber Crime | 2021-06-11 | ||
| 3168 | Conflict of Interest Declaration | 2021-06-10 | ||
| 3169 | Data Sharing Statement | 2021-06-10 | ||
| 3170 | Methodologies of Sad | 2021-06-09 | ||
| 3171 | Software Systems | 2021-06-09 | ||
| 3172 | Challenges and Way Forward | 2021-06-09 | ||
| 3173 | Use Cases | 2021-06-09 | ||
| 3174 | Benefits of Blockchain Based Supply Chain Applications | 2021-06-09 | ||
| 3175 | Traditional Versus Blockchain Applications | 2021-06-09 | ||
| 3176 | Value of Blockchain in Supply Chain | 2021-06-09 | ||
| 3177 | Will Auto ml Replace Data Scientists? | 2021-06-09 | ||
| 3178 | Resources available for learning Data Science | 2021-06-09 | ||
| 3179 | High Demand for Data Scientists | 2021-06-09 | ||
| 3180 | Auto ML | 2021-06-09 | ||
| 3181 | Role of Machine Learning in Data Science | 2021-06-09 | ||
| 3182 | Artificial Intelligence | 2021-06-09 | ||
| 3183 | Machine Learning | 2021-06-09 | ||
| 3184 | Data science vs. Auto ML | 2021-06-09 | ||
| 3185 | Patient | 2021-06-09 | ||
| 3186 | Significance Statement | 2021-06-08 | ||
| 3187 | Wheezing - Asthma Relationship | 2021-06-07 | ||
| 3188 | Wheezing Phenotypes in Children | 2021-06-07 | ||
| 3189 | Diagnosis Approach | 2021-06-07 | ||
| 3190 | Common and Manufactured Polymer Nanoparticles | 2021-06-07 | ||
| 3191 | Nanotechnology and Nanoparticles | 2021-06-07 | ||
| 3192 | The Development Factor/RTK Hub in Metazoans Is the Foundation of Organic entity Uprightness | 2021-06-07 | ||
| 3193 | Sonic Hedgehog Pathway and Ameloblastoma | 2021-06-07 | ||
| 3194 | Sonic Hedgehog Flagging Pathway | 2021-06-07 | ||
| 3195 | Advancement | 2021-06-07 | ||
| 3196 | Sorts of Transplantation | 2021-06-07 | ||
| 3197 | What is End-stage Renal Illness | 2021-06-07 | ||
| 3198 | Competing Interest Statement | 2021-06-05 | ||
| 3199 | Laboratory Findings and Diagnostics | 2021-06-04 | ||
| 3200 | Improving Healthcare Team Outcomes | 2021-06-04 | ||
| 3201 | Monitoring | 2021-06-04 | ||
| 3202 | Antagonistic Effects | 2021-06-04 | ||
| 3203 | Organization | 2021-06-04 | ||
| 3204 | Destinations and Signs | 2021-06-04 | ||
| 3205 | Conclusions and Future Direction | 2021-06-03 | ||
| 3206 | Noteworthy Points When Establishing the IONM Protocol | 2021-06-03 | ||
| 3207 | Ethics and Legal Obligations | 2021-06-03 | ||
| 3208 | Advantages and Disadvantages of Telephone Consultation | 2021-06-03 | ||
| 3209 | Evidence Base for Telephone Consultation | 2021-06-03 | ||
| 3210 | Occupational Health Controls | 2021-06-03 | ||
| 3211 | Telemedicine and SARS COV 2 | 2021-06-03 | ||
| 3212 | Conclusion on ‘He Way From Here’ | 2021-06-03 | ||
| 3213 | Working-or not-in a Pandemic | 2021-06-03 | ||
| 3214 | Brexit and the Mental Health of the Uk | 2021-06-03 | ||
| 3215 | Promoting Mental Health at Work in the Uk | 2021-06-03 | ||
| 3216 | Crossover study | 2021-06-01 | ||
| 3217 | Self-controlled study | 2021-06-01 | ||
| 3218 | Randomised controlled trial (RCT) | 2021-06-01 | ||
| 3219 | Experimental (Interventional) Studies | 2021-06-01 | ||
| 3220 | Analytical (inferential) studies | 2021-06-01 | ||
| 3221 | Descriptive Studies | 2021-06-01 | ||
| 3222 | Cohort Study | 2021-06-01 | ||
| 3223 | Materials Used | 2021-06-01 | ||
| 3224 | Exercises Protocol | 2021-06-01 | ||
| 3225 | How to get help for addiction? | 2021-06-01 | ||
| 3226 | Pharmacological Treatment | 2021-06-01 | ||
| 3227 | Classification of Osteoporosis | 2021-06-01 | ||
| 3228 | Types of Osteoporosis | 2021-06-01 | ||
| 3229 | Composition of Bone | 2021-06-01 | ||
| 3230 | How should you talk to someone with anxiety? | 2021-05-31 | ||
| 3231 | Essential Influences | 2021-05-31 | ||
| 3232 | Major Contexts in Child Psychology | 2021-05-31 | ||
| 3233 | History and Development | 2021-05-31 | ||
| 3234 | Types of Fractures | 2021-05-31 | ||
| 3235 | Signs and Indications of A Fracture | 2021-05-31 | ||
| 3236 | Treatment of Osteoporosis | 2021-05-31 | ||
| 3237 | Diagnosis of Osteoporosis | 2021-05-31 | ||
| 3238 | Dietary Factors | 2021-05-31 | ||
| 3239 | Main Risk Factors | 2021-05-31 | ||
| 3240 | The Stages of Osteoporosis | 2021-05-31 | ||
| 3241 | Announcement: Call For Paper (Gynecology And Obstetrics) | 2021-05-31 | ||
| 3242 | Webinar on Gynecology and Womens Health | 2021-05-31 | ||
| 3243 | Clinical Symptoms and Prognosis | 2021-05-31 | ||
| 3244 | Ultrasound Characteristics | 2021-05-31 | ||
| 3245 | Histopsthology | 2021-05-31 | ||
| 3246 | Macroscopy | 2021-05-31 | ||
| 3247 | Epidimiology | 2021-05-31 | ||
| 3248 | Message from Editorial Office | 2021-05-31 | ||
| 3249 | Steps To Be Followed In Respiration Exercise | 2021-05-31 | ||
| 3250 | Meditation and Emotional Well-Being | 2021-05-31 | ||
| 3251 | Clinical Significance of UTIS | 2021-05-30 | ||
| 3252 | Chemokines | 2021-05-28 | ||
| 3253 | Patterns of Tissue Pathology | 2021-05-28 | ||
| 3254 | The Electrochemical Portrayal of Old Coins | 2021-05-28 | ||
| 3255 | Graphical Abstract | 2021-05-28 | ||
| 3256 | Occupational Infection And Occupational Injury | 2021-05-27 | ||
| 3257 | Outline Portraying Ankylosing Spondylitis | 2021-05-27 | ||
| 3258 | Signs And Indications | 2021-05-27 | ||
| 3259 | Public Administration | 2021-05-27 | ||
| 3260 | Sexual Offenders | 2021-05-27 | ||
| 3261 | Clinical Forensic Psychology | 2021-05-27 | ||
| 3262 | Difference between Psychitary and Neurology | 2021-05-27 | ||
| 3263 | Professional Path | 2021-05-27 | ||
| 3264 | Job Purpose | 2021-05-27 | ||
| 3265 | Similarities between Forensic Psychology and Psychotherapy | 2021-05-27 | ||
| 3266 | Forensic Clinical Psychology | 2021-05-27 | ||
| 3267 | Sensational Aspects of Forensic Psychology | 2021-05-27 | ||
| 3268 | Saprogenesis and Pathogenesis | 2021-05-26 | ||
| 3269 | Evolution Health Care | 2021-05-25 | ||
| 3270 | Types Of Cross Infection | 2021-05-25 | ||
| 3271 | How Do These Communicable Disesase Spread | 2021-05-25 | ||
| 3272 | What Is An Communicable Disease | 2021-05-25 | ||
| 3273 | Health Care Associated Infections | 2021-05-25 | ||
| 3274 | How to Deal with Covid-19-Related Iprs | 2021-05-25 | ||
| 3275 | The Covid-19 Infection | 2021-05-25 | ||
| 3276 | Conference Details | 2021-05-25 | ||
| 3277 | Case Illustrations | 2021-05-25 | ||
| 3278 | Methods and Collection of Data | 2021-05-25 | ||
| 3279 | Mental Disorder | 2021-05-24 | ||
| 3280 | Aim and Objectives | 2021-05-24 | ||
| 3281 | Limitations and Strengths | 2021-05-24 | ||
| 3282 | Significance of Risk Factors | 2021-05-24 | ||
| 3283 | Issues and Way Forward | 2021-05-24 | ||
| 3284 | Search Strategy | 2021-05-24 | ||
| 3285 | Study Design and Methods | 2021-05-24 | ||
| 3286 | Diagnosis for Brain Cancer | 2021-05-24 | ||
| 3287 | Side Effects of Brain Cancer | 2021-05-24 | ||
| 3288 | General Side Effects | 2021-05-24 | ||
| 3289 | Symptoms of Brain Cancer | 2021-05-24 | ||
| 3290 | But did we Really got Things Right | 2021-05-24 | ||
| 3291 | What we Learned from the First Wave and what we got Right | 2021-05-24 | ||
| 3292 | Autonomy and the Principle of Autonomy | 2021-05-24 | ||
| 3293 | Paternalism and Respect for People | 2021-05-24 | ||
| 3294 | Hotel Management | 2021-05-22 | ||
| 3295 | Administration of Justice | 2021-05-22 | ||
| 3296 | Accounting-Innovations | 2021-05-22 | ||
| 3297 | Climate Change Issues and Way Forward | 2021-05-21 | ||
| 3298 | Impact of Climate Change in Nepal | 2021-05-21 | ||
| 3299 | Survey and Feedback | 2021-05-21 | ||
| 3300 | Memberships and Reprints | 2021-05-21 | ||
| 3301 | Advertisement Platfrom | 2021-05-21 | ||
| 3302 | Submission Process | 2021-05-21 | ||
| 3303 | Article Types | 2021-05-21 | ||
| 3304 | History And Biology | 2021-05-21 | ||
| 3305 | Behavior | 2021-05-21 | ||
| 3306 | Data Collection and Analysis | 2021-05-20 | ||
| 3307 | Danaparoid And Sulodexide | 2021-05-20 | ||
| 3308 | Gags As Potential Treatment | 2021-05-20 | ||
| 3309 | Editors Words | 2021-05-20 | ||
| 3310 | Study Observations | 2021-05-20 | ||
| 3311 | Conflicts of Interests | 2021-05-19 | ||
| 3312 | Physiological and Psychological Response of Comfort during the Exposure to an Environmental Stressor | 2021-05-19 | ||
| 3313 | Authorsâ?? Information | 2021-05-18 | ||
| 3314 | Authorsâ?? Information | 2021-05-18 | ||
| 3315 | Authorsâ?? Information | 2021-05-18 | ||
| 3316 | Authorsâ?? Information | 2021-05-18 | ||
| 3317 | Methodology and Patients | 2021-05-17 | ||
| 3318 | Methodology and Study Area | 2021-05-17 | ||
| 3319 | Proximal Origin of the Novel Coronavirus | 2021-05-17 | ||
| 3320 | SARS-COV-2: Structural Features and Notable Attributes in the Genome | 2021-05-17 | ||
| 3321 | What is Coronavirus? | 2021-05-17 | ||
| 3322 | USTH Administrative Policy Assessment on Hemophilia | 2021-05-17 | ||
| 3323 | Aknowledgement | 2021-05-17 | ||
| 3324 | Institutional Structures Have Become Weaker In Sustaining Peace In Communities | 2021-05-17 | ||
| 3325 | THe Decline In Social and Public Services Will Become Prolonged Issues of The After Pandemic Era | 2021-05-17 | ||
| 3326 | He Decline In Social and Public Services Will Become Prolonged Issues of The After Pandemic Era | 2021-05-17 | ||
| 3327 | Ethnic Inequalities are Hidden but are No Myth | 2021-05-17 | ||
| 3328 | Health Inequalities are Widespread Around The World | 2021-05-17 | ||
| 3329 | Author Declaration | 2021-05-17 | ||
| 3330 | Future Requirements | 2021-05-17 | ||
| 3331 | Disease Puzzle Studies | 2021-05-17 | ||
| 3332 | The New Concepts | 2021-05-17 | ||
| 3333 | Visual Analogue Scale | 2021-05-17 | ||
| 3334 | Instruments | 2021-05-17 | ||
| 3335 | Study Strength | 2021-05-16 | ||
| 3336 | Factors Associated With Contraceptive Uptake | 2021-05-16 | ||
| 3337 | Prior Presentation | 2021-05-15 | ||
| 3338 | Revelance of the Study | 2021-05-15 | ||
| 3339 | Limitation on the Study | 2021-05-15 | ||
| 3340 | Neuromuscular Adaptations | 2021-05-14 | ||
| 3341 | Behavioural Adaptations | 2021-05-14 | ||
| 3342 | Psychological Adaptations | 2021-05-14 | ||
| 3343 | Disclousers | 2021-05-14 | ||
| 3344 | Diagnostic Criteria for Frailty | 2021-05-14 | ||
| 3345 | Various concepts advocated as related to “frailty” | 2021-05-14 | ||
| 3346 | Cryopreservation and Liquid Nitrogen | 2021-05-14 | ||
| 3347 | Tearcare System: An Innovation for the Treatment of MGD and DED | 2021-05-14 | ||
| 3348 | Methods of Data Analysis | 2021-05-14 | ||
| 3349 | Data Processing and Analyses | 2021-05-14 | ||
| 3350 | Data Collection Technique and Quality Control | 2021-05-14 | ||
| 3351 | What this Paper Adds | 2021-05-14 | ||
| 3352 | What was Known | 2021-05-14 | ||
| 3353 | Usability Testing | 2021-05-14 | ||
| 3354 | Transformation Issues | 2021-05-14 | ||
| 3355 | Alternatives to Open Dumping | 2021-05-13 | ||
| 3356 | Waste Disposal in Jorhat | 2021-05-13 | ||
| 3357 | The Future of Data Mining | 2021-05-13 | ||
| 3358 | How Data Mining Works | 2021-05-13 | ||
| 3359 | What is Data Mining? | 2021-05-13 | ||
| 3360 | Ectosomes | 2021-05-13 | ||
| 3361 | Exosomes | 2021-05-13 | ||
| 3362 | Extracellular Vesicles | 2021-05-13 | ||
| 3363 | Integration of Other Technologies | 2021-05-13 | ||
| 3364 | What is blockchain? | 2021-05-13 | ||
| 3365 | Disadvantage of Mobile Computing | 2021-05-13 | ||
| 3366 | Advantage of Mobile Computing | 2021-05-13 | ||
| 3367 | Features of Mobile Computing | 2021-05-13 | ||
| 3368 | Future of Mobile Computing | 2021-05-13 | ||
| 3369 | Fundametals of Data Mining | 2021-05-13 | ||
| 3370 | Uses of DNA Sequencing | 2021-05-13 | ||
| 3371 | Understanding the Accumulation of Old and Insoluble Proteins with Age | 2021-05-12 | ||
| 3372 | A Better Strategy for Proteome Maintenance | 2021-05-12 | ||
| 3373 | Longevity is Correlated with Longer Protein Half-Lives in Mammals | 2021-05-12 | ||
| 3374 | Rights and Permissions | 2021-05-12 | ||
| 3375 | Will the Emerging Variants Create a Vaccine Problem? | 2021-05-12 | ||
| 3376 | Nucleic Acid (DNA and RNA) Based Vaccine | 2021-05-12 | ||
| 3377 | Replication Incompetent and Replication Competent Vector Vaccine | 2021-05-12 | ||
| 3378 | Subunit Vaccine (Recombinant Protein Vaccines) | 2021-05-12 | ||
| 3379 | Whole Virus Vaccine (Inactivated and Live-Attenuated Vaccine) | 2021-05-12 | ||
| 3380 | Vaccine Strategies | 2021-05-12 | ||
| 3381 | Detection Methods other than RT-PCR | 2021-05-12 | ||
| 3382 | Transmissibility of these New Variants | 2021-05-12 | ||
| 3383 | The Emerging New Variants of SARS-COV-2 | 2021-05-12 | ||
| 3384 | Different Clades of SARS-COV-2 | 2021-05-12 | ||
| 3385 | Method of Collection of Data | 2021-05-12 | ||
| 3386 | Future Considerations | 2021-05-11 | ||
| 3387 | Protocols for Inspection and Detection | 2021-05-11 | ||
| 3388 | Grant Information | 2021-05-11 | ||
| 3389 | Human Rights | 2021-05-11 | ||
| 3390 | Source(s) of Support Finance | 2021-05-11 | ||
| 3391 | Anaphase | 2021-05-11 | ||
| 3392 | Prophase | 2021-05-11 | ||
| 3393 | Methods and Results | 2021-05-11 | ||
| 3394 | History of Animal Genetic Resources | 2021-05-11 | ||
| 3395 | Animal Genetic Resources | 2021-05-11 | ||
| 3396 | Depiction | 2021-05-11 | ||
| 3397 | Birthplaces | 2021-05-11 | ||
| 3398 | Illustrative Cases | 2021-05-11 | ||
| 3399 | Test-Retest Reliability | 2021-05-11 | ||
| 3400 | Item Analysis | 2021-05-11 | ||
| 3401 | Confirmatory Factor Analysis | 2021-05-11 | ||
| 3402 | Translation Process | 2021-05-11 | ||
| 3403 | Data Collecting Tools | 2021-05-11 | ||
| 3404 | Common Risk Factors for Periodontal Disease and Covid-19 | 2021-05-11 | ||
| 3405 | Oncological Outcomes in MIDP | 2021-05-11 | ||
| 3406 | Left-to-Right and Right-to-Left Dissection Procedures in DP for the Management of Cancer of the Body or Tail of the Pancreas | 2021-05-11 | ||
| 3407 | Financial Interest Statement | 2021-05-11 | ||
| 3408 | SUSD2 is a Double Agent | 2021-05-11 | ||
| 3409 | Therapeutic Strategy for NAFLD/NASH-Related HCC | 2021-05-11 | ||
| 3410 | Risk Stratification in NAFLD/NASH-Related HCC | 2021-05-11 | ||
| 3411 | Combined Effect of Variants | 2021-05-11 | ||
| 3412 | Current Genetic Advances in NAFLD/NASH-Related HCC | 2021-05-11 | ||
| 3413 | Characteristic Clinical Manifestations in NAFLD/NASH-Related HCC | 2021-05-11 | ||
| 3414 | Link Between NAFLD/NASH and Atherosclerosis | 2021-05-11 | ||
| 3415 | Discussion and Limitations | 2021-05-11 | ||
| 3416 | The Data which were Collected | 2021-05-10 | ||
| 3417 | Partial Budget Analysis | 2021-05-10 | ||
| 3418 | Functional Networks | 2021-05-10 | ||
| 3419 | Target Formation Mapping with Seismoelectric Data | 2021-05-10 | ||
| 3420 | Seismoelectric Survey Principle and Method | 2021-05-10 | ||
| 3421 | Data Acquisition and Display | 2021-05-10 | ||
| 3422 | Disadvantages of Gene Therapy | 2021-05-10 | ||
| 3423 | Advantages of Gene Therapy | 2021-05-10 | ||
| 3424 | Types of Gene Therapy | 2021-05-10 | ||
| 3425 | Gene Therapy and its Importance | 2021-05-10 | ||
| 3426 | Role of MBL2 Gene In Malaria | 2021-05-10 | ||
| 3427 | Genetics and BWF | 2021-05-10 | ||
| 3428 | Action of Quinine On Red Blood Cells (Rbc) | 2021-05-10 | ||
| 3429 | Action of P. Falciparum On Red Blood Cells (Rbc) | 2021-05-10 | ||
| 3430 | Immunology Pathogenesis Of Bwf | 2021-05-10 | ||
| 3431 | Indications | 2021-05-10 | ||
| 3432 | Obscure | 2021-05-10 | ||
| 3433 | Post-Testicular | 2021-05-10 | ||
| 3434 | Pretesticular | 2021-05-10 | ||
| 3435 | Plasmid DNA | 2021-05-07 | ||
| 3436 | Vaccine Development | 2021-05-07 | ||
| 3437 | Vitamins Prophylactic Therapy | 2021-05-07 | ||
| 3438 | Staph Infections | 2021-05-07 | ||
| 3439 | Voluntary Administration | 2021-05-06 | ||
| 3440 | Social Security Funds | 2021-05-06 | ||
| 3441 | Scientific Managements | 2021-05-06 | ||
| 3442 | Public Financial Management | 2021-05-06 | ||
| 3443 | Explanation | 2021-05-03 | ||
| 3444 | Donating Peripheral Blood Stem Cells | 2021-05-03 | ||
| 3445 | Reasons for a PBSCT | 2021-05-03 | ||
| 3446 | Purpose of Stem Cell Transplants | 2021-05-03 | ||
| 3447 | Format of Problem-Solving Therapy | 2021-05-01 | ||
| 3448 | Types of Problems Treated | 2021-05-01 | ||
| 3449 | Psychological Disorder Prevalence | 2021-05-01 | ||
| 3450 | Purpose of Getting a Diagnosis | 2021-05-01 | ||
| 3451 | How are Psychological Disorders Diagnosed? | 2021-05-01 | ||
| 3452 | What is a Psychological Disorder? | 2021-05-01 | ||
| 3453 | What to Expect? | 2021-05-01 | ||
| 3454 | How It Helps? | 2021-05-01 | ||
| 3455 | What It Involves? | 2021-05-01 | ||
| 3456 | Benefits | 2021-05-01 | ||
| 3457 | Benefits of Psychoanalytic Therapy | 2021-05-01 | ||
| 3458 | Dealing with Unconscious Forces | 2021-05-01 | ||
| 3459 | Intensive Treatment | 2021-05-01 | ||
| 3460 | How it Works? | 2021-05-01 | ||
| 3461 | Summary and Hypothesis | 2021-05-01 | ||
| 3462 | Confounded UTIs | 2021-05-01 | ||
| 3463 | The Board | 2021-05-01 | ||
| 3464 | Asymptomatic bacteriuria | 2021-05-01 | ||
| 3465 | Intermittent UTI | 2021-05-01 | ||
| 3466 | Simple versus convoluted UTI | 2021-05-01 | ||
| 3467 | What is Urinary lot contaminations | 2021-05-01 | ||
| 3468 | Updating Healthcare Team Outcomes | 2021-05-01 | ||
| 3469 | Staging | 2021-05-01 | ||
| 3470 | History and Physical | 2021-05-01 | ||
| 3471 | Difficulties | 2021-05-01 | ||
| 3472 | Ends | 2021-04-30 | ||
| 3473 | Non Infectious Complications | 2021-04-30 | ||
| 3474 | Infectious Complications | 2021-04-30 | ||
| 3475 | MR Peritoneography | 2021-04-30 | ||
| 3476 | CT Peritoneography | 2021-04-30 | ||
| 3477 | CT Peritoneography | 2021-04-30 | ||
| 3478 | Vaginismus | 2021-04-30 | ||
| 3479 | Dyspareunia and Vulvodynia | 2021-04-30 | ||
| 3480 | HPV Causes | 2021-04-30 | ||
| 3481 | Distribution | 2021-04-30 | ||
| 3482 | Diagnosis and Tests | 2021-04-30 | ||
| 3483 | Aims and scope | 2021-04-30 | ||
| 3484 | Integrating the Online Mental Services in Health Services in the DRC: Developing a New Model | 2021-04-29 | ||
| 3485 | Opportunities to Improve the Mental Health during the COVID-19 Pandemic and the Related Lock-Down Measures in the DRC | 2021-04-29 | ||
| 3486 | Mental Health Challenges and Perspectives Associated with the COVID-19 and Related Lock-Down | 2021-04-29 | ||
| 3487 | Neuralink Brain Computer Interfaces | 2021-04-29 | ||
| 3488 | Big Data with AI in Fighting Covid-19 | 2021-04-29 | ||
| 3489 | Artificial Intelligence in Combating Covid-19 | 2021-04-29 | ||
| 3490 | Conflict of Interest Disclosure | 2021-04-29 | ||
| 3491 | Funding Disclosure | 2021-04-29 | ||
| 3492 | Indian Scenario | 2021-04-28 | ||
| 3493 | 2021-04-28 | |||
| 3494 | Treatment Strategies | 2021-04-27 | ||
| 3495 | Feeding Automation | 2021-04-26 | ||
| 3496 | Milking Automation | 2021-04-26 | ||
| 3497 | Artificial Breeding Process | 2021-04-26 | ||
| 3498 | Computer and Internet Usage | 2021-04-26 | ||
| 3499 | Coral Bleaching | 2021-04-26 | ||
| 3500 | White Band Disease | 2021-04-26 | ||
| 3501 | Black Band Disease | 2021-04-26 | ||
| 3502 | About the Study | 2021-04-26 | ||
| 3503 | Disadvantages and Limitations | 2021-04-26 | ||
| 3504 | Ethnoveterinary Practice in India | 2021-04-26 | ||
| 3505 | Results of Descriptive Analysis | 2021-04-26 | ||
| 3506 | Scientific Responsibility Statement | 2021-04-26 | ||
| 3507 | Abbreviation/Acronyms | 2021-04-23 | ||
| 3508 | Barukenedamu | 2021-04-22 | ||
| 3509 | Steps and Procedures Used in Feragezgn Customary Conflict Resolution Mechanisms | 2021-04-22 | ||
| 3510 | Feragezagn Institution: The Customary Conflict Resolution Mechanism in Meskan Society | 2021-04-22 | ||
| 3511 | Neighbour Conflict | 2021-04-22 | ||
| 3512 | Alcoholism | 2021-04-22 | ||
| 3513 | Family Related Conflicts | 2021-04-22 | ||
| 3514 | Methods Data Analysis | 2021-04-22 | ||
| 3515 | Scope of the Study | 2021-04-22 | ||
| 3516 | Proposed System | 2021-04-21 | ||
| 3517 | Related Works | 2021-04-21 | ||
| 3518 | Supplementary Material | 2021-04-21 | ||
| 3519 | Study Funding | 2021-04-20 | ||
| 3520 | Traditional and Medicinal Uses | 2021-04-20 | ||
| 3521 | Phytochemistry | 2021-04-20 | ||
| 3522 | Botanical Description | 2021-04-20 | ||
| 3523 | Jel Classification | 2021-04-19 | ||
| 3524 | Cloud Implementation | 2021-04-19 | ||
| 3525 | Highlighting | 2021-04-19 | ||
| 3526 | Critical Path View | 2021-04-19 | ||
| 3527 | Bill-Of-Materials Plus Operations View | 2021-04-19 | ||
| 3528 | The CMSD Data Model | 2021-04-19 | ||
| 3529 | Data Collection Results | 2021-04-19 | ||
| 3530 | Scope and Objective | 2021-04-19 | ||
| 3531 | ECG Intervals | 2021-04-19 | ||
| 3532 | Electrocardiogram | 2021-04-19 | ||
| 3533 | Information on Financing | 2021-04-19 | ||
| 3534 | Opposition Opportunity | 2021-04-19 | ||
| 3535 | Body Counts | 2021-04-19 | ||
| 3536 | Hunger Pangs | 2021-04-19 | ||
| 3537 | Vladimir Putin is in Deep Trouble | 2021-04-19 | ||
| 3538 | Review As Soon As Possible | 2021-04-19 | ||
| 3539 | Peptic Ulcer Treatment | 2021-04-17 | ||
| 3540 | Management Strategies | 2021-04-17 | ||
| 3541 | Challenges to Fish Production | 2021-04-17 | ||
| 3542 | Fishery Potentials in Ethiopian Water Bodies | 2021-04-17 | ||
| 3543 | Fish Diversity in Ethiopia | 2021-04-17 | ||
| 3544 | Analysis of the Results | 2021-04-16 | ||
| 3545 | Fourth Year | 2021-04-16 | ||
| 3546 | Third Year | 2021-04-16 | ||
| 3547 | Second Year | 2021-04-16 | ||
| 3548 | Introducing Nirs into the Iomt System for the Health Promotion of the Elderly | 2021-04-16 | ||
| 3549 | Evaluation of Very Early Mobilization by Nirs for Patients with Hyperacute Subarachnoid Hemorrhage | 2021-04-16 | ||
| 3550 | Evaluation of Very Early Mobilization by Nirs for Patients with Hyperacute Subarachnoid Hemorrhage | 2021-04-16 | ||
| 3551 | Effect of Aerobic Exercise on Cognitive Function in Post-Chronic Stroke Patients | 2021-04-16 | ||
| 3552 | Herd Size | 2021-04-16 | ||
| 3553 | Availability of Supporting Data | 2021-04-16 | ||
| 3554 | Ethics Approval and Consent to Participate | 2021-04-16 | ||
| 3555 | Medications developed from natural products | 2021-04-14 | ||
| 3556 | Medications developed from traditional medicines that follow the traditional uses | 2021-04-14 | ||
| 3557 | Customary Medicines | 2021-04-14 | ||
| 3558 | Regular Products | 2021-04-14 | ||
| 3559 | Quality norms and legitimate prerequisites in Germany: | 2021-04-14 | ||
| 3560 | Investigation Populace | 2021-04-14 | ||
| 3561 | Blinding | 2021-04-14 | ||
| 3562 | Randomization | 2021-04-14 | ||
| 3563 | Brazil (LATAM) | 2021-04-14 | ||
| 3564 | European Union | 2021-04-14 | ||
| 3565 | Unites States of America | 2021-04-14 | ||
| 3566 | Documenting a Generic Drug Application | 2021-04-14 | ||
| 3567 | Nonexclusive Drug Development | 2021-04-14 | ||
| 3568 | Essential Pathways to Medical Device Approval | 2021-04-14 | ||
| 3569 | Prerequisites for Clinical Trials | 2021-04-14 | ||
| 3570 | The Pre-Clinical Stages: Prototype Development and Testing | 2021-04-14 | ||
| 3571 | Testing the Hypothesis | 2021-04-14 | ||
| 3572 | Other Clues | 2021-04-14 | ||
| 3573 | TH17, THE LINK BETWEEN COVID-19 AND H4R | 2021-04-14 | ||
| 3574 | H4R AND LUNG FIBROSIS | 2021-04-14 | ||
| 3575 | HISTAMINE | 2021-04-14 | ||
| 3576 | CYTOKINE STORM AND IMMUNE DYSREGULATION | 2021-04-14 | ||
| 3577 | COVID-19 AND LUNG FIBROSIS | 2021-04-14 | ||
| 3578 | Clinical Presentation | 2021-04-14 | ||
| 3579 | Environmental Impacts of Plastics | 2021-04-13 | ||
| 3580 | Short Review | 2021-04-08 | ||
| 3581 | Treatments and Results | 2021-04-08 | ||
| 3582 | Quality Assessment of the Included Studies | 2021-04-08 | ||
| 3583 | Study | 2021-04-08 | ||
| 3584 | Cytoskeleton | 2021-04-08 | ||
| 3585 | A Prokaryotic Cell has Three Distinct Parts | 2021-04-08 | ||
| 3586 | Development of An Ordinary Prokaryotic Cell | 2021-04-08 | ||
| 3587 | Function | 2021-04-07 | ||
| 3588 | Neurotransmission | 2021-04-07 | ||
| 3589 | Myelin sheath creation | 2021-04-07 | ||
| 3590 | Neuron Repair and Development | 2021-04-07 | ||
| 3591 | Advances since 2015 | 2021-04-07 | ||
| 3592 | Advanves since 2015 | 2021-04-07 | ||
| 3593 | Viewpoint Before 2015 | 2021-04-07 | ||
| 3594 | Limitations and Challenges | 2021-04-07 | ||
| 3595 | EXPLOSIVE STRENGTH | 2021-04-07 | ||
| 3596 | Obstructive Uropathy | 2021-04-07 | ||
| 3597 | Diabetic Kidney Illness | 2021-04-07 | ||
| 3598 | Clinical Manifestation | 2021-04-07 | ||
| 3599 | BENEFITS OF YOGA IN A PANDEMIC | 2021-04-07 | ||
| 3600 | YOGA ON ONLINE PLATFORMS | 2021-04-07 | ||
| 3601 | Depression and Anxiety Disorders: Not the Same | 2021-04-07 | ||
| 3602 | Renal Failure | 2021-04-07 | ||
| 3603 | HYDROGEN CAN BE PRODUCED BY FOLLOWING METHODS | 2021-04-07 | ||
| 3604 | THE METHOD OF PRODUCTION ALGAE FROM POND CAN BE DONE BE BY 3 METHODS | 2021-04-07 | ||
| 3605 | The Dopamine-Depletion Hypothesis of Drug Addiction | 2021-04-07 | ||
| 3606 | Attachment and the Establishment of Unique Modes of Communication between Parents and Children | 2021-04-07 | ||
| 3607 | Testing | 2021-04-07 | ||
| 3608 | Risks | 2021-04-07 | ||
| 3609 | The Healthcare System in B & H | 2021-04-06 | ||
| 3610 | Conditions Associated with a Hyperfibrinolytic State | 2021-04-06 | ||
| 3611 | Challenges in Developing a Successful T Cell Based Therapeuti | 2021-04-06 | ||
| 3612 | CHALLENGES IN DEVELOPING A SUCCESSFUL T CELL BASED THERAPEUTIC HIV VACCINE | 2021-04-06 | ||
| 3613 | SPERMATOGENESIS | 2021-04-06 | ||
| 3614 | MALE'S REPRODUCTIVE ORGAN | 2021-04-06 | ||
| 3615 | Announcement | 2021-04-06 | ||
| 3616 | Prevention | 2021-04-06 | ||
| 3617 | Goals in Submitting for Publication | 2021-04-06 | ||
| 3618 | MICROARRAY INVESTIGATION | 2021-04-06 | ||
| 3619 | Healthy Food for Pregnant Woman | 2021-04-06 | ||
| 3620 | Things Happening in Pregnancy | 2021-04-06 | ||
| 3621 | Healthy Food Toward Healthy Diet | 2021-04-06 | ||
| 3622 | The Sperm Dark Matter | 2021-04-06 | ||
| 3623 | The Female Burden | 2021-04-06 | ||
| 3624 | "Cotes' Spiral" and Results | 2021-04-05 | ||
| 3625 | Date of Synoptic Charts of CB and Satellite Images | 2021-04-05 | ||
| 3626 | The Anatomy of a Cyclone | 2021-04-05 | ||
| 3627 | Policy and Government | 2021-04-05 | ||
| 3628 | Constraints for Tropical Agroforestry System | 2021-04-05 | ||
| 3629 | Agroforestry for Climate Change Mitigation | 2021-04-05 | ||
| 3630 | Agroforestry for Food and Income Security | 2021-04-05 | ||
| 3631 | Agroforestry for Soil Improvement | 2021-04-05 | ||
| 3632 | Classification of Agroforestry System | 2021-04-05 | ||
| 3633 | Agroforestry: A Global Overview | 2021-04-05 | ||
| 3634 | Trauma detection | 2021-04-02 | ||
| 3635 | The structures | 2021-04-02 | ||
| 3636 | Why adolescents utilize web-based media | 2021-04-02 | ||
| 3637 | Portable game addiction and depression | 2021-04-02 | ||
| 3638 | Evaluation of psychiatric disorders in adolescents | 2021-04-02 | ||
| 3639 | Pediatric Urology | 2021-04-02 | ||
| 3640 | Challenging stigma related to mental disease | 2021-04-02 | ||
| 3641 | Steps to address stigma | 2021-04-02 | ||
| 3642 | Risk factors of depression and suicide | 2021-04-02 | ||
| 3643 | To assess delirium, NICE (2010a) suggests numerous tools, together with the: | 2021-04-02 | ||
| 3644 | Assessment tools | 2021-04-02 | ||
| 3645 | Dementia and depression among older folks as public health problems | 2021-04-02 | ||
| 3646 | To the Editors of the Clinics in Mother and Child Health | 2021-04-02 | ||
| 3647 | Pharmacological Inhibition of PARP | 2021-04-02 | ||
| 3648 | Involvement of PARP in Various Pathological Conditions | 2021-04-02 | ||
| 3649 | Different Types of PARP | 2021-04-02 | ||
| 3650 | PARP Structure | 2021-04-02 | ||
| 3651 | Salinity Stress | 2021-04-02 | ||
| 3652 | Combined Temperature and Drought Stress | 2021-04-02 | ||
| 3653 | Temperature Stress | 2021-04-02 | ||
| 3654 | Drought Stress | 2021-04-02 | ||
| 3655 | An Approach to Monitor the Pathophysiological Status of Hdp, An Intractable Disease of Unknown Etiology, Using Peptidomics | 2021-04-02 | ||
| 3656 | Transplantation and Lineage Tracing to Study Clonal Dynamics | 2021-04-02 | ||
| 3657 | Transplantation of Transgenic or Pulse-Labeled Pgcs in Male and Female Gonads | 2021-04-02 | ||
| 3658 | Clonal Tracking of Transplanted Transgenic Pluripotent Stem Cells in Non-Human Primate Models | 2021-04-02 | ||
| 3659 | Multi-lineage Tracing | 2021-04-02 | ||
| 3660 | Ssc Culture Approaches | 2021-04-02 | ||
| 3661 | Genome-Editing Tools | 2021-04-02 | ||
| 3662 | An Approach to Monitor the Pathophysiological Status of Hdp, An Intractable Disease of Unknown Etiology, Using Peptidomics | 2021-04-02 | ||
| 3663 | Implementation and Impact | 2021-04-01 | ||
| 3664 | Clinimetric Properties of the Himat | 2021-04-01 | ||
| 3665 | The High-Level Mobility Assessment Tool (Himat) | 2021-04-01 | ||
| 3666 | High-Level Mobility | 2021-04-01 | ||
| 3667 | Bile Acids and Gut Microbiota | 2021-04-01 | ||
| 3668 | Interaction Between Cdca and Intestinal Mucosa | 2021-04-01 | ||
| 3669 | Interaction Between Lca and Intestinal Mucosa | 2021-04-01 | ||
| 3670 | Interaction Between Dca and Intestinal Mucosa | 2021-04-01 | ||
| 3671 | Interaction Between Udca and Intestinal Mucosa | 2021-04-01 | ||
| 3672 | Introduction of Bile Acids | 2021-04-01 | ||
| 3673 | Insulin | 2021-04-01 | ||
| 3674 | Objectives and Methods | 2021-04-01 | ||
| 3675 | Empirical Studies on Customary Dispute Settlement in Africa and Ethiopia | 2021-04-01 | ||
| 3676 | ELDERSâ?? COUNCIL | 2021-04-01 | ||
| 3677 | ELDERSâ?? COUNCIL | 2021-04-01 | ||
| 3678 | ELDERSâ?? COUNCIL | 2021-04-01 | ||
| 3679 | ELDERSâ?? COUNCIL | 2021-04-01 | ||
| 3680 | Dispute Settlement Institutions and their Different Mechanisms | 2021-04-01 | ||
| 3681 | Conceptualizing Dispute Settlement | 2021-04-01 | ||
| 3682 | Definition of key Terms and Concepts | 2021-04-01 | ||
| 3683 | Asherman Syndrome | 2021-04-01 | ||
| 3684 | Pcos | 2021-04-01 | ||
| 3685 | Reproductive System Disorders | 2021-04-01 | ||
| 3686 | Editorial Note on Biology and Medicine Journal | 2021-04-01 | ||
| 3687 | CRISPR and Genetic Engineering | 2021-04-01 | ||
| 3688 | Cancer Biology in Biology and Medicine | 2021-04-01 | ||
| 3689 | Data Analysis and Description | 2021-04-01 | ||
| 3690 | Pharmacological Approaches | 2021-04-01 | ||
| 3691 | Advanced Techniques in Biology & Medicine | 2021-04-01 | ||
| 3692 | Biology and Medicine: A Multidisciplinary Approach for Promoting Healthy Life | 2021-04-01 | ||
| 3693 | Covid-19 and Pregnancy | 2021-04-01 | ||
| 3694 | Low Back Pain: Its Mechanisms, Symptoms and Diagnosis | 2021-04-01 | ||
| 3695 | Market Review and Growth Analysis on Generic Medicine | 2021-04-01 | ||
| 3696 | Conclusion and Future Prespective | 2021-03-31 | ||
| 3697 | Classification of Biosensors | 2021-03-31 | ||
| 3698 | Biosensors in Pathogens Detection | 2021-03-31 | ||
| 3699 | Main Area Requiring Pathogen Detection | 2021-03-31 | ||
| 3700 | Molecule Channels Underlying the Cardiac Action Potential | 2021-03-31 | ||
| 3701 | The Relationship Between the Cardiac Action Potential and the Electrocardiogram | 2021-03-31 | ||
| 3702 | The Ventricular Cardiac Action Potential | 2021-03-31 | ||
| 3703 | The Initiation of the Heart Beat | 2021-03-31 | ||
| 3704 | Etiology and Pathogenesis of Syncope | 2021-03-31 | ||
| 3705 | Diagnostic Approach to Cardiogenic Syncope | 2021-03-31 | ||
| 3706 | Footnote References | 2021-03-31 | ||
| 3707 | Discussions in our Research Team | 2021-03-31 | ||
| 3708 | Discussions at Three Academic Conferences | 2021-03-31 | ||
| 3709 | Mechanisms Employed in the Potential Antiviral Activity of MB against SARS-CoV-2 | 2021-03-31 | ||
| 3710 | Results and Data Analysis | 2021-03-31 | ||
| 3711 | Potential Therapeutic Implications | 2021-03-31 | ||
| 3712 | Macrophages, Hypoxia, and Infectious Diseases | 2021-03-31 | ||
| 3713 | Macrophages, Hypoxia, and Inflammatory Diseases | 2021-03-31 | ||
| 3714 | Macrophages | 2021-03-31 | ||
| 3715 | Neutrophils, Hypoxia, and Infectious Diseases | 2021-03-31 | ||
| 3716 | Neutrophils, Hypoxia, and Inflammatory Diseases | 2021-03-31 | ||
| 3717 | Neutrophils | 2021-03-31 | ||
| 3718 | Infection and Hypoxia | 2021-03-31 | ||
| 3719 | Inflammation and Hypoxia | 2021-03-31 | ||
| 3720 | Clinical Trials Prs | 2021-03-30 | ||
| 3721 | Surgical Videoscope | 2021-03-30 | ||
| 3722 | Tools for Visualization | 2021-03-30 | ||
| 3723 | Treatment Result | 2021-03-30 | ||
| 3724 | Gel Electrophoresis | 2021-03-30 | ||
| 3725 | Techniques for Extraction & Storage of Biomolecules | 2021-03-30 | ||
| 3726 | Blotting Techniques | 2021-03-30 | ||
| 3727 | Clinical Features and Diagnosis | 2021-03-30 | ||
| 3728 | The Experience | 2021-03-30 | ||
| 3729 | Cognitive Performance as a Function of Job Match Logic Aptitude Test | 2021-03-30 | ||
| 3730 | Diabetes in Kids | 2021-03-30 | ||
| 3731 | Diagnosis and Diet Control | 2021-03-30 | ||
| 3732 | Types of Diabetes Mellitus | 2021-03-30 | ||
| 3733 | Conclusions and Suggestions | 2021-03-30 | ||
| 3734 | Blood Types and Systemic Diseases | 2021-03-30 | ||
| 3735 | Structured Question | 2021-03-30 | ||
| 3736 | Cutaneous Polyarteritis Nodosa | 2021-03-30 | ||
| 3737 | Cell Culture Method | 2021-03-30 | ||
| 3738 | Serological Method | 2021-03-30 | ||
| 3739 | Molecular Method | 2021-03-30 | ||
| 3740 | Laboratory Testing Methods | 2021-03-30 | ||
| 3741 | Biosafety Measures | 2021-03-30 | ||
| 3742 | The Detection Rate of SARS-COV-2 from Various Specimens | 2021-03-30 | ||
| 3743 | Factors Influencing Diagnostic Accuracy | 2021-03-30 | ||
| 3744 | Serum | 2021-03-30 | ||
| 3745 | Lower Respiratory Tracts Specimens | 2021-03-30 | ||
| 3746 | Upper Respiratory Tract Specimens | 2021-03-30 | ||
| 3747 | Specimen Types | 2021-03-30 | ||
| 3748 | Specimen Collection: General Considerations | 2021-03-30 | ||
| 3749 | Etiologic Agent | 2021-03-30 | ||
| 3750 | Competing Interests Statement | 2021-03-29 | ||
| 3751 | Narcissistic Personality Disorder | 2021-03-29 | ||
| 3752 | Editorial Note for Journal of Alcoholism and Drug Dependence | 2021-03-29 | ||
| 3753 | Short Note on Dark Side of Addiction | 2021-03-29 | ||
| 3754 | A Note on Drug Addiction | 2021-03-29 | ||
| 3755 | Short note on Hangover and its Effects | 2021-03-29 | ||
| 3756 | Current Challenges Impairing Health Care Facilities Due to the Impact of SARS-CoV2 | 2021-03-29 | ||
| 3757 | Materials and Experimental | 2021-03-29 | ||
| 3758 | Selection of Sampling Sites | 2021-03-29 | ||
| 3759 | Macronutrients and Trace Elements | 2021-03-29 | ||
| 3760 | Nutrient Balance | 2021-03-29 | ||
| 3761 | Conflicts of Interest | 2021-03-27 | ||
| 3762 | Military Doctrine | 2021-03-26 | ||
| 3763 | Visualization | 2021-03-26 | ||
| 3764 | Maritime Security and Operations | 2021-03-26 | ||
| 3765 | Management Information Systems | 2021-03-26 | ||
| 3766 | Management Accounting | 2021-03-26 | ||
| 3767 | Finance Ethics | 2021-03-26 | ||
| 3768 | Clinical History | 2021-03-26 | ||
| 3769 | Mental Imbalance | 2021-03-26 | ||
| 3770 | Elements of Management | 2021-03-26 | ||
| 3771 | Side Effects | 2021-03-26 | ||
| 3772 | Effects of Obstructive Sleep Apnea by Amedeoxu | 2021-03-26 | ||
| 3773 | Generator Set | 2021-03-25 | ||
| 3774 | Algorithm of Imitation | 2021-03-25 | ||
| 3775 | Algorithm of Generating of Free Energy | 2021-03-25 | ||
| 3776 | Performance | 2021-03-25 | ||
| 3777 | Biographical Notes | 2021-03-25 | ||
| 3778 | Ethical Approvals | 2021-03-25 | ||
| 3779 | Funding Information | 2021-03-25 | ||
| 3780 | Therapeutic Options for Cle | 2021-03-24 | ||
| 3781 | Immune Factors | 2021-03-24 | ||
| 3782 | Genetics | 2021-03-24 | ||
| 3783 | Management of Pregnant Women | 2021-03-24 | ||
| 3784 | Treatment of Pregnant Women with Corona Virus | 2021-03-24 | ||
| 3785 | Precautions to be Taken by Pregnant Women | 2021-03-24 | ||
| 3786 | Susceptibility of Pregnant Women | 2021-03-24 | ||
| 3787 | Futher Directions and Perspectives | 2021-03-24 | ||
| 3788 | Fecal Microbiotia Transplantation | 2021-03-24 | ||
| 3789 | Prebiotics | 2021-03-24 | ||
| 3790 | Probiotics | 2021-03-24 | ||
| 3791 | Therapeutics in Microbiota-ble Acid Pathway | 2021-03-24 | ||
| 3792 | Mechanisms Underlying the Gut Microbiota-Bile Acid Pathway and Cvds | 2021-03-24 | ||
| 3793 | Impact of Gut Microbiota on Bile Acid Metabolism | 2021-03-24 | ||
| 3794 | Conclusion and Suggestions | 2021-03-24 | ||
| 3795 | Prognosis | 2021-03-24 | ||
| 3796 | Clinical Picture | 2021-03-24 | ||
| 3797 | Etiology and Cause | 2021-03-24 | ||
| 3798 | Dairy Industry: The quality, food safety, and regulatory affairs of food manufacturing, FSMA, and food industries challenges and taking initiatives for preventative control. | 2021-03-23 | ||
| 3799 | Dairy Industry: Soil management and soil health | 2021-03-23 | ||
| 3800 | Community Health Components | 2021-03-23 | ||
| 3801 | What do we know and what should we explore? | 2021-03-22 | ||
| 3802 | Does COVID-19 Alter or Complicate Aesthetic Outcomes? | 2021-03-22 | ||
| 3803 | Methods and Methodology | 2021-03-19 | ||
| 3804 | Pediatric Multiple Sclerosis | 2021-03-17 | ||
| 3805 | Mechanism of Action | 2021-03-17 | ||
| 3806 | Iron Mineral Formation | 2021-03-17 | ||
| 3807 | Ultrastructure of Biofilm | 2021-03-17 | ||
| 3808 | Biofilm Formation | 2021-03-17 | ||
| 3809 | MRI in Paediatric Multiple Sclerosis | 2021-03-17 | ||
| 3810 | Multiple Sclerosis in Children | 2021-03-17 | ||
| 3811 | Calcium Channel Blockers | 2021-03-17 | ||
| 3812 | 2d-LC Solutions for Organic Compound Applications | 2021-03-17 | ||
| 3813 | Treating | 2021-03-17 | ||
| 3814 | Saperation | 2021-03-17 | ||
| 3815 | Peritoneal dialysis | 2021-03-17 | ||
| 3816 | Medication Interactions | 2021-03-17 | ||
| 3817 | Antagonistic Reactions | 2021-03-17 | ||
| 3818 | Pharmacology | 2021-03-17 | ||
| 3819 | Angiotensin II Receptor Blockers | 2021-03-17 | ||
| 3820 | Laser stylostixis for stroke and neurorehabilitation | 2021-03-17 | ||
| 3821 | Albumin Ratio | 2021-03-17 | ||
| 3822 | Signs and Symptoms of Neuroimmunological Disorders | 2021-03-17 | ||
| 3823 | Bilateral Nephrectomy | 2021-03-17 | ||
| 3824 | Neuroimmune disorders area unit characterised by inflammatory deregulating among the system. this issue can harvest developing analysis during this field. | 2021-03-17 | ||
| 3825 | Autoimmune medical specialty Disorders | 2021-03-17 | ||
| 3826 | Pathophysiology of MS | 2021-03-17 | ||
| 3827 | Membranous Nephropathy | 2021-03-17 | ||
| 3828 | Risk factors of Alcohol Neuropathy | 2021-03-17 | ||
| 3829 | Evaluation & Tests | 2021-03-17 | ||
| 3830 | Angiotensinogen | 2021-03-17 | ||
| 3831 | Renin Angiotensin | 2021-03-17 | ||
| 3832 | Treatment Alternatives | 2021-03-17 | ||
| 3833 | Sign and Symptoms | 2021-03-17 | ||
| 3834 | Symptomatology | 2021-03-17 | ||
| 3835 | Nephroptosis | 2021-03-17 | ||
| 3836 | Types of Submissions | 2021-03-17 | ||
| 3837 | Pee sodium focus | 2021-03-17 | ||
| 3838 | Fragmentary discharge of sodium | 2021-03-17 | ||
| 3839 | Scope Of PV | 2021-03-17 | ||
| 3840 | Urinalysis | 2021-03-17 | ||
| 3841 | Sepsis-Induced Acute Tubular Necrosis | 2021-03-17 | ||
| 3842 | Nephrotoxic-Induced Acute Tubular Necrosis | 2021-03-17 | ||
| 3843 | Dear Readers, | 2021-03-17 | ||
| 3844 | Tubular Necrosis | 2021-03-17 | ||
| 3845 | Proteinuria | 2021-03-17 | ||
| 3846 | Filtration and reabsorption of plasma proteins | 2021-03-17 | ||
| 3847 | Sampling Procedure | 2021-03-16 | ||
| 3848 | Empirical Framework | 2021-03-16 | ||
| 3849 | Competing of interests | 2021-03-16 | ||
| 3850 | Taxonomy and Biology of Penicillium Pinophilum (Talaromyces Pinophilus) | 2021-03-16 | ||
| 3851 | Diversity in Ecosystem and Potential Role of Biological Agents | 2021-03-16 | ||
| 3852 | Disease Management of Rhizoctonia Solani | 2021-03-16 | ||
| 3853 | Infection Process and Symptoms | 2021-03-16 | ||
| 3854 | Currently Available Diagnostic Tools For Congenital Cmv In Newborns In Africa | 2021-03-15 | ||
| 3855 | Neonatal Prevalence Of Congential Cmv In Africa | 2021-03-15 | ||
| 3856 | Approach | 2021-03-15 | ||
| 3857 | Distribution and Host Range | 2021-03-15 | ||
| 3858 | Taxonomy and Biology of Rhizoctonia Solani | 2021-03-15 | ||
| 3859 | Sugar Beet Domestication and US Commercialization | 2021-03-15 | ||
| 3860 | Graves' Disease | 2021-03-15 | ||
| 3861 | Multiple Sclerosis | 2021-03-15 | ||
| 3862 | Oral Health Conditions | 2021-03-15 | ||
| 3863 | Award for Human Genome 2020 | 2021-03-14 | ||
| 3864 | 2019 Highlights of JPHC | 2021-03-12 | ||
| 3865 | Authors Information | 2021-03-12 | ||
| 3866 | Important Milestones in Climate Control | 2021-03-12 | ||
| 3867 | Impact of Climate Change on Small Islands | 2021-03-12 | ||
| 3868 | Consequences of Climate Changes | 2021-03-12 | ||
| 3869 | Targeting the Needs of the Vulnerable | 2021-03-12 | ||
| 3870 | HIV Self-Testing | 2021-03-12 | ||
| 3871 | Social Perspective | 2021-03-12 | ||
| 3872 | Ground Reality | 2021-03-12 | ||
| 3873 | New Developments | 2021-03-12 | ||
| 3874 | O2, Ar, and N2 Generation Industries | 2021-03-12 | ||
| 3875 | CO and CO2 Generation, Capture Operation and their Conversion in Industrial Scale | 2021-03-12 | ||
| 3876 | Results and Observation | 2021-03-11 | ||
| 3877 | Immunosuppressive Agents | 2021-03-11 | ||
| 3878 | Systemic Steroids | 2021-03-11 | ||
| 3879 | Intravitreal Steroids | 2021-03-11 | ||
| 3880 | Periocular Steroids | 2021-03-11 | ||
| 3881 | Iontophoresis | 2021-03-11 | ||
| 3882 | Topical Corticosteroids | 2021-03-11 | ||
| 3883 | Local Delivery of Corticosteroids | 2021-03-11 | ||
| 3884 | Determining Relevant References of Published Reviews | 2021-03-11 | ||
| 3885 | Development of Search Strategies | 2021-03-11 | ||
| 3886 | Prescription Monitoring | 2021-03-11 | ||
| 3887 | Principles of Causality Assessment | 2021-03-11 | ||
| 3888 | About Vigimed | 2021-03-11 | ||
| 3889 | Treatments | 2021-03-11 | ||
| 3890 | Ethics Approval and Constant to Participate | 2021-03-08 | ||
| 3891 | Methods and Participants | 2021-03-08 | ||
| 3892 | Epidemiology and Coronavirus | 2021-03-06 | ||
| 3893 | Perspectives and Future Developments | 2021-03-06 | ||
| 3894 | Antimicrobial Photodynamic Therapy for Prevention of Hospital Pneumonia | 2021-03-06 | ||
| 3895 | Functionalization of Medical Devices with Photosensitizers | 2021-03-06 | ||
| 3896 | Antimicrobial Photodynamic Therapy and its Mechanism | 2021-03-06 | ||
| 3897 | Endotracheal Tube and its Complications and Risks | 2021-03-06 | ||
| 3898 | Respiratory Tract Infections | 2021-03-06 | ||
| 3899 | Strategies in Combating Covid-19 | 2021-03-05 | ||
| 3900 | Candidate Vaccines Trial for Sars-Cov-2 Infection | 2021-03-05 | ||
| 3901 | Laboratory Diagnosis for Covid-19 | 2021-03-05 | ||
| 3902 | Host Immune Response to Sars-Cov-2 Infection | 2021-03-05 | ||
| 3903 | Pathogenesis and Disease Characterization | 2021-03-05 | ||
| 3904 | Sars-cov-2 viral attachment and Penetration mechanisms | 2021-03-05 | ||
| 3905 | Transmission Route of Sar-Cov-2 Infection | 2021-03-05 | ||
| 3906 | Molecular Characterization and Genetic Makeup of Sars-Cov-2 | 2021-03-05 | ||
| 3907 | Epidemiology of Sars-Cov-2 | 2021-03-05 | ||
| 3908 | Availability of Data Material | 2021-03-05 | ||
| 3909 | Time Needed For A Newly Arisen Mutant To Increase Its Frequency To Become Dominant In The Sars-Cov-2 Population Depending On Its Selective Advantage Or Disadvantage | 2021-03-05 | ||
| 3910 | Fixation Likelihood Of A Newly Arisen Mutant, Within The Sars-Cov-2 Population, Depending On Its Selective Advantage Or Disadvantage | 2021-03-05 | ||
| 3911 | Probability That a New Sars-Cov-2 Mutant Newly Arisen In the Sars-Cov-2 Population Survives Through Time Depending On Its Selective Advantage Or Disadvantage | 2021-03-05 | ||
| 3912 | Fixation and Extinction Dynamics Of New Mutants In The Sars-Cov-2 Meta-Population | 2021-03-05 | ||
| 3913 | Dear Readers | 2021-03-05 | ||
| 3914 | Chemical Warfare | 2021-03-05 | ||
| 3915 | Effects of Nuclear Explosions | 2021-03-05 | ||
| 3916 | Finance and Marketing | 2021-03-05 | ||
| 3917 | Improvements in Defense Clinical Facilities | 2021-03-05 | ||
| 3918 | Military Science | 2021-03-05 | ||
| 3919 | Risk Mitigation | 2021-03-05 | ||
| 3920 | Experimental Study | 2021-03-05 | ||
| 3921 | Crisis management | 2021-03-05 | ||
| 3922 | Mark to Market | 2021-03-05 | ||
| 3923 | Defense Management | 2021-03-05 | ||
| 3924 | Biological and Clinical Features | 2021-03-05 | ||
| 3925 | Risk Assessment and Management | 2021-03-05 | ||
| 3926 | Public Organization | 2021-03-04 | ||
| 3927 | Democratic | 2021-03-04 | ||
| 3928 | Human Resource Management | 2021-03-04 | ||
| 3929 | Entrepreneurship | 2021-03-04 | ||
| 3930 | Editorial Note of Review of Public Administration and Management | 2021-03-04 | ||
| 3931 | Methodology and Procedures | 2021-03-04 | ||
| 3932 | Special Topics | 2021-03-04 | ||
| 3933 | Induction, Maintenance, and Taper | 2021-03-04 | ||
| 3934 | Buprenorphine | 2021-03-04 | ||
| 3935 | Data Collection Questionnaires | 2021-03-04 | ||
| 3936 | Regulation Management | 2021-03-04 | ||
| 3937 | Operations management | 2021-03-04 | ||
| 3938 | Strategic Management | 2021-03-04 | ||
| 3939 | Impact of Leadership and Learning Culture on Knowledge Management in Public Organizations | 2021-03-04 | ||
| 3940 | Public Civil Services | 2021-03-04 | ||
| 3941 | Pasteurization | 2021-03-04 | ||
| 3942 | Dairy Technology | 2021-03-04 | ||
| 3943 | Advances in Dairy Research | 2021-03-04 | ||
| 3944 | Milk Proteomics | 2021-03-04 | ||
| 3945 | Range of Diseases Affecting Dairy Cows | 2021-03-04 | ||
| 3946 | Materials and Chemicals | 2021-03-03 | ||
| 3947 | Editorial Note for Advances in Dairy Research | 2021-03-03 | ||
| 3948 | Limitations and Implications | 2021-03-03 | ||
| 3949 | Similar Trends | 2021-03-03 | ||
| 3950 | Present Study and Hypotheses | 2021-03-03 | ||
| 3951 | Social Consequences and Changes After Quarantine | 2021-03-03 | ||
| 3952 | Emotion Dynamics During Covid-19 Pandemic | 2021-03-03 | ||
| 3953 | Stressors During and After Quarantine | 2021-03-03 | ||
| 3954 | Impact of Quarantine and Pandemics on Mental Health and Prevalent Emotions | 2021-03-03 | ||
| 3955 | The Economic Loss of Dairy Cattle Poor Reproductive Performance in Central Highlands of Ethiopia | 2021-03-03 | ||
| 3956 | Appraisal and Evaluation | 2021-03-03 | ||
| 3957 | Limitations and Future Scope | 2021-03-03 | ||
| 3958 | Notes on the Contributors | 2021-03-03 | ||
| 3959 | Challenges Faced in Nanodentistry | 2021-03-02 | ||
| 3960 | Nanotechnology in Periodontics | 2021-03-02 | ||
| 3961 | Nanotechnology in Dentistry | 2021-03-02 | ||
| 3962 | Implications of Nanotechnology | 2021-03-02 | ||
| 3963 | Nanomedicine | 2021-03-02 | ||
| 3964 | Nanomaterials | 2021-03-02 | ||
| 3965 | Efficacy on Tocotrienols in the Treatment of non-alcoholic Steatohepatitis: A 10 year Systematic Review | 2021-03-02 | ||
| 3966 | Retrospective audit in use of hypertonic saline with the management of acute symptomatic hyponatraemia with hospitalized patients | 2021-03-02 | ||
| 3967 | Probiotics influence central nervous system | 2021-03-02 | ||
| 3968 | Editorial Highlights for International Journal of Waste Resources | 2021-03-02 | ||
| 3969 | Clinical Significance | 2021-03-02 | ||
| 3970 | Statement of Human and Animal Rights | 2021-03-02 | ||
| 3971 | Statement of Informed Consent | 2021-03-02 | ||
| 3972 | Awards Content for Euro Renewable Energy 2021 | 2021-03-02 | ||
| 3973 | Conference Announcement: 2nd International Conference on Current Trends in Recycling and E-Waste Management | 2021-03-02 | ||
| 3974 | Editorial-Journal of Diabetes and Metabolism -2021 | 2021-03-02 | ||
| 3975 | A Review on Role of Plant(s) Extracts and its Phytochemicals for the Management of Diabetes | 2021-03-02 | ||
| 3976 | Prevalence and correlates of herbal medicine use among type 2 diabetic patients in Teaching Hospital in Ethiopia: a cross sectional study | 2021-03-02 | ||
| 3977 | The Non Mineral Axis Klotho-Vitamin D in Diabetic Nephropathy: Review | 2021-03-02 | ||
| 3978 | Anti-diabetic, Haematinic and Anti-cholesterolmic Effects of Wheat (Triticum aestivum Linn.) Grass Juice Metabolites to Cure Alloxan Monohydrate induced type-1 Diabetes in Albino R | 2021-03-02 | ||
| 3979 | Awards 2021 | 2021-03-02 | ||
| 3980 | Technological improvement and biomedical application-oriented research | 2021-03-02 | ||
| 3981 | Ethical Considerations and Cosent | 2021-03-01 | ||
| 3982 | Dairy Industry: Innovative sensor system and evaluation procedure for monitoring of food processing | 2021-03-01 | ||
| 3983 | Dairy Industry: Food quality and health | 2021-03-01 | ||
| 3984 | Dairy Industry: Food and Beverages are the major industries for the improvement of health, daily use of life, reduction in financial crises, poverty and hunger in the world | 2021-03-01 | ||
| 3985 | Dairy Industry: Controlling Listeria monocytogenes & Salmonella in Food Processing using Phage technology | 2021-03-01 | ||
| 3986 | Dairy Industry: Processing and preserving strategies on antioxidant food tablets and supplements | 2021-03-01 | ||
| 3987 | Ethical Clearence | 2021-02-27 | ||
| 3988 | Place of Study | 2021-02-27 | ||
| 3989 | The Status of Infectious Bursal Diseases in Ethiopia | 2021-02-27 | ||
| 3990 | General Accounts of Infectious Bursal Disease | 2021-02-27 | ||
| 3991 | Measurement Procedures | 2021-02-27 | ||
| 3992 | Diagnosis and Staging | 2021-02-27 | ||
| 3993 | Method of Wood Property Analysis for Fuel Wood | 2021-02-26 | ||
| 3994 | Adherence to National and International Regulations | 2021-02-26 | ||
| 3995 | Declaration of Funding | 2021-02-26 | ||
| 3996 | Facts | 2021-02-26 | ||
| 3997 | Congnitive Psychology | 2021-02-26 | ||
| 3998 | Biopsychology | 2021-02-26 | ||
| 3999 | Developmental Psychology | 2021-02-26 | ||
| 4000 | Abnormal Psychology | 2021-02-26 | ||
| 4001 | Contraindications | 2021-02-26 | ||
| 4002 | Life Systems and Physiology | 2021-02-26 | ||
| 4003 | Cystourethroscopy | 2021-02-26 | ||
| 4004 | Factors Leading to Increased Detection of Thyroid Cancer | 2021-02-26 | ||
| 4005 | Treatment/Management | 2021-02-26 | ||
| 4006 | Histopathology | 2021-02-26 | ||
| 4007 | The Study of Disease Transmission | 2021-02-26 | ||
| 4008 | Kidney Biopsy | 2021-02-26 | ||
| 4009 | Causes of Systemic Mastocytosis | 2021-02-26 | ||
| 4010 | Types of Systemic Mastocytosis | 2021-02-26 | ||
| 4011 | Proposed Methodology | 2021-02-26 | ||
| 4012 | The Historical Development of Pharmacoepidemiology | 2021-02-25 | ||
| 4013 | Electronic Supplementary Material | 2021-02-25 | ||
| 4014 | Data Collection and Tool | 2021-02-25 | ||
| 4015 | Results and Discussion | 2021-02-24 | ||
| 4016 | Scope and Implications | 2021-02-24 | ||
| 4017 | Coping | 2021-02-24 | ||
| 4018 | But which Compounds have this Property? | 2021-02-24 | ||
| 4019 | Where is the Trps Located? | 2021-02-24 | ||
| 4020 | But what are the Physiopathological Mechanisms Underlying these Changes? | 2021-02-24 | ||
| 4021 | Types Of Local Anaesthetics In Oral And Maxillofacial Surgery | 2021-02-24 | ||
| 4022 | Recuperation Patterns Of Motor Impairment | 2021-02-23 | ||
| 4023 | Conversation | 2021-02-23 | ||
| 4024 | Convesation | 2021-02-23 | ||
| 4025 | Strategies | 2021-02-23 | ||
| 4026 | Re-Evaluation | 2021-02-23 | ||
| 4027 | Appraisal | 2021-02-23 | ||
| 4028 | Clinical Highlights | 2021-02-23 | ||
| 4029 | Cliniacal Highlights | 2021-02-23 | ||
| 4030 | Blastocyst Stage Cryopreservation | 2021-02-23 | ||
| 4031 | Oocyte Cryopreservation | 2021-02-23 | ||
| 4032 | Vitrification | 2021-02-23 | ||
| 4033 | Indications For Ovarian Tissue Cryopreservation (OTC) | 2021-02-23 | ||
| 4034 | Cryopreservation Of Ovarian Tissues And Embryos | 2021-02-23 | ||
| 4035 | Morphology of Apoptosis | 2021-02-20 | ||
| 4036 | Future of Nano Medicine and Drug Delivery System | 2021-02-20 | ||
| 4037 | Fundamentals of Nanotechnology Based Techniques in Designing of Drug | 2021-02-20 | ||
| 4038 | Nano Based Drug Delivery Systems | 2021-02-20 | ||
| 4039 | Therapeutic Potential of Adult Stem Cells | 2021-02-20 | ||
| 4040 | Maintenance of Adult Stem Cells in the Organism | 2021-02-20 | ||
| 4041 | Adult stem cells | 2021-02-20 | ||
| 4042 | Mode of Action | 2021-02-20 | ||
| 4043 | Coronavirus Classification | 2021-02-20 | ||
| 4044 | Protiens as Drug Targets | 2021-02-19 | ||
| 4045 | Membranes as Drug Targets | 2021-02-19 | ||
| 4046 | RNA As Drug Target | 2021-02-19 | ||
| 4047 | Nucleic Acids As Drug Targets | 2021-02-19 | ||
| 4048 | Genes As Drug Targets | 2021-02-19 | ||
| 4049 | Free Robux | 2021-02-18 | ||
| 4050 | The Result of Interaction | 2021-02-18 | ||
| 4051 | Ferrous Ion Oxidizers in the Marine Environment | 2021-02-18 | ||
| 4052 | Characteristics of Utilization of different Types of Exogenous Carbon Sources | 2021-02-18 | ||
| 4053 | Sole Carbon Source Tests | 2021-02-18 | ||
| 4054 | Water Quality Improvement of Black-Odor River | 2021-02-18 | ||
| 4055 | Avoidance | 2021-02-18 | ||
| 4056 | Tapeworm | 2021-02-18 | ||
| 4057 | Chagas Infection | 2021-02-18 | ||
| 4058 | Side Effects of Parasitic Contaminations | 2021-02-18 | ||
| 4059 | Instances of Parasitic Diseases | 2021-02-18 | ||
| 4060 | Effect of Changing Spectrum of Infectious Diseases on Lexicon | 2021-02-18 | ||
| 4061 | Applications Of Nanotechnology | 2021-02-18 | ||
| 4062 | Charateristics Of Nanoparticles | 2021-02-18 | ||
| 4063 | Anticipation | 2021-02-18 | ||
| 4064 | Possible Complications | 2021-02-18 | ||
| 4065 | Extent Of The Issue | 2021-02-18 | ||
| 4066 | White Blood Cell Receptor Coordinated Antibodies | 2021-02-18 | ||
| 4067 | Monoclonal Antibodies | 2021-02-18 | ||
| 4068 | Confirmed Coronavirus Cases and Deaths By Country and Territory Or Conveyance | 2021-02-18 | ||
| 4069 | Confirmed Coronavirus Cases and Deaths By Coutry and Territory Or Conveyance | 2021-02-18 | ||
| 4070 | Existing Situation | 2021-02-18 | ||
| 4071 | Spreads Of Coronavirus and Prevention | 2021-02-18 | ||
| 4072 | Covid -19 Symptoms | 2021-02-18 | ||
| 4073 | Morphology and Genome Sequence Of Coronavirus | 2021-02-18 | ||
| 4074 | Future Recommendations | 2021-02-17 | ||
| 4075 | Collaboration Of Veterinations and Medicos For Pandemic Preparedness | 2021-02-17 | ||
| 4076 | Importance Of Verterinary Medicine For Vaccine Development | 2021-02-17 | ||
| 4077 | Support Of Veterinary Laboratory | 2021-02-17 | ||
| 4078 | Host Range | 2021-02-17 | ||
| 4079 | Frameshift In Corona Virus | 2021-02-17 | ||
| 4080 | Introduction and Problem | 2021-02-17 | ||
| 4081 | Take Home Message | 2021-02-17 | ||
| 4082 | Past Conference Editorial of Dermatology Medicine 2020 | 2021-02-16 | ||
| 4083 | Speaker Publications | 2021-02-16 | ||
| 4084 | Oservation | 2021-02-16 | ||
| 4085 | Investigation Method | 2021-02-16 | ||
| 4086 | Therapeutic Strategy For Chronic Liver Disease | 2021-02-16 | ||
| 4087 | Liver Fibrosis In General Population | 2021-02-16 | ||
| 4088 | Non-Cld-Related Atherosclerosis | 2021-02-16 | ||
| 4089 | Cld-Related Atherosclerosis | 2021-02-16 | ||
| 4090 | Liver Fibrosis | 2021-02-16 | ||
| 4091 | Abstract Citation | 2021-02-16 | ||
| 4092 | Journal of Dermatology Case Reports | 2021-02-16 | ||
| 4093 | Treatment Methods | 2021-02-16 | ||
| 4094 | Prevention Techniques | 2021-02-16 | ||
| 4095 | Causes of Melanoma | 2021-02-16 | ||
| 4096 | Melanoma | 2021-02-16 | ||
| 4097 | Prevention and Management | 2021-02-15 | ||
| 4098 | Life Cycle of Sarcoptes scabiei | 2021-02-15 | ||
| 4099 | Treatment Methodology | 2021-02-15 | ||
| 4100 | Types of Acne | 2021-02-15 | ||
| 4101 | Phisiopathology of Acne | 2021-02-15 | ||
| 4102 | Factors Responsible for the Physiopathology of Acne | 2021-02-15 | ||
| 4103 | Decleration of Conflict of Interest | 2021-02-15 | ||
| 4104 | Life-Years Saved from Covid-19 versus Life-Years Lost from Cancer | 2021-02-15 | ||
| 4105 | Lives versus Life-Years | 2021-02-15 | ||
| 4106 | The Covid-19 Trade off | 2021-02-15 | ||
| 4107 | Therapeutic Routes of Androgenetic Alopecia Syndrome | 2021-02-12 | ||
| 4108 | Diagnosis of Androgenetic Alopecia Syndrome | 2021-02-12 | ||
| 4109 | Frequency of Androgenetic Alopecia Syndrome | 2021-02-12 | ||
| 4110 | Etiology of Androgenetic Alopecia Syndrome | 2021-02-12 | ||
| 4111 | Clinical Signs and Symptoms of Androgenetic Alopecia Syndrome | 2021-02-12 | ||
| 4112 | Generalities of Androgenetic Alopecia Syndrome | 2021-02-12 | ||
| 4113 | Withdrawals | 2021-02-12 | ||
| 4114 | Declaration Statements | 2021-02-12 | ||
| 4115 | Future Applications | 2021-02-12 | ||
| 4116 | Crispr–Cas Concerns That Need To Be Addressed | 2021-02-12 | ||
| 4117 | Addressing New Gene Editing Challenges In Clonal Hematopoiesis Research | 2021-02-12 | ||
| 4118 | Crispr–Cas Genome Editing To Study Clonal Hematopoiesis | 2021-02-12 | ||
| 4119 | Crispr-Cas Genome Editing To Study Clonal Hematopoiesis | 2021-02-12 | ||
| 4120 | Grants or Other Financial Supports | 2021-02-12 | ||
| 4121 | Authors's Contributions | 2021-02-11 | ||
| 4122 | Probable Suggested Solutions for Solid Waste Management in the IHR | 2021-02-10 | ||
| 4123 | Case Study: Alappuzha (Kerala) and Aima Panchayat (Himachal Pradesh) | 2021-02-10 | ||
| 4124 | Current Policy and Management Practices | 2021-02-10 | ||
| 4125 | Challenges and Issues of Solid Waste Management in the IHR | 2021-02-10 | ||
| 4126 | Status of Municipal Solid Waste in the Indian Himalayan Region (IHR) | 2021-02-10 | ||
| 4127 | Status of Municipal Solid Waste in India | 2021-02-10 | ||
| 4128 | Applying the Proposed Method on the Benchmark: Increasing the Exposure and Vulnerability of a Small Residential Community in the North of Tehran for Industrial Waste | 2021-02-10 | ||
| 4129 | Adaptive Decision Management System and Updating Game Theory for a Sequential Decision Scenario | 2021-02-10 | ||
| 4130 | Examining the Evolving Conditions and Their Impact on the Performance of Industrial Infrastructure Projects and Communities | 2021-02-10 | ||
| 4131 | Author Contributions and Acknowledgements | 2021-02-10 | ||
| 4132 | Association between CPAP Compliance and Outcomes | 2021-02-10 | ||
| 4133 | Sample Characteristics | 2021-02-10 | ||
| 4134 | Strategies To Resolve Problems | 2021-02-10 | ||
| 4135 | Model Of Nurse/Patient Empower | 2021-02-10 | ||
| 4136 | Sources Of Power | 2021-02-10 | ||
| 4137 | Component Of Kanter's Theory | 2021-02-10 | ||
| 4138 | Kanter's Theory Of Empowerment | 2021-02-10 | ||
| 4139 | Plan | 2021-02-09 | ||
| 4140 | Diagnostic Formulation | 2021-02-09 | ||
| 4141 | Laparoscopy | 2021-02-09 | ||
| 4142 | Swot Analysis Of Current Program Approach | 2021-02-04 | ||
| 4143 | Associated Factors in Malaria Transmission and Problem Exaggeration for Public Health in Baran | 2021-02-04 | ||
| 4144 | Magnitude of Problem | 2021-02-04 | ||
| 4145 | Program Approachs | 2021-02-04 | ||
| 4146 | Clinical Trials Standard Approaches | 2021-02-04 | ||
| 4147 | Key Concepts of Clinical Trails Design | 2021-02-04 | ||
| 4148 | Embryonic Stem Cells Factors and Cancer | 2021-02-02 | ||
| 4149 | Umbilical Cord Stem Cell Derived Exosomes and Cancer | 2021-02-02 | ||
| 4150 | Exosomes in Cancer Therapy: Multiple Roles | 2021-02-02 | ||
| 4151 | Exosomes and Cancer Diagnosis | 2021-02-02 | ||
| 4152 | Exosomes Formation and Structure | 2021-02-02 | ||
| 4153 | Declaration on Conflicts of Interests | 2021-02-02 | ||
| 4154 | Next Steps-Recommendations | 2021-02-02 | ||
| 4155 | Conclusion with Respect to Covid-19-Treatment | 2021-02-02 | ||
| 4156 | Complex Onion Chemistry | 2021-02-02 | ||
| 4157 | Practical Implications of the Study | 2021-02-02 | ||
| 4158 | Theoretical Review | 2021-02-02 | ||
| 4159 | Software and Computational Methods | 2021-02-01 | ||
| 4160 | Importance of Vaccine | 2021-02-01 | ||
| 4161 | Mechanism of HIV Drug Resistance | 2021-02-01 | ||
| 4162 | Immunological Aspects of HIV | 2021-02-01 | ||
| 4163 | Vaccine Prospect | 2021-02-01 | ||
| 4164 | Other Potential Therapies | 2021-02-01 | ||
| 4165 | Therapeutics | 2021-02-01 | ||
| 4166 | Co-Morbidities of COVID 19 | 2021-02-01 | ||
| 4167 | Pathogenesis and Clinical Manifestations | 2021-02-01 | ||
| 4168 | Virus Genome Structure | 2021-02-01 | ||
| 4169 | Descripition | 2021-01-30 | ||
| 4170 | Study Area and Data Set | 2021-01-29 | ||
| 4171 | Sourcing of Funding | 2021-01-29 | ||
| 4172 | Guidelines for Pain Prevention Exercises in Elderly Individuals | 2021-01-29 | ||
| 4173 | Vicious Cycle of Pain and Frailty | 2021-01-29 | ||
| 4174 | Relationship between Oral Frailty and Meal Satisfaction | 2021-01-29 | ||
| 4175 | Oral Frailty | 2021-01-29 | ||
| 4176 | Research in Context | 2021-01-28 | ||
| 4177 | Formation and Function of C@DNA as a Supra Molecular Catalyst | 2021-01-28 | ||
| 4178 | Morphological Changes in a Single GV Observed by High-Speed Confocal Microscopy | 2021-01-28 | ||
| 4179 | The increase in GVs (S) was 85% at 30 min after V* addition | 2021-01-28 | ||
| 4180 | Increase Ratios of GVs By Wide-View/ High-Precision Confocal Microscopy | 2021-01-28 | ||
| 4181 | Population Analysis of Selfreproducing GVs By Flow Cytometry | 2021-01-28 | ||
| 4182 | Population Analysis of Selfreproducing GVs By Flow Cytometry | 2021-01-28 | ||
| 4183 | Self-Reproducing GVs Containing DNAs of Different Lengths | 2021-01-28 | ||
| 4184 | Final Considerations | 2021-01-27 | ||
| 4185 | Development | 2021-01-27 | ||
| 4186 | Conflicts of Financial Interest | 2021-01-27 | ||
| 4187 | ACE2 Receptor and Vitamin D | 2021-01-23 | ||
| 4188 | ACE2 Receptor and Host–Virus Interaction | 2021-01-23 | ||
| 4189 | Immunopathology of SARS-CoV-2 | 2021-01-23 | ||
| 4190 | Vitamin D3 | 2021-01-23 | ||
| 4191 | Immunomodulatory Nanomedicine | 2021-01-23 | ||
| 4192 | Message for the Elderly With Hypertension and Diabetes Mellitus | 2021-01-23 | ||
| 4193 | The Latest Developments in the Covid-19 Outbreak in Indonesia | 2021-01-23 | ||
| 4194 | Parents as Models | 2021-01-23 | ||
| 4195 | Conception of a Child | 2021-01-23 | ||
| 4196 | Associated Risk Factors | 2021-01-23 | ||
| 4197 | Observations | 2021-01-22 | ||
| 4198 | Alternatives to Introducing Medicine Into a Child’s System | 2021-01-22 | ||
| 4199 | Consequences If Eb Problems are Left Untreated | 2021-01-22 | ||
| 4200 | The Factors That Can Cause Eb Problems | 2021-01-22 | ||
| 4201 | Specific Objectives | 2021-01-22 | ||
| 4202 | Types of Prostate Cancer | 2021-01-22 | ||
| 4203 | Other syndromes | 2021-01-22 | ||
| 4204 | Hamartoma PTEN Syndrome | 2021-01-22 | ||
| 4205 | Conflict of Interest and Source of Funding Statement | 2021-01-22 | ||
| 4206 | Information about the Authors | 2021-01-22 | ||
| 4207 | Contribution of author | 2021-01-22 | ||
| 4208 | Expert Opinion | 2021-01-22 | ||
| 4209 | Upcoming Conferences | 2021-01-22 | ||
| 4210 | Types of Research Work | 2021-01-22 | ||
| 4211 | Study Limitation and Future Scope | 2021-01-21 | ||
| 4212 | Topics and Practices | 2021-01-21 | ||
| 4213 | Overall Consensus | 2021-01-21 | ||
| 4214 | Decleration of Patient Consent | 2021-01-21 | ||
| 4215 | Study Outcome | 2021-01-21 | ||
| 4216 | Clinical Protocol | 2021-01-21 | ||
| 4217 | Clinical Outcome | 2021-01-21 | ||
| 4218 | Groups | 2021-01-21 | ||
| 4219 | Eligibility Criteria | 2021-01-21 | ||
| 4220 | Operation Procedure | 2021-01-20 | ||
| 4221 | Conclusion and Further Development | 2021-01-20 | ||
| 4222 | Convolutional Neural Network(CNN) | 2021-01-20 | ||
| 4223 | Process Description | 2021-01-20 | ||
| 4224 | System Architecture | 2021-01-20 | ||
| 4225 | Future Scope | 2021-01-20 | ||
| 4226 | Adverse Effects | 2021-01-20 | ||
| 4227 | Effects on Pediatric Patients | 2021-01-20 | ||
| 4228 | Methods of Administration | 2021-01-20 | ||
| 4229 | Drug Design | 2021-01-20 | ||
| 4230 | Drug Development | 2021-01-20 | ||
| 4231 | Data Mining | 2021-01-20 | ||
| 4232 | Therapeutic Applications | 2021-01-20 | ||
| 4233 | IBD or IBS | 2021-01-20 | ||
| 4234 | Conclusion and Discussions | 2021-01-20 | ||
| 4235 | ORCID IDs | 2021-01-20 | ||
| 4236 | Combinations of HPV Vaccines with Other Therapies | 2021-01-20 | ||
| 4237 | Combinations of Vaccine with Standard-of-Care Therapeutics | 2021-01-20 | ||
| 4238 | Combinations of Multiple Therapeutic Modalities | 2021-01-20 | ||
| 4239 | Preclinical Studies | 2021-01-20 | ||
| 4240 | Rationale for Combination Treatments with Vaccines and Other Modalities | 2021-01-20 | ||
| 4241 | Clinical Considerations and Conclusion | 2021-01-19 | ||
| 4242 | Samples and Methods | 2021-01-19 | ||
| 4243 | Epigenetic Genetic Modifications of Thymus Cancer | 2021-01-19 | ||
| 4244 | Epigenetic Genetic Modifications of Lung Cancer | 2021-01-19 | ||
| 4245 | Epigenetic Genetic Modifications of Pancreatic Cancer | 2021-01-19 | ||
| 4246 | Epigenetic Genetic Modifications of Pituitary Cancer | 2021-01-19 | ||
| 4247 | Epigenetic Genetic Modifications of Adrenocortical Cancer | 2021-01-19 | ||
| 4248 | Epigenetic Genetic Modifications of Thyroid Cancer | 2021-01-19 | ||
| 4249 | Epigenetic Targets for Treatment of Thyroid Cancer | 2021-01-19 | ||
| 4250 | The Role of Micrornas in Thyroid Cancer | 2021-01-19 | ||
| 4251 | Histone Modification in Thyroid Cancer | 2021-01-19 | ||
| 4252 | Aberrant Gene Methylation in Thyroid Cancer | 2021-01-19 | ||
| 4253 | Epigenetic Modifications in Thyroid Cancer | 2021-01-19 | ||
| 4254 | Micrornas and Ovarian Cancer | 2021-01-19 | ||
| 4255 | Histone Modification | 2021-01-19 | ||
| 4256 | Methylation of Imprinted Genes in Ovarian Cancer | 2021-01-19 | ||
| 4257 | CPG Island Methylator Phenotype Criteria (CIMP) | 2021-01-19 | ||
| 4258 | Ovarian Cancer | 2021-01-19 | ||
| 4259 | The Role of Micrornas in Prostate Cancer | 2021-01-19 | ||
| 4260 | The Role of Histone Modification in Prostate Cancer | 2021-01-19 | ||
| 4261 | The Role of Hypermethylation in Prostate Cancer | 2021-01-19 | ||
| 4262 | The Role of Hypomethylation in Prostate Cancer | 2021-01-19 | ||
| 4263 | Epigenetics Modifications in Prostate Cancer | 2021-01-19 | ||
| 4264 | Prostate Cancer | 2021-01-19 | ||
| 4265 | Imprinting Genes in Testicular Cancer | 2021-01-19 | ||
| 4266 | Histone Modifications | 2021-01-19 | ||
| 4267 | DNA Methylation | 2021-01-19 | ||
| 4268 | Epigenetic Modification in Testicular Cancer | 2021-01-19 | ||
| 4269 | Testicular Cancer | 2021-01-19 | ||
| 4270 | Epigenetic Alterations in Tumors of the Endocrine System | 2021-01-19 | ||
| 4271 | Histone Modifications and Carcinogenesis | 2021-01-19 | ||
| 4272 | Carcinogenesis and DNA Methylation | 2021-01-19 | ||
| 4273 | Liver Transplantation Types | 2021-01-19 | ||
| 4274 | Study Purpose | 2021-01-19 | ||
| 4275 | Exclusion Criteria | 2021-01-18 | ||
| 4276 | Inclusion Criteria | 2021-01-18 | ||
| 4277 | Contributions/Authorship | 2021-01-18 | ||
| 4278 | Members | 2021-01-18 | ||
| 4279 | Importance | 2021-01-18 | ||
| 4280 | Realization 0f the Systematic Cadastre | 2021-01-12 | ||
| 4281 | The Current Situation | 2021-01-12 | ||
| 4282 | Significance of the Work | 2021-01-12 | ||
| 4283 | Funds Received | 2021-01-11 | ||
| 4284 | Contact | 2021-01-11 | ||
| 4285 | Outstanding Masters/ Ph.D./ Post Doctorate thesis work Presentation in Mass Spectrometry Conference 2020 | 2021-01-11 | ||
| 4286 | Best Poster Presentation in Mass Spectrometry Conference 2020 | 2021-01-11 | ||
| 4287 | Best Keynote Speaker in Mass Spectrometry Conference 2020 | 2021-01-11 | ||
| 4288 | Outstanding Speaker in Mass Spectrometry Conference 2020 | 2021-01-11 | ||
| 4289 | List of Abbreviation/ Nomenclature | 2021-01-11 | ||
| 4290 | Major Adverse Events that Could be Anticipated from a Sub-optimal Vaccine | 2021-01-11 | ||
| 4291 | Criteria for a Successful Vaccine | 2021-01-11 | ||
| 4292 | Vaccines | 2021-01-11 | ||
| 4293 | Study Strengths and Limitations | 2021-01-09 | ||
| 4294 | HIV Medication | 2021-01-09 | ||
| 4295 | Methods and Findings | 2021-01-09 | ||
| 4296 | Discussions and Conclusion | 2021-01-08 | ||
| 4297 | Outcomes of Endotherapy: Unsettled Issues | 2021-01-08 | ||
| 4298 | Potential Predictors of Successful Endotherapy | 2021-01-08 | ||
| 4299 | Outcomes of Endotherapy: Facts | 2021-01-08 | ||
| 4300 | Endoscopic Therapy in PD | 2021-01-08 | ||
| 4301 | Which PD Patients Could Benefit from Endoscopic Therapy? | 2021-01-08 | ||
| 4302 | Which Criteria Should We Use When Deciding Surgical Procedure? | 2021-01-08 | ||
| 4303 | Surgical Options | 2021-01-08 | ||
| 4304 | What is the Effet of Surgery on Quality of Life? | 2021-01-08 | ||
| 4305 | What is Morbidity and Mortality? | 2021-01-08 | ||
| 4306 | Should Endoscopic or Surgical Treatmen be Preferred? | 2021-01-08 | ||
| 4307 | When To Consider Surgery? | 2021-01-08 | ||
| 4308 | Intent To Treat | 2021-01-08 | ||
| 4309 | Outcomes | 2021-01-08 | ||
| 4310 | Inclusion and Exclusion Criteria | 2021-01-08 | ||
| 4311 | Current Clinical Evidence | 2021-01-04 | ||
| 4312 | Brain Bioavailability and Biodistribution After Nose-To Brain Delivery | 2021-01-04 | ||
| 4313 | Novel Devices Not Yet Used in Clinical Trials | 2021-01-04 | ||
| 4314 | Devices for Nose-To-Brain Delivery | 2021-01-04 | ||
| 4315 | Overcoming Absorption Barriers | 2021-01-04 | ||
| 4316 | Pathways for Nose-to-Brain Drug Delivery | 2021-01-04 | ||
| 4317 | Arabic Medications in AA | 2021-01-04 | ||
| 4318 | Topical Therapy | 2021-01-04 | ||
| 4319 | Treatment of AA | 2021-01-04 | ||
| 4320 | Bad Prognostic Findings in AA | 2021-01-04 | ||
| 4321 | Progonstic Factors in AA Patients | 2021-01-04 | ||
| 4322 | Psychosocial Impact of Alopecia Areata | 2021-01-04 | ||
| 4323 | Famalial Incidene of Alopecia Areata | 2021-01-04 | ||
| 4324 | Linear Alopcia Areata | 2021-01-04 | ||
| 4325 | Theories Implicated in AA Phathogenisis | 2021-01-04 | ||
| 4326 | Financial Support & Sponsorship | 2021-01-01 | ||
| 4327 | Methodology and Findings | 2021-01-01 | ||
| 4328 | Background and Justification | 2021-01-01 | ||
| 4329 | Viral DM | 2021-01-01 | ||
| 4330 | DM | 2021-01-01 | ||
| 4331 | Satisfaction | 2021-01-01 | ||
| 4332 | Two Types of Elements | 2021-01-01 | ||
| 4333 | Effective Way to Stop or Kill Virus | 2021-01-01 | ||
| 4334 | According to Virologist | 2021-01-01 | ||
| 4335 | Aim of Research Work Plan | 2020-12-30 | ||
| 4336 | Characteristics of Thermosetting Polymer | 2020-12-30 | ||
| 4337 | Declaration of Interests | 2020-12-30 | ||
| 4338 | Ethics Declarations | 2020-12-30 | ||
| 4339 | Ways of Understanding Memory | 2020-12-30 | ||
| 4340 | Long-term Memory | 2020-12-30 | ||
| 4341 | Working Memory | 2020-12-30 | ||
| 4342 | Short-term Memory | 2020-12-30 | ||
| 4343 | Optimizing Energy Model | 2020-12-30 | ||
| 4344 | Self-Optimization Model | 2020-12-30 | ||
| 4345 | The Social Elements | 2020-12-30 | ||
| 4346 | The Mental or Psychological Elements | 2020-12-30 | ||
| 4347 | The Physical Elements | 2020-12-30 | ||
| 4348 | Elements of Emotional Resilience | 2020-12-30 | ||
| 4349 | How to Forestall Eye Infections | 2020-12-30 | ||
| 4350 | Eye Infection Treatments | 2020-12-30 | ||
| 4351 | Eye Infection Complications | 2020-12-30 | ||
| 4352 | Causes and Kinds of Eye Infections | 2020-12-30 | ||
| 4353 | Bronchitis Hindrance | 2020-12-30 | ||
| 4354 | Diagnosing | 2020-12-30 | ||
| 4355 | Types of Carcinoma | 2020-12-30 | ||
| 4356 | Causes of Airway Obstruction | 2020-12-30 | ||
| 4357 | Triggers | 2020-12-30 | ||
| 4358 | Classifications | 2020-12-30 | ||
| 4359 | Types | 2020-12-30 | ||
| 4360 | Access to Safe Abortion Protects Women’s and Girls’ Health and Human Rights | 2020-12-30 | ||
| 4361 | Justification and Consequences of My Position | 2020-12-30 | ||
| 4362 | Doing Bo Harm,Promoting Patient Safety | 2020-12-30 | ||
| 4363 | Virtual Ethics | 2020-12-30 | ||
| 4364 | Kantian Deontology | 2020-12-30 | ||
| 4365 | Professional Negligence | 2020-12-30 | ||
| 4366 | 2nd Position (From the Lens of Health Care Provider) | 2020-12-30 | ||
| 4367 | 1st Position (From the Lens of Family) | 2020-12-30 | ||
| 4368 | Analysis of the Scenario | 2020-12-30 | ||
| 4369 | Lego Medical Care Resources | 2020-12-30 | ||
| 4370 | What if my Kid does not like Legos? | 2020-12-30 | ||
| 4371 | Is Toy Medical Care Effective? | 2020-12-30 | ||
| 4372 | How Toy Medical Care Works | 2020-12-30 | ||
| 4373 | Why Toy Medical Care was Created | 2020-12-30 | ||
| 4374 | How to find a Behavioral Therapist | 2020-12-30 | ||
| 4375 | Types of Behavioral Therapy | 2020-12-30 | ||
| 4376 | Pharmacological Interventions | 2020-12-30 | ||
| 4377 | Non-Pharmacological Interventions | 2020-12-30 | ||
| 4378 | PDD and PDD-NOS | 2020-12-30 | ||
| 4379 | Epidemic of Weight Gain During Covid 19 Lockdowns | 2020-12-30 | ||
| 4380 | One Case History of A Post Covid Syndrome | 2020-12-30 | ||
| 4381 | The Genesis of Post-Covid Syndrome | 2020-12-30 | ||
| 4382 | Side Effects of Lupus Nephritis | 2020-12-30 | ||
| 4383 | Preventive Measures | 2020-12-30 | ||
| 4384 | Market Report | 2020-12-30 | ||
| 4385 | Why attend? | 2020-12-30 | ||
| 4386 | Best Poster Presentation in Plant Biology 2020 | 2020-12-30 | ||
| 4387 | Women Scientist (The Women of Science Award) | 2020-12-30 | ||
| 4388 | Professional Level (The Research Contribution Award) | 2020-12-30 | ||
| 4389 | Research on HIV | 2020-12-30 | ||
| 4390 | HIV Genome Replication | 2020-12-30 | ||
| 4391 | Novel Approach | 2020-12-30 | ||
| 4392 | The Ethical Complexity of Rcts in Pregnancy | 2020-12-29 | ||
| 4393 | Person's Challenge Trial | 2020-12-29 | ||
| 4394 | Human Challenge Trial | 2020-12-29 | ||
| 4395 | Availability of Data | 2020-12-29 | ||
| 4396 | Strength of Study | 2020-12-29 | ||
| 4397 | Data Quality Control | 2020-12-29 | ||
| 4398 | Sampling technique | 2020-12-29 | ||
| 4399 | Sample Size Determination | 2020-12-29 | ||
| 4400 | Highlights of the Conference | 2020-12-29 | ||
| 4401 | Nonclinical Considerations | 2020-12-29 | ||
| 4402 | Quality/Cmc Considerations | 2020-12-29 | ||
| 4403 | Humoral and Cellular Immunity | 2020-12-29 | ||
| 4404 | Antigen Presentation | 2020-12-29 | ||
| 4405 | Authors Statement of Consent | 2020-12-29 | ||
| 4406 | Social Connections | 2020-12-29 | ||
| 4407 | Journal Topics | 2020-12-29 | ||
| 4408 | About the Journal | 2020-12-29 | ||
| 4409 | Renal Stones | 2020-12-28 | ||
| 4410 | Danger Factors | 2020-12-28 | ||
| 4411 | Haematuria | 2020-12-28 | ||
| 4412 | Nephron Composition | 2020-12-28 | ||
| 4413 | Characterizations | 2020-12-26 | ||
| 4414 | Major Challenges and Future Prospects | 2020-12-26 | ||
| 4415 | Biodegradation as a Panacea to Pome Pollution | 2020-12-26 | ||
| 4416 | Environmental Potentials of Pome Pollution | 2020-12-26 | ||
| 4417 | Various Means of Remediating Pome | 2020-12-26 | ||
| 4418 | Prevalence of Pome | 2020-12-26 | ||
| 4419 | Results and Disussion | 2020-12-26 | ||
| 4420 | Supplement | 2020-12-24 | ||
| 4421 | Signs | 2020-12-24 | ||
| 4422 | Cause | 2020-12-24 | ||
| 4423 | Medical Uses | 2020-12-24 | ||
| 4424 | Exposure Variables | 2020-12-24 | ||
| 4425 | Clinical Background | 2020-12-24 | ||
| 4426 | Preventing HIV | 2020-12-23 | ||
| 4427 | Treatments and Follow-Up | 2020-12-22 | ||
| 4428 | Clinical Presentations of Late-Onset Complications Related to Local Silicone Injections | 2020-12-22 | ||
| 4429 | Autoimmune/Inflammatory Syndrome Induced by Adjuvants Related to Local Silicone Injections | 2020-12-22 | ||
| 4430 | Microscopic Analyses | 2020-12-22 | ||
| 4431 | Dermal Fillers and the Role of Silicone as an Adjuvant | 2020-12-22 | ||
| 4432 | Abbreviations List | 2020-12-22 | ||
| 4433 | Toxicity | 2020-12-22 | ||
| 4434 | Methods and Patients | 2020-12-18 | ||
| 4435 | Outcomes Measures | 2020-12-18 | ||
| 4436 | Background and Need of the Study | 2020-12-18 | ||
| 4437 | Long-Term Results | 2020-12-17 | ||
| 4438 | Advances in Technique | 2020-12-17 | ||
| 4439 | Aids | 2020-12-16 | ||
| 4440 | Therapy for Hiv Prevention in Animal Models | 2020-12-16 | ||
| 4441 | Hiv-1 Infection of Nonhuman Primates or Humanized Mice | 2020-12-16 | ||
| 4442 | Animal Models for Sars-Cov-2 Research | 2020-12-16 | ||
| 4443 | Cell Lines and Organoids for Sars-Cov-2 Research | 2020-12-16 | ||
| 4444 | 3rd World Congress on Antiviral Drug Discovery and Development Awards | 2020-12-16 | ||
| 4445 | 10th World Congress on Antiviral Drug Development | 2020-12-16 | ||
| 4446 | New Strategies In The Treatment Of Arthritis | 2020-12-16 | ||
| 4447 | Spondyloarthropathies (Spa) | 2020-12-16 | ||
| 4448 | Rheumatoid Arthritis (Ra) | 2020-12-16 | ||
| 4449 | Arthritis | 2020-12-16 | ||
| 4450 | Complications of Systemic Diseases | 2020-12-16 | ||
| 4451 | Associated Medicines | 2020-12-16 | ||
| 4452 | Distribution and Articular Size | 2020-12-16 | ||
| 4453 | Duration | 2020-12-16 | ||
| 4454 | Business Awards | 2020-12-16 | ||
| 4455 | General Objectives | 2020-12-15 | ||
| 4456 | Gains and Obstacles | 2020-12-15 | ||
| 4457 | Field of Action-Health | 2020-12-15 | ||
| 4458 | How Might Our Research 'Add Value' To the Subject ? | 2020-12-15 | ||
| 4459 | Concept | 2020-12-15 | ||
| 4460 | Completing Interests | 2020-12-15 | ||
| 4461 | Availiability of Data and Material | 2020-12-15 | ||
| 4462 | Clinical Trials of Radiotherapy for COVID-19 Pneumonia | 2020-12-15 | ||
| 4463 | Rational and Justification for the Use of Low-Dose Radiotherapy for COVID-19 Pneumonia | 2020-12-15 | ||
| 4464 | Cardio-HART™ (a.k.a. “CHART”) is Cardiac-Telemedicine™ | 2020-12-14 | ||
| 4465 | Post-Pandemic Cardiac-Telemedicine™ | 2020-12-14 | ||
| 4466 | Post-Pandemic Cardiac-Telemedicineâ?¢ | 2020-12-14 | ||
| 4467 | Post-Pandemic Cardiac-Telemedicineâ?¢ | 2020-12-14 | ||
| 4468 | Post-Pandemic Cardiac-Telemedicineâ?¢ | 2020-12-14 | ||
| 4469 | Post-Pandemic Cardiac-Telemedicineâ?¢ | 2020-12-14 | ||
| 4470 | CE-Mark approved, just in time for the 2nd wave | 2020-12-14 | ||
| 4471 | CE-Mark approved, just in time for the 2nd wave | 2020-12-14 | ||
| 4472 | Sequencing Analysis | 2020-12-14 | ||
| 4473 | Causes and Symptoms | 2020-12-14 | ||
| 4474 | Causes of Transmission | 2020-12-14 | ||
| 4475 | Worldwide Analysis | 2020-12-14 | ||
| 4476 | Naturopathic Medicine | 2020-12-14 | ||
| 4477 | Discussion on Pre intervention assessment findings | 2020-12-13 | ||
| 4478 | A Community Based Cross-Methods and Materials | 2020-12-12 | ||
| 4479 | Case 3 | 2020-12-11 | ||
| 4480 | Histopathology of Dress Syndrome | 2020-12-11 | ||
| 4481 | Viral Reactivation | 2020-12-11 | ||
| 4482 | Genetic Factors | 2020-12-11 | ||
| 4483 | Culprit Drugs | 2020-12-11 | ||
| 4484 | Dress Syndrome Pathogenesis | 2020-12-11 | ||
| 4485 | Skin Involvement in Dress Syndrome | 2020-12-11 | ||
| 4486 | Diagnostic Criteria | 2020-12-11 | ||
| 4487 | Data Avaliability Statement | 2020-12-10 | ||
| 4488 | Conferences Highlights | 2020-12-10 | ||
| 4489 | Socio-Economic Impacts of Hydatidosis/Cystic Echinococcosis | 2020-12-09 | ||
| 4490 | Prevalence of Hydatidosis/Cystic Echinococcosis in Ethiopia | 2020-12-09 | ||
| 4491 | Herd Immunity | 2020-12-09 | ||
| 4492 | Diagnostic Techniques | 2020-12-09 | ||
| 4493 | Clinical Symptoms | 2020-12-09 | ||
| 4494 | Viral Structure and it's Bindings | 2020-12-09 | ||
| 4495 | Epidemology | 2020-12-09 | ||
| 4496 | Data Extraction | 2020-12-09 | ||
| 4497 | Antibodies | 2020-12-09 | ||
| 4498 | Prevention and Control of the Disease | 2020-12-09 | ||
| 4499 | Risk Factors for the Occurrence and Spread of Middle East Respiratory Syndrome-Coronavirus | 2020-12-09 | ||
| 4500 | Spatio Temporal Distributions and Spread of the Diseases | 2020-12-09 | ||
| 4501 | Occurences of Middle East Respiratory Syndrome–Coronaviruses in Camel | 2020-12-09 | ||
| 4502 | Etiology of Middle East Respiratory Syndrome Corona Virus | 2020-12-09 | ||
| 4503 | Disadvantages | 2020-12-09 | ||
| 4504 | Radio Protective Effects | 2020-12-08 | ||
| 4505 | Bronchodilator Activity | 2020-12-08 | ||
| 4506 | Immunomodulatory Activity | 2020-12-08 | ||
| 4507 | Anti-Inflammatory Activity | 2020-12-08 | ||
| 4508 | Anti-Oxidant and Radio-Protective Activity | 2020-12-08 | ||
| 4509 | Anti-Helmintic Activity | 2020-12-08 | ||
| 4510 | Anti-Virals | 2020-12-08 | ||
| 4511 | Anti-Ulcer Activity | 2020-12-08 | ||
| 4512 | Anti-Cancer Effect | 2020-12-08 | ||
| 4513 | Anti-Microbials | 2020-12-08 | ||
| 4514 | Anti-Oxidants | 2020-12-08 | ||
| 4515 | Code Availability | 2020-12-08 | ||
| 4516 | Conclusions and Future Work | 2020-12-08 | ||
| 4517 | Conflicts of Interest Statement | 2020-12-08 | ||
| 4518 | Prevention/Protection | 2020-12-08 | ||
| 4519 | Diagnosis of COVID-19 | 2020-12-08 | ||
| 4520 | Statical Analysis | 2020-12-02 | ||
| 4521 | Patients and Methods of Study | 2020-12-02 | ||
| 4522 | Blood Bank with Apheresis and CBSU facility | 2020-12-01 | ||
| 4523 | Author's Prespective | 2020-12-01 | ||
| 4524 | Public and Private Blood Bank | 2020-12-01 | ||
| 4525 | Blood Storage Units Facility | 2020-12-01 | ||
| 4526 | Anaesthesia Congress scheduled on April 13-14, 2020 at London, UK | 2020-12-01 | ||
| 4527 | Blood Bank with Population Study | 2020-12-01 | ||
| 4528 | Blood Bank Distribution | 2020-12-01 | ||
| 4529 | Working Definition | 2020-11-30 | ||
| 4530 | Responsibilities | 2020-11-30 | ||
| 4531 | Veterinary Pharmacovigilance | 2020-11-30 | ||
| 4532 | Adverse Drug Reactions | 2020-11-30 | ||
| 4533 | Over View | 2020-11-30 | ||
| 4534 | Study Type and Objectives | 2020-11-30 | ||
| 4535 | Ethics Review | 2020-11-30 | ||
| 4536 | Trial Status | 2020-11-28 | ||
| 4537 | Methods/Design | 2020-11-28 | ||
| 4538 | Assessing Progress, Measuring Improvement and Determining Benefit | 2020-11-28 | ||
| 4539 | Developing and Deploying an Effective CAGT Curriculum | 2020-11-28 | ||
| 4540 | Key CAGT Training Concepts That Address Organizational Needs | 2020-11-28 | ||
| 4541 | Educational Empowerment: Operational Delivery Teams, Sponsors and Sites | 2020-11-28 | ||
| 4542 | Sources | 2020-11-28 | ||
| 4543 | Personalized Medicine and Response to Novel Infectious Agents, Including COVID-19 | 2020-11-28 | ||
| 4544 | Concerns about an Individual Approach to Vaccination | 2020-11-28 | ||
| 4545 | Influenza as a Model for Population Based Infectious Disease Control | 2020-11-28 | ||
| 4546 | Understanding the Variables Contributing to Altered Vaccination in Infectious Disease | 2020-11-28 | ||
| 4547 | Major Types of Adjuvants | 2020-11-28 | ||
| 4548 | Why GBS Vaccine in Urgently Needed | 2020-11-28 | ||
| 4549 | Dangers of IAP | 2020-11-28 | ||
| 4550 | Factors Associated With GBS Colonization during Pregnancy | 2020-11-28 | ||
| 4551 | Global Prevalence of GBS Colonization among Pregnant Women | 2020-11-28 | ||
| 4552 | Support | 2020-11-28 | ||
| 4553 | Definition of Terms | 2020-11-27 | ||
| 4554 | Prevention at Individual Level | 2020-11-27 | ||
| 4555 | Advice for the Public | 2020-11-27 | ||
| 4556 | Preventive, Public Health Measures and Control | 2020-11-27 | ||
| 4557 | Factors Responsible for the Wide Spread of nCoV-19 | 2020-11-27 | ||
| 4558 | WWF - Pakistan Launches Project to tackle Plastic Pollution | 2020-11-27 | ||
| 4559 | Problems of Plastic Pollution | 2020-11-27 | ||
| 4560 | Problems and Causes of Plastic Pollution | 2020-11-27 | ||
| 4561 | My Position and Its Justification | 2020-11-26 | ||
| 4562 | Islamic Perspective | 2020-11-26 | ||
| 4563 | Global Perspective | 2020-11-26 | ||
| 4564 | Right Based and Duty Based Ethics versus Paternalism | 2020-11-26 | ||
| 4565 | Non-Maleficence versus Consequentialism | 2020-11-26 | ||
| 4566 | Case Analysis | 2020-11-26 | ||
| 4567 | Possible Reasons for Decision | 2020-11-26 | ||
| 4568 | Regional Anesthesia | 2020-11-26 | ||
| 4569 | Gabapentinoids | 2020-11-26 | ||
| 4570 | Opioids | 2020-11-26 | ||
| 4571 | Non-Steroidal Anti-Inflammatory Drugs (Nsaids) | 2020-11-26 | ||
| 4572 | Acetaminophen | 2020-11-26 | ||
| 4573 | Management During Pregnancy | 2020-11-26 | ||
| 4574 | Consequences of Pain During Pregnancy | 2020-11-26 | ||
| 4575 | Neuropathic Pain | 2020-11-26 | ||
| 4576 | Pregnancy-Related Causes | 2020-11-26 | ||
| 4577 | Guidelines for Young Researchers Forum | 2020-11-26 | ||
| 4578 | Importance and Scope | 2020-11-26 | ||
| 4579 | Learning Points | 2020-11-25 | ||
| 4580 | Author's Contribution | 2020-11-25 | ||
| 4581 | Authors Contribution Vailability Of Data And Materials | 2020-11-24 | ||
| 4582 | Authorâ??s Contribution Vailability Of Data And Materials | 2020-11-24 | ||
| 4583 | Image | 2020-11-24 | ||
| 4584 | Conclusion and Future Directions | 2020-11-24 | ||
| 4585 | Global Stability | 2020-11-24 | ||
| 4586 | Financial Support and Sponsorship | 2020-11-24 | ||
| 4587 | Frequency Distribution of Comorbidities in Studied Patients | 2020-11-24 | ||
| 4588 | Material and Method | 2020-11-24 | ||
| 4589 | Contributor Statement | 2020-11-23 | ||
| 4590 | Innate Immune Enhancement with HSNIG | 2020-11-23 | ||
| 4591 | Statement of Human Rights | 2020-11-23 | ||
| 4592 | As A Critical View On The Trans Generational Inheritance Model In Humans Through Epigenetic Changes In Gametes | 2020-11-23 | ||
| 4593 | As An Adult Disease Onset Model | 2020-11-23 | ||
| 4594 | Expansion Of The Insulin Scenario For Learning And Memory To Other Animals | 2020-11-23 | ||
| 4595 | MIPs For Memory Recall In Snail | 2020-11-23 | ||
| 4596 | Insulin Resistance In Pancreatic A-Cells | 2020-11-23 | ||
| 4597 | Insulin Resistance In Pancreatic Α-Cells | 2020-11-23 | ||
| 4598 | Regulation Of Glucagon Secretion By Islet Hormones | 2020-11-23 | ||
| 4599 | Introduction | 2020-11-21 | ||
| 4600 | Osteoporosis | 2020-11-21 | ||
| 4601 | Footnotes | 2020-11-21 | ||
| 4602 | Trail Redistration | 2020-11-21 | ||
| 4603 | Hashimoto's Thyroiditis Disease | 2020-11-21 | ||
| 4604 | Hashimoto’s Thyroiditis Disease | 2020-11-21 | ||
| 4605 | Case History and Detail | 2020-11-20 | ||
| 4606 | Abbreviation List | 2020-11-20 | ||
| 4607 | Bullet Point Highlights | 2020-11-20 | ||
| 4608 | Data and Materials Availability | 2020-11-20 | ||
| 4609 | Ethical Approval for Human | 2020-11-20 | ||
| 4610 | Limitation and Future Direction | 2020-11-19 | ||
| 4611 | Clinical Report | 2020-11-19 | ||
| 4612 | Acknowledgments and Disclosure Statements | 2020-11-19 | ||
| 4613 | Treatment and Management | 2020-11-19 | ||
| 4614 | Pathophisiology | 2020-11-19 | ||
| 4615 | Occurance and Epidemiology | 2020-11-19 | ||
| 4616 | Subjects, Materials and Methods | 2020-11-19 | ||
| 4617 | Method of Registration | 2020-11-19 | ||
| 4618 | Non-Pharmacological Theraphy | 2020-11-19 | ||
| 4619 | Aim/Objectives | 2020-11-19 | ||
| 4620 | Brief Introduction to the Konso | 2020-11-19 | ||
| 4621 | Sarhul Ritual Subsumed | 2020-11-19 | ||
| 4622 | The Ritual Space - sarna sthals (The Sacred Groves): An Enactment Of Symbolic Capital | 2020-11-19 | ||
| 4623 | Sarhul Ritual as Memory and Belonging | 2020-11-19 | ||
| 4624 | Sarhul Festival | 2020-11-19 | ||
| 4625 | Traditional Leaders’ Interface with Municipal Councilors in Zimbabwe | 2020-11-19 | ||
| 4626 | Governance and Institution of Traditional Leadership in Uganda | 2020-11-19 | ||
| 4627 | Governance and Institution of Traditional Leadership in Namibia | 2020-11-19 | ||
| 4628 | Governance and Institution of Traditional Leadership in Kenya | 2020-11-19 | ||
| 4629 | Governance and Institution of Traditional Leadership in Ghana | 2020-11-19 | ||
| 4630 | Traditional Leaders and Municipal Council in the Case Of Botswana | 2020-11-19 | ||
| 4631 | Roles of Traditional Leaders in the New the New Democracy | 2020-11-19 | ||
| 4632 | Legislation Governing Traditional Leaders in South Africa | 2020-11-19 | ||
| 4633 | Background and History of Traditional Leaders During Colonization and Apartheid in South Africa | 2020-11-19 | ||
| 4634 | Human Role | 2020-11-18 | ||
| 4635 | Restricted Autonomy | 2020-11-18 | ||
| 4636 | Responsibility | 2020-11-18 | ||
| 4637 | Explain Ability | 2020-11-18 | ||
| 4638 | Reliability | 2020-11-18 | ||
| 4639 | Prudence | 2020-11-18 | ||
| 4640 | Deep Artificial Intelligence (IAp) Codes and Algorithms for Automatic Programming of your Own Program | 2020-11-18 | ||
| 4641 | Endocrine Oncology | 2020-11-18 | ||
| 4642 | About Special Issue | 2020-11-18 | ||
| 4643 | Cushing's Disease | 2020-11-18 | ||
| 4644 | Remdesivir | 2020-11-18 | ||
| 4645 | Other Adjunct Therapies | 2020-11-17 | ||
| 4646 | Varenicline | 2020-11-17 | ||
| 4647 | Counseling and Nicotine Replacement Therapy | 2020-11-17 | ||
| 4648 | Antimalarial Drugs | 2020-11-16 | ||
| 4649 | Lopinavir/Ritonavir | 2020-11-16 | ||
| 4650 | Antiviral Drugs | 2020-11-16 | ||
| 4651 | Properties of Edible Oil | 2020-11-13 | ||
| 4652 | Material Needed | 2020-11-13 | ||
| 4653 | Cooling Effectivity Assessment | 2020-11-13 | ||
| 4654 | Innovative Sen Methods | 2020-11-13 | ||
| 4655 | Artificial Neural Networks | 2020-11-13 | ||
| 4656 | The Role of Biotechnology | 2020-11-13 | ||
| 4657 | Targets for Biomass Manipulation | 2020-11-13 | ||
| 4658 | Conclusions and Outlook | 2020-11-13 | ||
| 4659 | Towards A National Bioeconomy Strategy | 2020-11-13 | ||
| 4660 | Bioinitiatives in Colombia | 2020-11-13 | ||
| 4661 | Transition towards Bioeconomy | 2020-11-13 | ||
| 4662 | New Bio-Based Strategies, Increased Sustainability | 2020-11-13 | ||
| 4663 | Accelerated Aging Tests | 2020-11-13 | ||
| 4664 | Aging Characterization | 2020-11-13 | ||
| 4665 | Materials Tested and Corresponding CSP Plants | 2020-11-13 | ||
| 4666 | Approaches and Methodology | 2020-11-13 | ||
| 4667 | Theory | 2020-11-13 | ||
| 4668 | Cooperation between GCC Countries and Europe | 2020-11-13 | ||
| 4669 | Renewable Energy Developments in Europe | 2020-11-13 | ||
| 4670 | Challenges to Renewable Energy Community in GCC Countries | 2020-11-13 | ||
| 4671 | Legal Structures for Energy Communities in GCC Countries and Iran | 2020-11-13 | ||
| 4672 | Usage Scenario in Other Major German Cities | 2020-11-13 | ||
| 4673 | Further Improvements | 2020-11-13 | ||
| 4674 | Impact in Berlin | 2020-11-13 | ||
| 4675 | Calculations for Energy Generation | 2020-11-13 | ||
| 4676 | Infrastructure - Concept and Design | 2020-11-13 | ||
| 4677 | Pointingonthetechnicalopportunities of Solar Energy Generation | 2020-11-13 | ||
| 4678 | Emphasising the Implementation of Renewable Resourses Primarily With Solar Energy Application | 2020-11-13 | ||
| 4679 | Considering the Transition between Centralized and Decentralised Energy Generations | 2020-11-13 | ||
| 4680 | Comprising the Political Theories on the Nexus between Market and Energy Affairs | 2020-11-13 | ||
| 4681 | Antitumor Function Of NK Cells | 2020-11-13 | ||
| 4682 | Ccl2-Ccr2 Axis Inhibition For Treatment Of Cancer | 2020-11-13 | ||
| 4683 | Anticancer Therapy By Propagermanium | 2020-11-13 | ||
| 4684 | Propagermanium-Induced Nk Cell Activation | 2020-11-13 | ||
| 4685 | Chemical And Pharmacological Properties Of Propagermanium | 2020-11-13 | ||
| 4686 | Nickel And The Brain | 2020-11-13 | ||
| 4687 | Arsenic And The Brain | 2020-11-13 | ||
| 4688 | Cadmium And The Brain | 2020-11-13 | ||
| 4689 | Chromium Toxicity To The Brain | 2020-11-13 | ||
| 4690 | Gene Polymorphisms And DNA Methylation In Gastric Cancer | 2020-11-13 | ||
| 4691 | DNA Methylation as a Biomarker In Gastric Cancer Predication And Disease Progression | 2020-11-13 | ||
| 4692 | H. Pylori- Induced DNA Methylation in Gastric Cancer | 2020-11-13 | ||
| 4693 | H. pylori Virulent Factors And Gastric Cancer | 2020-11-13 | ||
| 4694 | In Vivo Studies Of Salivary Gland Regeneration | 2020-11-11 | ||
| 4695 | KAMPO Treatment For Xerostomia | 2020-11-11 | ||
| 4696 | Xerostomia Leads To Candidiasis | 2020-11-11 | ||
| 4697 | Salivary Glands In Humans | 2020-11-11 | ||
| 4698 | From Prevention To Treatment | 2020-11-11 | ||
| 4699 | Therapeutic Mechanisms Of CBSCs | 2020-11-11 | ||
| 4700 | Treatment Of Hie With Autologous CBSCS | 2020-11-11 | ||
| 4701 | Risks and Complications | 2020-11-10 | ||
| 4702 | Useful Preventive Herbal Medicines | 2020-11-10 | ||
| 4703 | Ayurvedic Treatment | 2020-11-10 | ||
| 4704 | Pandemic Diseases in Ayurveda | 2020-11-10 | ||
| 4705 | COVID-19 Era and Challenges in Uro-Oncology | 2020-11-10 | ||
| 4706 | Tackling the Risk of Patients Contracting COVID-19 during Hospital Stay | 2020-11-10 | ||
| 4707 | Major Agricultural Industries in Worldwide | 2020-11-09 | ||
| 4708 | Editoral | 2020-11-09 | ||
| 4709 | Energy Transfer from Phycobiliproteins to Ps Ii In Cryptophytes Algae | 2020-11-09 | ||
| 4710 | Energy Transfer from Pbs To Ps I | 2020-11-09 | ||
| 4711 | Energy Transfer from Pbs To Ps Ii | 2020-11-09 | ||
| 4712 | Can Good Nutrition Enhance Immunity? | 2020-11-09 | ||
| 4713 | Other Factors That May Affect Nutrition | 2020-11-09 | ||
| 4714 | Likely Interventions Required | 2020-11-09 | ||
| 4715 | Occurrence of Malnutrition | 2020-11-09 | ||
| 4716 | Association of Income Loss and Food Intake | 2020-11-09 | ||
| 4717 | Relationship between Income and Food Intake | 2020-11-09 | ||
| 4718 | Symptoms and Complications | 2020-11-06 | ||
| 4719 | Treatment of Emotional Aspects | 2020-11-06 | ||
| 4720 | Natural Remedies | 2020-11-06 | ||
| 4721 | Menopause and Effects | 2020-11-06 | ||
| 4722 | Ethical Standards | 2020-11-05 | ||
| 4723 | Physical Examination | 2020-11-04 | ||
| 4724 | Methodology and Methods | 2020-11-04 | ||
| 4725 | Conservative Mangement | 2020-11-03 | ||
| 4726 | Impacts of Oophorectomy | 2020-11-03 | ||
| 4727 | Current Management | 2020-11-03 | ||
| 4728 | Investigations and Imaging | 2020-11-03 | ||
| 4729 | Clinical Representation | 2020-11-03 | ||
| 4730 | Epidemiology and Risk Factors | 2020-11-03 | ||
| 4731 | Biography | 2020-11-03 | ||
| 4732 | Past Conference Report Petro Chemistry 2020 | 2020-11-03 | ||
| 4733 | A Glimpse at Nicotinamide Riboside (NR) | 2020-11-03 | ||
| 4734 | Nicotinamide Mononucleotide or Nicotinamide Riboside: Which One is Better? | 2020-11-03 | ||
| 4735 | Natural Prevention of Glaucoma | 2020-10-31 | ||
| 4736 | Natural Remedies for Glaucoma | 2020-10-31 | ||
| 4737 | Diagnosis and Treatment | 2020-10-31 | ||
| 4738 | Wet vs. Dry Macular Degeneration | 2020-10-31 | ||
| 4739 | Penetrating Eye Injury | 2020-10-31 | ||
| 4740 | Hyphaema | 2020-10-31 | ||
| 4741 | Blunt Trauma | 2020-10-31 | ||
| 4742 | Glaucoma Diagnosis | 2020-10-31 | ||
| 4743 | Proposed Framework | 2020-10-31 | ||
| 4744 | Nanotechnology in Medical Imaging | 2020-10-31 | ||
| 4745 | Financial/Grant Support | 2020-10-30 | ||
| 4746 | Proprietorship | 2020-10-30 | ||
| 4747 | Global Burden of infectious Diseases | 2020-10-30 | ||
| 4748 | Thromboembolism | 2020-10-29 | ||
| 4749 | Conclusion: The Benefit of Carrageenans | 2020-10-29 | ||
| 4750 | How to Use Carrageenan in Spray | 2020-10-29 | ||
| 4751 | Therapeutic Proposal for the Child Population, In Order to Cut the Chain of Contagion | 2020-10-29 | ||
| 4752 | Forms of Contagion | 2020-10-29 | ||
| 4753 | COVID-19 and Saliva | 2020-10-29 | ||
| 4754 | Patient Update | 2020-10-29 | ||
| 4755 | Lymphoma | 2020-10-29 | ||
| 4756 | Erythrocytosis | 2020-10-29 | ||
| 4757 | Adenocarcinoma | 2020-10-29 | ||
| 4758 | Hemostasis and Coagulation | 2020-10-29 | ||
| 4759 | Bone Mineral Density Test | 2020-10-28 | ||
| 4760 | Bardiet-Biedl Syndrome | 2020-10-28 | ||
| 4761 | Syndromic Retinis Pigmentosa | 2020-10-28 | ||
| 4762 | Factors Affecting the Retinitis Pigmentosa | 2020-10-28 | ||
| 4763 | Causes of RP | 2020-10-28 | ||
| 4764 | Prevalence | 2020-10-28 | ||
| 4765 | Reserach Methodology | 2020-10-27 | ||
| 4766 | Conflicts | 2020-10-27 | ||
| 4767 | Prespective | 2020-10-27 | ||
| 4768 | Drug-Drug Interactions | 2020-10-26 | ||
| 4769 | Medication Evaluated in Clinical Trials | 2020-10-26 | ||
| 4770 | Observations and Results | 2020-10-26 | ||
| 4771 | Community Participation Framework Ledder | 2020-10-22 | ||
| 4772 | Community Participation Framework as a Tool to Explain Stigma in Nursing | 2020-10-22 | ||
| 4773 | The Antecedent of Nursing Image | 2020-10-22 | ||
| 4774 | Rogers Used a Model to Understand Public Perception | 2020-10-22 | ||
| 4775 | Historical Perspective | 2020-10-22 | ||
| 4776 | Risk Fact | 2020-10-22 | ||
| 4777 | Medical Treatment | 2020-10-22 | ||
| 4778 | From the Lens of Family | 2020-10-22 | ||
| 4779 | From the Lens of Patient | 2020-10-22 | ||
| 4780 | From the Lens of Health Care Provider | 2020-10-22 | ||
| 4781 | Assumptions of Ethical Dilemma | 2020-10-22 | ||
| 4782 | Bioethical Implications | 2020-10-22 | ||
| 4783 | Spanish Flu and Covid-19: Historical Considerations | 2020-10-22 | ||
| 4784 | From the Lens of a Healthcare Provider | 2020-10-22 | ||
| 4785 | From the Lens of the Organization | 2020-10-22 | ||
| 4786 | Analysis of Ethical Dilemma | 2020-10-22 | ||
| 4787 | Reflection on Contemporary Issues of Developing Countries | 2020-10-22 | ||
| 4788 | Introduction and Background | 2020-10-22 | ||
| 4789 | Aims and Methods | 2020-10-22 | ||
| 4790 | Conclusion and Future Prospects | 2020-10-22 | ||
| 4791 | COVID Era and Challenges in Uro-Oncology | 2020-10-21 | ||
| 4792 | Risk Stratification | 2020-10-21 | ||
| 4793 | Tackling Risk of Patient Contracting COVID in Hospital Stay | 2020-10-21 | ||
| 4794 | Patient Isolation | 2020-10-21 | ||
| 4795 | Different Classifications Used for Severity and Nature of Ureterocele | 2020-10-21 | ||
| 4796 | Discussions and Literature Review | 2020-10-21 | ||
| 4797 | Important Points to Follow in Indian Scenario to Prevent COVID-19 Infection | 2020-10-21 | ||
| 4798 | Possible Therapeutic Targets | 2020-10-21 | ||
| 4799 | Clinical Management | 2020-10-21 | ||
| 4800 | Virology | 2020-10-21 | ||
| 4801 | Origin of Covid-19 | 2020-10-21 | ||
| 4802 | Therapeutic Role of Phytochemicals | 2020-10-21 | ||
| 4803 | Lineage Relationship Between Ly6cHi Classical Monocytes And Ly6cLo Non-Classical Monocytes | 2020-10-20 | ||
| 4804 | Immune System Mitigation Of Perinatal Liver Inflammation | 2020-10-20 | ||
| 4805 | Case Summary | 2020-10-20 | ||
| 4806 | Bioassays | 2020-10-20 | ||
| 4807 | Results of Findings | 2020-10-20 | ||
| 4808 | Soft Computing (Sc) | 2020-10-20 | ||
| 4809 | Conflicts of Interest Disclosure | 2020-10-20 | ||
| 4810 | Statistical Methods | 2020-10-19 | ||
| 4811 | Conclusion, Current Challanges and Future Prespective | 2020-10-19 | ||
| 4812 | Structuring an Article | 2020-10-19 | ||
| 4813 | The Manuscript | 2020-10-19 | ||
| 4814 | Submission Procedure | 2020-10-19 | ||
| 4815 | Introduction to Authors | 2020-10-19 | ||
| 4816 | Editorial Article | 2020-10-19 | ||
| 4817 | Human Factors and Ergonomics in Healthcare | 2020-10-19 | ||
| 4818 | Human Growth and Posture | 2020-10-19 | ||
| 4819 | Scope of Ergonomics | 2020-10-19 | ||
| 4820 | Editorial Commentary | 2020-10-16 | ||
| 4821 | Test | 2020-10-16 | ||
| 4822 | Detailed Description | 2020-10-16 | ||
| 4823 | Conclusion and Limitations of The Research | 2020-10-16 | ||
| 4824 | Background Information | 2020-10-16 | ||
| 4825 | Countermeasures for Future Hospitality and Tourism Industry | 2020-10-16 | ||
| 4826 | Impact of Covid-19 on Tourism Industry | 2020-10-16 | ||
| 4827 | Impact of Covid-19 on Hospitality Industry | 2020-10-16 | ||
| 4828 | Comparison of SARS and Covid-19 | 2020-10-16 | ||
| 4829 | Impact of SARS happened in 2002 | 2020-10-16 | ||
| 4830 | Accomplishments and Future Research | 2020-10-16 | ||
| 4831 | Cultural Tourism Attractions of Dorzé Village | 2020-10-16 | ||
| 4832 | Cultural Tourism Attractions of Dorzé Village | 2020-10-16 | ||
| 4833 | Credit Authorship Contribution Statement | 2020-10-15 | ||
| 4834 | Entomotoxicology | 2020-10-14 | ||
| 4835 | DNA Analysis For Identification Of Different Species | 2020-10-14 | ||
| 4836 | To Determine Elapsed Time Since Death | 2020-10-14 | ||
| 4837 | Post-Mortem Changes And Entomological Association | 2020-10-14 | ||
| 4838 | Solid Waste Problem In India | 2020-10-10 | ||
| 4839 | Limitations of Clinical Trials | 2020-10-10 | ||
| 4840 | Pharmacovigilace in Clinical Trails | 2020-10-10 | ||
| 4841 | Goals of Pharmacovigilance | 2020-10-10 | ||
| 4842 | Review Literature | 2020-10-10 | ||
| 4843 | Other Adjuvants | 2020-10-10 | ||
| 4844 | CpG ODN | 2020-10-10 | ||
| 4845 | Montanide ISA51 | 2020-10-10 | ||
| 4846 | Virsomes | 2020-10-10 | ||
| 4847 | As Adjuvants | 2020-10-10 | ||
| 4848 | MF59 | 2020-10-10 | ||
| 4849 | Aluminum-Containing Adjuvants | 2020-10-10 | ||
| 4850 | Necrosis | 2020-10-08 | ||
| 4851 | Molecular Diagnostics | 2020-10-08 | ||
| 4852 | Conclusion/Chorology of the Species and Origin of the Turkish Population | 2020-10-08 | ||
| 4853 | Contribution of our Study to Science | 2020-10-07 | ||
| 4854 | Limits of our Study | 2020-10-07 | ||
| 4855 | Data Collected | 2020-10-07 | ||
| 4856 | Data Collecte | 2020-10-07 | ||
| 4857 | Study Population | 2020-10-07 | ||
| 4858 | Authors Role | 2020-10-07 | ||
| 4859 | Intervention | 2020-10-07 | ||
| 4860 | Supplementary Data | 2020-10-07 | ||
| 4861 | Availability of The Data And Materials | 2020-10-07 | ||
| 4862 | Relevance To Clinical Practice | 2020-10-07 | ||
| 4863 | Appendix: Proofs of F-Norm Theorems | 2020-10-05 | ||
| 4864 | Treatment Using IFNs | 2020-10-03 | ||
| 4865 | Antiviral Activity of Interferons | 2020-10-03 | ||
| 4866 | Randomized Controlled Clinical Studies | 2020-10-03 | ||
| 4867 | Retrospective and Observational Studies Using HCQ for Prophylaxis | 2020-10-03 | ||
| 4868 | The Identification of HCQ And Type I Interferon as Potential Therapy for COVID-19 | 2020-10-03 | ||
| 4869 | Mechanism of Viral Entry and Hallmarks of Severe COVID-19 | 2020-10-03 | ||
| 4870 | Responding to Attacks | 2020-10-01 | ||
| 4871 | Impact on the Response | 2020-10-01 | ||
| 4872 | Theorems and Proofs | 2020-10-01 | ||
| 4873 | Application Example | 2020-10-01 | ||
| 4874 | Distributed Algorithm | 2020-10-01 | ||
| 4875 | Social Media Addiction | 2020-09-30 | ||
| 4876 | Malnutrition | 2020-09-29 | ||
| 4877 | Age Related Diseases | 2020-09-29 | ||
| 4878 | Declaration of Competing Interests | 2020-09-28 | ||
| 4879 | Different ethnic group of tribals in Western Ghats | 2020-09-28 | ||
| 4880 | Estimation Of Prediction Output | 2020-09-28 | ||
| 4881 | Building a Prediction Model | 2020-09-28 | ||
| 4882 | Feature and Data Analysis | 2020-09-28 | ||
| 4883 | Data Resources | 2020-09-28 | ||
| 4884 | Declaration on Conflict of Interest | 2020-09-28 | ||
| 4885 | Proposed Interventions | 2020-09-26 | ||
| 4886 | Malnourishment and Undernourishment | 2020-09-26 | ||
| 4887 | Traditional Medicine versus Precision Medicine | 2020-09-26 | ||
| 4888 | Research Contribution and Achievement | 2020-09-25 | ||
| 4889 | Guarantor | 2020-09-25 | ||
| 4890 | Ethical Approval and Registration of Research Studies | 2020-09-25 | ||
| 4891 | Results and Calculations | 2020-09-25 | ||
| 4892 | Investigating Tools | 2020-09-25 | ||
| 4893 | A Peer to Peer Network for Healthcare Payment Method | 2020-09-25 | ||
| 4894 | An Algorithm for Identification of Pairing Members | 2020-09-25 | ||
| 4895 | An Algorithm for Identification of Pairing Members | 2020-09-25 | ||
| 4896 | Research tools | 2020-09-23 | ||
| 4897 | Limitation of Study | 2020-09-22 | ||
| 4898 | Rational Study | 2020-09-22 | ||
| 4899 | Treatment of Diabetes at Some Stage in Covid 19 Contamination | 2020-09-22 | ||
| 4900 | Metabolic Active Abdominal Obesity Is Associated With an Accelerated Risk | 2020-09-22 | ||
| 4901 | What Increases the Risk of Diabetes? | 2020-09-22 | ||
| 4902 | Type 2 Diabetes as a Risk Element | 2020-09-22 | ||
| 4903 | Generalized Anxiety | 2020-09-20 | ||
| 4904 | Panic Attacks | 2020-09-20 | ||
| 4905 | Psychosis | 2020-09-20 | ||
| 4906 | Bipolar and Depression | 2020-09-20 | ||
| 4907 | Objects of Research | 2020-09-19 | ||
| 4908 | Competing Interests (optional as appropriate) | 2020-09-18 | ||
| 4909 | Authors' Contributions (optional as needed) | 2020-09-18 | ||
| 4910 | Factors associated with outcomes of ICCM of Childhood Illnesses | 2020-09-18 | ||
| 4911 | Very High Global Risk of Transmission | 2020-09-18 | ||
| 4912 | Circular Economics is the Next Economics | 2020-09-18 | ||
| 4913 | Discussion and Concluding Remarks | 2020-09-17 | ||
| 4914 | Research/Design Methodology | 2020-09-17 | ||
| 4915 | Aim Of This Work | 2020-09-17 | ||
| 4916 | Dependence of the Force on the Earth Motion in Space | 2020-09-17 | ||
| 4917 | Electrostatic Pendulum Experiment | 2020-09-17 | ||
| 4918 | Previous Experimental Work | 2020-09-17 | ||
| 4919 | Pattern of Articular Affection | 2020-09-17 | ||
| 4920 | Characteristics of Pain | 2020-09-17 | ||
| 4921 | Age and Gender | 2020-09-17 | ||
| 4922 | Diagnostic Tests | 2020-09-17 | ||
| 4923 | Lifestyles | 2020-09-17 | ||
| 4924 | Risk Factor's | 2020-09-17 | ||
| 4925 | Polyarthralgias | 2020-09-17 | ||
| 4926 | Complementary Exams | 2020-09-17 | ||
| 4927 | Toxic Myopathy | 2020-09-17 | ||
| 4928 | Hereditary Myopathies | 2020-09-17 | ||
| 4929 | Specific Clinical Characteristics | 2020-09-17 | ||
| 4930 | Inflammatory Myopathies | 2020-09-17 | ||
| 4931 | Types and Classification | 2020-09-17 | ||
| 4932 | Generalities | 2020-09-17 | ||
| 4933 | Other Causes Not Visible With Dinamic Rx | 2020-09-17 | ||
| 4934 | Other Causes Not Visible With Dinamic Rx | 2020-09-17 | ||
| 4935 | Lesions Observed In The Dynamics Rx | 2020-09-17 | ||
| 4936 | Measurement Of Angles | 2020-09-17 | ||
| 4937 | Dynamic Radiological Examination | 2020-09-17 | ||
| 4938 | Secondary Symptoms | 2020-09-17 | ||
| 4939 | Definition | 2020-09-17 | ||
| 4940 | Anatomy | 2020-09-17 | ||
| 4941 | Author Disclosures | 2020-09-17 | ||
| 4942 | Co-Investigators | 2020-09-17 | ||
| 4943 | Principles and Strategies for Handling Healthcare Wastes | 2020-09-16 | ||
| 4944 | Dangers of Medical Waste from Health and Environmental Perspectives | 2020-09-16 | ||
| 4945 | Justification for the Study | 2020-09-16 | ||
| 4946 | Authors | 2020-09-16 | ||
| 4947 | Interview | 2020-09-16 | ||
| 4948 | Literary Review | 2020-09-16 | ||
| 4949 | Optional Use of Filter | 2020-09-15 | ||
| 4950 | With Thanks | 2020-09-15 | ||
| 4951 | Emotional Distress | 2020-09-15 | ||
| 4952 | Precedent Case Law Includes | 2020-09-15 | ||
| 4953 | Fresh Evidence | 2020-09-15 | ||
| 4954 | Evidence in the Authors Case Experience | 2020-09-15 | ||
| 4955 | Summary Investigation | 2020-09-15 | ||
| 4956 | Author’s Experience | 2020-09-15 | ||
| 4957 | A Mysterious Something | 2020-09-15 | ||
| 4958 | Forensic Aspects of Hypoglycaemia Investigation | 2020-09-15 | ||
| 4959 | Infracontrol-Ventilation | 2020-09-15 | ||
| 4960 | Safety Features | 2020-09-15 | ||
| 4961 | Professional Biography | 2020-09-15 | ||
| 4962 | Study Assessments | 2020-09-15 | ||
| 4963 | Research Design and Methods | 2020-09-15 | ||
| 4964 | Affirmations | 2020-09-15 | ||
| 4965 | Study Constraints | 2020-09-15 | ||
| 4966 | Techniques | 2020-09-15 | ||
| 4967 | Phase I | 2020-09-15 | ||
| 4968 | Phase I/II | 2020-09-15 | ||
| 4969 | Phase II Trials | 2020-09-15 | ||
| 4970 | Phase III Trials | 2020-09-15 | ||
| 4971 | Market Growth and Analysis in Healthcare Industry | 2020-09-15 | ||
| 4972 | Patients & Methods | 2020-09-14 | ||
| 4973 | Impact Factor | 2020-09-13 | ||
| 4974 | Surgical Technique | 2020-09-13 | ||
| 4975 | Conclusions: Professionalsâ?? Training | 2020-09-12 | ||
| 4976 | Conclusions: Professionals’ Training | 2020-09-12 | ||
| 4977 | Integrated Therapy (Main Text) | 2020-09-12 | ||
| 4978 | The Nursi Character Analysis (NURCA) Model | 2020-09-10 | ||
| 4979 | Awards 2020 | 2020-09-08 | ||
| 4980 | Situation Report and Ongoing Challenges on Zamfara Lead Poisoning | 2020-09-07 | ||
| 4981 | Potential Hazards of Lead Contamination | 2020-09-07 | ||
| 4982 | Mechanism of Lead Contamination | 2020-09-07 | ||
| 4983 | Sources of Lead Contamination | 2020-09-07 | ||
| 4984 | Lead Decontamination Activities | 2020-09-07 | ||
| 4985 | Assessment of Lead Contamination in Zamfara Communities | 2020-09-07 | ||
| 4986 | Heavy Metals Concentration and Environmental Concerns | 2020-09-07 | ||
| 4987 | “A guidance at the Addiction and the recovery science” | 2020-09-05 | ||
| 4988 | Journal Scope | 2020-09-04 | ||
| 4989 | Antibiotic Use In Treatment Of Cholera | 2020-09-04 | ||
| 4990 | Host Factor | 2020-09-04 | ||
| 4991 | 2021 Conference Announcement | 2020-09-03 | ||
| 4992 | Outstanding Thesis | 2020-09-03 | ||
| 4993 | Outstanding speaker | 2020-09-03 | ||
| 4994 | Prospective | 2020-09-03 | ||
| 4995 | Lactic Acid Bacteria | 2020-09-02 | ||
| 4996 | Benefits of Probiotics and How They Work | 2020-09-02 | ||
| 4997 | New Status Regarding The Strategy To Protect Healthy Gut Microbes From Antibiotics | 2020-09-02 | ||
| 4998 | Role Of The Gut Microbiota In The Health And Diseases Of Pigs | 2020-09-02 | ||
| 4999 | Brief Summary | 2020-09-02 | ||
| 5000 | Biochemistry | 2020-09-01 | ||
| 5001 | Prevention of HIV Transmission | 2020-09-01 | ||
| 5002 | To the Horizon Twenty-Twenty (2020) | 2020-09-01 | ||
| 5003 | Types of Cancer | 2020-09-01 | ||
| 5004 | Personal Genetic Chart (Pass) | 2020-09-01 | ||
| 5005 | Clinical Relevance | 2020-09-01 | ||
| 5006 | Immunotherapy and COVID-19: Hope or Fear? | 2020-08-31 | ||
| 5007 | COVID-19 | 2020-08-31 | ||
| 5008 | Immunotherapy and COVID-19 Available Data | 2020-08-31 | ||
| 5009 | Covid-19 Global Epidemiology and Evidence in Cancer Patients | 2020-08-31 | ||
| 5010 | Conclusion of Interest | 2020-08-31 | ||
| 5011 | Food for Covid-19 patient | 2020-08-31 | ||
| 5012 | Multidisciplinary Approach | 2020-08-31 | ||
| 5013 | FMR | 2020-08-31 | ||
| 5014 | Thrower's Ten Protocol | 2020-08-31 | ||
| 5015 | Editorial Comment | 2020-08-31 | ||
| 5016 | The Limitations of this Study | 2020-08-30 | ||
| 5017 | Paraganglioma | 2020-08-29 | ||
| 5018 | Hematoma | 2020-08-29 | ||
| 5019 | Advance Treatment in Thyroid | 2020-08-28 | ||
| 5020 | SGLT2 Inhibitors and Its Role in Diabetes | 2020-08-28 | ||
| 5021 | Method of Induction of Ulcer | 2020-08-27 | ||
| 5022 | Botanical Aspects | 2020-08-27 | ||
| 5023 | Dear Editor, | 2020-08-26 | ||
| 5024 | Respected Sir, | 2020-08-26 | ||
| 5025 | Data Analysis and Result | 2020-08-26 | ||
| 5026 | Review of the Related Literature | 2020-08-26 | ||
| 5027 | Side Effect | 2020-08-26 | ||
| 5028 | Clinical Benefit of Favipiravir | 2020-08-26 | ||
| 5029 | Mechanism of Action of Favipiravir | 2020-08-26 | ||
| 5030 | Circular Economics: The Case | 2020-08-25 | ||
| 5031 | Circular Economics in Detail | 2020-08-25 | ||
| 5032 | Circular Economics is the Next Economics | 2020-08-25 | ||
| 5033 | Circular Economics in Action | 2020-08-25 | ||
| 5034 | Background and Focus | 2020-08-25 | ||
| 5035 | Dear Editor | 2020-08-25 | ||
| 5036 | Pathophysiology Of Aplastic Anemia | 2020-08-25 | ||
| 5037 | Infertility | 2020-08-25 | ||
| 5038 | Hormonal Therapy | 2020-08-25 | ||
| 5039 | Interpretation of Results | 2020-08-25 | ||
| 5040 | Classification | 2020-08-25 | ||
| 5041 | Management of Covid-19 | 2020-08-25 | ||
| 5042 | Origin and Spread of Infection | 2020-08-25 | ||
| 5043 | Epidemiology and Prevalance | 2020-08-25 | ||
| 5044 | Background and Objectives | 2020-08-25 | ||
| 5045 | Presentation of the Study Area and Methodology | 2020-08-21 | ||
| 5046 | Spatial Multiple Criteria Analysis (SMCA) | 2020-08-21 | ||
| 5047 | Scope of Study | 2020-08-21 | ||
| 5048 | Statement Of Financial Disclosure And Conflict Of Interest | 2020-08-21 | ||
| 5049 | Institutional Review Board Of Ethics Committee | 2020-08-21 | ||
| 5050 | Two of the following: | 2020-08-19 | ||
| 5051 | Primary progressive MS (PPMS) | 2020-08-19 | ||
| 5052 | Secondary progressive MS (SPMS) | 2020-08-19 | ||
| 5053 | Relapsing-remitting MS (RRMS) | 2020-08-19 | ||
| 5054 | Clinically Isolated Syndrome (CIS) | 2020-08-19 | ||
| 5055 | Tools for making a diagnosis | 2020-08-19 | ||
| 5056 | Criteria for a diagnosis of MS | 2020-08-19 | ||
| 5057 | How does PPMS differ from the other disease courses? | 2020-08-19 | ||
| 5058 | Why are modifiers used to characterize PPMS? | 2020-08-19 | ||
| 5059 | How does SPMS differ from the other disease courses? | 2020-08-19 | ||
| 5060 | Why are modifiers used to characterize SPMS? | 2020-08-19 | ||
| 5061 | How does RRMS differ from progressive types of MS? | 2020-08-19 | ||
| 5062 | Why are modifiers used to describe RRMS? | 2020-08-19 | ||
| 5063 | How is CIS different from MS? | 2020-08-19 | ||
| 5064 | CIS progression to MS | 2020-08-19 | ||
| 5065 | Types of MS | 2020-08-19 | ||
| 5066 | Previous Presentation | 2020-08-19 | ||
| 5067 | Financial Disclosures | 2020-08-19 | ||
| 5068 | Conclusions and Clinical Implications | 2020-08-19 | ||
| 5069 | Limitations and Recommendations for Future Research | 2020-08-19 | ||
| 5070 | Clinical Characteristic and Diagnosis | 2020-08-19 | ||
| 5071 | Locality Of Study | 2020-08-18 | ||
| 5072 | Advantages and Limitations of Using Polysaccharide-Based Materials For Adsorption oF Metal Ions | 2020-08-18 | ||
| 5073 | Recent Developments On New Polysaccharidebased Materials | 2020-08-18 | ||
| 5074 | Review of Metal Ion Biosorption Processes | 2020-08-18 | ||
| 5075 | Modelling Approach | 2020-08-18 | ||
| 5076 | Binding Mechanisms Of Metal Ions Onto Monoand Polysaccharides | 2020-08-18 | ||
| 5077 | Influence Of Experimental Conditions | 2020-08-18 | ||
| 5078 | General Considerations On Metal Ions Complexation Process | 2020-08-18 | ||
| 5079 | Chikungunya Virus | 2020-08-18 | ||
| 5080 | Bottlenecks And Transmission Of West Nile Virus | 2020-08-18 | ||
| 5081 | Studied Cases | 2020-08-18 | ||
| 5082 | Fitness Potentials And Evolutionary Pressures On Arboviruses | 2020-08-18 | ||
| 5083 | Viral Diversity And Transmission Cycles | 2020-08-18 | ||
| 5084 | Bottlenecks | 2020-08-18 | ||
| 5085 | 1. Bottlenecks | 2020-08-18 | ||
| 5086 | Inflammation | 2020-08-18 | ||
| 5087 | Proposed Treament Of Covid-19 | 2020-08-18 | ||
| 5088 | Covid-19 In India | 2020-08-18 | ||
| 5089 | Proposed Treatment Of Covid-19 | 2020-08-18 | ||
| 5090 | Strengths and Limitations of the Study | 2020-08-18 | ||
| 5091 | Aims And Objectives Of The Study | 2020-08-18 | ||
| 5092 | Strannik Neuromodulation Therapy - Outcomes | 2020-08-18 | ||
| 5093 | SVS Results | 2020-08-18 | ||
| 5094 | Cardiology Diagnostic Devices | 2020-08-17 | ||
| 5095 | Advantages | 2020-08-17 | ||
| 5096 | Medical Procedure | 2020-08-17 | ||
| 5097 | Editorial Note for Journal of Sleep Disorders & Therapy | 2020-08-14 | ||
| 5098 | Predictors of Mad Withdrawal | 2020-08-14 | ||
| 5099 | Evaluation of the Mad During Phone Contact | 2020-08-14 | ||
| 5100 | Report of Case | 2020-08-14 | ||
| 5101 | List of Abbrivations | 2020-08-14 | ||
| 5102 | Risk | 2020-08-14 | ||
| 5103 | Preventions | 2020-08-14 | ||
| 5104 | Symptoms | 2020-08-14 | ||
| 5105 | Lessons that can be Learned from Global Eradication Of Rinderpest (Grep) | 2020-08-14 | ||
| 5106 | Global Paste Des Petits Ruminants Eradication Campaigns | 2020-08-14 | ||
| 5107 | Control Paste Des Petits Ruminant | 2020-08-14 | ||
| 5108 | Founding Facts about Paste Des Petits Ruminants | 2020-08-14 | ||
| 5109 | Current State of the Art | 2020-08-13 | ||
| 5110 | Example of an Ethical Situation | 2020-08-13 | ||
| 5111 | The Medical Data Collection Issue by the Robot and the Manufacturer or a Secondhand Buyer | 2020-08-13 | ||
| 5112 | Concept of Damage and Insurance | 2020-08-13 | ||
| 5113 | The Responsibility of the Robot for Its Decision Making | 2020-08-13 | ||
| 5114 | Editor’s Note | 2020-08-13 | ||
| 5115 | Major Food Poisoning Bacteria | 2020-08-13 | ||
| 5116 | Food Safety in Lebanon | 2020-08-13 | ||
| 5117 | Food Safety in Arab Countries | 2020-08-13 | ||
| 5118 | The Impact of Foodborne Illnesses on Human Health | 2020-08-13 | ||
| 5119 | Fortified Products of Quince Cydonia Oblonga | 2020-08-13 | ||
| 5120 | Processed/ Value Added Productsfrom Quince Cydonia Oblonga | 2020-08-13 | ||
| 5121 | Modern Medicinal Uses/ Pharmacological Uses of Quince | 2020-08-13 | ||
| 5122 | Traditional Medicinal Uses of Quince | 2020-08-13 | ||
| 5123 | Phytochemistry of Different Parts of Quince | 2020-08-13 | ||
| 5124 | Quince Profile | 2020-08-13 | ||
| 5125 | Origin and geographical Distribution | 2020-08-13 | ||
| 5126 | Technique | 2020-08-12 | ||
| 5127 | Presentation of Findings and Discussions | 2020-08-12 | ||
| 5128 | Study Area and Methodology | 2020-08-12 | ||
| 5129 | How Supportive is the Prediction that Chinese Flows Can Alleviate or Support this European Challenge? | 2020-08-12 | ||
| 5130 | Demand for European Tourism (Changes and Elasticity) and Investment Orientation Policies | 2020-08-12 | ||
| 5131 | Strategic Orientation and Measurement Policies | 2020-08-12 | ||
| 5132 | European Tourism and the New Trends | 2020-08-12 | ||
| 5133 | Tourists Statistics of Kerala | 2020-08-12 | ||
| 5134 | Collection of Data | 2020-08-12 | ||
| 5135 | Objectives of Research | 2020-08-12 | ||
| 5136 | Glycosphingolipid | 2020-08-12 | ||
| 5137 | Glycosylation | 2020-08-12 | ||
| 5138 | Monosaccharides | 2020-08-12 | ||
| 5139 | Causes | 2020-08-11 | ||
| 5140 | Signs and Symptoms | 2020-08-11 | ||
| 5141 | Executive Summary | 2020-08-11 | ||
| 5142 | Conflicts of Interest/Competing Interests | 2020-08-11 | ||
| 5143 | Declerations | 2020-08-11 | ||
| 5144 | Autoimmune Disease | 2020-08-11 | ||
| 5145 | Registries | 2020-08-11 | ||
| 5146 | Causes of Syndrome | 2020-08-11 | ||
| 5147 | Implementation Examples | 2020-08-07 | ||
| 5148 | Incorporation of Ergonomics into Architecture | 2020-08-07 | ||
| 5149 | Spectroscopic Analytical Methods | 2020-08-07 | ||
| 5150 | Aim of the Work | 2020-08-05 | ||
| 5151 | Quantitative analytical validation | 2020-08-05 | ||
| 5152 | How Can We Control Plant Pathogens? | 2020-08-05 | ||
| 5153 | Genetically Modified Food | 2020-08-05 | ||
| 5154 | Genetically Modified Organisms | 2020-08-05 | ||
| 5155 | Current Trends In Genetically Modified Crops | 2020-08-05 | ||
| 5156 | How Can We Control Plant Pathogens | 2020-08-05 | ||
| 5157 | RNA Interface Technology | 2020-08-05 | ||
| 5158 | How do Farmers Incresase the Yield of their Crops? | 2020-08-05 | ||
| 5159 | How Can We Protect Crops From Pathogens? | 2020-08-05 | ||
| 5160 | How Can We Protect Crops From Pathogens | 2020-08-05 | ||
| 5161 | Market Value on Nursing | 2020-08-05 | ||
| 5162 | Research Methodology/Protocol | 2020-08-05 | ||
| 5163 | Cases | 2020-08-04 | ||
| 5164 | Psychosomatic Medicine 2017: Depression and impulsivity mediating the relationship between social anxiety and Internet addiction-Catherine So-Kum Tang-National University of Singap | 2020-08-03 | ||
| 5165 | Psychiatrists and Forensic Psychology 2016: The resilience of personality disorders: The possible change through an integrated approach-Barbara Sartini-Università Cattolica del Sa | 2020-08-03 | ||
| 5166 | Psychiatrists and Forensic Psychology 2016: The effects of the location of a bed in a ward on the length of stay-Jai Sung NOH-Ajou University School of Medicine | 2020-08-03 | ||
| 5167 | Psychiatrists and Forensic Psychology 2016: Early attachment trauma and the impact on childâ??s development-Doris D'Hooghe-EMDR Practitioner | 2020-08-03 | ||
| 5168 | Forensic Research 2016: Are We Contaminating Victims in Sexual Assault Referral Centres?-Lucy Love-Mountain Healthcare | 2020-08-03 | ||
| 5169 | Forensic 2020: Comparative study of the mental health of hate crime and crime victims-Ishangi Mishra-Jain (Deemed-to-be-university) | 2020-08-03 | ||
| 5170 | Forensic 2020: Meeting the Pedophile: Attitudes toward Pedophilia among Psychology Students-Rebecca Heron-University of Houston-Victoria | 2020-08-03 | ||
| 5171 | Forensic 2020: Assessing Symptom Exaggeration of Psychopathology in Forensic Contexts: Correctional Inmates and Mentally Ill Offenders- Natthawut Arin- Chiang Mai University | 2020-08-03 | ||
| 5172 | Induction of Diabetes | 2020-08-03 | ||
| 5173 | What's New in our Paper | 2020-08-03 | ||
| 5174 | What is known about this Subject? | 2020-08-03 | ||
| 5175 | Current State of Knowledge | 2020-08-03 | ||
| 5176 | The Limitation of this Study | 2020-08-03 | ||
| 5177 | Author Contributorship | 2020-08-02 | ||
| 5178 | Strength and Weakness | 2020-08-01 | ||
| 5179 | Case and Method | 2020-08-01 | ||
| 5180 | Letter to Editor | 2020-08-01 | ||
| 5181 | Data Analysis and Findings | 2020-08-01 | ||
| 5182 | Authors’ affiliations and contacts | 2020-07-31 | ||
| 5183 | Authors affiliations and contacts | 2020-07-31 | ||
| 5184 | Description of the Clinical Image | 2020-07-31 | ||
| 5185 | Conclusion/Final Reflection | 2020-07-31 | ||
| 5186 | Trial Registration (Name Of The Registry And Url) | 2020-07-31 | ||
| 5187 | Detectors of Gases | 2020-07-30 | ||
| 5188 | Detection of Volatile Organic Compounds for Lung Cancer Diagnosis | 2020-07-30 | ||
| 5189 | Detection of H2s for Diagnosing Halitosis | 2020-07-30 | ||
| 5190 | Detection of Acetone for Diagnosing Diabetes | 2020-07-30 | ||
| 5191 | Detection of No2 and Nh3 for the Diagnosis of Asthma and Renal Disease | 2020-07-30 | ||
| 5192 | Nano-Based Antiviral Therapy | 2020-07-30 | ||
| 5193 | General Discussion and Conclusion | 2020-07-30 | ||
| 5194 | Homosexuality and Voiding Troubles | 2020-07-30 | ||
| 5195 | Classes of Relations | 2020-07-30 | ||
| 5196 | Recommendations for Further Studies | 2020-07-30 | ||
| 5197 | Prophylactic and Therapeutic use of Probiotics in Covid-19 | 2020-07-30 | ||
| 5198 | Covid-19-Specific Alterations in Intestinal Microbiome | 2020-07-30 | ||
| 5199 | Intestinal Microbiota and Host’s Inflammatory Tone | 2020-07-30 | ||
| 5200 | Intestinal Microbiota and Host’s Inflammatory Tone | 2020-07-30 | ||
| 5201 | Intestinal Dysbiosis Associated with Covid-19 | 2020-07-30 | ||
| 5202 | Recommendations For Future Studies | 2020-07-29 | ||
| 5203 | Sub-Questions | 2020-07-29 | ||
| 5204 | Population and Sample | 2020-07-29 | ||
| 5205 | Research Method and Design | 2020-07-29 | ||
| 5206 | Research Question | 2020-07-29 | ||
| 5207 | Treatment and Prevention of ASD | 2020-07-29 | ||
| 5208 | Results in Level of Activity | 2020-07-29 | ||
| 5209 | Results for Stereotypic Behaviour | 2020-07-29 | ||
| 5210 | Results in Sleep | 2020-07-29 | ||
| 5211 | Results for Social Interaction | 2020-07-29 | ||
| 5212 | Results for Eye Contact | 2020-07-29 | ||
| 5213 | Results for Verbal Communication | 2020-07-29 | ||
| 5214 | First Published Evidence to Support Our Treatment | 2020-07-29 | ||
| 5215 | How We Treat Our Patients | 2020-07-29 | ||
| 5216 | Prevalence of Clinical Manifestations of Food Allergy in Patients with Autistic Spectrum Disorder | 2020-07-29 | ||
| 5217 | Food Allergy is a Pre-Existing Condition for ASD | 2020-07-29 | ||
| 5218 | Malt's Affecteds in ASD and FA | 2020-07-29 | ||
| 5219 | Immune Medications | 2020-07-29 | ||
| 5220 | Immune Medication and "Homing" in ASD and FA | 2020-07-29 | ||
| 5221 | Epidemiology Aspects | 2020-07-29 | ||
| 5222 | Brain-Gut Connection | 2020-07-29 | ||
| 5223 | Etiology and Pathology | 2020-07-29 | ||
| 5224 | Data Availablity | 2020-07-29 | ||
| 5225 | Author Contributors | 2020-07-29 | ||
| 5226 | Pancreatic Cancer Treatment | 2020-07-29 | ||
| 5227 | Pancreatic Cancer and Its Complications | 2020-07-29 | ||
| 5228 | Editorial Letter | 2020-07-29 | ||
| 5229 | Objectives for 2020 | 2020-07-28 | ||
| 5230 | Journal of Clinical Research & Bioethics - 2019 Highlights | 2020-07-28 | ||
| 5231 | HOME-MADE Kits | 2020-07-27 | ||
| 5232 | ONE-POT Methods | 2020-07-27 | ||
| 5233 | PCR Product Quantification | 2020-07-27 | ||
| 5234 | PCR Overcycling | 2020-07-27 | ||
| 5235 | Cloning Modified Small RNAs | 2020-07-27 | ||
| 5236 | Cloning Strategies | 2020-07-27 | ||
| 5237 | RNA Quality And Quantity | 2020-07-27 | ||
| 5238 | Vascular Aging And Sex Hormones | 2020-07-27 | ||
| 5239 | Sirt1 And Vascular Aging | 2020-07-27 | ||
| 5240 | Sex Hormones And Aging | 2020-07-27 | ||
| 5241 | Author’s Contribution | 2020-07-27 | ||
| 5242 | End of Life Care | 2020-07-27 | ||
| 5243 | General Comparisons | 2020-07-27 | ||
| 5244 | Small Hecs | 2020-07-27 | ||
| 5245 | Large Regional Medical Center Hecs | 2020-07-27 | ||
| 5246 | 2nd Position From The Lens Of Organization | 2020-07-27 | ||
| 5247 | 1st Position (From The Lens Of Health Care Leader) | 2020-07-27 | ||
| 5248 | Justification of My Position | 2020-07-27 | ||
| 5249 | 2nd Position (From the Lens of Parents) | 2020-07-27 | ||
| 5250 | 1st Position (From the Lens of Health Care Provider) | 2020-07-27 | ||
| 5251 | Data Sources and Methods | 2020-07-25 | ||
| 5252 | Climate and Environment of Kenya | 2020-07-25 | ||
| 5253 | Recent Efforts at Resource Recovery by Lagos State | 2020-07-24 | ||
| 5254 | Disclousures and Ethics | 2020-07-24 | ||
| 5255 | Compting Interests | 2020-07-24 | ||
| 5256 | Case-2 | 2020-07-24 | ||
| 5257 | Case-1 | 2020-07-24 | ||
| 5258 | Consent to Publication | 2020-07-24 | ||
| 5259 | Scope of The Journal | 2020-07-24 | ||
| 5260 | Disease | 2020-07-24 | ||
| 5261 | Investigations | 2020-07-23 | ||
| 5262 | Types and Pathophysiology | 2020-07-23 | ||
| 5263 | Role of Extracellular Histones in Infectious Sepsis | 2020-07-22 | ||
| 5264 | Role of C5a in Sepsis (Infectious, Non-Infectious) | 2020-07-22 | ||
| 5265 | An Overview | 2020-07-22 | ||
| 5266 | Human and Animal Participants | 2020-07-21 | ||
| 5267 | Further Researches | 2020-07-21 | ||
| 5268 | Genetically Engineered Biomaterials | 2020-07-21 | ||
| 5269 | Ecopolitical and psychological Motivation | 2020-07-21 | ||
| 5270 | Environmentalism | 2020-07-21 | ||
| 5271 | Presentation | 2020-07-21 | ||
| 5272 | Ethics Approval & Consent to Participate | 2020-07-21 | ||
| 5273 | Authors Contribution Statement | 2020-07-20 | ||
| 5274 | Author’s Contribution Statement | 2020-07-20 | ||
| 5275 | Miracles of Alkalizing Diet In Combating Disease | 2020-07-20 | ||
| 5276 | Integrative Approach to Disease | 2020-07-20 | ||
| 5277 | Planets and Disease | 2020-07-20 | ||
| 5278 | Text | 2020-07-20 | ||
| 5279 | Data and Methodology | 2020-07-19 | ||
| 5280 | Methods of Study | 2020-07-19 | ||
| 5281 | Decleration of Interests | 2020-07-19 | ||
| 5282 | Study Area and Methods | 2020-07-19 | ||
| 5283 | Future Suggestions | 2020-07-17 | ||
| 5284 | Level Of Functional Abilities | 2020-07-17 | ||
| 5285 | Sit To Stand Task | 2020-07-17 | ||
| 5286 | Forward Reaching Task | 2020-07-17 | ||
| 5287 | Test Procedure | 2020-07-17 | ||
| 5288 | Conflicts of Attentiveness | 2020-07-17 | ||
| 5289 | Editorial Highlights | 2020-07-17 | ||
| 5290 | Letter | 2020-07-16 | ||
| 5291 | Editor Note | 2020-07-16 | ||
| 5292 | Ethical Issues | 2020-07-16 | ||
| 5293 | Do the following; Fighting with me is no Rocket Science. | 2020-07-16 | ||
| 5294 | Our Existence in Nature | 2020-07-16 | ||
| 5295 | Political Factors | 2020-07-16 | ||
| 5296 | Socioeconomic | 2020-07-16 | ||
| 5297 | Environment | 2020-07-16 | ||
| 5298 | Study Analysis | 2020-07-16 | ||
| 5299 | The Real Me | 2020-07-16 | ||
| 5300 | My Origin | 2020-07-16 | ||
| 5301 | Diagnosis Capacities | 2020-07-16 | ||
| 5302 | Can Covid-19 Transmit Vertically? | 2020-07-16 | ||
| 5303 | Lasers and Forensic Dentistry | 2020-07-15 | ||
| 5304 | Funding Details | 2020-07-15 | ||
| 5305 | Therapeutic Improvements | 2020-07-15 | ||
| 5306 | Optimisation of the Reaction Condition and Reagents for the Colour Development | 2020-07-14 | ||
| 5307 | Optimisation of the Reaction Condition and Reagents for the Colour Development | 2020-07-14 | ||
| 5308 | Instrumentation | 2020-07-14 | ||
| 5309 | Chemicals and Reagent Preparations | 2020-07-14 | ||
| 5310 | Validation of Developed Method | 2020-07-14 | ||
| 5311 | Robustness | 2020-07-14 | ||
| 5312 | Mobilephase Stability | 2020-07-14 | ||
| 5313 | Filter Validation | 2020-07-14 | ||
| 5314 | Linearity | 2020-07-14 | ||
| 5315 | Precision | 2020-07-14 | ||
| 5316 | Accuracy | 2020-07-14 | ||
| 5317 | Validation Parameters | 2020-07-14 | ||
| 5318 | Preparation Methods | 2020-07-14 | ||
| 5319 | Access to Material | 2020-07-14 | ||
| 5320 | Material Selection | 2020-07-14 | ||
| 5321 | Intervention Options for Veterans | 2020-07-14 | ||
| 5322 | New Research on Veterans and Hearing Loss | 2020-07-14 | ||
| 5323 | Risk Factors | 2020-07-14 | ||
| 5324 | Caspian Tern | 2020-07-14 | ||
| 5325 | Discussion And Future Directions | 2020-07-14 | ||
| 5326 | The Study | 2020-07-14 | ||
| 5327 | Provenance and Peer Review | 2020-07-14 | ||
| 5328 | Patients Consent For Publication | 2020-07-14 | ||
| 5329 | Consultation With A Yoga Instructor | 2020-07-14 | ||
| 5330 | Chronic Illness | 2020-07-14 | ||
| 5331 | Demographic Characteristics | 2020-07-14 | ||
| 5332 | Mirror Therapy Combined With Different Techniques | 2020-07-14 | ||
| 5333 | Mirror Therapy On Acute Stroke Patients | 2020-07-14 | ||
| 5334 | Mirror Therapy On Subacute Stroke Patients | 2020-07-14 | ||
| 5335 | Mirror Therapy On Chronic Stroke Patients | 2020-07-14 | ||
| 5336 | Usefulness Of Ventilatory Gas Analysis | 2020-07-14 | ||
| 5337 | Distinguishing Between CTEPH and PAH Using Posture-Based Ventilatory Gas Analysis | 2020-07-14 | ||
| 5338 | Evaluation Of Severity Using Posture-Based Ventilatory Gas Analysis | 2020-07-14 | ||
| 5339 | Ventilatory Gas Parameters In The Sitting And Supine Positions | 2020-07-14 | ||
| 5340 | Cardiopulmonary Exercise Testing For Pulmonary Hypertension | 2020-07-14 | ||
| 5341 | Association Between The Risk of LS and Blood Parameters | 2020-07-14 | ||
| 5342 | Vascular Dementia | 2020-07-14 | ||
| 5343 | Stroke | 2020-07-14 | ||
| 5344 | Authors Declaration | 2020-07-13 | ||
| 5345 | Discussion on the Frame of Practices | 2020-07-13 | ||
| 5346 | Frame of Research: A Selective Review | 2020-07-13 | ||
| 5347 | Proposed Biosecurity Measures | 2020-07-11 | ||
| 5348 | List of Abbrevations | 2020-07-11 | ||
| 5349 | Examples Of Cancer Biomineralization | 2020-07-09 | ||
| 5350 | Dual Inhibition Of Mir-92a-3p And Mir-489-3p In Atherosclerosis-Related CKD | 2020-07-09 | ||
| 5351 | Mir-92a In Atherosclerosis-Related CKD | 2020-07-09 | ||
| 5352 | Mir-92a In Atherosclerosis - Related Cad (Inverse Relationship Between Mir-92a Expression And Fmd Study) | 2020-07-09 | ||
| 5353 | Mir-92a As Therapeutic Target In Atherosclerosisrelated Disease | 2020-07-09 | ||
| 5354 | Associations Of Cvd And Ckd With Early Stage Mediated By Endothelial Dysfunction | 2020-07-09 | ||
| 5355 | Frailty | 2020-07-09 | ||
| 5356 | Covid-19 And Probiotics | 2020-07-09 | ||
| 5357 | Ethics Statement File | 2020-07-09 | ||
| 5358 | Ethics and Consent to Participate | 2020-07-08 | ||
| 5359 | Importance of Technologies in RBM | 2020-07-08 | ||
| 5360 | Ethics Approval and Informed Consent | 2020-07-08 | ||
| 5361 | Contribution of the Study to Science | 2020-07-08 | ||
| 5362 | History Taking and Past History | 2020-07-08 | ||
| 5363 | Target Volumes and Organs at Risk Planning | 2020-07-08 | ||
| 5364 | Informed Consent for participation | 2020-07-08 | ||
| 5365 | Consent to Publish | 2020-07-08 | ||
| 5366 | Heat Tolerance Mechanism in Wheat | 2020-07-07 | ||
| 5367 | Effect of Heat Stress on Wheat | 2020-07-07 | ||
| 5368 | Measure | 2020-07-07 | ||
| 5369 | Supplementary Materials | 2020-07-07 | ||
| 5370 | Symptoms Appear Within 2 To 14 Days of Exposure to the Virus People with These Symptoms or Combination of Symptoms May Have Covid-19 | 2020-07-07 | ||
| 5371 | Updates on Covid-19 Pandemic | 2020-07-07 | ||
| 5372 | Copingtips for Nurses with the Covid-19 Pandemic “by Dr. Bernadette Melnyk” | 2020-07-07 | ||
| 5373 | Other Considerations | 2020-07-07 | ||
| 5374 | Boosting your Immune System against Coronavirus: How to minimize the Risk of Infection? | 2020-07-07 | ||
| 5375 | The System Has Two Types of Response: Innate and Adaptive | 2020-07-07 | ||
| 5376 | Innate Immune Responses to SARS-CoV-2 Infection: Gaining Insight from Strategies Used By SARS-CoV and MERS-CoV | 2020-07-07 | ||
| 5377 | Hyaluronan: A Potential Cause of Fatalities | 2020-07-07 | ||
| 5378 | HLA Haplotypes and SARS-CoV-2 Infection | 2020-07-07 | ||
| 5379 | Cytokine Storm and Lung Damage | 2020-07-07 | ||
| 5380 | Two-Phase Immune Responses Induced By Covid-19 Infection | 2020-07-07 | ||
| 5381 | Articles Published In 2019 | 2020-07-06 | ||
| 5382 | 2020 Objectives | 2020-07-06 | ||
| 5383 | Main Results | 2020-07-06 | ||
| 5384 | Preliminaries | 2020-07-06 | ||
| 5385 | Ethical Committee Approval | 2020-07-04 | ||
| 5386 | Fundings | 2020-07-04 | ||
| 5387 | Summary and Implications of Hypothesis | 2020-07-04 | ||
| 5388 | Rationale for Hyperoxic Therapy for ASD | 2020-07-04 | ||
| 5389 | ATEC | 2020-07-04 | ||
| 5390 | Ablls-R | 2020-07-04 | ||
| 5391 | Strength | 2020-07-04 | ||
| 5392 | Future Significance | 2020-07-04 | ||
| 5393 | Publication Time Scale | 2020-07-04 | ||
| 5394 | Need to Evaluate the Role of Probiotics as a Therapeutic Tool to Manage the Gastrointestinal Dysfunction Among Children With ASD | 2020-07-04 | ||
| 5395 | Ethics and Approval | 2020-07-04 | ||
| 5396 | Transparency Decleration | 2020-07-04 | ||
| 5397 | Material & Methods | 2020-07-04 | ||
| 5398 | Using Social Media/Digital Marketing to Showcase Articles Published In Your Journal | 2020-07-04 | ||
| 5399 | Conclusion: The Future Roadmap | 2020-07-04 | ||
| 5400 | All is Not Lost: Resurgence in Market is Anticipated in Long-Run | 2020-07-04 | ||
| 5401 | Global Electric Vehicles Market Prospects Set to Dim Across 2020 Amid Covid-19 Pandemic | 2020-07-04 | ||
| 5402 | Context | 2020-07-03 | ||
| 5403 | Funding Resources | 2020-07-03 | ||
| 5404 | Discussion and Comments | 2020-07-03 | ||
| 5405 | Declarations of Competing Interest | 2020-07-03 | ||
| 5406 | Contributers Statement | 2020-07-03 | ||
| 5407 | Ethics Approval and Consent | 2020-07-03 | ||
| 5408 | The Ethics Committee's Approval | 2020-07-03 | ||
| 5409 | Ethical Perspective | 2020-07-03 | ||
| 5410 | Economical Analysis and Political Perspective | 2020-07-03 | ||
| 5411 | Clinical and Epidemiologic Perspective | 2020-07-03 | ||
| 5412 | Results, Discussion and Conclusion | 2020-07-03 | ||
| 5413 | Description of Study Area | 2020-07-03 | ||
| 5414 | Subjective | 2020-07-02 | ||
| 5415 | Sources of Support | 2020-07-02 | ||
| 5416 | Role of Cxcr2 in the Epithelial-Mesenchymal Transition via Expression of Snail | 2020-07-02 | ||
| 5417 | Family of Cxc Chemokines and Cxcr2 Receptor in the Tumor Microenvironment | 2020-07-02 | ||
| 5418 | Epithelial-Mesenchymal Transition | 2020-07-02 | ||
| 5419 | Laparoscopic Liver Resection in Cancer Patients | 2020-07-02 | ||
| 5420 | Data And Methods | 2020-07-02 | ||
| 5421 | Nutritional Aspects of Seed Oil of C. Moschata | 2020-07-02 | ||
| 5422 | Feeding Use and Nutritional Aspects of Fruit Pulp of C. Moschata | 2020-07-02 | ||
| 5423 | C. Moschata is a Vegetable of High Socioeconomic Importance | 2020-07-02 | ||
| 5424 | Domestication and Genetic Diversity of C. Moschata | 2020-07-02 | ||
| 5425 | Botanical aspects of C. Moschata | 2020-07-02 | ||
| 5426 | Literature Review and Discussion | 2020-07-01 | ||
| 5427 | Results and Presentation | 2020-07-01 | ||
| 5428 | Description of Procedures | 2020-07-01 | ||
| 5429 | HIV Associated Eye Diseases | 2020-07-01 | ||
| 5430 | Materials and Method | 2020-07-01 | ||
| 5431 | Ending for a Happy World | 2020-07-01 | ||
| 5432 | Education for a New World | 2020-07-01 | ||
| 5433 | Ethics for a Better World | 2020-07-01 | ||
| 5434 | Proposed Model Validation | 2020-06-28 | ||
| 5435 | PV System Modelling | 2020-06-28 | ||
| 5436 | A Case Study | 2020-06-28 | ||
| 5437 | A Case Study< | 2020-06-28 | ||
| 5438 | Function to failure structures | 2020-06-28 | ||
| 5439 | Concept and functions | 2020-06-28 | ||
| 5440 | Agile methodology | 2020-06-28 | ||
| 5441 | What are social impacts? | 2020-06-28 | ||
| 5442 | Experimentation | 2020-06-28 | ||
| 5443 | CAD Technology and Model | 2020-06-28 | ||
| 5444 | The Different Uses of Analyses | 2020-06-28 | ||
| 5445 | Mechanical Analysis in Embodiment Design | 2020-06-28 | ||
| 5446 | Fault Diagnosis | 2020-06-28 | ||
| 5447 | Multiple Models Adaptive Estimation (MMAE) Technique | 2020-06-28 | ||
| 5448 | Electrochemical Battery Model | 2020-06-28 | ||
| 5449 | Battery chargers | 2020-06-28 | ||
| 5450 | Motor | 2020-06-28 | ||
| 5451 | DC to AC converter | 2020-06-28 | ||
| 5452 | Battery | 2020-06-28 | ||
| 5453 | Structure of Electric Vehicle | 2020-06-28 | ||
| 5454 | Design Specifications | 2020-06-28 | ||
| 5455 | Component Design | 2020-06-28 | ||
| 5456 | Expermental Procedure | 2020-06-28 | ||
| 5457 | Design Validation | 2020-06-28 | ||
| 5458 | Experimental layout | 2020-06-28 | ||
| 5459 | Transformation | 2020-06-28 | ||
| 5460 | Integration | 2020-06-28 | ||
| 5461 | Simulation | 2020-06-28 | ||
| 5462 | Rediscovering | 2020-06-28 | ||
| 5463 | Experimental Method | 2020-06-28 | ||
| 5464 | Analyses | 2020-06-28 | ||
| 5465 | Logic Programming Technique (LPT) | 2020-06-28 | ||
| 5466 | Epidemiologic Theory | 2020-06-28 | ||
| 5467 | Domino Theory | 2020-06-28 | ||
| 5468 | Risk Analysis | 2020-06-28 | ||
| 5469 | Statistical Analysis and Trends | 2020-06-28 | ||
| 5470 | Culture And End Of Life Events | 2020-06-25 | ||
| 5471 | End Of Life: The Terri And Michael Schiavo Case 1998 | 2020-06-25 | ||
| 5472 | Conclusions and Research Implications | 2020-06-24 | ||
| 5473 | Ergonomic Synthesis and Recommendations | 2020-06-24 | ||
| 5474 | Scope for Future Research | 2020-06-24 | ||
| 5475 | Accreditation | 2020-06-23 | ||
| 5476 | Hemovigilance Program | 2020-06-23 | ||
| 5477 | Product Issuance, and Transport | 2020-06-23 | ||
| 5478 | Product Qualification, Processing and Release | 2020-06-23 | ||
| 5479 | Product Collection and Transport | 2020-06-23 | ||
| 5480 | Donor Evaluation | 2020-06-23 | ||
| 5481 | Challenges of Management of Infectious Medical Waste in Taraba State | 2020-06-23 | ||
| 5482 | Result of the Findings | 2020-06-23 | ||
| 5483 | Conceptual Clarification | 2020-06-23 | ||
| 5484 | What Was Done? | 2020-06-23 | ||
| 5485 | Methods and Design | 2020-06-23 | ||
| 5486 | Abstract | 2020-06-13 | ||
| 5487 | Best E-Poster Award | 2020-06-11 | ||
| 5488 | Best Poster Award | 2020-06-11 | ||
| 5489 | Best Young Researcher Award | 2020-06-11 | ||
| 5490 | Best Research Award | 2020-06-11 | ||
| 5491 | Best Speaker Award | 2020-06-11 | ||
| 5492 | Young Research Forum | 2020-06-11 | ||
| 5493 | Awards | 2020-06-11 | ||
| 5494 | Results and Analytics | 2020-06-11 | ||
| 5495 | Case History | 2020-06-11 | ||
| 5496 | Short Commentary | 2020-06-11 | ||
| 5497 | Special Acknowledgment | 2020-06-11 | ||
| 5498 | Therapeutic Options | 2020-06-09 | ||
| 5499 | Differential Diagnosis | 2020-06-09 | ||
| 5500 | Immune Histochemical Elucidation | 2020-06-09 | ||
| 5501 | Histological Elucidation | 2020-06-09 | ||
| 5502 | Genetic Elucidation | 2020-06-09 | ||
| 5503 | Telehealth Programs | 2020-06-09 | ||
| 5504 | Medical Devices | 2020-06-09 | ||
| 5505 | Case Representation | 2020-06-06 | ||
| 5506 | Experimental Methods | 2020-06-06 | ||
| 5507 | Reviewers | 2020-06-01 | ||
| 5508 | Editors | 2020-06-01 | ||
| 5509 | Editor-In-Chief | 2020-06-01 | ||
| 5510 | Journal Highlights | 2020-06-01 | ||
| 5511 | Bioremediation by Trichoderma SP. | 2020-06-01 | ||
| 5512 | Bioremediation by Trichoderma SP. | 2020-06-01 | ||
| 5513 | Trichoderma as A Biofertilizer | 2020-06-01 | ||
| 5514 | Trichoderma and Its Interaction With Microorganism | 2020-06-01 | ||
| 5515 | Discussion of Numerical | 2020-06-01 | ||
| 5516 | Declaration of Curiosity | 2020-06-01 | ||
| 5517 | Clinical Trial 3: Chinese Noodles | 2020-06-01 | ||
| 5518 | Clinical Trial 2: Soba Noodles | 2020-06-01 | ||
| 5519 | Clinical Trial 1: Udon (Japanese Traditional Noodles) | 2020-06-01 | ||
| 5520 | Examination of the Influence of Ca-Alg Content and Particle Size | 2020-06-01 | ||
| 5521 | Mechanism of Suppression of Sugar Absorption | 2020-06-01 | ||
| 5522 | Immunopathogenesis and Advantages of Convalescent Sera | 2020-06-01 | ||
| 5523 | Convalescent Sera | 2020-06-01 | ||
| 5524 | Level of evidence - Level I | 2020-06-01 | ||
| 5525 | Consideration | 2020-06-01 | ||
| 5526 | Study Description | 2020-06-01 | ||
| 5527 | Surgical Repair | 2020-05-28 | ||
| 5528 | Transcatheter Therapy | 2020-05-28 | ||
| 5529 | Indications for Reintervention after Coa Repair | 2020-05-28 | ||
| 5530 | Theoretical Perspectives | 2020-05-26 | ||
| 5531 | Conclusion and Policy Implications | 2020-05-25 | ||
| 5532 | Study Sites and Data Collection Method | 2020-05-25 | ||
| 5533 | Analysis Theories and Models | 2020-05-25 | ||
| 5534 | Editorial Note | 2020-05-23 | ||
| 5535 | Disclosure of Conflict of Interest | 2020-05-22 | ||
| 5536 | Concluding Remarks and Future Prospects | 2020-05-22 | ||
| 5537 | Receptor of Irisin | 2020-05-22 | ||
| 5538 | Other Effects of Irisin | 2020-05-22 | ||
| 5539 | Irisin Combats Obesity in Human | 2020-05-22 | ||
| 5540 | Irisin Combats Obesity in Mice | 2020-05-22 | ||
| 5541 | Irisin, A Promising Myokine and Adipokine | 2020-05-22 | ||
| 5542 | Three Types of Adipocytes | 2020-05-22 | ||
| 5543 | Branched Chain Amino Acids | 2020-05-20 | ||
| 5544 | Management of Frailty in Liver Cirrhosis Patients | 2020-05-20 | ||
| 5545 | Frailty Scoring | 2020-05-20 | ||
| 5546 | Frailty and Liver Transplantation | 2020-05-20 | ||
| 5547 | Frailty and Meld Score | 2020-05-20 | ||
| 5548 | Pathophysiology of Frailty in Liver Cirrhosis | 2020-05-20 | ||
| 5549 | Frailty in Patients with Cirrhosis | 2020-05-20 | ||
| 5550 | Major Findings | 2020-05-20 | ||
| 5551 | Method of Data Collection | 2020-05-20 | ||
| 5552 | Synthesis of Various Nanoparticles | 2020-05-14 | ||
| 5553 | Experimental Setup | 2020-05-14 | ||
| 5554 | Methods and Testing | 2020-05-14 | ||
| 5555 | Statistical Analysis and Data Collection | 2020-05-13 | ||
| 5556 | Social Media | 2020-05-13 | ||
| 5557 | From All Authors | 2020-05-13 | ||
| 5558 | Some Existing Models of Eco Tourism in India | 2020-05-13 | ||
| 5559 | Discussions on Strategies | 2020-05-13 | ||
| 5560 | Guiding Principles for Eco-Tourism Policy | 2020-05-13 | ||
| 5561 | Central Theme of the Proposed Policy | 2020-05-13 | ||
| 5562 | Sponsorship | 2020-05-12 | ||
| 5563 | Characterization Of Partial Purified P.Javanicum Glucoamylase | 2020-05-12 | ||
| 5564 | Our Findings | 2020-05-12 | ||
| 5565 | Environmental Qualification Test Strategy | 2020-05-09 | ||
| 5566 | Results and Conclusion | 2020-05-09 | ||
| 5567 | Design and Information Gathering Approach | 2020-05-09 | ||
| 5568 | Ethics Approval and Consent to Partcipate | 2020-05-06 | ||
| 5569 | Aloe Vera Heals Gastric Ulcer in 7 Days than Omeprazole and Cimetidine: Prostaglandin? | 2020-05-05 | ||
| 5570 | Availability of Data and Material | 2020-05-05 | ||
| 5571 | Recent Land and Forest Rights Movements in Jharkhand | 2020-03-18 | ||
| 5572 | Alternative Development Paradigm in Social Movements | 2020-03-18 | ||
| 5573 | Alternative Development | 2020-03-18 | ||
| 5574 | Development Debate | 2020-03-18 | ||
| 5575 | Jharkhand State and Development Discourse | 2020-03-18 | ||
| 5576 | Post-Independence Policy Framework | 2020-03-18 | ||
| 5577 | Ecological Impact | 2020-03-17 | ||
| 5578 | Temperature Effect on Product Specificity | 2020-03-17 | ||
| 5579 | Effect of Ph on The Product Profile of Mttps5 | 2020-03-17 | ||
| 5580 | Metal Cofactors as Regulators of Terpene Biosynthesis | 2020-03-17 | ||
| 5581 | Terpenoid Synthases Using Isomeric Prenyl Diphosphates | 2020-03-17 | ||
| 5582 | Diterpene Promiscuity | 2020-03-17 | ||
| 5583 | Terpene Synthases Utilizing Prenyl-Disphosphates of Different Chain Length | 2020-03-17 | ||
| 5584 | Multiproduct Terpene Synthases | 2020-03-17 | ||
| 5585 | Client Perspective | 2020-03-16 | ||
| 5586 | 3rd Position (Justification from My Side) | 2020-03-16 | ||
| 5587 | 2nd Position (From the Lens of Health Care Providers) | 2020-03-16 | ||
| 5588 | 1st Position (From the Lens of Organization) | 2020-03-16 | ||
| 5589 | Unicondylar Knee Arthroplasty In Patellectomized Patients | 2020-03-16 | ||
| 5590 | Case Scenario | 2020-03-16 | ||
| 5591 | Osteoarthritis In Patellectomized Patients | 2020-03-16 | ||
| 5592 | Patellectomy And Knee Function | 2020-03-16 | ||
| 5593 | Practical Applications Of Gut Microbiota Manipulation | 2020-03-13 | ||
| 5594 | Fa Therapies Targeting The Microbiota | 2020-03-13 | ||
| 5595 | The Relevance Of Murine Studies In Elucidating Immunologic Pathways Involved In Human Pathology | 2020-03-13 | ||
| 5596 | GI Microbiota And Immune Tolerance | 2020-03-13 | ||
| 5597 | Factors That Influence The Composition Of The Gi Microbiota And Their Association With Predisposition To Fa Development | 2020-03-13 | ||
| 5598 | GI Microbiota Composition Associated With Fa Immune Phenotype | 2020-03-13 | ||
| 5599 | Composition And Development Of Microbiota In Healthy Gut | 2020-03-13 | ||
| 5600 | Industrial Production Of Recombinant Monoclonal Antibody | 2020-03-13 | ||
| 5601 | Batch Cultivation Of Hybridoma For Large Scale Production | 2020-03-13 | ||
| 5602 | Small And Industrial Scale Production Of Therapeutics Monoclonal Antibodies | 2020-03-13 | ||
| 5603 | Immunoglobulin G Subclasses | 2020-03-13 | ||
| 5604 | Immunoglobulin G | 2020-03-13 | ||
| 5605 | Discussion And Limitation | 2020-03-12 | ||
| 5606 | Credit Author Statement | 2020-03-12 | ||
| 5607 | Studies on Synthetic Derivatives of Solanum Alkaloids and Their Biological Activity Published in the Last 15 Years | 2020-03-12 | ||
| 5608 | Biological Activity of Natural Glycoalkaloids | 2020-03-12 | ||
| 5609 | Steroidal Alkaloids/Glycoalkaloids | 2020-03-12 | ||
| 5610 | Techniques for Increasing TCR | 2020-03-12 | ||
| 5611 | Theoretical Principles of TCR | 2020-03-12 | ||
| 5612 | Discussion and Key Learnings | 2020-03-11 | ||
| 5613 | Findings of the Study | 2020-03-11 | ||
| 5614 | Interaction of Rpn2 And Egfr in Colorectal Cancer | 2020-03-11 | ||
| 5615 | Rpn Ii Expression in Chemotherapeutic Resistant Cancer Cells | 2020-03-11 | ||
| 5616 | Rpn Ii Silencing Contributes to the Inhibition of Crc Growth and Enhance Apoptosis of Drug Resistance Tumour | 2020-03-11 | ||
| 5617 | Rpn Ii Promotes Crc Cell Cycle Progression and Proliferation | 2020-03-11 | ||
| 5618 | Limitations of Our Study | 2020-03-11 | ||
| 5619 | Study Methodology | 2020-03-06 | ||
| 5620 | Area of Study | 2020-03-06 | ||
| 5621 | Awards & Rewards: | 2020-03-06 | ||
| 5622 | Neonatal 2020 Young Scientist Awards: | 2020-03-06 | ||
| 5623 | Conference Highlights: | 2020-03-06 | ||
| 5624 | Criteria for Selection: | 2020-03-06 | ||
| 5625 | Neonatal Market Analysis | 2020-03-06 | ||
| 5626 | Result and Findings | 2020-03-05 | ||
| 5627 | Best Outstanding Speaker | 2020-03-05 | ||
| 5628 | Women Scientist | 2020-03-05 | ||
| 5629 | Scholar Level | 2020-03-05 | ||
| 5630 | Professional Level | 2020-03-05 | ||
| 5631 | Best Video Presentation Award | 2020-03-05 | ||
| 5632 | Best Exhibitor Award | 2020-03-05 | ||
| 5633 | Best Student Presentation Award | 2020-03-05 | ||
| 5634 | Best Presentation Award | 2020-03-05 | ||
| 5635 | Session`s Best Presentation Award | 2020-03-05 | ||
| 5636 | The Gynecology 2020 Conference will have a keen focus on: | 2020-03-05 | ||
| 5637 | Limitations In The Literature | 2020-03-05 | ||
| 5638 | Field Case Studies | 2020-03-04 | ||
| 5639 | Experemental Work | 2020-03-04 | ||
| 5640 | Limitations and Future Directions | 2020-03-03 | ||
| 5641 | Data Sources | 2020-03-03 | ||
| 5642 | The Prevalence of Molecular Breast Cancer Subtypes in Ethiopia | 2020-03-02 | ||
| 5643 | The Prevalence of Hormone Receptor Breast Cancer in Ethiopia | 2020-03-02 | ||
| 5644 | Prognostic and Predictive Factors in Breast Cancer | 2020-03-02 | ||
| 5645 | Contribution of Authors | 2020-03-02 | ||
| 5646 | Pregnancy Counselling | 2020-03-02 | ||
| 5647 | Pregnancy Outcomes In Kidney Transplantation | 2020-03-02 | ||
| 5648 | Mini Review | 2020-03-02 | ||
| 5649 | Disclosure of Interest | 2020-03-02 | ||
| 5650 | Patient Consent | 2020-03-02 | ||
| 5651 | Ethical Aspects | 2020-02-28 | ||
| 5652 | Sample Size | 2020-02-28 | ||
| 5653 | Applications | 2020-02-28 | ||
| 5654 | Results in Testing of Particle Board Composite | 2020-02-28 | ||
| 5655 | Materials Used in Preparation of Particle Board | 2020-02-28 | ||
| 5656 | Clinical Cases and Methods | 2020-02-28 | ||
| 5657 | Research Excellence Awards | 2020-02-28 | ||
| 5658 | Preparation of Solutions | 2020-02-28 | ||
| 5659 | Instrumentation and Chromatographic Conditions | 2020-02-28 | ||
| 5660 | Materials and Reagents | 2020-02-28 | ||
| 5661 | Optimization Experiments | 2020-02-28 | ||
| 5662 | Young Researchers Forum | 2020-02-28 | ||
| 5663 | Importance & Scope | 2020-02-28 | ||
| 5664 | Management Options | 2020-02-27 | ||
| 5665 | General Procedure | 2020-02-27 | ||
| 5666 | Target Audience: | 2020-02-27 | ||
| 5667 | Ophthalmic Therapeutic Drugs: | 2020-02-27 | ||
| 5668 | Excipients in Pharmaceuticals: | 2020-02-27 | ||
| 5669 | Antibiotics: | 2020-02-27 | ||
| 5670 | Advanced Drug Delivery Systems: | 2020-02-27 | ||
| 5671 | Metabolic Syndrome | 2020-02-26 | ||
| 5672 | Oral Glucose Tolerance Test | 2020-02-26 | ||
| 5673 | Metabolic Screening Test | 2020-02-26 | ||
| 5674 | Hirsutism | 2020-02-26 | ||
| 5675 | Psychosocial Element | 2020-02-26 | ||
| 5676 | Fertility and Ovulation | 2020-02-26 | ||
| 5677 | Obstructive Sleep Apnea (OSA) | 2020-02-26 | ||
| 5678 | Research Gap Where the Work is Aimed | 2020-02-25 | ||
| 5679 | Applications of Fly Ash/Epoxy/Nanocomposites | 2020-02-25 | ||
| 5680 | Effect of Nanofillers on Mechanical, Morphological, and Thermal Properties of Polymer Nanocomposites | 2020-02-25 | ||
| 5681 | Characterization of Polymer Nanocomposites | 2020-02-25 | ||
| 5682 | Limitations and Process of Improvements | 2020-02-25 | ||
| 5683 | Methods for Dispersion of Various Nanofillers in Matrix | 2020-02-25 | ||
| 5684 | General Methods of Fabrication of Filler/Polymer-Based Nanocomposites | 2020-02-25 | ||
| 5685 | Characteristics of Nanofillers | 2020-02-25 | ||
| 5686 | Fabrication of Epoxy/Fly Ash Composites | 2020-02-25 | ||
| 5687 | Characteristics of Epoxy Resin | 2020-02-25 | ||
| 5688 | Trends of Fly Ash Production, Utilization, and Problems Encountered in Disposal of Fly ash | 2020-02-25 | ||
| 5689 | Classification of Fly Ash | 2020-02-25 | ||
| 5690 | Chemical and Physical Characteristics of Fly Ash | 2020-02-25 | ||
| 5691 | Raw Materials for the Fabrication of Fly Ash/Epoxy Nanocomposite | 2020-02-25 | ||
| 5692 | Adsorption Experiments | 2020-02-25 | ||
| 5693 | Statement of Novelty | 2020-02-25 | ||
| 5694 | Primary Surgical Repair | 2020-02-24 | ||
| 5695 | Treatment Plan | 2020-02-24 | ||
| 5696 | Data Analysis Procedure | 2020-02-20 | ||
| 5697 | Data Collection Procedure | 2020-02-20 | ||
| 5698 | Problem Statement | 2020-02-20 | ||
| 5699 | Data Analysis and Interpretation | 2020-02-20 | ||
| 5700 | Headaches | 2020-02-20 | ||
| 5701 | Obesity | 2020-02-20 | ||
| 5702 | Cardiovascular Diseases | 2020-02-20 | ||
| 5703 | Diabetes | 2020-02-20 | ||
| 5704 | Validity and Trustworthiness of the Data | 2020-02-20 | ||
| 5705 | Analytic Approach | 2020-02-20 | ||
| 5706 | Purpose and Aims of the Study | 2020-02-20 | ||
| 5707 | Terminology and Concepts | 2020-02-18 | ||
| 5708 | Application | 2020-02-18 | ||
| 5709 | Therom 2 | 2020-02-18 | ||
| 5710 | Theorem 1 | 2020-02-18 | ||
| 5711 | Theoretical Results and Discussion | 2020-02-18 | ||
| 5712 | Theory and Experimentation | 2020-02-18 | ||
| 5713 | Contribution to Knowledge | 2020-02-18 | ||
| 5714 | Data and Method | 2020-02-17 | ||
| 5715 | Why to attend??? | 2020-02-11 | ||
| 5716 | Importance and Scope: | 2020-02-11 | ||
| 5717 | Limitations and Future Study | 2020-02-11 | ||
| 5718 | Analysis and Discussion | 2020-02-11 | ||
| 5719 | Disclosure Statement | 2020-02-11 | ||
| 5720 | Sources of MSW | 2020-02-10 | ||
| 5721 | Methods of the Data Collection | 2020-02-10 | ||
| 5722 | Top Toxicology Companies: | 2020-02-10 | ||
| 5723 | Top Universities in Europe: | 2020-02-10 | ||
| 5724 | Top 10 Global Toxicology Laboratories | 2020-02-10 | ||
| 5725 | Major Associations and Organizations around the Globe: | 2020-02-10 | ||
| 5726 | Toxicology 2020 | 2020-02-10 | ||
| 5727 | Applicants must: | 2020-02-10 | ||
| 5728 | Benefits: | 2020-02-10 | ||
| 5729 | Best Poster Presentation Award | 2020-02-10 | ||
| 5730 | Why Toxicology 2020?? | 2020-02-10 | ||
| 5731 | Discussion, Conclusion & Policy Implications | 2020-02-05 | ||
| 5732 | Best Keynote speaker Awards | 2020-02-04 | ||
| 5733 | MNP Based Cholesterol Biosensors | 2020-02-04 | ||
| 5734 | Implications | 2020-02-04 | ||
| 5735 | The Anti-Apoptotic Properties of H2 | 2020-02-04 | ||
| 5736 | Anti-Inflammatory Effects of H2 in Different Disease Models | 2020-02-04 | ||
| 5737 | H2 Acts As an Anti-Oxidant Agent | 2020-02-04 | ||
| 5738 | Molecular Mechanisms of H2 Effects | 2020-02-04 | ||
| 5739 | Methods of Administration of H2 | 2020-02-04 | ||
| 5740 | Dental Patients Receiving Oral Anticoagulant Therapy | 2020-02-03 | ||
| 5741 | Review of the Literature | 2020-02-03 | ||
| 5742 | Health Care Manager/Professional with Spirituality | 2020-02-03 | ||
| 5743 | Spirituality and Management Students | 2020-02-03 | ||
| 5744 | Spirituality and Stress | 2020-02-03 | ||
| 5745 | Design | 2020-02-03 | ||
| 5746 | Subject and Methods | 2020-02-03 | ||
| 5747 | RESULT AND DISCUSION | 2020-02-01 | ||
| 5748 | Statistics | 2020-01-31 | ||
| 5749 | Analysis and Measurements | 2020-01-31 | ||
| 5750 | Discussion and Analysis | 2020-01-30 | ||
| 5751 | Summary and Recommendations | 2020-01-30 | ||
| 5752 | Challenges and Opportunities | 2020-01-30 | ||
| 5753 | Factors for the Collapse of the Harla Culture and Civilization of Derbé Belanbel | 2020-01-30 | ||
| 5754 | Geographical Location and Description of the Study Area | 2020-01-30 | ||
| 5755 | Methodology of the Study | 2020-01-30 | ||
| 5756 | Research Questions | 2020-01-30 | ||
| 5757 | Finding and Result | 2020-01-29 | ||
| 5758 | ISO Quality Standards | 2020-01-29 | ||
| 5759 | Total Quality Management | 2020-01-29 | ||
| 5760 | Future Prospects | 2020-01-29 | ||
| 5761 | Algeriaâ??s Tourist Potentials | 2020-01-29 | ||
| 5762 | Reasons for Adopting ICTS in the Tourismindustry in Algeria | 2020-01-29 | ||
| 5763 | ICT and its Role in Tourism Sustainable Development | 2020-01-29 | ||
| 5764 | Definition of Tourism Sustainable Development | 2020-01-29 | ||
| 5765 | The Literature Review | 2020-01-29 | ||
| 5766 | Topical Therapy, Evolving Scenario’s Application in Day-to-Day Practice | 2020-01-29 | ||
| 5767 | Filaggrin | 2020-01-29 | ||
| 5768 | Microanatomy and Physiology of Stratum Corneum | 2020-01-29 | ||
| 5769 | Further Directions | 2020-01-28 | ||
| 5770 | Effects of Autism Spectrum Disorder on the Endocannabinoid System | 2020-01-28 | ||
| 5771 | Marijuana and the Endocannabinoid System | 2020-01-28 | ||
| 5772 | Overview of the Endocannabinoid System | 2020-01-28 | ||
| 5773 | Social Impact | 2020-01-28 | ||
| 5774 | Financial Impact | 2020-01-28 | ||
| 5775 | Sibling Impact | 2020-01-28 | ||
| 5776 | The Stress of Father | 2020-01-28 | ||
| 5777 | Maternal Stress | 2020-01-28 | ||
| 5778 | Autism Impact on Parent | 2020-01-28 | ||
| 5779 | Salmon Farming Production and Economic Impact in an International Perspective | 2020-01-28 | ||
| 5780 | Salmon Farming Production and Economic Impact in an International Perspective | 2020-01-28 | ||
| 5781 | Salmon Farming Production and Economic Impact in an International Perspective | 2020-01-28 | ||
| 5782 | The Salmon Farming Licences Process | 2020-01-28 | ||
| 5783 | Law and Regulations Governing Salmon Farming | 2020-01-28 | ||
| 5784 | Guidelines: | 2020-01-27 | ||
| 5785 | Criteria: | 2020-01-27 | ||
| 5786 | Experimental Procedure | 2020-01-25 | ||
| 5787 | Main Body | 2020-01-25 | ||
| 5788 | Funding Organizations | 2020-01-25 | ||
| 5789 | Subjects and Methodology | 2020-01-25 | ||
| 5790 | Study inclusion | 2020-01-24 | ||
| 5791 | Higher-esteem types supported in substance amalgamation | 2020-01-24 | ||
| 5792 | Polymerization impetuses to ascend at solid pace | 2020-01-24 | ||
| 5793 | World interest to rise 4.8% yearly through 2019 | 2020-01-24 | ||
| 5794 | Review Of The Two Landmark Studies on SLE | 2020-01-24 | ||
| 5795 | Kozhikode Criteria [1-3] | 2020-01-24 | ||
| 5796 | Haematological Manifestations of SLE | 2020-01-24 | ||
| 5797 | Case History 17 | 2020-01-24 | ||
| 5798 | Case History 16 | 2020-01-24 | ||
| 5799 | Case History 15 | 2020-01-24 | ||
| 5800 | Case History 14 | 2020-01-24 | ||
| 5801 | Case History 13 | 2020-01-24 | ||
| 5802 | Case History 12 | 2020-01-24 | ||
| 5803 | Case History 11 | 2020-01-24 | ||
| 5804 | Case History 10 | 2020-01-24 | ||
| 5805 | Case History 9 | 2020-01-24 | ||
| 5806 | Case History 8 | 2020-01-24 | ||
| 5807 | Case History 7 | 2020-01-24 | ||
| 5808 | Case History 6 | 2020-01-24 | ||
| 5809 | Case History 5 | 2020-01-24 | ||
| 5810 | Case History 4 | 2020-01-24 | ||
| 5811 | Case History 3 | 2020-01-24 | ||
| 5812 | Case History 2 | 2020-01-24 | ||
| 5813 | Case History 1 | 2020-01-24 | ||
| 5814 | Systemic Lupus Erythematosus (SLE) | 2020-01-24 | ||
| 5815 | Award Announcements: | 2020-01-23 | ||
| 5816 | Conditions of Acceptance: | 2020-01-23 | ||
| 5817 | Strength and Limitation | 2020-01-23 | ||
| 5818 | Outcome Measures | 2020-01-23 | ||
| 5819 | Source and Study Population | 2020-01-22 | ||
| 5820 | Ethical Clearance | 2020-01-22 | ||
| 5821 | Data Processing And Analysis | 2020-01-22 | ||
| 5822 | Study Variables | 2020-01-22 | ||
| 5823 | Importance & Scope | 2020-01-22 | ||
| 5824 | A Glance at Market of Nutrition and Food | 2020-01-22 | ||
| 5825 | Best Poster Award Euro Nutrition 2020 | 2020-01-22 | ||
| 5826 | Outstanding Masters/Ph.D./PostDoc Thesis work presentation Euro Nutrition 2020 | 2020-01-22 | ||
| 5827 | Best Organising Committee Member Euro Nutrition 2020 | 2020-01-22 | ||
| 5828 | Best Key Note Speaker Euro Nutrition 2020 | 2020-01-22 | ||
| 5829 | Outstanding Speaker Euro Nutrition 2020 | 2020-01-22 | ||
| 5830 | Awards at Nutrition & Fitness 2020 | 2020-01-22 | ||
| 5831 | Award recognizes Masters/Ph. D./Post Ph.D | 2020-01-22 | ||
| 5832 | Best Poster Presentation | 2020-01-22 | ||
| 5833 | Best Keynote Speaker | 2020-01-22 | ||
| 5834 | Excellence Award | 2020-01-22 | ||
| 5835 | Out Standing Award | 2020-01-22 | ||
| 5836 | List of Related Journals | 2020-01-21 | ||
| 5837 | Privileges | 2020-01-21 | ||
| 5838 | Best Questioner award: | 2020-01-21 | ||
| 5839 | Young Scientist Award: | 2020-01-21 | ||
| 5840 | Poster Presentation Award: | 2020-01-21 | ||
| 5841 | Best Speaker: | 2020-01-21 | ||
| 5842 | Best Keynote Speaker: | 2020-01-21 | ||
| 5843 | Glycolysis And Age-Related Macromolecular Modification | 2020-01-21 | ||
| 5844 | Expert Level (Scientific service Achievement Award psychology congress 2020) | 2020-01-20 | ||
| 5845 | Best E- poster Award in psychology congress 2020 | 2020-01-20 | ||
| 5846 | Best Poster Presentation in psychology congress 2020 | 2020-01-20 | ||
| 5847 | Best speaker in psychology congress 2020 | 2020-01-20 | ||
| 5848 | Best Keynote Speaker in psychology congress 2020 | 2020-01-20 | ||
| 5849 | Best Organizing Committee Member in Psychology congress 2020 | 2020-01-20 | ||
| 5850 | Award Announcements | 2020-01-20 | ||
| 5851 | Conditions of Acceptance | 2020-01-20 | ||
| 5852 | Guidelines | 2020-01-20 | ||
| 5853 | Criteria | 2020-01-20 | ||
| 5854 | Dissemination Plan | 2020-01-14 | ||
| 5855 | What is the Evidence? Is Risk Pooling Equitable and Lead to Financial Protection? | 2020-01-13 | ||
| 5856 | Brief Overview of Issues related to various Risk Pooling Schemes [9] | 2020-01-13 | ||
| 5857 | Where is Health Expenditure being done? | 2020-01-13 | ||
| 5858 | Has Health Expenditure increased in India since 2004? What is the evidence available from National Health Accounts 2014 of India [11]? | 2020-01-13 | ||
| 5859 | Where is the Gap? – Less % Total Health Expenditure (THE) of GDP or Less allocation of Government Spending on Health? | 2020-01-13 | ||
| 5860 | Can Funding from Donor Agencies Solve the Problem? | 2020-01-13 | ||
| 5861 | Press Release of Optics and Photonics 2020: | 2020-01-13 | ||
| 5862 | Author information | 2020-01-10 | ||
| 5863 | Exploring the limitless potential of Aerospace for creation of better world Technology | 2020-01-10 | ||
| 5864 | First Case Report | 2020-01-09 | ||
| 5865 | Ethical Approval | 2020-01-09 | ||
| 5866 | The Future of Device Treatments | 2020-01-08 | ||
| 5867 | Congestive Heart Faliure (Novel Therapy) | 2020-01-08 | ||
| 5868 | Problems Associated with the Treatment | 2020-01-08 | ||
| 5869 | Surgery | 2020-01-08 | ||
| 5870 | Devices | 2020-01-08 | ||
| 5871 | Treatment & Conventional Therapies for Congestive Heart Failure | 2020-01-08 | ||
| 5872 | Limitations of Study | 2020-01-07 | ||
| 5873 | Author Contribution | 2020-01-06 | ||
| 5874 | Fundamental Experiments that Ensures this Review Proposal | 2020-01-06 | ||
| 5875 | Advantages of Embryonic Cell Molecules over Stem Cells | 2020-01-06 | ||
| 5876 | Authors' Contribution | 2020-01-06 | ||
| 5877 | Declarations of Interest | 2020-01-06 | ||
| 5878 | Clinical Observations | 2020-01-06 | ||
| 5879 | Methodology and Experimental | 2020-01-06 | ||
| 5880 | Study Area Description | 2020-01-06 | ||
| 5881 | Ethics Statement and Consent | 2020-01-06 | ||
| 5882 | Strengths and Limitations | 2020-01-06 | ||
| 5883 | Adapting To Bereavement | 2020-01-04 | ||
| 5884 | Emotional Crises | 2020-01-04 | ||
| 5885 | Particular problems in adapting to dying | 2020-01-04 | ||
| 5886 | Adapting To Dying | 2020-01-04 | ||
| 5887 | Personal Spirituality | 2020-01-04 | ||
| 5888 | Secrets Of Death System | 2020-01-04 | ||
| 5889 | Fear Of Death In Society | 2020-01-04 | ||
| 5890 | Clinical Evolution | 2020-01-04 | ||
| 5891 | Data and Statistical Analysis | 2020-01-03 | ||
| 5892 | Trial Objectives, Materials and Methods | 2020-01-03 | ||
| 5893 | Declaration of Conflicts of Interest | 2020-01-03 | ||
| 5894 | Various Clinical Observations | 2020-01-03 | ||
| 5895 | Technical Measurements | 2020-01-03 | ||
| 5896 | Potential Conflicts of Interest | 2020-01-03 | ||
| 5897 | Case Synopsis | 2020-01-03 | ||
| 5898 | Antibody Mechanism of Action Against Leukemia and Lymphoma Treatment | 2020-01-02 | ||
| 5899 | Monoclonal Antibody for Lymphoma Treatment | 2020-01-02 | ||
| 5900 | Monoclonal Antibody Treatment of Leukemia and Lymphoma in Recent Perspectives | 2020-01-02 | ||
| 5901 | Development of Therapeutic Antibody Technologies | 2020-01-02 | ||
| 5902 | Voriconazole Prophylaxis | 2020-01-02 | ||
| 5903 | Patient and Methods | 2020-01-02 | ||
| 5904 | Methodological Approach | 2020-01-02 | ||
| 5905 | Suggestions and Recommendations | 2020-01-02 | ||
| 5906 | Future Work | 2019-12-31 | ||
| 5907 | Open doors for Conference Attendees: | 2019-12-31 | ||
| 5908 | Target Audience | 2019-12-31 | ||
| 5909 | Key Major Trends | 2019-12-31 | ||
| 5910 | Major players | 2019-12-31 | ||
| 5911 | Results of Our Pilot Study | 2019-12-31 | ||
| 5912 | Noheading | 2019-12-28 | ||
| 5913 | Confidentiality | 2019-12-27 | ||
| 5914 | Clinical Trial Registry And Registration Number | 2019-12-27 | ||
| 5915 | Study Analysis Considerations | 2019-12-27 | ||
| 5916 | Study Setup and Conduct | 2019-12-27 | ||
| 5917 | Patient Recruitment and Retention | 2019-12-27 | ||
| 5918 | Strength and Limitation of the Study | 2019-12-26 | ||
| 5919 | Business Awards (In conference) | 2019-12-26 | ||
| 5920 | Author´s Contributions | 2019-12-26 | ||
| 5921 | Thermotherapy Application Results | 2019-12-26 | ||
| 5922 | Previous Confeernce Conference Gallery Proof | 2019-12-24 | ||
| 5923 | Quality in Primary Care | 2019-12-24 | ||
| 5924 | Contributorship | 2019-12-24 | ||
| 5925 | Scope and Importance | 2019-12-23 | ||
| 5926 | Call for Nominations | 2019-12-23 | ||
| 5927 | Developing trends and modern diagnosis in Neurological Disorders and Stroke Treatment | 2019-12-23 | ||
| 5928 | Annual Congress on Diabetes and Endocrinology-Endocrinology 2020 | 2019-12-23 | ||
| 5929 | Conference Announcement | 2019-12-23 | ||
| 5930 | Expert Level (Scientific Service Achievement Award) | 2019-12-23 | ||
| 5931 | Expert Level | 2019-12-21 | ||
| 5932 | International Conference on Gastroenterology and Digestive Disorders- Gastroenterology and Digestive Disorders 2020 | 2019-12-21 | ||
| 5933 | Business Awards (In conference): | 2019-12-20 | ||
| 5934 | Academic Awards (In conference): | 2019-12-20 | ||
| 5935 | Aim of the Study | 2019-12-19 | ||
| 5936 | Need of the Study | 2019-12-19 | ||
| 5937 | Discussion and Avenues for Further Research | 2019-12-16 | ||
| 5938 | The Age Profile of Successful Aging | 2019-12-16 | ||
| 5939 | Implementation with Share | 2019-12-16 | ||
| 5940 | Measures of Successful Aging | 2019-12-16 | ||
| 5941 | Ethical and Legal Considerations | 2019-12-16 | ||
| 5942 | Market Analysis | 2019-12-12 | ||
| 5943 | Best Poster Awards | 2019-12-11 | ||
| 5944 | Best Abstract Awards | 2019-12-11 | ||
| 5945 | Outstanding Speaker Awards | 2019-12-11 | ||
| 5946 | Survey Tools | 2019-12-11 | ||
| 5947 | Materials and Methods of Work | 2019-12-11 | ||
| 5948 | Conclusions And Future Directions | 2019-12-11 | ||
| 5949 | Survival Outcomes | 2019-12-10 | ||
| 5950 | Cancer-Related Outcomes | 2019-12-10 | ||
| 5951 | Obstetric Outcomes | 2019-12-10 | ||
| 5952 | Gastrointestinal Consequences | 2019-12-10 | ||
| 5953 | Endocrine and Metabolic Consequences | 2019-12-10 | ||
| 5954 | Respiratory Consequences | 2019-12-10 | ||
| 5955 | Geophysical Survey | 2019-12-09 | ||
| 5956 | Geological Setting and Seismicity of the Study Area | 2019-12-09 | ||
| 5957 | Result and Interpretation | 2019-12-09 | ||
| 5958 | Advanced Materials Market Research Scope: | 2019-12-07 | ||
| 5959 | Advanced Materials Market Trends: | 2019-12-07 | ||
| 5960 | Advanced Materials Market Key Players Perspective: | 2019-12-07 | ||
| 5961 | Advanced Materials Market Report: Industry Coverage | 2019-12-07 | ||
| 5962 | Advanced Materials Market Outlook: | 2019-12-07 | ||
| 5963 | Advanced Materials Market Overview: | 2019-12-07 | ||
| 5964 | The Proof of Theorem | 2019-12-06 | ||
| 5965 | Acknowledgements and conflict of Interest | 2019-12-06 | ||
| 5966 | Us Assessment | 2019-12-06 | ||
| 5967 | Recommendations and Conclusion | 2019-12-06 | ||
| 5968 | Future Developments | 2019-12-06 | ||
| 5969 | Osteoarthritis | 2019-12-06 | ||
| 5970 | Psoriatic Arthritis | 2019-12-06 | ||
| 5971 | Systemic Lupus Erythematosus | 2019-12-06 | ||
| 5972 | Rheumatoid Arthritis | 2019-12-06 | ||
| 5973 | Exosome Functions | 2019-12-06 | ||
| 5974 | Exosomes as Biomarkers | 2019-12-06 | ||
| 5975 | Once exosomes are isolated from physiological fluids, it is essential to determine their purity. Exosomes contain certain universal lipids and proteins, including membrane t |
2019-12-06 | ||
| 5976 | Markers Of Exosomes | 2019-12-06 | ||
| 5977 | Immunological Separation | 2019-12-06 | ||
| 5978 | Precipitation | 2019-12-06 | ||
| 5979 | Chromatography | 2019-12-06 | ||
| 5980 | Centrifugation | 2019-12-06 | ||
| 5981 | Methods Of Isolation | 2019-12-06 | ||
| 5982 | Biogenesis | 2019-12-06 | ||
| 5983 | Review Of The History | 2019-12-06 | ||
| 5984 | The Current Malariotherapy For Autoimmune Diseases | 2019-12-04 | ||
| 5985 | The Other Face: Malariotherapy Of Psychiatric Diseases | 2019-12-04 | ||
| 5986 | Malaria As A Lethal Disease | 2019-12-04 | ||
| 5987 | Plant Growth Promoting Bacteria and their Applications | 2019-12-04 | ||
| 5988 | Genomics of Endophytic Bacteria | 2019-12-04 | ||
| 5989 | Current Culture-Independent Techniques for Studying Bacterial Endophytes | 2019-12-04 | ||
| 5990 | Isolation and Identification of Endophytes Using Culture Dependent Methods | 2019-12-04 | ||
| 5991 | Colonization of Endophytes | 2019-12-04 | ||
| 5992 | Biodiversity of Endophytes | 2019-12-04 | ||
| 5993 | Irb Approval | 2019-12-03 | ||
| 5994 | Future Prospectus | 2019-12-03 | ||
| 5995 | Significance of this Case | 2019-12-03 | ||
| 5996 | History and MCG Impressions in January 2019 | 2019-12-03 | ||
| 5997 | Parents Provided QST Therapy Beginning in the Fall of 2015 | 2019-12-03 | ||
| 5998 | E.P. Response to the 12 Step QST Massage | 2019-12-03 | ||
| 5999 | MCG Impressions in Aug 2015 | 2019-12-03 | ||
| 6000 | Subject | 2019-12-03 | ||
| 6001 | Generalizability | 2019-11-29 | ||
| 6002 | Translational Statement | 2019-11-29 | ||
| 6003 | Data Sources/Measurement | 2019-11-29 | ||
| 6004 | Discussion and Literature Review | 2019-11-29 | ||
| 6005 | Foundation | 2019-11-28 | ||
| 6006 | Experiment Consents | 2019-11-28 | ||
| 6007 | Conclusion And Future Prospective | 2019-11-28 | ||
| 6008 | Planktonic Foraminiferal Biozones | 2019-11-27 | ||
| 6009 | Lithostratigraphy | 2019-11-27 | ||
| 6010 | Geological Setting | 2019-11-27 | ||
| 6011 | Biological Pretreatment | 2019-11-27 | ||
| 6012 | Physical-Chemical Pretreatment | 2019-11-27 | ||
| 6013 | Physical Pretreatment | 2019-11-27 | ||
| 6014 | Chemical Pretreatment | 2019-11-27 | ||
| 6015 | Footnote | 2019-11-26 | ||
| 6016 | Comorbidities and Risk Factors | 2019-11-26 | ||
| 6017 | Conclusion and Future Studies | 2019-11-26 | ||
| 6018 | The Limitations of the Study | 2019-11-25 | ||
| 6019 | Notes | 2019-11-25 | ||
| 6020 | Conclusion and Policy Implication | 2019-11-25 | ||
| 6021 | Empirical Analysis and Discussion | 2019-11-25 | ||
| 6022 | The Presented Algorithm | 2019-11-22 | ||
| 6023 | The Acknowledgment of Bloom Filter and Cryptography Algorithm | 2019-11-22 | ||
| 6024 | Conclusion and Future Scope | 2019-11-22 | ||
| 6025 | Study Method and Population | 2019-11-18 | ||
| 6026 | Case Study: Adama Agricultural Solutions | 2019-11-15 | ||
| 6027 | Case Study: Microsoft India and Icrisat | 2019-11-15 | ||
| 6028 | Methodology and Data Collection | 2019-11-15 | ||
| 6029 | Test Methodologies | 2019-11-15 | ||
| 6030 | Artificial Neural Network | 2019-11-15 | ||
| 6031 | Ethical Approval and Informed Consent | 2019-11-15 | ||
| 6032 | Seismogenic Losses | 2019-11-13 | ||
| 6033 | Secondary Seismic Hazard | 2019-11-13 | ||
| 6034 | Seismic Vulnerability of Built Environment | 2019-11-13 | ||
| 6035 | About the Study | 2019-11-13 | ||
| 6036 | Evaluation | 2019-11-13 | ||
| 6037 | Key Message | 2019-11-12 | ||
| 6038 | Investigations on Admission | 2019-11-12 | ||
| 6039 | Conclusions and Outlooks | 2019-11-12 | ||
| 6040 | Time to Act | 2019-11-12 | ||
| 6041 | Child Abuse Cases Reported in Pakistan | 2019-11-12 | ||
| 6042 | Psychological Therapies for Pedophiles | 2019-11-12 | ||
| 6043 | Pharmacological Therapy for Pedophiles | 2019-11-12 | ||
| 6044 | Level of Testosterone in Pedophiles | 2019-11-12 | ||
| 6045 | Behavioural Changes and Eye Movements of Pedophiles | 2019-11-12 | ||
| 6046 | Mental Illness of Pedophiles | 2019-11-12 | ||
| 6047 | Pedophilia-A Psychiatric Disorder | 2019-11-12 | ||
| 6048 | Groups, Modeling & Drug Administration | 2019-11-11 | ||
| 6049 | Common Drug Carriers used in Breast Cancer | 2019-11-11 | ||
| 6050 | Therapeutics Strategies Based on Telomeres and Telomerase | 2019-11-11 | ||
| 6051 | Role of Telomeres and Telomerase in Colorectal Cancer | 2019-11-11 | ||
| 6052 | Telomere Length in Multistep Carcinogenesis | 2019-11-11 | ||
| 6053 | Telomere Homeostasis and Cancer | 2019-11-11 | ||
| 6054 | Mechanisms of Cellular Senescence Induction and Their Connection with Cancer Biology | 2019-11-11 | ||
| 6055 | Structure and Function | 2019-11-11 | ||
| 6056 | Anti-inflammatory Effects of 4-HR | 2019-11-11 | ||
| 6057 | 4-Hexylresorcinol as a Non-Enzymatic Glycosylation Inhibitor | 2019-11-11 | ||
| 6058 | 4-Hexylresorcinol as Antioxidant | 2019-11-11 | ||
| 6059 | 4-Hexylresorcinol as Melanogenic Inhibitor | 2019-11-11 | ||
| 6060 | What is 4-hexylresorcinol? | 2019-11-11 | ||
| 6061 | Recombinant Antibodies | 2019-11-11 | ||
| 6062 | High Mobility Group | 2019-11-11 | ||
| 6063 | Hair Pin Formation | 2019-11-11 | ||
| 6064 | Non-Homologous End Joining | 2019-11-11 | ||
| 6065 | Limitation | 2019-11-09 | ||
| 6066 | VR and Pregnancy | 2019-11-09 | ||
| 6067 | Interactions between climate and Land-use | 2019-11-08 | ||
| 6068 | Climate and Growth | 2019-11-08 | ||
| 6069 | Assay Procedures of ELISA | 2019-11-06 | ||
| 6070 | Description | 2019-11-06 | ||
| 6071 | Complications and Adverse Events | 2019-11-06 | ||
| 6072 | Post-Operative Medication Reduction and IOP Reduction | 2019-11-06 | ||
| 6073 | Success Rates | 2019-11-06 | ||
| 6074 | Lessons Learned | 2019-11-06 | ||
| 6075 | Reasons for Case Selection | 2019-11-06 | ||
| 6076 | Theoretical Background and Literature Review | 2019-11-06 | ||
| 6077 | Surgical Procedure | 2019-11-04 | ||
| 6078 | Statistical Analysis | 2019-11-04 | ||
| 6079 | Review | 2019-11-04 | ||
| 6080 | Limitations and directions for Future research | 2019-11-04 | ||
| 6081 | Results of Factor Analysis and Regression | 2019-11-04 | ||
| 6082 | Recommendations and Contribution to Knowledge | 2019-11-04 | ||
| 6083 | Data Analysis, Results and Discussions | 2019-11-04 | ||
| 6084 | Literature and Hypothesis Development | 2019-11-04 | ||
| 6085 | Limitations of the Study and Direction for Future Research | 2019-11-04 | ||
| 6086 | Conclusions and Policy Implications | 2019-11-04 | ||
| 6087 | Empirical Studies and Hypothesis of the Study | 2019-11-04 | ||
| 6088 | Analysis of Empirical Results | 2019-11-04 | ||
| 6089 | Research Context | 2019-11-04 | ||
| 6090 | Empirical Analysis | 2019-11-04 | ||
| 6091 | Background/Significance | 2019-11-04 | ||
| 6092 | Author’s Contributions | 2019-11-02 | ||
| 6093 | Author’s Contributions | 2019-11-02 | ||
| 6094 | Strengths and limitation of the Study | 2019-11-02 | ||
| 6095 | Factors associated with birth Outcomes among postnatal mothers With diabetes delivered at mkh Hospital | 2019-11-02 | ||
| 6096 | Fetal Outcome | 2019-11-02 | ||
| 6097 | Purpose | 2019-11-01 | ||
| 6098 | Fracture Mode Assessment | 2019-11-01 | ||
| 6099 | Management of Oroantral Fistula | 2019-11-01 | ||
| 6100 | Future Perspective | 2019-10-31 | ||
| 6101 | Applications of the I-Screen | 2019-10-31 | ||
| 6102 | Characteristics of the I-Screen | 2019-10-31 | ||
| 6103 | Study Methods | 2019-10-30 | ||
| 6104 | Treatment Options | 2019-10-30 | ||
| 6105 | Sampling | 2019-10-30 | ||
| 6106 | The Process of Regulation | 2019-10-30 | ||
| 6107 | The Historical Context | 2019-10-30 | ||
| 6108 | Ethical And Professional Considerations | 2019-10-30 | ||
| 6109 | Data Collection and Statistics | 2019-10-30 | ||
| 6110 | Nurses' Professional Needs | 2019-10-30 | ||
| 6111 | The Perceived Ambiguity of Nurses’ Roles | 2019-10-30 | ||
| 6112 | The Perceived Ambiguity of Nurses’ Roles | 2019-10-30 | ||
| 6113 | The Role of Nurses: Nurses' Perceptions | 2019-10-30 | ||
| 6114 | Quality of Nursing Care for Diabetes Patients In Kuwait | 2019-10-30 | ||
| 6115 | Nurses' knowledge and Skills in Diabetes Care in Kuwait | 2019-10-30 | ||
| 6116 | Conclusion and Suggestion | 2019-10-29 | ||
| 6117 | Analysis and Results | 2019-10-29 | ||
| 6118 | On-the-Spot Customer Complaints Feedback | 2019-10-29 | ||
| 6119 | Enhanced Future Service | 2019-10-29 | ||
| 6120 | Tipping | 2019-10-29 | ||
| 6121 | Quality Control | 2019-10-29 | ||
| 6122 | Computational Model | 2019-10-29 | ||
| 6123 | Drift Flux Theory | 2019-10-29 | ||
| 6124 | Flow Patterns | 2019-10-29 | ||
| 6125 | Theoretical Framework | 2019-10-29 | ||
| 6126 | Limitations and Suggestions | 2019-10-29 | ||
| 6127 | Research Method | 2019-10-28 | ||
| 6128 | Major Hypothesis of Fear of Crime | 2019-10-28 | ||
| 6129 | Factors Affecting Fear of Crime | 2019-10-28 | ||
| 6130 | Relevant Literature Linking Fear of Crime | 2019-10-28 | ||
| 6131 | Empirical Background | 2019-10-28 | ||
| 6132 | Scope | 2019-10-28 | ||
| 6133 | Theoretical Justification | 2019-10-28 | ||
| 6134 | Pottery-Making Craftmanship and Economic Empowerment | 2019-10-28 | ||
| 6135 | Public Communication and Investigation | 2019-10-28 | ||
| 6136 | What is Criminological Communication? | 2019-10-28 | ||
| 6137 | “Pathologies” in the Human and digital Communication | 2019-10-28 | ||
| 6138 | Media and Global Information | 2019-10-28 | ||
| 6139 | Intervention Design | 2019-10-28 | ||
| 6140 | Expository Profiles of Educated and Employed Youth Who Joined Anti-India Militant Organization | 2019-10-28 | ||
| 6141 | Bioactive Components in Peanuts | 2019-10-26 | ||
| 6142 | Health Benefits of Peanuts | 2019-10-26 | ||
| 6143 | Peanut as a Functional Food | 2019-10-26 | ||
| 6144 | Histopathological Results | 2019-10-26 | ||
| 6145 | Histological Examination | 2019-10-26 | ||
| 6146 | Material and Methodology | 2019-10-26 | ||
| 6147 | Aim and Objectives of the Study | 2019-10-24 | ||
| 6148 | Suggestions and Countermeasures | 2019-10-23 | ||
| 6149 | Acknowledgment/Funding Sources | 2019-10-23 | ||
| 6150 | Funding/Acknowledgments | 2019-10-23 | ||
| 6151 | Conceptual Framework | 2019-10-22 | ||
| 6152 | Objective of the Study | 2019-10-22 | ||
| 6153 | Observation And Results | 2019-10-22 | ||
| 6154 | Aim and Objective | 2019-10-22 | ||
| 6155 | Assessment | 2019-10-22 | ||
| 6156 | Advantages and Limitations with Using NHPS in Research | 2019-10-22 | ||
| 6157 | Streptozocin-Induced Diabetes In Nhps | 2019-10-22 | ||
| 6158 | Spontaneously Developed Diabetes In Nhps | 2019-10-22 | ||
| 6159 | Different Scaffolds for Targeting Denv Proteins | 2019-10-21 | ||
| 6160 | Composition of Denv | 2019-10-21 | ||
| 6161 | Conclusion and Future Perspectives | 2019-10-21 | ||
| 6162 | Limitations and Future Research | 2019-10-18 | ||
| 6163 | Pilot Study | 2019-10-15 | ||
| 6164 | Pragmatic Judgment Subtests | 2019-10-15 | ||
| 6165 | The Clinical Assessment Of Pragmatics(Caps) | 2019-10-15 | ||
| 6166 | Six Distinct Pragmatic Language Constructs | 2019-10-15 | ||
| 6167 | Determinants of RTCs | 2019-10-14 | ||
| 6168 | Strengths | 2019-10-14 | ||
| 6169 | Procedures | 2019-10-14 | ||
| 6170 | Materials | 2019-10-14 | ||
| 6171 | Nonverbal Language Interventions | 2019-10-14 | ||
| 6172 | Non-Verbal Language | 2019-10-14 | ||
| 6173 | Commonly Occuring Viral Diseases | 2019-10-11 | ||
| 6174 | ED Treatments | 2019-10-07 | ||
| 6175 | OSA Treatment | 2019-10-07 | ||
| 6176 | Association of OSA and ED | 2019-10-07 | ||
| 6177 | Data Collection | 2019-10-07 | ||
| 6178 | Polysomnography | 2019-10-07 | ||
| 6179 | Method and Description of Sample Population | 2019-10-07 | ||
| 6180 | Consent to Participate | 2019-10-07 | ||
| 6181 | Objectives and Methodology | 2019-10-07 | ||
| 6182 | Dosage form Performance | 2019-10-07 | ||
| 6183 | Pharmacokinetics Proprieties | 2019-10-07 | ||
| 6184 | Chemical Properties | 2019-10-07 | ||
| 6185 | Therapeutic Indication | 2019-10-07 | ||
| 6186 | General Characteristics | 2019-10-07 | ||
| 6187 | Glossary of Terms | 2019-10-07 | ||
| 6188 | General Approaches to Establish Bioequivalence | 2019-10-07 | ||
| 6189 | Molecular Data Analysis | 2019-10-07 | ||
| 6190 | Research Aim and Objectives | 2019-10-04 | ||
| 6191 | Data Analysis Results | 2019-10-04 | ||
| 6192 | Disclosures | 2019-10-04 | ||
| 6193 | Statement of Ethics | 2019-10-04 | ||
| 6194 | Histogram Equalization | 2019-10-04 | ||
| 6195 | Percentiles of Pregnancy Outcomes with Maternal Age | 2019-10-04 | ||
| 6196 | Adaptive Immune Response | 2019-10-01 | ||
| 6197 | Innate Immune Response | 2019-10-01 | ||
| 6198 | Immune Response | 2019-10-01 | ||
| 6199 | Suggestions and counter measures | 2019-10-01 | ||
| 6200 | Acknowledegements | 2019-09-28 | ||
| 6201 | Competing Financial Interest | 2019-09-28 | ||
| 6202 | Roles and Responsibilities of the Advanced Practice Nurse | 2019-09-27 | ||
| 6203 | Bioethical Principles | 2019-09-27 | ||
| 6204 | Analysis | 2019-09-27 | ||
| 6205 | Current Issues & Future trends | 2019-09-27 | ||
| 6206 | Health System Transformation | 2019-09-27 | ||
| 6207 | National Health Stack | 2019-09-27 | ||
| 6208 | The National Health Resource Repositor | 2019-09-27 | ||
| 6209 | Financing NHPS | 2019-09-27 | ||
| 6210 | Factors Necessitating Health Reform | 2019-09-27 | ||
| 6211 | Others | 2019-09-27 | ||
| 6212 | Enhancing the Capacity of Metabolite Transport Processes and Carbon Utilization | 2019-09-27 | ||
| 6213 | Enhancing Enzyme Activity of Calvin Cycle | 2019-09-27 | ||
| 6214 | Enhancing Rate of Chloroplast Electron Transport | 2019-09-27 | ||
| 6215 | Enhancing CO2 Levels Around Rubisco to Maximize Catalytic Rate and Minimize Photorespiration | 2019-09-27 | ||
| 6216 | Enhancing CO2 Levels Around Rubisco to Maximize Catalytic Rate and Minimize Photorespiration | 2019-09-27 | ||
| 6217 | Increasing the Thermotolerance of Rubisco Activase to Sustain Rubisco Activity under High Temperatures | 2019-09-27 | ||
| 6218 | Improving the Rubisco Performance via Quality Control and/or Quantity Control | 2019-09-27 | ||
| 6219 | Conclusions and Future Perspectives | 2019-09-27 | ||
| 6220 | Hormone Interactions During Nodule Development | 2019-09-27 | ||
| 6221 | Hormones and Autoregulation of Nodulation | 2019-09-27 | ||
| 6222 | Regulation of Cortex Responses and Primordium Formation | 2019-09-27 | ||
| 6223 | Regulation of Cortex Responses and Primordium Formation | 2019-09-27 | ||
| 6224 | Hormone Regulation of Root Hair and Epidermal Responses | 2019-09-27 | ||
| 6225 | Concluding Remarks | 2019-09-26 | ||
| 6226 | Physiological Roles of Oxylipins Produced via the HPL Branch | 2019-09-26 | ||
| 6227 | Endocellular Localisation of HPLs | 2019-09-26 | ||
| 6228 | Plant HPLs are Involved in Stress Induced Biosynthesis of Volatile Aldehydes | 2019-09-26 | ||
| 6229 | The CYP74 Cytochrome P450 Family | 2019-09-26 | ||
| 6230 | Supporting Information | 2019-09-26 | ||
| 6231 | Conclusion and Further Research | 2019-09-25 | ||
| 6232 | Methods of Treating Chronic Pain | 2019-09-25 | ||
| 6233 | Economic Impact of Pain | 2019-09-25 | ||
| 6234 | Way Forward | 2019-09-23 | ||
| 6235 | Design Optimization | 2019-09-23 | ||
| 6236 | Silicon Mechanical Properties | 2019-09-23 | ||
| 6237 | Structural Design | 2019-09-23 | ||
| 6238 | Model Validation and Numerical Results | 2019-09-23 | ||
| 6239 | Mathematical Modelling | 2019-09-23 | ||
| 6240 | FEM Simulation | 2019-09-23 | ||
| 6241 | Methodology and Experiment | 2019-09-23 | ||
| 6242 | Recomendations | 2019-09-20 | ||
| 6243 | Consequence | 2019-09-20 | ||
| 6244 | Opposing Point | 2019-09-20 | ||
| 6245 | Thermodynamic Analysis of Test Cases | 2019-09-20 | ||
| 6246 | Silver Oxygen Desorption Experiments | 2019-09-20 | ||
| 6247 | Silver Aerosolization Experiments | 2019-09-20 | ||
| 6248 | LMMHD Cycle | 2019-09-20 | ||
| 6249 | Ethics approval and consent to Participate | 2019-09-19 | ||
| 6250 | Acknowledgment | 2019-09-19 | ||
| 6251 | Patents | 2019-09-19 | ||
| 6252 | EBC pH as a Biomarker of Clinical Conditions | 2019-09-19 | ||
| 6253 | Physiological Ph of EBC | 2019-09-19 | ||
| 6254 | Sample Issues | 2019-09-19 | ||
| 6255 | Meta-Analysis | 2019-09-19 | ||
| 6256 | Discussion and Conclusions | 2019-09-19 | ||
| 6257 | Effect of NPs on the carbon particle clearance of mice | 2019-09-19 | ||
| 6258 | GAP ON LAW | 2019-09-19 | ||
| 6259 | Lack of Awareness | 2019-09-19 | ||
| 6260 | Causes for the Destruction | 2019-09-19 | ||
| 6261 | The Current Situation of Archives | 2019-09-19 | ||
| 6262 | Discussion of Findings | 2019-09-18 | ||
| 6263 | Research Methods and Materials | 2019-09-18 | ||
| 6264 | Summary and Concluding Remarks | 2019-09-18 | ||
| 6265 | The Results and Findings | 2019-09-18 | ||
| 6266 | Experimental Section | 2019-09-16 | ||
| 6267 | Pathophysiology | 2019-09-16 | ||
| 6268 | The Aim of the Work | 2019-09-14 | ||
| 6269 | Overview of Pocket Parks | 2019-09-14 | ||
| 6270 | Measures | 2019-09-12 | ||
| 6271 | Availability of Data and Materials Section | 2019-09-12 | ||
| 6272 | Clinical Observation | 2019-09-11 | ||
| 6273 | Study Design | 2019-09-10 | ||
| 6274 | Introduction And Objectives | 2019-09-10 | ||
| 6275 | Clinical Studies | 2019-09-10 | ||
| 6276 | Transparency | 2019-09-10 | ||
| 6277 | Emulsion Characterization And Stability Tests | 2019-09-10 | ||
| 6278 | Study Aim | 2019-09-10 | ||
| 6279 | Complications | 2019-09-09 | ||
| 6280 | Conservative Management and its limitation- Page Kidney | 2019-09-09 | ||
| 6281 | Management According to Grade of Renal Injury | 2019-09-09 | ||
| 6282 | Case 2 | 2019-09-09 | ||
| 6283 | Case 1 | 2019-09-09 | ||
| 6284 | Grant | 2019-09-09 | ||
| 6285 | Method for Literature Review | 2019-09-07 | ||
| 6286 | Discussion about Diagnostic Methods | 2019-09-07 | ||
| 6287 | Calculation of the Mooring Force | 2019-09-06 | ||
| 6288 | Calculation of the Wave Load and Motion Response | 2019-09-06 | ||
| 6289 | Basic Theory | 2019-09-06 | ||
| 6290 | Experimental Methodology | 2019-09-06 | ||
| 6291 | Materials and Methodology | 2019-09-06 | ||
| 6292 | Methods of Preparation | 2019-09-06 | ||
| 6293 | Process Management and Change Management in the Organization | 2019-09-05 | ||
| 6294 | Process Management and Change Management in the Organization | 2019-09-05 | ||
| 6295 | Organization's Ability to Change | 2019-09-05 | ||
| 6296 | The Role of Manager in Counteracting Crisis Phenomena | 2019-09-05 | ||
| 6297 | The Reasons for the Crisis in the Enterprise | 2019-09-05 | ||
| 6298 | Crisis Management and Risk Management Process in the Enterprise | 2019-09-05 | ||
| 6299 | Literature Review | 2019-09-05 | ||
| 6300 | Future Perspectives | 2019-09-05 | ||
| 6301 | Geographic Distribution | 2019-09-05 | ||
| 6302 | When Analysis Can Be Useful | 2019-09-05 | ||
| 6303 | What Cell To Examine | 2019-09-05 | ||
| 6304 | Why Membrane Phospholipids | 2019-09-05 | ||
| 6305 | Eligibility | 2019-09-03 | ||
| 6306 | Data Management | 2019-09-03 | ||
| 6307 | Data Collection Methods | 2019-09-03 | ||
| 6308 | Measurement of Variables | 2019-09-03 | ||
| 6309 | Opinion | 2019-09-03 | ||
| 6310 | Methods and Material | 2019-09-03 | ||
| 6311 | Acronyms and Abbreviations | 2019-09-03 | ||
| 6312 | Conclusions: Implications for Policy and Law Reform | 2019-09-03 | ||
| 6313 | Sexual and Stress Immunisation Protocols | 2019-09-03 | ||
| 6314 | Relapse-Prevention Innovation and Guided Stimulant Use | 2019-09-03 | ||
| 6315 | The Fortified-Cognition Hypothesis and Psychopharmacological Treatment Potential Of Methamphetamine | 2019-09-03 | ||
| 6316 | Evaluation of Immunohistochemically Stained Tissue Sections (Α-Smooth Muscle Actin) | 2019-09-03 | ||
| 6317 | Evaluation of Immunohistochemically Stained Tissue Sections (Α-Smooth Muscle Actin) | 2019-09-03 | ||
| 6318 | Procedure for Immunohistochemical Staining using Α- Smooth Muscle Actin | 2019-09-03 | ||
| 6319 | Disclamier | 2019-09-03 | ||
| 6320 | Research Methods | 2019-08-29 | ||
| 6321 | Discussion | 2019-08-28 | ||
| 6322 | Data Presentation and Analysis | 2019-08-28 | ||
| 6323 | Background of the Study | 2019-08-28 | ||
| 6324 | Outcomes/Recommendations | 2019-08-28 | ||
| 6325 | Authorship | 2019-08-28 | ||
| 6326 | Future Directions/Follow-Up | 2019-08-28 | ||
| 6327 | Due To This Discrepancy A Bioavailability Problem Is To Be Considered | 2019-08-28 | ||
| 6328 | Physiochemical Data and Calculations | 2019-08-28 | ||
| 6329 | Clinical Pharmaceutics Issues | 2019-08-28 | ||
| 6330 | Additional Details | 2019-08-28 | ||
| 6331 | Description Of The Problem | 2019-08-28 | ||
| 6332 | FT–IR analysis of Alternanthera sessilis (Linn) | 2019-08-26 | ||
| 6333 | GC-MS Analysis of Alternanthera sessilis (Linn) | 2019-08-26 | ||
| 6334 | Cytotoxic Study of Alternanthera sessilis (Linn) Leaf and Stem Extracts on Corneal Cell Line (SIRC) Proliferation | 2019-08-26 | ||
| 6335 | Antibacterial Activities of Alternanthera sessilis (Linn) Leaf and Stem Extract | 2019-08-26 | ||
| 6336 | Ferric Reducing Ability (FRAP) Test | 2019-08-26 | ||
| 6337 | Antioxidant activities | 2019-08-26 | ||
| 6338 | Effect of Alternanthera sessilis (Linn) Aqueous Extracts on Corneal Cell (SIRC) Proliferation | 2019-08-26 | ||
| 6339 | Antibacterial Activity | 2019-08-26 | ||
| 6340 | Antioxidant Activity | 2019-08-26 | ||
| 6341 | Mechanism of Pain Generation | 2019-08-24 | ||
| 6342 | Diagnosis and Imaging | 2019-08-24 | ||
| 6343 | Epidemiology | 2019-08-24 | ||
| 6344 | Anatomical Changes and Pathology | 2019-08-24 | ||
| 6345 | Prognosis of MD and Conclusion | 2019-08-24 | ||
| 6346 | Treatment and Management of MD | 2019-08-24 | ||
| 6347 | Pathophysiology of MD | 2019-08-24 | ||
| 6348 | Clinical Signs and Symptoms of MD | 2019-08-24 | ||
| 6349 | Risk Factors of MD | 2019-08-24 | ||
| 6350 | Duchenne MD | 2019-08-24 | ||
| 6351 | Facioscapulohumeral MD (FSHD) | 2019-08-24 | ||
| 6352 | Genetic Predisposition and Variation in MD | 2019-08-24 | ||
| 6353 | Complication of MD | 2019-08-24 | ||
| 6354 | Emery-dreifuss MD | 2019-08-24 | ||
| 6355 | Different Types of MD | 2019-08-24 | ||
| 6356 | Incidence and Prevalence of MD Worldwide | 2019-08-24 | ||
| 6357 | Bone Reconstruction | 2019-08-24 | ||
| 6358 | Wound Coverage | 2019-08-24 | ||
| 6359 | Internal Fixation | 2019-08-24 | ||
| 6360 | Temporary Skeletal Stabilization | 2019-08-24 | ||
| 6361 | Acute Compartment Syndrome | 2019-08-24 | ||
| 6362 | Bone and Soft Tissue Debridement | 2019-08-24 | ||
| 6363 | Evaluation of Vascular Injury | 2019-08-24 | ||
| 6364 | Antibiotherapy | 2019-08-24 | ||
| 6365 | Scores | 2019-08-24 | ||
| 6366 | Open Fracture Classification | 2019-08-24 | ||
| 6367 | Algorithm and Initial Evaluation | 2019-08-24 | ||
| 6368 | Epidemiology and Etiology | 2019-08-24 | ||
| 6369 | History | 2019-08-24 | ||
| 6370 | Findings and Conclusion | 2019-08-23 | ||
| 6371 | Palliative Therapy | 2019-08-23 | ||
| 6372 | Forecast | 2019-08-23 | ||
| 6373 | Data/Data Analysis | 2019-08-23 | ||
| 6374 | Experiment Session | 2019-08-23 | ||
| 6375 | Study Objectives | 2019-08-23 | ||
| 6376 | Participants | 2019-08-23 | ||
| 6377 | Preliminary Study | 2019-08-23 | ||
| 6378 | Right-to-Live (RtL) Autism Centre | 2019-08-23 | ||
| 6379 | Findings and Discussions | 2019-08-22 | ||
| 6380 | Seasonal Outlook | 2019-08-22 | ||
| 6381 | Rainfall Season Characteristics | 2019-08-22 | ||
| 6382 | Mean Monthly Rainfall | 2019-08-22 | ||
| 6383 | Boundary Conditions and Inputs | 2019-08-22 | ||
| 6384 | CFD Modelling and Meshing | 2019-08-22 | ||
| 6385 | Problem Definition | 2019-08-22 | ||
| 6386 | Objective | 2019-08-22 | ||
| 6387 | Location of the Municipalities of Rio Branco do Ivaí and Rosario do Ivai | 2019-08-22 | ||
| 6388 | Tornadoes | 2019-08-22 | ||
| 6389 | Data Base and Methodology | 2019-08-22 | ||
| 6390 | Study Area | 2019-08-22 | ||
| 6391 | Quality Assurance, Certification and Standardisation | 2019-08-22 | ||
| 6392 | Rapid Tooling and Repairing | 2019-08-22 | ||
| 6393 | Critical Attributes and Significant Applications of AM in the Aircraft Industry | 2019-08-22 | ||
| 6394 | Melanin and Synthesis of Vitamin D3 | 2019-08-21 | ||
| 6395 | Determination of curcumin content in turmeric extracts | 2019-08-20 | ||
| 6396 | Biomarkers for Tailored Probiotics | 2019-08-20 | ||
| 6397 | Dietary Globalization | 2019-08-20 | ||
| 6398 | Factors Determine Probiotic Effects | 2019-08-20 | ||
| 6399 | Microorganisms Activity in Food and its Impact on Human Beings | 2019-08-20 | ||
| 6400 | Nutrifortified Diets and Preparations | 2019-08-20 | ||
| 6401 | Future Research Work Recommendation | 2019-08-20 | ||
| 6402 | Experimental | 2019-08-20 | ||
| 6403 | The Potential of Membrane Application | 2019-08-20 | ||
| 6404 | Membrane Separation | 2019-08-20 | ||
| 6405 | Metals Impurities | 2019-08-20 | ||
| 6406 | The Problem of Thickening and Hydration | 2019-08-20 | ||
| 6407 | Coalescence | 2019-08-20 | ||
| 6408 | Oswald Ripening | 2019-08-20 | ||
| 6409 | Flocculation | 2019-08-20 | ||
| 6410 | Creaming and Sedimentation | 2019-08-20 | ||
| 6411 | Emulsions Stability | 2019-08-20 | ||
| 6412 | Conflict of Interest Disclosures | 2019-08-16 | ||
| 6413 | Summary of Results | 2019-08-16 | ||
| 6414 | Patient Consent for Publication | 2019-08-16 | ||
| 6415 | Need Assessment and the Socio-Cultural and Technical Feasibility Assessment | 2019-08-16 | ||
| 6416 | Study Location | 2019-08-16 | ||
| 6417 | Sustainable and User-Friendly Aspects of Developing a Mobile Application | 2019-08-16 | ||
| 6418 | Theoretical Background | 2019-08-16 | ||
| 6419 | Information Technological Interventions for Prevention of Dengue in Sri Lanka | 2019-08-16 | ||
| 6420 | Open Source Technology as a Tool in the Field of Public Health Sector | 2019-08-16 | ||
| 6421 | Authors' Information | 2019-08-16 | ||
| 6422 | Patient Presentation | 2019-08-16 | ||
| 6423 | Skin and Synthesis of Vitamin D3 | 2019-08-16 | ||
| 6424 | Melanocytes | 2019-08-16 | ||
| 6425 | Epidermal Cells | 2019-08-16 | ||
| 6426 | Anatomy of Human Skin | 2019-08-16 | ||
| 6427 | Authors’ Competing Interests | 2019-08-14 | ||
| 6428 | Health System Leadership & Governance Situation | 2019-08-14 | ||
| 6429 | Declaration | 2019-08-14 | ||
| 6430 | Ethical Consideration | 2019-08-14 | ||
| 6431 | Quality Assurance | 2019-08-14 | ||
| 6432 | Time Plan for the Study | 2019-08-14 | ||
| 6433 | Data Collection, Management, and Analysis | 2019-08-14 | ||
| 6434 | Study Design and Sampling | 2019-08-14 | ||
| 6435 | The Rationale for the Study | 2019-08-14 | ||
| 6436 | Background of the Country and Sample District | 2019-08-14 | ||
| 6437 | Prevention and Control Strategies | 2019-08-14 | ||
| 6438 | Treatment and Antimicrobial Resistance | 2019-08-14 | ||
| 6439 | Clinical Features | 2019-08-14 | ||
| 6440 | The Status of Foodborne Campylobacter Spp. in Ethiopia | 2019-08-14 | ||
| 6441 | Economic Significance | 2019-08-14 | ||
| 6442 | Public Health Significance | 2019-08-14 | ||
| 6443 | Zoonotic Potential and Sources Of Infection | 2019-08-14 | ||
| 6444 | Host Distribution | 2019-08-14 | ||
| 6445 | Survival and Growth Characteristics | 2019-08-14 | ||
| 6446 | Morphology and Biochemical Properties | 2019-08-14 | ||
| 6447 | Taxonomy | 2019-08-14 | ||
| 6448 | Etiology | 2019-08-14 | ||
| 6449 | Sources of Funding | 2019-08-14 | ||
| 6450 | Possible Risks | 2019-08-14 | ||
| 6451 | Potassium Intake Studies | 2019-08-14 | ||
| 6452 | Adequate Potassium Intake and Its Benefits | 2019-08-14 | ||
| 6453 | Potassium Homeostasis | 2019-08-14 | ||
| 6454 | Review of HBM Constructs | 2019-08-14 | ||
| 6455 | Neurogenic Tumors | 2019-08-14 | ||
| 6456 | Germ Cell Tumors | 2019-08-14 | ||
| 6457 | Clinical And Imaging Findings | 2019-08-14 | ||
| 6458 | Results of the Study | 2019-08-14 | ||
| 6459 | Introduction: Overview of Back Pain | 2019-08-13 | ||
| 6460 | Explaining the Dependent Variable | 2019-08-13 | ||
| 6461 | Discussing the Independent Variables | 2019-08-13 | ||
| 6462 | Aims and Objectives | 2019-08-12 | ||
| 6463 | Summary And Perspective | 2019-08-10 | ||
| 6464 | Technologies For Mapm Fabrication | 2019-08-10 | ||
| 6465 | Mechanism Of The Perm-Selective Separation Of Masms | 2019-08-10 | ||
| 6466 | Results of Digital Human Modelling | 2019-08-02 | ||
| 6467 | Mannequin posture during lifting Weight | 2019-08-02 | ||
| 6468 | Second Line Therapy | 2019-08-02 | ||
| 6469 | First Line Therapy | 2019-08-02 | ||
| 6470 | Experimental and Practical Investigation of the Methodology Accepted | 2019-08-02 | ||
| 6471 | Treatment Options | 2019-08-02 | ||
| 6472 | Current Status of the Problem of Multiple Sclerosis | 2019-08-02 | ||
| 6473 | Interest Conflict | 2019-08-02 | ||
| 6474 | Integrated Pest Management (Ipm) | 2019-08-01 | ||
| 6475 | Sterile Insect Release (Sir) | 2019-08-01 | ||
| 6476 | Sterile Insect Technique (Sit) | 2019-08-01 | ||
| 6477 | Sterile Insect Technique (Sit) | 2019-08-01 | ||
| 6478 | Control and management strategies of sweet potato weevils | 2019-08-01 | ||
| 6479 | Causes of Infestation of Sweet Potato Weevils | 2019-08-01 | ||
| 6480 | Major sweet potato weevils; mode of Infestation | 2019-08-01 | ||
| 6481 | Hemolytic Uremic Syndromes | 2019-08-01 | ||
| 6482 | Case Series | 2019-08-01 | ||
| 6483 | Headform kinematics | 2019-07-29 | ||
| 6484 | Helmets | 2019-07-29 | ||
| 6485 | Storage and Statistical Processing | 2019-07-27 | ||
| 6486 | Ethical Repairs | 2019-07-27 | ||
| 6487 | Source of Support | 2019-07-27 | ||
| 6488 | Cost Comparision | 2019-07-27 | ||
| 6489 | Future Directions | 2019-07-26 | ||
| 6490 | Short Communication | 2019-07-26 | ||
| 6491 | Data Collection Tools | 2019-07-26 | ||
| 6492 | Suggestions For Further Research | 2019-07-26 | ||
| 6493 | Suggestions Based On The Study | 2019-07-26 | ||
| 6494 | Tenability Of Hypotheses | 2019-07-26 | ||
| 6495 | Objective Wise Analysis | 2019-07-26 | ||
| 6496 | Conclusion Based On The Findings Of The Study | 2019-07-26 | ||
| 6497 | Sample | 2019-07-26 | ||
| 6498 | Variables | 2019-07-26 | ||
| 6499 | Discrimination Of The Tool | 2019-07-26 | ||
| 6500 | Tools | 2019-07-26 | ||
| 6501 | Research Design | 2019-07-26 | ||
| 6502 | Hypothesis | 2019-07-26 | ||
| 6503 | Operational Definitions | 2019-07-26 | ||
| 6504 | Justification | 2019-07-26 | ||
| 6505 | Purpose of the Study | 2019-07-26 | ||
| 6506 | Loan And Credits | 2019-07-26 | ||
| 6507 | Barriers To Pulmonary Rehabilitation: Poor Referral And Pr Completion Rates | 2019-07-25 | ||
| 6508 | Literature Search | 2019-07-25 | ||
| 6509 | Low Toxicity Of Functionalized Gd@C82 | 2019-07-24 | ||
| 6510 | Antineoplastic activities of Functionalized Gd@C82 via disrupting Vasculature under radiofrequency | 2019-07-24 | ||
| 6511 | Antineoplastic activities of Functionalized Gd@C82 via inhibiting Angiogenesis | 2019-07-24 | ||
| 6512 | Fullerenes And Metallofullerenes | 2019-07-24 | ||
| 6513 | Research Tasks | 2019-07-24 | ||
| 6514 | Goal of Research | 2019-07-24 | ||
| 6515 | Author's Contributions | 2019-07-24 | ||
| 6516 | Rock Magnetic Results | 2019-07-23 | ||
| 6517 | Sampling and Methods | 2019-07-23 | ||
| 6518 | Literature Review: Characteristics of Dairy Value Chain in Ethiopia | 2019-07-23 | ||
| 6519 | General Conclusions | 2019-07-23 | ||
| 6520 | Afterword | 2019-07-23 | ||
| 6521 | Modified Henderson | 2019-07-23 | ||
| 6522 | DARKNESS INTO LIGHT | 2019-07-23 | ||
| 6523 | Episode 3 of 3 | 2019-07-23 | ||
| 6524 | Episode 2 of 3 | 2019-07-23 | ||
| 6525 | Episode 1 of 3 | 2019-07-23 | ||
| 6526 | Responding Methods | 2019-07-22 | ||
| 6527 | Hardware | 2019-07-22 | ||
| 6528 | Data Recording | 2019-07-22 | ||
| 6529 | Declaration of Patient Consent | 2019-07-20 | ||
| 6530 | Prevention and Control | 2019-07-15 | ||
| 6531 | Antibiotic Resistance | 2019-07-15 | ||
| 6532 | Laboratory Diagnosis | 2019-07-15 | ||
| 6533 | Diseases | 2019-07-15 | ||
| 6534 | Pathogenesis | 2019-07-15 | ||
| 6535 | Transmission | 2019-07-15 | ||
| 6536 | Growth and Biochemical Properties | 2019-07-15 | ||
| 6537 | Epidemiological View of Campylobacter in Pakistan | 2019-07-15 | ||
| 6538 | Review of Literature | 2019-07-15 | ||
| 6539 | Perspective | 2019-07-15 | ||
| 6540 | Authors Contribution | 2019-07-15 | ||
| 6541 | Molecular Characterization of Bacterial Isolates | 2019-07-15 | ||
| 6542 | Animal Based Fats | 2019-07-15 | ||
| 6543 | Pathogens of Concern | 2019-07-15 | ||
| 6544 | Undersea Acoustic Sensing | 2019-07-15 | ||
| 6545 | Sound Speed Profiles | 2019-07-15 | ||
| 6546 | Experiment | 2019-07-15 | ||
| 6547 | Description Of Aquaqaud | 2019-07-15 | ||
| 6548 | Future Research | 2019-07-08 | ||
| 6549 | Mathematical Modeling | 2019-07-08 | ||
| 6550 | Study Tasks and Justification | 2019-07-08 | ||
| 6551 | Theoretical Research | 2019-07-08 | ||
| 6552 | Management | 2019-07-06 | ||
| 6553 | Statistical Analysis And Results | 2019-07-03 | ||
| 6554 | Clinical Implications | 2019-07-03 | ||
| 6555 | Ethics Statement | 2019-07-01 | ||
| 6556 | Ethical Approval and Consent to Participate | 2019-07-01 | ||
| 6557 | Limitation of the Study | 2019-07-01 | ||
| 6558 | Strength of the Study | 2019-07-01 | ||
| 6559 | Contributors Statement Page | 2019-06-29 | ||
| 6560 | Clinical trial registration | 2019-06-29 | ||
| 6561 | Funding Source | 2019-06-29 | ||
| 6562 | Implementation | 2019-06-29 | ||
| 6563 | Neutralizing Buffered Peptone Water | 2019-06-29 | ||
| 6564 | Sanitizer Carry-Over | 2019-06-29 | ||
| 6565 | Result and Discussion | 2019-06-28 | ||
| 6566 | Definitions | 2019-06-28 | ||
| 6567 | Submitral Aneurysm | 2019-06-28 | ||
| 6568 | Treatment | 2019-06-28 | ||
| 6569 | Diagnosis | 2019-06-28 | ||
| 6570 | Microbiological Profile and Modified Duke’s Criteria | 2019-06-28 | ||
| 6571 | Infective Endocarditis | 2019-06-28 | ||
| 6572 | Procedure | 2019-06-28 | ||
| 6573 | Case Description | 2019-06-28 | ||
| 6574 | Experimental Design | 2019-06-27 | ||
| 6575 | The Complex and Amazing Interpretation of Nature | 2019-06-27 | ||
| 6576 | Symphonic Poem of 100 Metronomes and the Experimental Model | 2019-06-27 | ||
| 6577 | Results of Experimental Assays | 2019-06-27 | ||
| 6578 | Competing Interest | 2019-06-27 | ||
| 6579 | Authors’ Contribution | 2019-06-27 | ||
| 6580 | Component of Snake Venom (Bj46a) and Mmps | 2019-06-27 | ||
| 6581 | OMEGA-3 FATTY ACIDS AND MMPs | 2019-06-27 | ||
| 6582 | The Dependence between the Stress and MMPs | 2019-06-27 | ||
| 6583 | The Relation between Caffeine and MMPs | 2019-06-27 | ||
| 6584 | The Relation between Melatonin and MMPs Enzyme | 2019-06-27 | ||
| 6585 | The Role of Vitamin C and E in MMPs Inactivity | 2019-06-27 | ||
| 6586 | Correlations | 2019-06-18 | ||
| 6587 | Possible Consequences | 2019-06-18 | ||
| 6588 | Counter Arguments | 2019-06-18 | ||
| 6589 | My Position | 2019-06-18 | ||
| 6590 | Analysis of the Issue in Pakistani Context | 2019-06-18 | ||
| 6591 | Scenario | 2019-06-18 | ||
| 6592 | Method of the Study | 2019-06-18 | ||
| 6593 | Conservative Management | 2019-06-17 | ||
| 6594 | Operative Considerations | 2019-06-17 | ||
| 6595 | Timing of Delivery | 2019-06-17 | ||
| 6596 | Preoperative Planning | 2019-06-17 | ||
| 6597 | Significance | 2019-06-17 | ||
| 6598 | Ethical Statement | 2019-06-17 | ||
| 6599 | Humanization as A Possible Solution to Overcoming the Psychological Vulnerability of A Mother Who Has Given Birth to A Preterm Baby | 2019-06-15 | ||
| 6600 | The Psychological Vulnerability ofA Mother Giving Birth to A Premature Baby | 2019-06-15 | ||
| 6601 | The Psychology of the Child and of the Mother in Preterm Birth | 2019-06-15 | ||
| 6602 | Abbrevations and Acronyms | 2019-06-13 | ||
| 6603 | Problems Facing The American Health Care System | 2019-06-12 | ||
| 6604 | Factors Leading To The Native American Health Disparity | 2019-06-12 | ||
| 6605 | Factors For The African Americans Health Disparity | 2019-06-12 | ||
| 6606 | E-Hiv Disease | 2019-06-12 | ||
| 6607 | Access Inequality To Health Care In The United States | 2019-06-12 | ||
| 6608 | Comparative Analysis of the Australian Health Care System vs. The American Health Care System | 2019-06-12 | ||
| 6609 | The United States of America | 2019-06-12 | ||
| 6610 | Health Services Delivery In Australia | 2019-06-12 | ||
| 6611 | Funding The Australian Health Care System | 2019-06-12 | ||
| 6612 | Results and Analysis | 2019-06-11 | ||
| 6613 | Method Validation | 2019-06-10 | ||
| 6614 | Validation of Proposed Method | 2019-06-10 | ||
| 6615 | SOURCE(S) OF SUPPORT | 2019-06-10 | ||
| 6616 | Reforms In Health Sector Include | 2019-06-10 | ||
| 6617 | Possible Solutions And Its Benefit | 2019-06-10 | ||
| 6618 | Challenges For Health Ministry On Provincial Level Post 18th Amendment | 2019-06-10 | ||
| 6619 | Health System Information, Communication & Technology Situation | 2019-06-10 | ||
| 6620 | Health System Medical Products & Technologies Situation | 2019-06-10 | ||
| 6621 | Health System Human Resource Situation | 2019-06-10 | ||
| 6622 | Health System Finance And Expenditure Situation | 2019-06-10 | ||
| 6623 | Health Care Service Delivery Situation | 2019-06-10 | ||
| 6624 | Health System Leadership & Governance Situation | 2019-06-10 | ||
| 6625 | Health Situation Post 18 Amendment | 2019-06-10 | ||
| 6626 | The Road Ahead | 2019-06-10 | ||
| 6627 | The Current Scenario | 2019-06-10 | ||
| 6628 | Treatment Of Neurodegenerative Disease Through Diet | 2019-06-08 | ||
| 6629 | Epigenetic Biomarker In Neurodegenerative Disease | 2019-06-08 | ||
| 6630 | Epigenetics Biomarker In Huntington's Disease | 2019-06-08 | ||
| 6631 | Epigenetic Biomarker In Parkinson’s Disease | 2019-06-08 | ||
| 6632 | Epigenetic Biomarker In Alzheimer Disease | 2019-06-08 | ||
| 6633 | Epigenetic Mechanism | 2019-06-08 | ||
| 6634 | Declaration of Interest | 2019-06-07 | ||
| 6635 | Limitations and Strengths of the Study | 2019-06-07 | ||
| 6636 | Abbreviations and Acronyms | 2019-06-07 | ||
| 6637 | Recommendations and Suggestions | 2019-06-07 | ||
| 6638 | Summary of Findings | 2019-06-07 | ||
| 6639 | E-Tailers in Indian Market | 2019-06-07 | ||
| 6640 | Author’s Contributions | 2019-06-07 | ||
| 6641 | Author’s Contributions | 2019-06-07 | ||
| 6642 | Author’s Contributions | 2019-06-07 | ||
| 6643 | Availability Of Data And Material | 2019-06-07 | ||
| 6644 | Declarations | 2019-06-07 | ||
| 6645 | Factors Associated With Fertility Intention | 2019-06-07 | ||
| 6646 | List of Abbreviations | 2019-06-06 | ||
| 6647 | Post Aruna Ramchandra Shanbaug Judgment | 2019-06-06 | ||
| 6648 | Indian Scenario Pre Aruna Ramchandra Shanbaug Judgment | 2019-06-06 | ||
| 6649 | Dutch Law On Euthanasia | 2019-06-06 | ||
| 6650 | Ethics Approval and Consent-to-Participate | 2019-06-06 | ||
| 6651 | Growth Conditions and Media Standardizations | 2019-06-06 | ||
| 6652 | Rational Perturbations of Metabolic Pathways for Yield Enhancement | 2019-06-06 | ||
| 6653 | Enhancing Flux Towards Isoprene | 2019-06-06 | ||
| 6654 | Strategies Based on Plasmids and Chromosomal Integrations | 2019-06-06 | ||
| 6655 | Metabolic Engineering of MVA Pathway | 2019-06-06 | ||
| 6656 | Metabolic Engineering of MEP Pathway | 2019-06-06 | ||
| 6657 | Mechanism of Isoprene Production | 2019-06-06 | ||
| 6658 | Marine-Sourced Steroidal Compounds Having Cytotoxic Activity | 2019-06-06 | ||
| 6659 | Further Work | 2019-06-05 | ||
| 6660 | Implications For Clinical Work | 2019-06-05 | ||
| 6661 | Application Of Conceptual Model On Composite Case Examples | 2019-06-05 | ||
| 6662 | Insecure Attachment Styles’ Resilience Patterns Conceptual Model | 2019-06-05 | ||
| 6663 | Process Capacities | 2019-06-05 | ||
| 6664 | Resilience | 2019-06-05 | ||
| 6665 | Recovery | 2019-06-05 | ||
| 6666 | Attachment Styles | 2019-06-05 | ||
| 6667 | Teachers’ Training Program: Facts and Figures | 2019-06-05 | ||
| 6668 | Analysis of Data | 2019-06-05 | ||
| 6669 | Current Recommendations | 2019-06-03 | ||
| 6670 | Strengths and Weaknesses of the Study | 2019-06-03 | ||
| 6671 | Summary and Future Directions | 2019-06-03 | ||
| 6672 | Pitfalls and Alternative Strategies | 2019-06-03 | ||
| 6673 | Potential Results | 2019-06-03 | ||
| 6674 | Research Design and Methodology | 2019-06-03 | ||
| 6675 | Research Plan | 2019-06-03 | ||
| 6676 | Implications for Clinical Practice | 2019-06-01 | ||
| 6677 | Observation | 2019-06-01 | ||
| 6678 | Highlights | 2019-05-29 | ||
| 6679 | Theory of Transmission of Traditional Cuisine | 2019-05-28 | ||
| 6680 | Festival Tourism | 2019-05-28 | ||
| 6681 | Traditional Cuisine Tourism | 2019-05-28 | ||
| 6682 | Objectives | 2019-05-28 | ||
| 6683 | Core Tip | 2019-05-28 | ||
| 6684 | Conceptual Modeling: Definition, Purpose and Benefits | 2019-05-28 | ||
| 6685 | Operative Report and Post-Operative Course | 2019-05-28 | ||
| 6686 | Pre-Operative Studies | 2019-05-28 | ||
| 6687 | Historical/Cultural Tourism Resources | 2019-05-28 | ||
| 6688 | Potential Nature based Tourism Resources of Elkere District | 2019-05-28 | ||
| 6689 | Tourism Industry in Ethiopia | 2019-05-28 | ||
| 6690 | Literature | 2019-05-28 | ||
| 6691 | No heading | 2019-05-28 | ||
| 6692 | Opinion Article | 2019-05-28 | ||
| 6693 | Human and Animal Rights | 2019-05-24 | ||
| 6694 | Preoperative Imaging and Tumor Staging | 2019-05-24 | ||
| 6695 | Evaluation at Diagnosis | 2019-05-24 | ||
| 6696 | Overview | 2019-05-24 | ||
| 6697 | Safety Requirements | 2019-05-23 | ||
| 6698 | The General Principles | 2019-05-23 | ||
| 6699 | The Technical Safety Standards Of Industrial Robotics | 2019-05-23 | ||
| 6700 | The Eu Regulatory Framework For Robotics Safety | 2019-05-23 | ||
| 6701 | Robotic Technology As A Source Of Risk And Improvement Of Working Conditions | 2019-05-23 | ||
| 6702 | Declaration of Conflicting Interests | 2019-05-20 | ||
| 6703 | Delta Plan 2100 has the following Specific Objectives | 2019-05-20 | ||
| 6704 | Delta Plan 2100 | 2019-05-20 | ||
| 6705 | Ocean Governance Framework | 2019-05-20 | ||
| 6706 | Initiatives of Bangladesh for Coast and Marine Management | 2019-05-20 | ||
| 6707 | Present Status and Future Trend of Coastal Zone Management | 2019-05-20 | ||
| 6708 | Integrated Coastal Zone Management ICZM) Approach | 2019-05-20 | ||
| 6709 | Coastal Hazards in Bangladesh Coast | 2019-05-20 | ||
| 6710 | Coastal Habitat and Biodiversity of Bangladesh | 2019-05-20 | ||
| 6711 | Conclusion and Recommendation | 2019-05-20 | ||
| 6712 | Conclusion and Limitations | 2019-05-17 | ||
| 6713 | A Letter to the Editor | 2019-05-17 | ||
| 6714 | Data Availability | 2019-05-16 | ||
| 6715 | Financial Disclosure | 2019-05-16 | ||
| 6716 | Ethics Committee Approval | 2019-05-16 | ||
| 6717 | Administration of HBO and NBO oxygen therapy | 2019-05-16 | ||
| 6718 | Funding Statement | 2019-05-16 | ||
| 6719 | Data Availability Statement | 2019-05-16 | ||
| 6720 | Referees Comments | 2019-05-16 | ||
| 6721 | Ancel keys and the U.S. government | 2019-05-16 | ||
| 6722 | Insulin Resistance: Down Regulation of Insulin Receptor Sensitivity | 2019-05-16 | ||
| 6723 | Author Contributions | 2019-05-16 | ||
| 6724 | Quantitative Results Findings | 2019-05-16 | ||
| 6725 | Contributors | 2019-05-13 | ||
| 6726 | Author Disclosure Statement | 2019-05-13 | ||
| 6727 | Disclaimer | 2019-05-13 | ||
| 6728 | Source of Funding | 2019-05-04 | ||
| 6729 | Lipid Profile | 2019-05-04 | ||
| 6730 | Future Direction | 2019-05-03 | ||
| 6731 | Hypothetical Integration and Updating | 2019-05-03 | ||
| 6732 | Where does life come from? Insider or Outside | 2019-05-03 | ||
| 6733 | Single Model (RNA World) vs Multitude Model | 2019-05-03 | ||
| 6734 | Physical or Chemical Factor Comparisons | 2019-05-03 | ||
| 6735 | Clinical Case | 2019-05-03 | ||
| 6736 | Research Gaps Identified | 2019-05-03 | ||
| 6737 | The Way Forward | 2019-05-03 | ||
| 6738 | Closeness to the nature | 2019-05-02 | ||
| 6739 | Current State Of The Art Technologies | 2019-05-02 | ||
| 6740 | Therapy | 2019-05-02 | ||
| 6741 | Surgical Planning And Navigation | 2019-05-02 | ||
| 6742 | Training | 2019-05-02 | ||
| 6743 | Medical Applications | 2019-05-02 | ||
| 6744 | Definitions And Brief History | 2019-05-02 | ||
| 6745 | Coming up Short: Linking the Quantitative and Qualitative | 2019-04-30 | ||
| 6746 | A Case in Point: Budding in Hydras | 2019-04-30 | ||
| 6747 | The Problem and Solution | 2019-04-30 | ||
| 6748 | Contributions | 2019-04-26 | ||
| 6749 | Hospital Course | 2019-04-22 | ||
| 6750 | Case | 2019-04-22 | ||
| 6751 | Conflict of Interest and Funding | 2019-04-22 | ||
| 6752 | Retraction Note | 2019-04-20 | ||
| 6753 | Clinical Implication | 2019-04-17 | ||
| 6754 | Experience Post Treatment Completion | 2019-04-17 | ||
| 6755 | First Reaction After Diagnosis | 2019-04-17 | ||
| 6756 | Pre-Diagnosis Stage | 2019-04-17 | ||
| 6757 | Ethics Approval | 2019-04-17 | ||
| 6758 | Authors' Contributions | 2019-04-17 | ||
| 6759 | Transparency Declaration | 2019-04-17 | ||
| 6760 | Availability of Data and Material | 2019-04-17 | ||
| 6761 | Background and Aim | 2019-04-17 | ||
| 6762 | The Exemplary Pilot Study | 2019-04-17 | ||
| 6763 | Experimental Results | 2019-04-16 | ||
| 6764 | Vanadium in Marine Algae | 2019-04-16 | ||
| 6765 | Vanadium in Ascidians | 2019-04-16 | ||
| 6766 | Statistical Analysis | 2019-04-16 | ||
| 6767 | Data Analysis And Interpretation | 2019-04-13 | ||
| 6768 | Services To Be Provided By Udc | 2019-04-13 | ||
| 6769 | Significance Of The Study | 2019-04-13 | ||
| 6770 | Rationale Of The Study | 2019-04-13 | ||
| 6771 | Statement of the Problem | 2019-04-13 | ||
| 6772 | Comparative Evaluation Of The Social Implication Of The Defined Contributory Pension Scheme In Nigeria And Chile | 2019-04-13 | ||
| 6773 | Comparative Evaluation Of The Economic Implication Of The Defined Contributory Scheme In Nigeria And Chile | 2019-04-13 | ||
| 6774 | Implementation Of Defined Contributory Pension Scheme In Nigeria And Chile | 2019-04-13 | ||
| 6775 | jgh | 2019-04-13 | ||
| 6776 | Pros And Cons Of Defined Contributory Pension Scheme | 2019-04-13 | ||
| 6777 | Research Limitations | 2019-04-13 | ||
| 6778 | Discussion and Explanation | 2019-04-13 | ||
| 6779 | Results and Findings | 2019-04-13 | ||
| 6780 | Research Methodology | 2019-04-13 | ||
| 6781 | Hypotheses | 2019-04-13 | ||
| 6782 | Study Procedures | 2019-04-13 | ||
| 6783 | Summary and Conclusion | 2019-04-12 | ||
| 6784 | Conclusion and Recommendations | 2019-04-12 | ||
| 6785 | Glycan Reactions | 2019-04-09 | ||
| 6786 | Author’s Contribution | 2019-04-08 | ||
| 6787 | Funding/Support | 2019-04-08 | ||
| 6788 | Aim | 2019-04-08 | ||
| 6789 | Financial Disclosure Statement | 2019-04-08 | ||
| 6790 | Funding Source | 2019-04-08 | ||
| 6791 | Conflicts of Interest | 2019-04-08 | ||
| 6792 | Acknowledgment | 2019-04-08 | ||
| 6793 | Result | 2019-04-08 | ||
| 6794 | Patients and Methods | 2019-04-08 | ||
| 6795 | Abbreviations | 2019-04-08 | ||
| 6796 | Conflict Interests | 2019-04-08 | ||
| 6797 | Case Reports | 2019-04-05 | ||
| 6798 | Limitations of this Study | 2019-04-05 | ||
| 6799 | Subjects and Methods | 2019-04-05 | ||
| 6800 | Clinical Image | 2019-04-05 | ||
| 6801 | HPV Infections, Immunity and Cancer | 2019-04-05 | ||
| 6802 | The Impact of Human Papilloma Virus in the Upper Aerodigestive Tract | 2019-04-05 | ||
| 6803 | The Role of HPV Seminal Infection | 2019-04-05 | ||
| 6804 | HPV Virion or Virus: Infection or Cancer | 2019-04-05 | ||
| 6805 | Funding Sources | 2019-04-05 | ||
| 6806 | Conflict Of Interest Statement | 2019-04-05 | ||
| 6807 | Human Subjects Approval Statement | 2019-04-05 | ||
| 6808 | Disclosure | 2019-03-27 | ||
| 6809 | Nanocellulose | 2019-03-27 | ||
| 6810 | Cellulose | 2019-03-27 | ||
| 6811 | Conclusions and Recommendations | 2019-03-26 | ||
| 6812 | Discussions | 2019-03-26 | ||
| 6813 | Level of Vitamin D in our Body, Effects of Vitamin D and Requirement of Vitamin D in our Body | 2019-03-25 | ||
| 6814 | Sources of Vitamin D | 2019-03-25 | ||
| 6815 | Introduction about Vitamin D | 2019-03-25 | ||
| 6816 | Constraint | 2019-03-25 | ||
| 6817 | Key Points | 2019-03-25 | ||
| 6818 | Review of Literature | 2019-03-25 | ||
| 6819 | Discussions and Implications | 2019-03-25 | ||
| 6820 | Literature Review | 2019-03-25 | ||
| 6821 | Boosting Tourism Development in Meghalaya-Challenges and Prospects | 2019-03-25 | ||
| 6822 | Trend of Tourist Inflow in Meghalaya | 2019-03-25 | ||
| 6823 | Scope of Tourism in Meghalaya | 2019-03-25 | ||
| 6824 | Discussion of Results and Policy Implications | 2019-03-25 | ||
| 6825 | Data Analysis and Results | 2019-03-25 | ||
| 6826 | Review of Related Literature | 2019-03-25 | ||
| 6827 | Prediction Results | 2019-03-23 | ||
| 6828 | Experimental Results and Analysis | 2019-03-23 | ||
| 6829 | System Validation | 2019-03-23 | ||
| 6830 | Related Work | 2019-03-23 | ||
| 6831 | 3R-Protocol | 2019-03-22 | ||
| 6832 | Energy Efficient Clustering Algorithms | 2019-03-22 | ||
| 6833 | GSO Algorithm | 2019-03-22 | ||
| 6834 | Genetic Algorithm Based Energy Efficient Clustering Hierarchy | 2019-03-22 | ||
| 6835 | Optimal-Distance Based Transmission Strategy (ODTS) | 2019-03-22 | ||
| 6836 | Bat Optimization Algorithm | 2019-03-22 | ||
| 6837 | Enhanced Optimized Energy Efficient Routing Protocol (E-OEERP) | 2019-03-22 | ||
| 6838 | Hybrid Meta-Heuristic Based Routing Protocol in WSN | 2019-03-22 | ||
| 6839 | Energy Aware Routing protocol (PDORP) | 2019-03-22 | ||
| 6840 | Position Responsive Routing Protocol (PRRP) | 2019-03-22 | ||
| 6841 | Co-operative Multiple Input and Multiple Output Spatial Modulation (CMIMO-SM) | 2019-03-22 | ||
| 6842 | Energy Consumption Routing Protocol | 2019-03-22 | ||
| 6843 | Energy Productive Routing | 2019-03-22 | ||
| 6844 | Balanced Energy Consuming and Hole Alleviating and Energy Aware BECHA (EA-BECHA) | 2019-03-22 | ||
| 6845 | Literature Survey | 2019-03-22 | ||
| 6846 | Energy Efficient Routing Protocol | 2019-03-22 | ||
| 6847 | Study Limitations | 2019-03-22 | ||
| 6848 | Aim of Study | 2019-03-21 | ||
| 6849 | Research Findings | 2019-03-21 | ||
| 6850 | Implications for Practice | 2019-03-21 | ||
| 6851 | Aim and Objectives of Study | 2019-03-21 | ||
| 6852 | Objectives of Study | 2019-03-20 | ||
| 6853 | Calculations | 2019-03-19 | ||
| 6854 | Theory and Calculations | 2019-03-19 | ||
| 6855 | Authors Contributions | 2019-03-18 | ||
| 6856 | Competing Interests | 2019-03-18 | ||
| 6857 | Availability of Data and Materials | 2019-03-18 | ||
| 6858 | Consent for Publication | 2019-03-18 | ||
| 6859 | Ethics Approval and Consent to Participate | 2019-03-18 | ||
| 6860 | Background | 2019-03-18 | ||
| 6861 | Conflict of Interests | 2019-03-18 | ||
| 6862 | Compliance with Ethical Standards | 2019-03-18 | ||
| 6863 | Data Analysis | 2019-03-18 | ||
| 6864 | Data Collection and Methods | 2019-03-18 | ||
| 6865 | Results and Discussions | 2019-03-14 | ||
| 6866 | Recommendations | 2019-03-14 | ||
| 6867 | Experimental Work | 2019-03-14 | ||
| 6868 | Objectives of the Study | 2019-03-14 | ||
| 6869 | Superscript | 2019-03-14 | ||
| 6870 | Summary | 2019-03-14 | ||
| 6871 | Model | 2019-03-14 | ||
| 6872 | Subscripts | 2019-03-14 | ||
| 6873 | Greek letters | 2019-03-14 | ||
| 6874 | List of Symbols | 2019-03-14 | ||
| 6875 | Measurements | 2019-03-14 | ||
| 6876 | Authorship contributions | 2019-03-14 | ||
| 6877 | Case Report | 2019-03-14 | ||
| 6878 | Effect of therapy | 2019-03-14 | ||
| 6879 | Life Style Modifications | 2019-03-13 | ||
| 6880 | Characteristic Feature | 2019-03-13 | ||
| 6881 | Case Report 2 | 2019-03-13 | ||
| 6882 | Case Report 1 | 2019-03-13 | ||
| 6883 | Methods and Materials | 2019-03-13 | ||
| 6884 | Commentary | 2019-03-13 | ||
| 6885 | Recommendation | 2019-03-12 | ||
| 6886 | Results and Discussion | 2019-03-12 | ||
| 6887 | Financial Support | 2019-03-06 | ||
| 6888 | Ethical Approval | 2019-03-02 | ||
| 6889 | Method | 2019-03-02 | ||
| 6890 | Authors’ Contributions | 2019-03-01 | ||
| 6891 | Limitations of the Study | 2019-03-01 | ||
| 6892 | Material and Methods | 2019-03-01 | ||
| 6893 | Suggestions | 2019-03-01 | ||
| 6894 | Ethical Considerations | 2019-03-01 | ||
| 6895 | Discussion and Conclusion | 2019-03-01 | ||
| 6896 | Ethics Concentration | 2019-03-01 | ||
| 6897 | Some Recent Studies | 2019-03-01 | ||
| 6898 | Special Items | 2019-03-01 | ||
| 6899 | Case Study | 2019-03-01 | ||
| 6900 | Informed Consent | 2019-03-01 | ||
| 6901 | Limitations | 2019-03-01 | ||
| 6902 | Findings | 2019-03-01 | ||
| 6903 | Funding | 2019-03-01 | ||
| 6904 | Conflict of Interest | 2019-03-01 | ||
| 6905 | Conclusion | 2019-03-01 | ||
| 6906 | Acknowledgements | 2019-02-19 | ||
| 6907 | Letter to the Editor | 2019-02-19 | ||
| 6908 | Consent | 2019-02-18 | ||
| 6909 | Case Presentation | 2019-02-18 | ||
| 6910 | Dear Editor in Chief | 2019-02-16 | ||
| 6911 | Conflict of Interest | 2019-02-15 | ||
| 6912 | Acknowledgments | 2019-02-15 | ||
| 6913 | Questionnaire | 2019-01-18 | ||
| 6914 | Clinical Examination | 2018-12-21 | ||
| 6915 | Methodology | 2018-12-21 | ||
| 6916 | Acknowledgement | 2018-11-14 | ||
| 6917 | Materials and Methods | 2018-11-14 | ||
| 6918 | Discussion | 2018-11-05 | ||
| 6919 | Results | 2018-11-05 | ||
| 6920 | Methods | 2018-11-05 | ||
| 6921 | Abbrevations | 2018-11-05 | ||
| 6922 | Keywords | 2018-11-05 | ||
| 6923 | Editorial | 2018-11-05 | ||
| 6924 | References | 2018-11-05 | ||
| 6925 | Conclusion | 2018-11-05 | ||
| 6926 | Pediatric Resuscitation at School: Legally Ambiguous and Morally Troubling Policies | 2018-11-05 | ||
| 6927 | End-of-Life in Pediatrics and the Child’s Right to an Open Future | 2018-11-05 | ||
| 6928 | Introduction | 2018-11-05 |